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With the aim of designing appropriate hybrid molecules as a strategy to fight drug 
resistant malaria parasites, 4-aminoquinoline-3,4-hydroxypyridinone hybrids were 
designed and synthesized. Their hypothesized mode of action was studied with respect to 
inhibition of hemozoin formation. 
 
Precursor N-alkyl-3,4-hydroxypyridinones and selected gallium (III) complexes were 
synthesized and evaluated for in vitro antiplasmodial activity. The activity of the most 
potent N-alkyl-3,4-hydroxypyridinone 2h had was IC50 = 2.38 µM and 1.8 µM against 
sensitive strain 3D7 and resistant strain K1 of Plasmodium falciparum respectively. In 
vitro antimalarial activity of these compounds was negated by blocking the chelator 
moiety via complexation with gallium (III) or protection by a benzyl group. None of 
these compounds inhibited β-hematin formation. Antiplasmodial activity of the 
combination of 2h with chloroquine-diphosphate or dihydroartemisinin was studied using 
the isobologram method. The combination resulted in a synergistic effect in the K1 and 
the 3D7 strains, justifying the synthesis of antimalarial aminoquinoline-3,4-
hydroxypyridinone hybrids.  
 
The synthesis of the hybrid molecules involved the Michael addition of N-(7-chloro-4-
quinolinyl)-diaminoalkanes to 3-benzyl or methoxy protected maltol or ethylmaltol, and 
by coupling of N-(7-chloro-4-quinolinyl)-diaminoalkane to 2-(chloromethyl)-5 
(benzyloxy)-1-alkylpyridin-4-(1H)-one. Deprotection of the benzyl group was via 
hydrogenolysis or acid hydrolysis delivering the target hybrids. 
 
The resistant strains of P. falciparum (K1 and W2) were more susceptible to the iron 
chelating hybrids. The presence of an amine group in the alkyl side chain enhanced 
activity against the resistant K1 strain presumably via enhanced accumulation in the 
parasitic food vacuole. Incorporation of a tertiary amino group enhanced antimalarial 
activity despite causing a decrease in β-hematin inhibition. Most of the compounds were 










32 having the highest activity (IC50/equiv. = 0.07µM). Correlation between 
antiplasmodial activity (against W2 or 3D7) and β-hematin inhibition was observed only 
for benzylated ethylmaltol/maltol derived hybrids (R2 = 0.8). The most potent compounds 
against K1 and 3D7 respectively were 16 (0.08 µM and 0.007 µM); 32 (0.001 µM and 
0.123 µM); 13a (0.03 µM and 0.07 µM) and 24a (0.05 µM and 0.01µM). Blocking the 
chelator group by benzyl or methoxy protection or pre-complexation with iron (III) and 
gallium (III) did not negate nor alter significantly the antimalarial activity of these 
hybrids implying that iron abrogation is not their main mode of action. The 
dihydrochloride salt of Compound 16 (16.HCl salt) and its deprotected analogue 16a 
were evaluated for in vivo activity in a mouse model of P. berghei and the percent 
survival observed after 15 days for animals treated with chloroquine, 16.HCl salt and 
16a was 80%, 40% and 0% respectively at a dosage of 2x day 50mg/kg administered 
intraperitoneally. 
 
Only the ethylmaltol/maltol-derived hybrids were tested in vitro for CYP3A4 inhibition 
in the presence of testosterone as the substrate and 85% of the compounds tested showed 
potential to cause drug-drug interaction (IC50 < 10µM). In vitro data indicated that the 
protected hybrids were more potent inhibitors than their deprotected analogues, and a 
similar trend was predicted using in silico tools (AutoDock4.2.3, MoKa and Volsurf).  
 
The predicted CYP4A4 affinity constants (Ki) correlated significantly (R2=0.6) with the 
in vitro determined Ki values. For a number of compounds the predicted Ki values were 
close to the in vitro Ki values e.g. 16 (Ki predicted = 0.79µM, in vitro Ki = 0.97µM). 
Significant correlations were observed between β-hematin inhibition and CYP3A4 
inhibition (R2>0.8) for the benzylated hybrids only. Some Weak hematin inhibitors were 
predicted to have high affinity for CYP3A4 confirming tentatively that strong hematin 
inhibitors are not necessarily potent CYP3A4 inhibitors. Unique docking modes in 
AutoDock4.2 that distinguished weak from strong CYP3A4 inhibitors were observed and 
from this, structural modification strategies to improve CYP3A4 inhibition profiles were 
proposed. Among the potent antimalarial hybrids 24a and 13a were predicted to have the 










in silico predicted physicochemical data alongside the Lipinski guidelines, over 75% of 
the deprotected hybrids and about 30% of the benzyl protected hybrids were observed to 
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ADMET        Absorption, distribution, metabolism, excretion and toxicity 
AQ                 amodiaquine 
Bn                   benzyl 
CQ                  chloroquine 
CYPs               cytochrome P450 isozymes 
DFO                desferroxamine 
DFP                 deferiprone 
DHA               dihydroartemisinin 
DNA               deoxyribonucleic acid 
DMF               dimethyl formamide 
DMSO            dimethylsulphoxide 
DV                  digestive vacuole 
Equiv.             equivalents 
EtOAc            ethylacetate 
EtOH              ethanol 
FGI                 functional group interconversion 
FV                  food vacuole 
HEPES           4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
3,4-HPOs     3,4-hydroxypyridinones 
HR-MS          high resolution mass spectroscopy 
IC50                concentration needed to cause 50% inhibition in activity or growth  
IR                   infra red 
MeOH            methanol 
MHz               mega hertz 
Min.                minutes 
MMV            malaria medicine venture 
m.p                  melting point 










m/z                  mass to charge ratio 
PD/PK            pharmacodynamics/pharmacokinetics 
PfCRT             Plasmodium falciparum Chloroquine Resistance Transporter 
PK/Tox            pharmacokinetics/toxicity 
Rf                    ratio of movement of solute to solvent in thin layer chromatography 
Rt                              retention time 
RPMI 1640    a cell culture medium (Seromed, Munich) 
SP                  sulphadoxine-pyrimethamine 
SN                   nucleophilic substitution reaction 
THF                tetrahydrofuran 
UV                 ultra violet 
WHO            World Health Organization 
QD                quinidin 
QN                quinine 
QSAR         quantitative structure activity relationship 




Nuclear Magnetic resonance (NMR) abbreviations 
Ar                   aromatic 
br.                    broad 
CDCl3             deuterated chloroform 
CD3CN           deuterated acetonitrile 
13C NMR       carbon 13 NMR 
d                      doublet 
dd                    doublet of doublets 
D2O                 deuterated water 
1H NMR         proton NMR 
J                      coupling constant 










MeOD             deuterated methanol 
ppm                  parts per million 
s                       singlet 
δ                       chemical shift in ppm 
t                        triplet 
TMS                 tetramethylsilane 
Infrared (IR) abbreviations 
 br                     broad 
m                      medium 
s                       strong 
vmax                  maximal velocity (cm-1) 
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Malaria is the most lethal human parasitic infection with over 250 million annual cases 
reported worldwide in 2008; of this 86% were in Africa. The World Health Organization 
(WHO) estimated 0.881 million deaths due to malaria worldwide of which 90% were in 
the African region and 4% in each of the South East Asia and eastern Mediterranean 
regions (WHO, 2009). The disease is particularly fatal among children under the age of 
five, and pregnant women. The disease which is both a consequence and a cause of 
poverty has been reported by Gallup and Sachs (2001) to slow down economic growth in 
endemic countries by about 1.3% per annum, and it costs sub-Sahara Africa US$12 




Figure 1.1:  Global distribution of malaria (CDC website 2010) 
 
The disease now threatens to affect over 40% of the population and even though it was 
primarily a tropical problem (Fig 1.1), it is now found in many temperate regions of the 
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The problem of endemic malaria has been exacerbated by the emergence of widespread 
resistance to the once effective first line treatment drugs such as chloroquine (CQ) and 
sulphadoxine-pyrimethamines (Wells et al., 2009). Increasing resistance of Anopheles 
mosquito to insecticides has also been linked to the problem (Weissbuch and Leiserowitz, 
2008). Ironically, at a time when exciting scientific advances are offering the opportunity 
to successfully manage previously untreatable diseases, our ability to reliably treat 
malaria has actually diminished over the last half century (Rosenthal and Miller, 2001).  
 
Artemisinin based combination therapies, ACTs, have replaced the failed therapies and 
are the recommended first line treatments of falciparum malaria in all endemic countries. 
However, artemisinin monotherapy has been reported to be facing the prospects of 
declined efficacy due to the emergence of resistance. This has been reported on the Thai-
Cambodian border, historically a site of emerging antimalarial resistance (Dondorp et al., 
2009, Wiwanitkit., 2010). With increasing resistance to available agents, intensive drug 
discovery efforts aimed at developing new antimalarial drugs or modifying existing ones 
are on going (Guantai et al., 2010). 
 
1.1.2 Biology of Malaria 
 
Malaria is caused by protozoan parasites of the genus Plasmodium and is spread by the 
female Anopheles mosquito (Weissbuch and Leiserowitz, 2008). The parasites infect and 
destroy the red blood cells, leading to fever, severe anaemia and in some cases cerebral 
malaria and if untreated, death.  
 
Human malaria is caused by five protozoan types of the genus Plasmodium: P. 
falciparum, P. vivax, P. ovale P malariae and P. knowlesi.  P. falciparum is the most 
prevalent and virulent and it accounts for 95% of malaria related deaths (WHO, 2005). 
Plasmodium requires two hosts to complete its life cycle (Fig 1.2), namely, a mosquito 
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When a female Anopheles mosquito with Plasmodium bites humans, it transmits 
sporozoites into the human body. The sporozoites enter the blood circulatory system and 
infect liver cells within one hour (liver stage) where they develop into schizonts. After 
about one to two weeks, the schizonts rupture each releasing thousands of “daughter” 
parasites called merozoites into the blood stream (Weissbuch and Leiserowitz, 2008). 
The merozoites then invade the red blood cells (RBCs) inside which they mature to 
schizonts. Each new schizont contains several merozoites and it eventually ruptures to 
release the merozoites, which are then free to infect other RBCs. This process (blood 
stage) is responsible for the clinical symptoms of malaria. A small number of the 
merozoites differentiate into male and female gametocytes (sexual stages), which are 
ingested by a mosquito when it bites an infected person. 
 
 Inside the mosquito gut another cycle of growth and multiplication occurs, eventually 
resulting in sporozoites, which are liberated into the mosquito‟s salivary glands. From the 
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1.1.3 Clinical Symptoms of Malaria  
 
The fever or flu-like symptoms associated with malaria are caused by the rapture of the 
infected RBCs to release the merozoites and starts around 8-30 days after infection. The 
resulting cell debris and toxins are released into the blood and this causes an immune 
response (fever) to promote other immune defences to combat the foreign material. The 
fever includes bouts of sudden chills followed by intense fever and sweating. Anaemia 
can result from repeated malaria parasite infections. 
 
P. falciparum produces specific proteins that are transported and embedded in the cell 
membrane of the infected red blood cells. As a consequence, the erythrocytes stick to the 
walls of the pre-venous capillaries causing obstruction and inflammation of these vessels. 
This phenomenon occurs in brain vessels during cerebral malaria leading to loss of 
consciousness (coma and convulsions) and this is lethal if not treated immediately 
(Wiesner et al., 2003). Other symptoms of malaria include glomerulonephritis (kidney 
inflammation), hypoglycaemia (low glucose levels), and accumulation of fluids in the 
lungs (pulmonary oedema), acute renal failure and metabolic acidosis (Winstanley, 2001; 
Wilairatana et al., 2002). Humans in endemic areas who have survived an attack of 
malaria are semi-immune and in such cases the disease is characterised by headache and 
mild fever (Wilairatana et al., 2002, Winstanley, 2001) 
 
P. ovale and P. vivax can persist for up to 5 years as dormant stages in the liver 




Diagnosis is mainly by microscopy and is used to determine the presence of the parasites 
in the RBCs. The method is documented in the WHO bench aids for the diagnosis of 
malaria (WHO, 2000). It is difficult to detect malaria in its early stages or if the 
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and the method works by detecting the replicating Plasmodium proteins or genetic 
material in a human host‟s blood. 
 
1.2 Hemoglobin Catabolism in the Plasmodium 
 
Haemoglobin is imported in transport vesicles into a specialised compartment in the 
parasite; the food vacuole FV, where it is degraded by four types of proteolytic enzymes 
(Fig. 1.3). The enzymes include four aspartic proteases plasmepsin I, II, IV and 
histoaspartic protease HAP (Omara-Opyene et al., 2004), three cysteine proteases 
falcipain 1, 2 and 3 (Rosenthal et al., 2002) and a zinc metalloproteases falcilysin 














Figure 1.3: Uptake and Degradation of haemoglobin by the parasite inside the 
 RBC. Adapted from Egan, (2003) 
 
The FV is an acidic (pH 5.0-5.4) degradative organelle optimised for haemoglobin 
catabolism (Banerjee and Goldberg, 2001, Krogstad et al., 1985, Yayon et al., 1984). It is 
a site of acidification, proteolysis, peptide transport, haemozoin formation, detoxification 
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During development inside the RBC, P. falciparum digests between 60-80% of the 
available haemoglobin in the FV (Egan et al., 2002, Krogstad et al., 1985, Hayward et 
al., 2006). The digestion results in smaller peptides and free haem [Fe2+-protoporphyrin 
IX] or [Fe(II)-PPIX] (Weissbuch and Leiserowitz, 2008).  Fe(II)PPIX is released into an 
aqueous environment where the metal centre is irreversibly oxidised to Fe (III) 
presumably by molecular oxygen (de Villiers and Egan, 2009) to give HO-/H2O-
Fe(III)PPIX also referred to as hydroxo/aqua ferritoprotoporphyrin IX or haematin, 
which is toxic to the parasite (Chou et al., 1980). 
 
Though insoluble in the acidic aqueous environment, haematin is soluble in a lipid 
environment and as such causes lipid peroxidation and membrane damage. Vertebrates 
detoxify haematin by catabolism using the haem oxygenase, which P falciparum lacks 
(Banerjee and Goldberg, 2001). The parasite detoxifies haematin by sequestering the free 
haematin into a microcrystalline form known as haemozoin or the malaria pigment 
(Brown 1911). The compact insoluble haemozoin has decreased pro-oxidant capability 
and hence is non toxic to the parasite (Oliveira et al., 2002). It has been demonstrated that 
at least 95% of the haem released in the parasite is converted to haemozoin (Egan, 2008) 
 
1.2.1 Mechanism of Haemozoin Formation   
 
Haemozoin has been discovered in other blood feeding organisms including the insect 
Rhodnius prolixus ,(Oliveira et al.,  1999), helminth worms Schistosoma mansoni the 
causative agent for bilharzias (Oliveira et al., 2000, Chen et al., 2001), Echinostoma 
trivolvis (Pisciotta et al., 2005) and the bird infecting protozoan Haemoproteus columbae 
(Chen et al., 2001). The Figure below shows some of the haemozoin crystals retrieved 
























            A                           B                                C 
Figure 1.4: Field emission inlens scanning electron microscopy micrographs of 
haemozoin purified from (A) Hemoproteus columbae (B) S. mansoni (C) P. falciparum 
(Buller et al., 2002) 
 
A primary cause of the re-emergence of malaria is a consequence of developing parasite 
resistance to antimalarial drugs in particular some of the widely used synthetic 
quinolines. Several workers have shown that antimalarial quinolines act by binding to 
haemozoin crystal faces, which would inhibit their growth and result in a build up of the 
toxic haematin and thus death of the parasite (Weissbuch and Leiserowitz, 2008).  Thus, 
understanding the mechanisms of haemozoin formation in vivo and under biomimetic 
conditions is important in elucidating the modes of action of quinoline antimalarials. 
 
Haemozoin is chemically and structurally identical to a synthetic haematin product called 
β-haematin (Slater et al., 1999, Bohle et al., 1997), which is a cyclic dimer of 
Fe(III)PPIX (Pagola et al., 2000). The dimer‟s structure consists of reciprocal 
coordination of the ionised haem-propionate side chain of one haem to the iron centre of 
the other haem (Fig. 1.5). CQ and structurally related antimalarial compounds are known 
to inhibit β-haematin and evidence shows that by the same mechanism these drugs exert 
their antimalarial activity by inhibiting haemozoin formation in the intraerythrocytic 
parasite. (Egan and Ncokazi, 2005, Sullivan et al., 2002, Kaschula et al., 2002, Dorn et 
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Figure 1.5: Structure of β-haematin dimer on the left (Egan, 2008) and haem on the right 
 
The formation of β-haematin from haematin appears to be a thermodynamically 
spontaneous process under acidic conditions and requires the presence of a suitable 
catalyst eg acetic acid (Egan and Kanyile, 2005). Evidence from electron microscopy of 
three different haemozoin forming organisms P. falciparum, S. mansoni and R. prolixus 
provide strong evidence that the formation occurs in close association with lipids (Egan, 
2008; Oliveira et al., 2005; Soares et al., 2007; Pisciotta et al., 2007; Coppeus et al., 
2005) 
 
Indeed in the case of P. falciparum and S. mansoni, the formation occurs within lipid 
bodies. Biomimetic studies by Hoang et al (2010) strongly support the hypothesis that 
haemozoin formation is caused by lipid droplets/nanospheres in the FV of P. falciparum.  
Supported by insights from molecular dynamic simulations, it has been suggested that the 
lipid/aqueous interface that these bodies present is key to the formation of haemozoin 
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1.3 Malaria Chemotherapy 
 
Several antimalarial drugs are in use for the treatment or prevention of the disease. The 
drugs are classified according to their molecular structure and their mode of action. The 
most important antimalarials currently in clinical use include quinolines, antifolates, 
antibiotics, endoperoxides related to artemisinin and the hydroxynaphthoquinone 
atovaquone (Table 1.1) 
Table 1.1.  The main antimalarial drugs in current use. 
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1.3.1 Aminoquinolines and Arylmethanols 
The first widely used antimalarial drug was quinine a natural product extracted from the 
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acts primarily as a blood schizonticide and has little effect on sporozoites (pre-
erythrocytic) forms of malaria parasites hence cannot control all stages of malaria.  
Arylmethanols were developed as alternatives to amodiaquine, which was considered to 
have some toxic side effects; they include mefloquine, halofantrine, pyronaridine, 
piperaquine and lumefantrine (Fig. 1.6), and are used to treat uncomplicated malaria 
(Wells et al., 2010). All the aryl amino alcohols have side effects eg neuropsychiatric 
problems and arrhythmia associated with the use of mefloquine and halofantrine 
respectively (Wiesner et al., 2003).  
The 4-aminoquinolines have been proven to be the most successful class of compounds 
for malaria treatment and prophylaxis because they are cheap, easy to synthesize, have 
acceptable toxicity profiles, are well tolerated and effective against a number of 
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1.3.2 Antifolates 
These antimalarials act by inhibiting the enzymes involved in folate metabolism in the 
parasite. The antifolates include sulfadoxine, pyrimethamine, commonly called SP drugs, 
and proguanil (Fig. 1.7). SP combination therapy has emerged as a cheap and effective 
drug against chloroquine-resistant strains of P. falciparum (Oketch-Rabah, 1996). 
However, excess use has caused development of resistance [Wiesner et al., 2003]. 
Proguanil was developed during the Second World War by British scientists and later 
became the template for the synthesis of pyrimethamine. For effectiveness, proguanil is 
combined with chloroquine (Wiesner et al., 2003) or with atovaquone [Malarone®] 

























Figure 1.7: Chemical structures of Antifolates 
1.3.3 Artemisinin Derivatives 
The development of resistance and toxic side effects of some of the synthetic antimalarial 
drugs rejuvenated the interest in searching for antimalarials from natural sources. This is 
exemplified by the discovery of the sesquiterpene lactone artemisinin from the Chinese 
medicinal plant Artemisia annua (Asteraceae). The semi-synthetic artemisinin derivatives 
include artemether, arteether, artelinic acid, artelinate and artesunate (Fig. 1.8). 
Artemisinin and its derivatives are metabolized to dihydroartemisinin DHA, the main 
bioactive molecule. (Meshnick, 2002; Wiesner et al., 2003) 
This class of compounds acts faster than all the rest of the antimalarial drugs with an 
approximate parasite and fever clearance time of 32 hours, in contrast to 2-3 days 
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Price, 2000).  Artemisinins are associated with high rates of recrudescence (treatment 






















C(O)(CH2)2CO2Na        Artesunate
Me             Artemether
Et               Arteether
  CH2C6H4CO2H              Artelinic acid




Figure 1.8: Chemical structures of artemisinins 
Recrudescence occurs because of the rapid clearance of the drug from the blood stream 
(shorter plasma half life). To correct this, artemisinins are used in combination with other 
antimalarials that have longer plasma half life for example mefloquine– artesunate, 
artemether –lumefantrine combinations. 
Some derivatives of artemisinin such as artelinic acid and its sodium salts have been 
synthesized to increase the plasma half-life of the artemisinins (Wilairatana, et al., 2002; 
Meshnick, 2002; Wongsrichanalai et al., 2001; Borsnick et al., 2002) Much research is 
still going on with the sole purpose of generating more stable, less neurotoxic, simpler, 
more soluble and highly bioavailable derivatives of artemisinin (Oketch-Rabah, 1996; 
WHO, 1996; Ekthawatchai et al., 2001). 
1.3.4 Antibiotics  
Several antibiotics that are known to be antibacterial act as antimalarials.  An example is 
the tetracyclines such as doxycycline and tetracycline (Fig. 1.9). Antibiotics are applied 
as prophylactics, or in combination with other antimalarial drugs for the treatment. In 
practice doxycycline is the most frequently used antibiotic in antimalarial therapy, either 
on its own as a prophylactic or in combination with quinine or artesunate for treatment of 
multi-drug resistance (Wiesner et al., 2003). Other commonly used antibiotics are 
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vivax (Wiesner et. al., 2003; Taylor et al., 1999), with clindamycin being the one 









































Figure 1.9: Chemical structures of Antiplasmodial Antibiotics and Atovaquone 
 
Furthermore these antibiotics are under investigation for combination therapy with 
known antimalarial drugs. For instance combinations of oral quinine and antibiotics have 
been proposed in regions with declining quinine sensitivity. Proposals under investigation 
include quinine–clindamycin and quinine–azithromycin regimens in Africa, and the 7- 
day quinine–tetracycline regimen in Thai-Burma (Philippe and Milller, 2002)    
 
1.4 Approaches to Discovery of New Antimalarial agents 
 
The discovery of new antimalarial agents is important in the fight against drug resistance. 
Six approaches to discovery of new antimalarial agents have been identified namely 
combination therapy, structural modification of old drugs, use of natural products and 
their derivatives, use of compounds active against other diseases and use of resistance 
reversers and the use of compounds against new parasitic targets. Globally a number 
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the clinical phases (Olliaro and Wells 2009; Wells et al., 2010).   The majour one are 
depicted in Table 1.2. 
 
 Table 1.2. Global malaria development pipeline of new antimalarial combinations and 
chemical entities by 2009. 
Derivative/active ingredient Commercial name Clinical phase and 
reference 
Ozonide or artificial peroxide  OZ 439 II  (Charman et al., 2011) 
4‟-fluoro-N-tert-butylamodiaquine Isoquine I   (O‟Neil et al. 2009) 
Tafenoquine Tafenoquine II (Olliaro and Wells, 2009) 
A pyridone 4-pyridone I ( Olliaro and Wells 2009) 
N1 – (7- chloroquinolin-4-yl) - N3, 
N3- diethylpropane -1, 3- diamine. 
AQ-13 I  (Mzayek et al, 2007) 
1, 2, 4 - trioxane CDRI 97/78 I (O‟Neil and Wells 2009) 
Artemisone Artemisone II  (Pooley et al., 2011) 
Fosmidomycin-clindamycin Fosmidomycin-
clindamycin 
II (O‟Neil and Wells 2009) 





SAR 97276 II  (Margout et al., 2009) 
Methylene blue and amodiaquine Methylene blue-
amodiaquine 
II  ( O‟Neil and Wells 
2009) 
Tinidazole Tinidazole II  (O‟Neil and Wells 2009) 
Dihydroartemisinin-piperaquine Euratesim III (O‟Neil and Wells 2009) 
Dihydroartemisinin-pyronaridine Pyramax III (O‟Neil and Wells 2009) 
Artesunate -mefloquine ASMQ III (O‟Neil and Wells 2009) 
Azithromycin-Chloroquine Azithromycin-
Chloroquine 
III (O‟Neil and Wells 2009) 
Arterolane-piperaquine Arterolane III (Vennerstrom et al., 
2011) 
Arthemether-lumefantrine Coartem D Approved in 2009 (O‟Neil 
and Wells 2009) 
Artesunate - amodiaquine Coarsucam Approved in 2008 (O‟Neil 
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The use of combination therapy is currently mandated by the WHO (WHO, 2001), as the 
best way to counter resistance. This is the only viable method for restoring or maintaining 
usefulness of antifolates and atovaquone, where resistance arises from mutations in the 
target proteins themselves (Egan and Kaschula, 2007). Evidence shows that combination 
therapies of drugs with different resistance mechanisms greatly reduces the chances of 
mutants resistant to any of the individual drugs surviving (White 1999) hence potent and 
long lasting combinations must constitute drugs that act by different modes and have 
different resistance mechanisms (White 1999, Berenbaum, 1977)  
 
Examples of combination therapies in current use include suphadoxine-pyrimethamine 
(SP), atovaquone-proguanil (malarone®), chlorproguanil/dapsone (Lapdap ®), 
mefloquine-artesunate, ®), azithromycin-CQ with the latter being in phase three of 
clinical trials. Amodiaquine-sulphadoxine-pyrimethamine has shown encouraging 
clinical activity (Sendagire et al., 2005). Non artemisinin combination therapies have 
been important to counteract resistance to artemisinin (Ohrt et al., 2002, Dunne et al., 
2005) Fixed dose artemisinin combination therapies ACTs available or in late stage 
development include lumefantrine/artemether (Coartem), artesunate-pyronaridine 
(pyramax®), dihydroartemisin/piperaquine (eurarte sim), artesunate–amodiaquine 
(coarsucam®), artesunate-mefloquine (ASMQ), CQ-artemisisnin and CQ-
azithromycin(Wells, 2010, MMV 2011; Weissbuch and Leiserowitz 2008).   
 
Many of the current antimalarial agents were developed via new analogues of existing 
antimalarial drugs. CQ, mefloquine and primaquine were developed as synthetic 
analogues of quinine and the analogues have proven to be better against resistant strains 
of plasmodia than the parent drug (Rosenthal and Miller, 2001). Lumefantrine and 
pyronaridine were developed through such a strategy. New synthetic endoperoxides 
related to artemisinin have proven to be more potent than artemisinin (Wells et al., 2010). 
Natural products and their derivatives present another major strategy. This method has 
identified the most important drugs currently available to treat severe P. falciparum 
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approach involves screening plant extracts and the potential drugs isolated from these 
extracts. 
 
The use of compounds active against other diseases is a viable strategy for discovery of 
new antimalarials. Folate inhibitors and other antibiotics were developed for their 
antibacterial activity and later found to be active against malaria eg doxycycline, 
azithromycin and atovaquone (Rosenthal and Miller, 2001).  Iron chelators which were 
designed and used in treatment of iron overload were found to have antimalarial activity 
(Mabeza et al., 1999; Weinberg et al., 2009).  
 
Combining effective antimalarial agents with compounds that reverse parasite resistance 
to these agents (resistance reversers or “chemosensitizers”) is an important strategy. The 
activity of CQ against resistant parasites has been enhanced by a number of compounds 
including verapamil, despiramine, and chlorpheniramine (Martin et al., 1987, Basco et 
al., 1994, Bitonti et al., 1988) in vitro, in animal models and in man. The mechanisms of 
these chemosensitizers is unclear although many appear to work by enhancing the 
accumulation of CQ (Bray and Ward 1998), or by interfering with the transmembrane 
proteins involved in drug efflux or uptake (Henry et al., 2006). Some reversers are known 
to clearly increase drug susceptibility in CQ resistant parasites and not in sensitive ones 
(Millet et al., 2004). The resistance reversers belong to different pharmacological classes 
such as calcium ion channel blockers, tricyclic antidepressants, antipsychotic calmodulin 
antagonists, histamine receptor antagonists and antifungals. In deed CQ-resistance 
reversers have been identified to have the key elements of a CQ resistance reverser 
pharmacophore i.e. hydrogen bond acceptor and two hydrophobic aromatic rings (Egan 
and van Schwalkwyk, 2006; Martin et al., 2010) and this is irrespective of the class of 
compounds it belongs to.  
  
The use of compounds against new targets involves identification of the new targets in P. 
falciparum and subsequent discovery of compounds that act on these targets. With the 
recent mapping of the P. falciparum genome (Gardner et al., 2002), it is hoped that the 
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Plasmodial proteases which are appealing targets for chemotherapy because they are 
critical for parasite survival. These enzymes are used in haemoglobin degradation and in 
the rupture of the red blood cells to release the schizonts (Rosenthal, 2001). The SP drugs 
are known to inhibit two of the five enzymes required for the folate synthesis that is 
dihydrofolate reductase and dihydropteroate synthase (Hyde 2005, Bzik et al., 1987, 
Triglia et al., 1994). Aspartyl proteases (Plasmepsins I, II and V) and cysteine proteases 
(Falcipains 1, 2, and 3) are potential targets for antimalarials (Russo et al., 2010).  New 
permeability pathways (NPPs) are induced into the hosts cell membrane, making the 
latter more permeable to a variety of low molecular weight compounds required by the 
invading P. falciparum and these are potentially good drug targets (Staines et al., 2005). 
All pathogenic protozoan parasites do not synthesize their purines de novo and they rely 
on the host for this (Sherman et al., 1979), thus the identification of the purine and 
nucleoside transporters and purine salvage enzymes, hypoxanthine 
phosphoribosyltransferase, HPRT, and purine nucleoside phosphorylase, PNP) from the 


























Andayi AW                                                                                                                    UCT 21 
1.5 Haemozoin and Antimalarial Quinolines 
 
Quinolines and other antimalarials that target haemozoin are believed to inhibit 
haemozoin crystal nucleation and growth (Weissbuch and Leiserowitz, 2008). Over all 
the absence of indisputable structural evidence of the interaction of antimalrial drugs with 
haem has hampered the rational design of novel compounds (de Villiers and Egan, 2009). 
However, two set of proposals on the interaction of antimalarials with haem have been 










Figure 1.10:  The external morphology of the haemozoin crystal, the heme molecules are 
linked to each other via a carboxylate - iron coordination. The figure shows the 
corrugated face and its interaction with CQ as proposed by Leiserowitz and coworkers.  
The interaction is between the 4-amino group and the porphyrin vinyl group (1), the 7-Cl 
and the porphyrin methyl and quinoline N with the porphyrin vinyl group (2), and the 
positively charged amino group with the negatively charged propionate group forming a 











Andayi AW                                                                                                                    UCT 22 
The first is a mechanism proposed by Buller et al., 2002; it involves the interaction of the 
inhibiting compound (quinolines) with the fastest growing faces of the haemozoin crystal. 
Weissbuch and Leiserowitz (2010), further proposed that artemisinins interact with the 
slowest growing faces of the haemozoin crystal. On the corrugated surface of the 
haemozoin crystal the propionic acid and vinyl group of the Fe (III)PPIX are exposed and 
the antimalarials are thought to interact with these moieties as shown in Figure 1.10. A 
criticism levelled against this model is that CQ was modelled in its monoprotonated state; 
under the FV conditions where CQ is thought to accumulate and interact with haemozoin, 
the diprotonated form is the major species. With the discovery of lipid involvement in 
haemozoin formation, the monoprotonated species may be present in a lipid environment, 






Figure 1.11: Interaction of quinine with haematin (Leeds et al., 2002) 
 
In the second model or mechanism, it is assumed that the principle bonding interactions 
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forces of the quinoline ring over the porphyrin with possible weak electrostatic 
interactions between the protonated amino group of the quinoline and the carboxylate of 
the haem (Moreau et al., 1982, O‟Neil et al., 1997). In the case of arylmethanol 
antimalarials such as quinine (QN) and quinidine (QD), it has been proposed that in 
addition to the π-π stacking, coordination to the iron centre of Fe(III)PPIX through the  
hydroxy occurs (Warhurst 1981; Behere and Goff 1984; Constantinidis et al., 1988; 
Marques et al., 1996).  
 
UV Vis, NMR and X-ray crystallography data has been used to confirm these 
interactions. An example is from solution chemistry, NMR and computational studies 
done by Roepe and co-workers; Figure 1.11 illustrates the interaction between quinine 
and haem as proposed by the group (Leed et al., 2002). The figure 1.11 shows there is π-
π stacking interaction between the heme porphyrin ring and the quinoline nucleus for 
different species of CQ i.e.. CQ neutral, CQH+ and .CQH2 
 
Figure 1.12: Computational model of halofantrine – haem complex depicting the 
intramolecular H-bond that was proposed in the isolated complex [Fig. 1.13a] (de 
Villiers et al., 2008) 
The most convincing evidence was when the first crystal structure of an antimalarial-Fe 
(III)PPIX complex ie halofantrine-haem complex, was elucidated, as shown in Figures 
1.13(a) and 1.12 (de Villiers et al., 2008). It was shown that in addition to the envisaged 
ππ stacking of the phenanthrene ring of halofantrine over the porphyrin ring, the drug 
coordinates to the iron centre of the monomeric Fe(III)PPIX via its alcohol functionality 
















Figure 1.13: (a) The halofantrine (Hf) - Fe(III)PPIX crystal structure. Thermal ellipses 
are drawn at 50% probability illustrating significant disorder in the Fe(III)PPIX vinyl 
group, butyl chain termini of Hf and the included acetone molecule. (b) A packing 
showing π-stacking a d hydrogen bonding in the crystal. (c) a packing viewed down the 
a-axis of the unit cell emphasising the included acetone and water molecules in channels 
running down this axis. H-bonding was omitted for clarity. Atom colour coding: C, grey; 
H, white; Cl, lime green; F, Prussian blue; Fe, cyan; N, blue; O, red.(Adapted from de 
Villiers et al., 2008) 
 
An important intermolecular hydrogen bonding between the protonated terminal N atom 
of the halofantrine and the propionate group of a neighbouring Fe(III)PPIX molecule 
were observed (Fig. 1.13b; 1.13c). Using computational tools and spectroscopic 
investigation de Villiers et al.,(2008), showed that favourable formation of an intra 
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from the Fe(III)PPIX thus essentially blocking the iron centre from coordinating to a 
second molecule of Fe(III)PPIX and this was proposed to block haemozoin formation 
(Fig. 1.13). 
 
On this basis the authors proposed a novel pharmacophore for haem targeting 
compounds. The model consisted of a 3-point interaction that involves ππ stacking, 
coordination and intramolecular hydrogen bonding. Thus the mechanism of action of 
halofantrine and related antimalarials in the inhibition of haemozoin involves firstly 
anchoring the molecule to haematin through coordination to the iron centre and ππ 
stacking with the protoporphyrin system. 
This then allows the hydrogen bonding interactions with the propionate side chain to 
occur resulting in the inhibition of haemozoin formation (Kuter, 2008). The shortcoming 
of this second proposal is that the interactions observed were in aqueous/solid state and 
may not necessarily be the same as in the lipid (non-aqueous) environment in which 
haemozoin formation occurs (de Villiers and Egan, 2009) 
 
1.6 Mechanisms of Quinoline Resistance-the Biochemical Basis of CQ Resistance 
 
Chloroquine, a 4- aminoquinoline was the mainstay for treatment and prevention of 
malaria because of its low cost, safety and efficacy. CQ resistance by P. falciparum and 
P. vivax has been reported in every malaria endemic country and this drug is no longer 
considered appropriate for the treatment of malaria in many areas (Barat et al., 1997, 
Whitby et al., 1997). Despite massive drug pressure following its introduction in the 
1940s, the resistance of P. falciparum to CQ was not recognised until in the late 1950s 
when treatment failures were reported from distinct foci in SE Asia and S America. 
Afterwards it spread to almost all malaria areas around the world (Barat et al., 1997, 
Wernsdorfer, 1994). Gradual development of resistance to other aminoquinolines like 
mefloquine, quinine and quinidine has been reported (Grant et al., 2001). Also some 
strains of P. falciparum from Cambodia and Thailand are resistant to all antimalarial 
drugs except artemisinin combined therapies (Dondorp et al., 2009, Wiwanitkit., 2010, 
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A wide range of drug transport studies using intact infected red blood cells, isolated 
malarial parasites, heterogenous expression systems and purified protein, combined with 
genetic experiments have suggested that CQ transport mechanism by the Plasmodium 
falciparum Chloroquine Resistance Transporter (PfCRT) is a key aspect of the molecular 
mechanism of quinoline antimalarial drug resistance (Roepe, 2011). Nearly all evidence 
has been in favour of a digestive vacuole (DV) membrane drug pump or drug channel 
explanation for CQ resistance and the digestive vacuole as the principle site of CQ 
accumulation because haem released via haemoglobin catabolism within the DV is the 
principle molecular target of CQ. So far it has been demonstrated that resistance is 
conferred by mutations of the CQ resistance transporter PfCRT, an integral protein 
membrane localised to the parasites internal digestive vacuole. The mutations were 
showed to cause a marked reduction in the accumulation of CQ by the parasite (Martin et 
al., 2010). 
 
CQ is a diprotic weak base (pKa of 8.1 and 10.2, where pKa is the acid dissociation 
constant) The relative proportions of the neutral, mono-protonated (CQH+), and 
diprotonated (CQH22+ ) species vary with pH. The neutral species enters the parasite and 
its acidic DV (pH~5) via diffusion. Inside the DV the equilibrium is shifted toward the 
CQH22+ species, which is unable to diffuse across the membrane and becomes trapped by 
accumulating to high concentrations within the DV (Klonis et al., 2007). In side the DV 
chloroquine exerts its antimalarial activity via haemozoin inhibition. From a biochemical 
standpoint, CQ resistant parasites have been found to accumulate less CQ when 
compared to the sensitive parasites (Dorsey et al., 2001).  
 
Chemosensitizing agents such as verapamil are reported to reverse resistance by 
enhancing drug accumulation in the resistant parasites and not the sensitive ones hence 
cancelling out the difference in accumulation (Foley et al., 1998).  
 
From a genetic standpoint the goal has been to identify genes that encode proteins that 
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and a number of hypotheses have been proposed to explain the differences in CQ 
accumulation between CQ resistant and sensitive parasites. Verdier et al., (1985) and 
Krogstad et al., (1987) proposed that CQ efflux occurs at a greatly enhanced rate in CQ 
resistant parasites and this prevents its accumulation in the parasitic FV. They proposed a 
mechanism similar to that mediated by P-glycoprotein molecules in drug resistant 
mammalian cancer cells (Martin et al., 1987). They stated that the lack of accumulation is 
caused by a mutated membrane transport protein and this causes an increase in CQ efflux 
resulting in decreased concentration that is too low to inhibit haemozoin formation.  
 
Initial studies were able to associate CQ resistance with point mutations in the gene 
PfCRT (Fidock et al., 2000; Sidhu et al., 2002). A direct proof of a casual relationship 
remained elusive therefore models prior to the work by Fidock and co-workers (2002), 
posited a multigenic basis of CQ resistance. Fidock and co-workers gave evidence that 
mutant halotypes of the PfCRT gene conferred resistance with characteristic verapamil 
reversibility and reduced accumulation.  The PfCRT mediated resistance mechanism is 
structural specific and this has been underscored by findings that PfCRT-modified clones 
remain susceptible to amodiaquine a compound similar to CQ but with a modified 
aminoquinoline side chain. This promoted the use of amodiaquine and related compounds 
that have a modified aminoquinoline side chain in their structures for the treatment of CQ 
resistant falciparum malaria (Sidhu et al., 2002). 
 
A current model demonstrates that CQ resistance is due to direct transport of the drug via 
mutant PfCRT and that resistant reversers act by inhibiting the PfCRT transport 
mechanism (Martin et al., 2010; Krogstad et al,. 1987). The mutant form of the 
transporter was found to transport CQ while the wild one (sensitive) did not. The 
experiment to demonstrate this involved the use of Xenopus laevis oocytes (frog eggs) to 
simulate the FV membrane of the P. falciparum. Localization of CQ sensitive and 
resistance forms of PfCRT (PfCRTCQS) and PfCRTCQR respectively) on the Xenopus 
laevis oocytes plasma afforded a method to study the differential efflux of CQ by the 
PfCRT in resistant and sensitive strains. The uptake of [3H]CQ was measured in an acidic 
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PfCRTCQR showed marked (5-10 fold) increase in the [3H]CQ uptake relative to the non 
injected controls and the oocytes expressing PfCRT. This effect was demonstrated to be 
due to PfCRTCQR but not PfCRTCQS mediating the transport because the membrane 
potential and cytosolic pH in PfCRTCQR  expressing oocytes were the same as those in the 
PfCRTCQS expressing oocytes. The main resistance conferring mutant in PfCRT (K76T) 
was found to be necessary but not sufficient for the transport of CQ via PfCRT and that 
other PfCRT mutations act in synergy with K76T to confer CQ resistance. The K76T is 
located in a region of the protein that is known to be involved in the recognition of the 
substrate (Martin et al., 2004). It was demonstrated that the presence of a positive charge 
(K76 or R163) in the PfCRT substrate binding site prevents CQH22+ (or CQH+) from 
interacting with the transporter. The K76T mutation removes the positive charge altering 
the substrate specificity of PfCRT to allow the transport of the protonated drug (Martin et 
al., 2010). The presence of mutant PfCRT on the digestive vacuole was hypothesised to 
allow the protonated drug to be transported down its electrochemical gradient, out of the 
digestive vacuole, and thus away from the site of action and this was found to be 
consistent with previous reports (Bray et al., 2006; Sanchez et al., 2005; Sanchez et al., 
2005; Naude et al., 2005). The work by Martin et al, 2010, provides a convincing 
evidence of the involvement of PfCRT in CQ resistance however, it is still important to 
consider alternative models because CQ resistance appears to be multifaceted. 
 
Alternative findings show that CQ efflux rates in CQR and CQS parasites are similar and 
that the decreased steady state levels of CQ in the resistant strains are a result of a 
diminished accumulation rather than a drug export mechanisms (Bray et al., 1994., 
Ginsburg 1991). The specific hypotheses also incorporated the concept that decreased CQ 
accumulation can be the result of diminished drug accumulation. Increases in the pH of 
the parasitic FV could explain the decreased accumulation of CQ in the resistant strain 
(Geary et al., 1990, Bray et al., 1992). It has been proven that that the FV pH is actually 
decreased in CQ resistant parasites by 0.4-0.5 pH units relative to CQ sensitive parasites 
(Dzekunov et al., 2000). The proposal and results appear paradoxical if vacuolar 
accumulation were explained only by weak-base trapping (Dorsey et al., 2001). 
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soluble haem (Bray et al., 1998, Fitch et al., 1970). Given that there is a steep effect of 
pH on the conversion of soluble haem to insoluble haemozoin, and that the formation of 
haemozoin is much more efficient at the low FV pH value of CQR parasites, then 
vacuolar acidification would leave significantly less free haem available for the formation 
of toxic complexes with CQ (Dzekunov et al., 2000). The result would be reduced 
accumulation of CQ in CQR parasites and this is consistent with experimental data which 
shows a reduction in high affinity drug receptor sites (Dorsey et al., 2001, Dzekunov et 
al., 2000, Bray et al., 1998, Fitch et al., 1970).   
 
Diminished drug accumulation has also been explained in terms of differences in drug 
susceptibility between CQR and CQS parasites (Bray et al., 1996). For instance, parasites 
demonstrating a 4-fold to 5-fold difference in CQ accumulation were found to exhibit a 
10-fold to 20-fold difference in susceptibility (Bray et al., 1996). This shows that CQ 
resistance may be mediated by a reduction in target site sensitivity/affinity or 
accessibility (Dorsey et al., 2001, Bray et al., 1998) 
 
Alternative explanations for the decreased accumulation of CQ in the resistant parasite 
proposes the loss or alteration of a protein involved in the CQ uptake or alteration in the 
intracellular “receptor” (Bray et al., 1998, Hawley et al., 1996, Warhurst et al., 1986, , 
Chou et al., 1980). An amiloride-sensitive Na+/H+ exchanger was proposed to actively 
transport CQ into the FV (Sanchez et al., 1997, Wunsch et al., 1998), and that this 
activity is decreased in CQR parasites. More evidence, however, implicates indirect 
involvement of Na+/H+ in the resistance mechanism (Dorsey et al., 2001) 
 
1.6.1 Drug Molecular Structure and Resistance Mechanisms 
 
It appears that CQ resistance mechanisms recognize the aminoalkyl side of CQ (Egan, 
2001), and this is indicated by the fact that CQ analogues with side chains much shorter 
(2-3 carbon atoms long) or much longer (10-12 carbon atoms long) maintain full activity 
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CQ analogues with chain lengths closer to that of CQ have intermediate activities 
between that of CQ and the fully active compounds. This change of activity has been 
related to the distance between aminoquinoline amine group and the terminal tertiary 
amino group of the side chain (De et al., 1996). To affirm this, amodiaquine which has a 





Figure 1.14: A summary of findings regarding the roles of various substituents on 4-
aminoquinolines with respect to antiplasmodial activity and activity against CQ resistant 
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Even minor alteration of the side chain of 4-amino-7-chloroquinolines restores activity 
against CQR parasites. For example the incorporation of ferrocenyl groups, replacement 
of the ethyl groups with bulky butyl groups or incorporation of additional quinoline 
nucleus to form bisquinolines (Biot 2007, Raynes et al., 1999, Biot, 1997) 
By contrast, changes solely in the aminoquinoline nucleus, only restores activity 
marginally as exemplified by the replacement of the Cl with a Br or I (Vippagunta et al., 
1999; De et al., 1998). Despite this, replacements of Cl with 7-CF3 and the insertion of 3-
CH3 seem to restore some degree of activity (De et al., 1998). Metallation of the 
quinoline N with a variety metals seems to restore activity (Navarro, 2009; Ajibade et al, 
2008, Navarro et al., 1997). Figure 1.14 summarises the effect of modifications of the 
substituents on the activity of quinolines against CQ resistant strains. 
 
This suggests that the aminoalkyl side chain and the quinoline N may be involved in the 
molecular recognition associated with CQ resistance (Egan, 2001) 
 
1.7 Iron Chelators and Malaria 
1.7.1 Iron Loading as a Risk Factor for Malaria 
Clinicians have reported that elevated host iron is a serious risk factor for human malaria 
(Weinberg et al., 2009), for example, during the third trimester of pregnancy, a 9-fold 
increase in the quantity of absorbed dietary iron provides a sufficient amount of the 
growth essential metal to the rapidly developing foetus (Barret et al., 1994) As gestation 
proceeds latent malarial protozoa in pregnant women become active especially in the iron 
rich placenta. This in one way explains why pregnant women are more vulnerable to 
malaria. Indeed during the later half of gestation, women are advised to forego travel to 
malarial regions (Diro and Beydoun, 1982; Bruce-Chwatt, 1983).  
 
In malaria regions, iron loading in non-pregnant persons likewise increases the risk of 
developing malaria. Iron supplements in adults and feeds for children have been observed 
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1.7.2. Iron chelators as antimalarials 
One important strategy for fighting malaria drug resistance is the development of drugs 
with new mechanisms of action. Iron chelators have been proposed as potential 
antimalarial agents because of the central role of iron for the rapid proliferation of the 
malaria parasite and the arrest of parasite growth by iron chelators in vivo and in vitro 
(Cabantchik et al, 1996; Hershko et al, 1991a, b; Heppner et al, 1988; Raventos-Saurez et 
al, 1982). An example is deferiprone (DFP) and desferrioxamine (DFO), (Figure 1.15), 
which have been evaluated in vitro for activity against a chloroquine (CQ) resistant strain 
(FCR-3) and P. berghei in rat models. The activities are shown in Figures 1.16 and 1.17 
respectively (Hershko et al, 1991b). Clinical trials have even been conducted for DFO 




























R' = Me, Et
3,4-Hydroxypyridinones  
Figure 1.15: Some common iron chelators 
 
DF and DFO are used in the treatment of iron overload in β-thalassaemia. DFO, the most 
widely used iron chelator in haematology over the past 30 years, has a major 
disadvantage of being orally inactive, unlike hydroxypyridinones, specifically DFP. 
 
 Hershko and co-workers (1991a) demonstrated that DFP has optimal combination of 
limited toxicity and effective antimalarial activity for in vivo tests in animal models (Fig. 
1.16). This came after studies on the in vitro activities of the 3,4-hydroxypyridinones 
(3,4-HPOs). 3,4-HPOs exhibit a dose-related suppression of P. falciparum growth in 
vitro with IC50 values in the range 5-100 M, (Figure 1.17), when the parasites are 
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Figure 1.17: In vitro activity of 3,4-hydroxypyridinones (Heppner et al., 1988) 
 
It is important to note that iron chelators were initially designed to treat iron overload, 
therefore iron chelation may not achieve a defined role in the treatment of malaria until 
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1.7.3. Sources of Iron for the Malaria Parasite 
 
The intraerythrocytic P. falciparum degrades haemoglobin for nutrition (amino acids, 
probably for iron) and to create space for itself (Ginsburg et al, 1990; Sherman et al, 
1977, Francis et al, 1997; Kolakovich et al, 1997). The haem liberated by the proteolysis 
of haemoglobin is crystallized in the parasite food vacuole to form the non toxic 
haemozoin and the process is probably lipid mediated (Egan et al 2006, Slater et al, 
1992).  
 
How the intraerythrocytic phase parasite acquires iron has not been determined. 
However, several possible sources have been postulated, these include plasma transferin 
bound iron (Pollack et al, 1988a; 1984, Van Zyl et al, 1993); iron derived from red blood 
cell host ferritin (Gabay et al, 1993, Cazzola et al, 1983); Iron liberated from catabolism 
of host haemoglobin in the food vacuole of the parasite (Gamboa de Dominguez et al, 
1966, Francis 1997, Kolakovich et al, 1997) and labile intraerythrocytic iron pool 
(Hershko et al, 1988). Studies show that labile iron pools of the host red blood cells may 
be either utilized or stored during plasmodial growth (Loyevsky et al, 1999). This is 
because parasitized erythrocytes have lower concentrations of iron than normal 
erythrocytes.  
 
Abrogation of the labile iron by the introduction of iron chelators into the cytoplasm of 
the erythrocyte but not into the parasite compartment did not result in growth inhibition 
of the parasite (Loyevsky et al, 1993b, Scott et al, 1990). It is possible that both the host 
labile iron and another source such as the haemoglobin iron are used by the parasite and 
the abrogation of only one source of iron will not prevent parasite growth (Loyevsky and 
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1.7.4 Mechanisms of Antimalarial Activity of Iron Chelators 
 
Several classes of iron chelators have been shown to suppress the growth of the malaria 
parasite P. falciparum. The antimalarial iron chelators are classified into two broad 
groups based on the mode of activity.  
 
The first group consists of iron chelators that act by withholding iron from the plasmodial 
metabolic pathways. They include hydroxamate siderophores and derivatives; (Loyevsky 
et al, 1993, Fritsch et al, 1987) 3,4-hydroxypyridinones (α-ketohydroxypyridinones) 
(Heppner et al, 1988) catecholamide and catecholate siderophores; dihydroxycoumarins; 
polyanionic amines; acylhydrazones; aminothiols; aminophenols and bis-cyclic imides 
(Loyevsky and Gorduek 2001).The inhibitory action of these compounds on malaria 
cultures is fully abrogated upon pre-complexation with iron.  
 
The second class of antimalarial iron chelators acts by forming toxic complexes with 
iron. They include 2‟,2-bipyridyls (Loyevsky et al.,1999) and 8-hydroxyquinolines and 
alkylthiocarbamates (Scheibel et al, 1989) and certain aminophenols (Ocheskey et al, 
2005, Loyevsky et al, 1999).  The inhibitory effect of this class of chelators cannot be 
abrogated by precomplexation with iron before addition to the cultures (Loyevsky and 
Gorduek 2001). 
 
Since the utilization of identified scaffolds does not necessarily depend on prior 
knowledge of action or the biological target of the drug from which the scaffold is 
derived (Biot and Chibale, 2006), iron chelators still have a great potential for 
development into antimalarial drugs. 
 
The degree of antimalarial activity of iron chelators correlates with the degree of 
lipophilicity (ability to cross cell membranes) of the compound (Cabantichik et al, 1996, 
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hydrophilicity balance in this type of molecule is important for the effective 
transportation of the chelators across the cell bilayer membranes to reach the site of 
action. This has been improved by the use of certain metal (III) complexes of the 
chelators (Ocheskey et al, 2005). Lipophilicity has also been identified as an important 
factor in antimalarial drug resistance (Chibale, 2002) 
 
Iron withholding may cause the malfunction of certain enzymes for which iron is 
indispensable. These enzymes include those involved in DNA synthesis (ribonucleotide 
reductase); pyridine synthesis (dihydoorotate dehydrogenase); CO2 fixation (phosphoenol 
pyruvate carboxykinase); haem synthesis (delta- aminolevulinate synthase) and 
mitochondrial electron transport (cytochrome oxidase, cytochrome b) (Loyevsky and 
Gorduek 2001). Thus antimalarial iron chelators may affect the host or the parasite by 
interacting with the iron dependent enzymes. 
1.7.5. Physical Properties that Affect the Antimalarial Activity of Iron Chelators 
 
The site of action of iron chelators is in the parasitic compartment of the infected red 
blood cell (Scott et al, 1990, Hershko et al, 1988, Loyevsky et al, 1993). An effective 
iron chelator therefore must be lipophilic, have high affinity for iron and have selectivity 
for iron versus other cations and have an effective number of coordination sites.  
 
Lipophilicity directly correlates to the chelator‟s inhibitory action against malaria as 
demonstrated for reversed sidereophores, N-alkyl derivatives of 3,4-hydroxypyridinones 
and aminothiols (Shanzer et al, 1991, Hershko et al,  1991, Loyevsky et al, 1996). The 
3,4-HPOs  iron (III) chelates carry no net charge therefore can penetrate membranes 
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Maltol                                              Ethylmaltol  
Figure 1.18: Synthetic precursors of 3,4-HPOs 
 
Selectivity for iron versus other cations is important because (1) P. falciparum has 
limited capability to recover after deprivation compared to mammalian cells (Cabantchik 
1995). Hence it is reasonable to target iron as compared to other essential metals for 
which the ability to recover from deprivation has not been studied. (2) Removal by iron 
chelators of the other essential biometals (zinc, calcium and magnesium) may be 
detrimental for the mammalian host as well. In this regard the hydroxamate siderophores 
have a favourable profile because their affinity for iron is at least one order of magnitude 
higher than for calcium (Lytton 1994). The synthetic precursor of 3,4-
hydroxypyridinones, maltol (Fig 1.18), has an affinity for zinc, and there are studies 
under way to develop it for diabetes therapy as a vanadium complex (Sakurai and Adachi 
2005). However, this does not rule out the suitability of these compounds as antimalarial 
iron chelators because the iron affinity constants of antimalarial iron chelators are in the 
range 1024 to 1038, with the 3,4-HPOs and 8-hydroxyquinolines having the highest 
affinities of 1036 and 1038 respectively (Gorduek and Loyevsky 2001) 
 
1.7.6. DFP and DFO in Antimalarial Clinical Trials 
 
Clinical trials have been conducted in Zambia on subjects with asymptomatic P. 
falciparum parasitemia using DFP (Thuma et al., 1998). No reduction in asexual 
intraerythrocytic parasites was observed during or after DFP treatment. The failure was 
attributable to short plasma half life and short time taken to reach plasma peak. The 
remedy could have been prolonged use, but this resulted in neutropenia and other side 
effects. Neutropenia is abnormal low count of the type of white blood cells responsible 
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success was recorded in that DFO treatment significantly enhanced the rate of parasite 
clearance. 
 
In symptomatic uncomplicated P. falciparum and P. vivax malaria, DFO as a single agent 
was administered continuosly for 3 days at 100 mg/kg/d, i.v, parasitemia reduced to zero 
after 57 h and 105 h for the falciparum and vivax groups respectively. However, 
recrudescence was observed and the study failed to achieve radical cure (Gorduek et al, 
1992b). The addition of DFO to standard antimalarial drugs (sulfadoxine-pyrimethamine 
or quinine) shortened the rate of clearance of parasitemia and the recovery to full 
consciousness in children with deep coma by about two fold. Further clinical studies in 
which DFO was added to quinine in a regimen that included a loading dose of quinine 
were conducted (Gorduek et al, 1992a). Surprisingly this yielded negative results (higher 
mortality rates and poor parasite clearance were recorded). 
  
Combination of 3,4-HPOs with standard antimalarials (chloroquine, mefloquine, 
artesunate, tetracycline, atovaquone) showed addition or mild antagonism and this is 
similar to what has been reported about combinations involving DFO and other iron 
chelators (Pattanapanyasat et al,, 2001, Loyevsky and Gorduek 2001). Combination 
therapies of artemisinins and iron chelators including 3,4-HPOs have been unsuccessful 
because of antagonism. Meshnick et al., 1993 showed that there is specific need for iron 
(III) in addition to haem (III) or free iron (III) to activate artemisinins and it is assumed 
that iron chelators interfere with this process (Weinberg et al., 2009). 
 
DFO, desferrithiocin and dexrazoxane were reported to inhibit growth of exoerythrocytic 
hepatic phases of P. falciparum and P. yoelii (Loyevsky et al, 1991, Stahel et al, 1988). 
This demonstrated that iron chelators represent a potential antimalarial strategy with 
effectiveness against blood and liver phases of the parasite. In addition prodrugs of iron 
chelators have been found to be effective in hepatic activity (Loyevsky and Gorduek 
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1.7.7. Suitability of 3,4-HPOs for Antimalarial Chemotherapy 
 
In addition to thalasaemia treatment, 3,4-HPOs have been investigated for a variety 
medicinal applications; enzyme inhibitors, cell probes and labelling (Ellis 1996, 
Loyevsky et al, 1999b), HIV treatment (Barral et al, 2006), antidiabetic therapy 
(Thompson et al, 2003), aluminium detoxification (Amelia-Santos et al, 2005), 
antioxidants (Bebbington et al, 2002), imaging agents and diagnostics (Thompson et al, 
2006), removal of excess metal irons in neurodegenerative diseases i.e. Parkinsons and 
Alzheimers diseases (Bebbington et al, 2002; 2000). 
 
There are a number of reasons why 3,4-HPOs stand a better chance of being developed to 
better antimalarial agents. The 3,4-hydroxypyridinones are neutral bidentate ligands with 
high affinity for ferric iron and they form stable iron complexes. For instance DFP iron 
complexes have a stability constant = 37, which is six orders of magnitude higher than 
that of DFO (Loyevsky and Gorduek 2001). Therefore, 3,4-HPOS may effectively 
sequestrate iron from the parasite. 
 
These small ligands have a clear advantage over larger hexadentate ligands (eg DFO) 
with respect to oral bioavailability. Though DFO has been in use in haematology for the 
past 30 years, it has a disadvantage of being orally inactive as already mentioned (Liu et 
al, 2000).  
 
In combination therapy clinical studies where iron chelators were used to arrest microbial 
growth and cancer, DFO acted as a siderophore for the growth of invading cells instead 
of assisting the host cells. It was observed that DFO promoted the growth of Yersinia (a 
rare intestinal bacterial infection) and Mucormycosis (fungal infection of the brain, 
sinuses, lungs common in patients with immune disorder eg HIV-AIDS), 
(Kontoghiorghes et al., 2004). In contrast DFP and related derivatives did not appear to 
assist the growth of these or related bacteria or fungal strains at the doses used for 
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3,4-HPOs do not inhibit haem containing enzymes or iron sulfhur cluster proteins but  do 
interfere with enzymes containing mono-iron and bis-iron centres coordinated to oxygen 
ligands including lipoxygenases and aromatic amino acid hydroxylases (Liu et al, 2002). 
More lipophilic HPOs are better enzyme inhibitors (Kayyali et al, 1997, Hider et al, 
1989). Hence they may be used against targets in P. falciparum eg proteases. 
 
1.7.8. Metal Complexes for Antimalarial Chemotherapy 
 
Metal (III) as well as metal (II) complexes have been studied for various 
chemotherapeutic uses. Metal complexes have been successfully used in cancer 
chemotherapy. However, little attention has been paid so far to their uses in the treatment 
in tropical diseases (Sanchez et al, 2004).  
 
Zinc (II) metal complexes of DFO are known to result in increased in vivo activity of 
DFO due to transmetallation reactions with iron (III) and enhanced membrane 
permeation, (Chevion et al, 1995). Chloroquine-metal complexes of ruthenium and gold 
have been studied as well (Sharma et al, 1999; Ajibade et al, 2008, Navarro et al., 1997) 
and have been shown to have improved activity against chloroquine resistant strains. It 
has been postulated that high valent iron-oxo species may mediate the molecular 
mechanism of action of artemisinin (Posner et al, 1995). 
 
A number of antimalarial aminophenol metal (III) complexes of gallium, iron, and 
aluminium have been synthesized (Goldberg et al, 1997, Ocheskey et al, 2005; 2003, 
Sharma et al, 1997), to enhance activity of antimalarial aminophenols (Fig. 1.19). The 
gallium complexes were found to be selectively toxic against the CQ-resistant strain Dd2 
in a verapamil insensitive manner but less active against the sensitive strains HB3 
(Goldberg et al, 1997) in the nanomolar range. Incorporation of quinoline into the 
aromatic part of the organic scaffold of these complexes resulted in increased activity 
against the sensitive strain (>33 fold) but an insignificant effect on the potency against 
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inhibition of haemozoin formation. These iron chelators contain the N4O2 donor core and 
the gallium complexes are thought to have increased membrane permeability (Ocheskey 
et al, 2003). Some inactive metal complexes have been reported to have enhanced 
activity against resistant strains as well as sensitive strains when coupled to quinolines. 
For example ferrocene is known to be stable, non-toxic but inactive on its own. However, 
when linked with a CQ-like nucleus (Fig. 1.19), the hybrid molecule acts against resistant 
parasites (Biot C., et. al., 2006; Beagley et. al., 2003). Metal porphyrins have been shown 
to have a synergistic effect on artemisinins and the mechanism is via haem binding 
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Figure 1.19.  Structures of some antimalarial aminophenol iron (III) and gallium (III) 
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1.7.9. HPO Metal Complexes in Medicinal Chemistry 
 
Heppner et al 1988, showed that pre-formation of HPO-iron complexes completely 
obliterates the antimalarial activity of this type of iron chelator. No studies have been 
performed on antimalarial activities of 3,4-HPO-metal (III) complexes of other metals, 
nor the coupling of these complexes to standard antimalarial molecules to form „covalent 
bitherapies. However a lot of work has been conducted on HPO metal (III) complexes for 
other medicinal chemistry applications (Thompson et al, 2006). 
 
Maltol, the synthetic precursor of a number of 3,4-HPOs and its analogs have high 
affinity for a variety of metal ions ie trivalent ions of Al, Fe, Ga, and In, and the divalent 
ions of Zn, Ru, [VO]2+, [MoO2 ] 2+. Hence these ligands are used in applications that 
involve removal of excess metal ions while their complexes are used in absorption or 

























Figure 1.20: Geometry of the 3,4-HPO metal (III) complexes 
 
The metal complexes of 3,4-HPOs are neutral and stable and form extensive hydrogen 
bonding with water and amines and with compounds with hydroxyl and ketone 
functionalities. Also the ligands are non toxic and the high affinity for iron is desirable 
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usually assume a distorted octahedral geometry (Fig. 1.20), with all the six chelating O 
atoms hydrogen bonded to 3H2O molecules by a three-fold axis ie (ML3). 3H2O; M = Fe, 
Ga, Al (Thompson et al 2006, Xiao et al, 1992). 
3,4-HPOs tend to be insoluble in water. Their aqueous solubility is several hundred fold 
enhanced at the physiologically relevant temperature of 37 oC.  In addition under 
physiological conditions, they presented highest affinity for the hard trivalent metal ions 
of group 13 (Thompson et al 2006) and are resistant to acid catalysed and enzyme 
catalysed cleavage (Amelia-Santos et al 2004).The functionalizable ring nitrogen allows 
variation of lipophilicity without the sacrifice of thermodynamic stability of the 
complexes (Thompson et al 2006). Substitution at C-2 has an effect on iron affinity and 
bioavailability as seen in the enhancement of the two properties of 2-amido substituted 
3,4-HPOs. Also this modification affects enzyme inhibition as mentioned earlier. 
Therefore, the role of side chain modification is to tune physicochemical properties like 
molecular weight, hydrophilicity-lipophilicity balance and to improve interactions with 
biological receptors (Thompson et al 2004). 
 
Novartis has produced a range of bidentate HPO ligands, which possess an aromatic 
substitutent at the 2-position (Liu et al 2001). The aromatic ring is reported to stabilize 
the resulting iron complex (Liu et al 2001). The 1‟-hydroxyalkyl groups on the ring N in 
the Novartis HPO ligands enhances the stability of iron complexes formed in vivo via 
intramolecular hydrogen bonding (Liu et al 2001).  
 
The deferiprone iron complex was found to exchange its iron with apotransferrin and 
other proteins of iron metabolism much more readily than the DFO iron complex. Thus 
the physiological processes involving iron containing proteins may be affected by 
chelating drugs and their complexes (Kontoghiorghes et al 2004). However the extent of 
effect depends on many factors such as affinity for iron, iron accessibility, the form of 
interaction, the rate of reaction and the concentration of the chelator or its iron complex at 
the site where the enzyme or protein resides (Kontoghiorghes et al 2004). Possibly the 
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1.7.10. Hydroxypyridinone Hybrid Molecules 
 
Multitherapies associating long acting and short acting compounds with different modes 
of action potentially offer efficient treatment though they tend to be expensive (Biot and 
Chibale, 2006). Other multitherapies combine two or more biological characteristics in 
one hybrid molecule. For instance Bebbington and co-workers (2000) synthesized 
antioxidant-3,4-HPO hybrid molecules (Fig. 1.21), the purpose of which was to bestow 
more lipophilicity to the iron chelators as well as counteract the formation of reactive 








L =  CH2,  S,  CH2CH2
R =  tert Bu, OMe
 
Figure 1.21: 3,4-HPOs-antioxidant hybrid molecules 
It has been verified that hybrid molecules have higher activity than the dual 
administration of the constituent molecules (Bebbington et al., 2000).  
 
1.8 Catecholate Siderophores 
 
Siderophores are compounds produced by bacteria, fungi and graminaceaous plants for 
scavenging iron from the environment (Hider and Xiaole, 2010). Catecholate 
siderophores are considered of importance herein because they are bioisoteres of 3,4-
hydroxypyridinones (Von Kohler et al., 1970; Von Wallensfels, 1966). Although iron 
chelators have antimalarial activity, all have been developed more specifically either for 
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unique in that they have been developed specifically for their antimalarial activity and 











Figure 1.22: FR160 First iron chelator specifically developed with antimalarial 
properties. 
One of the compounds referred to as FR160  (Fig 1.22), was 7-60 times more potent than 
CQ against CQR and CQS strains of P. falciparum (Hammadi et al., 2003; Pradines et 
al., 1996). When FR160 was incubated with iron (III) chloride, its antimalarial activity 
was suppressed, while no effect was observed with the incubation of FR160 with copper 
(II) sulphate nor zinc (II) sulphate, suggesting that iron deprivation may be the main 
mechanism of action of FR160 against malarial parasites (Weinberg et al., 2009). FR160 
was found to affect the trophozoite stage of the parasite. This suggests that it acts 
presumably by inhibition of ribonucleotide reductase and inhibition of DNA synthesis as 
was previously suggested for other antimalarial iron (III) chelators (Pradines et al., 1996).   
 
Mono and tris acylated catecholates were investigated for antimalarial activity and were 
found to be more active than DFO and its derivatives (Rotheneder et al., 2002). The 
acylated catecholates were found to be more lipophilic than the free catecholates, and the 
former were assumed to be cleaved by esterases before iron chelation.  An example of 
































Figure 1.23:  Examples of mono and tris-catecholate compounds 
The antiparasitic effect of most of the triscatecholates was reversed by low concentrations 
of Fe (III) salts, suggesting that their antiparasitic effect maybe due to the iron 
abrogation. In contrast, the toxicity towards P. falciparum exerted by most 
monocatecholate compounds was not affected by exogenous ir n salts. This indicated 
that the antiplasmodial effect was independent of chelation of intracellular iron and 
instead could be via other mechanisms like inhibition of parasitic enzymes or interference 
with iron release from haem (Weinberg et al., 2009). 
 
1.8.1 Siderophore Antibiotics or Sideromycins 
 
Sideromycins are natural products in which the antibiotic component is covalently 
attached to a siderophore (Hider and Xiaole, 2010). These compounds are actively 
transported into bacteria and they have the effect of lowering the minimum inhibitory 
concentration (MIC) of the antibiotic by more than 100-fold.  The sideromycins were 
discovered simultaneously with hydroxamate siderophores, with ferrimycin (Figure 1.24) 
being the first to be reported in 1960 and was isolated from Streptomyces grieso-flavus 
(Gross et al., 1992; Bicket, 1960).  Ferrimycin A consists of ferrioxamine B linked via a 
bridging aminohydroxy benzoic acid, to an iminoester substituted lactam. Siderophores 
that are structurally related to ferrimycin, ie salymycin A, danomycins A and B and 
succinimycin exclusively inhibit Gram positive bacteria and gain access into the cells via 





































































Compound 1:  X=O Compound 2:  X= N NH2
O
Compound 3:  X = NH
albomycins
 
Figure 1.24: Ferrimycin and albomycins; (compound 1= albomycin δ1 , compound 2= 
albomycin δ2,  compound 3 = albomycin ε1) 
 
Albomycin is another iron containing antibiotic from Streptomyces species and has 
activity against Gram negative organisms unlike the ferrimycin group (Fig. 1.24). The 
albomycin-like siderophores (eg albomycin δ1, albomycin δ2, albomycin and albomycin 
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1.8.2 Siderophore Based Double Drugs 
 
On the basis of the properties of the sideromycins a range of siderophore drug conjugates 
have been designed and synthesised and the design was based on the template in Figure 
1.25 (Miller et al., 1993; Mollmann et al., 2009). The double drug was designed to act by 
dual mechanism i.e. iron chelation or deprivation and by the mode action similar to the 
attached drug moiety (chloroquinolinyl). Assuming a „Trojan horse‟ mechanism (Braun 
et al., 2009; Mollmann et al., 2009; Heinisch et al., 2002) then the siderophore group will 
enhance the uptake or transport of the attached drug across the microbial cell membrane 


































siderophore based double drug
 
Figure 1.25: Siderophore based double drug template and structures of 
sulphanilamidonicotinic acid and Ferricrocin. 
 
Initially sulfonamides were prepared by attaching sulfanilamidonicotinic acid to either 
DFO (Ferrioxamine B) or Ferricrocin, the resulting conjugates were found to be active 
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siderophore-β-lactam conjugates has been reported and has involved coupling of β-
lactams to hexadentate, tetradentate and bidentate iron (III) chelating ligands and out of 
these the biscatecholate conjugates were found to be potent (Miller et al., 1993; 
Watanabe et al., 1987; Imap et al., 1993; Miller et al., 1989). The structure of one of the 
dichatecholates is shown below (Fig. 1.25).  Mutant bacteria were found to lack 
hydroxamate and catechol receptors required for the uptake of drugs-siderophores and 
siderophores, and it is clear that conjugation promoted the transport of the antibiotics 



































Figure 1.26: β-lactam-dicatecholato and DFO-nalidixic acid drug conjugates 
 
The fundamental challenge associated with this approach is that most pathogenic 
organisms possess multiple routes for iron uptake, and the higher the number of genes 
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1.8.3 Antimalarial Siderophore Drug Conjugates 
 
A conjugate was prepared by coupling desferal/ferrioxamine (DFO) an antimalarial 
siderophore to nalidixic acid a DNA intercalator as illustrated in Figure 1.26 above, 
(Ghosh et al., ., 1995) The conjugate was found to have antimalarial activity against 
multidrug resistant strains of P .falciparum D6 and N2 (IC50 =0.6µg/mL for both strains). 
It was assumed that the conjugate killed the parasite via DNA intercalation (Hider et al., 
., 1997; Roosenberg II et al., 2000) 
 
1.9 ADMET Properties: Absorption, Distribution Excretion and Toxicity. 
 
After administration, a drug undergoes adsorption, distribution, metabolism and finally 



















Figure 1.27: Fate of a Drug (Adopted from Evans and Relling, 1999) 
 
Studies in the 1990s show that poor pharmacokinetics and toxicity (PK-Tox), were the 
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Waterbeemd and Gifford, 2003). It is therefore important to consider the PK-Tox as early 
as possible in the drug discovery process.  
 
ADMET data may be obtained from in vitro assays, in silico models and from predictive 
models. The ADMET data helps to inform whether to continue with synthesis or not and 
whether to modify the compounds to optimize its properties before proceeding to clinical 
studies. 
An orally administered drug will first dissolve in the gastrointestinal tract, and then will 
be absorbed through the gut wall passing the liver to get into the blood circulation. The 
percentage of the dose reaching circulation is referred to as its bioavailability (Fig. 1.28). 
The systemic circulation will distribute the drug to various tissues and organs. The extent 
of distribution will depend on the structure and physicochemical characteristics of the 
compound. Finally the drug will bind to its molecular target eg a receptor or ion channel 
and exert the desired effect (Evans and Riley, 1999). Alternatively it may bind to 
undesired sites and cause toxicity. 
 
 
                  
 
Figure 1.28: The path of an orally administered drug and processes in respective organs 
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1.9.1 Drug Physicochemical Properties that Affect ADMET 
1 1.9.1.Lipophilicity 
 
The gold standard for expressing lipophilicity is the partition coefficient P or log P in the 
octanol/water system. The calculated or predicted partition coefficient (cLog P) depends 
on molecular size/weight, polarity and hydrogen bonding. Poor aqueous solubility and 
slow dissolution rate can lead to poor oral absorption hence low oral bioavailability. In 
general poor solubility is related to high lipophilicity i.e.. high log P or clog P. 
Hydrophilic compounds (highly soluble compound) generally have poor permeability and 
thus low absorption.  It is clear that solubility and lipophilicity as well as ionization 
constant, pKa, affect permeability and absorption of a drug (Fig 1.29). A moderate log P 
(0-3) is desirable for good gastrointestinal absorption or for good oral bioavailability (Di 
and Kerns, 2008). Calculated or predicted log P values can be obtained by use of 




Figure 1.29: Relationships between some physicochemical and ADMET properties 
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1.9.1.2. Distribution Coefficient Log D 
 
Distribution coefficient is determined experimentally at pH 7.4 (blood pH) or pH 6.5 
(intestinal pH). It often provides a more meaningful description of lipophilicity especially 
for ionizable compounds. Log D affects clearance and volume of distribution of a drug 
which influence plasma half life (Fig 1.29). Programs that can reliably predict log D are 




Low solubility is detrimental to good oral absorption, so early measurement of solubility 
is important in drug discovery especially for antimalarials. The main experimental 
measurements rely on turbidimetry and nephelometry (Di and Kerns 2008). Solubility 
can be improved by preparation of salts or by structural modification. The structural 
modifications may involve inclusion of polar groups, decreasing the molecular weight, 
increasing the hydrogen bonding capability, increasing the ionizability and incorporating 
structures that will decrease crystal stacking (Di and Kerns, 2008). 
 
1.9.1.4 Ionizability (pKa) 
 
Ionizability or pKa is the negative log of the ionization or dissociation constant of a 
compound. A majority of drugs contain ionisable groups and ionization of a drug is 
known to affect its solubility, lipophilicity, permeability and absorption. It can be 
determined experimentally or by use of computer programs. 
 
1.9.1.5. Hydrogen Bonding  
 
The hydrogen bonding capacity is a determinant of permeability. In order to cross cell 
membranes a drug molecule needs to break hydrogen bonds within its aqueous 
environment. The more potential hydrogen bonding a molecule can make the more 
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permeability and poor absorption. Computational methods have been used to determine 
hydrogen bonding capacity ie by counting the hydrogen bond acceptors and donors and 




Permeability of compounds through the Caco-2 cells is used to model for human 
intestinal absorption. This is referred to as membrane quantitative structure activity 
relationship MI-QSAR (Kulkami et al., 2002). Hence permeability helps predict the 
degree of absorption after oral administration. A drug must be sufficiently permeable 
through the biological membranes present in order to enter the systemic circulation. 
 
1.9.2 ADMET Properties 
 
The ADMET properties are closely related or dependent upon the physicochemical 
properties of a drug (Fig. 1.30). Several researchers have used physicochemical 
properties to predict ADMET properties, notable examples are Lipinski (1997; 2004) and 
Gleeson (2008). 
 
1.9.2.1. Absorption  
 
Lipinski and coworkers formulated minimum physicochemical requirements for orally 
bioavailable drugs. The Lipinski rule of 5 which was derived from a database of clinical 
candidates reaching phase II trials identifies several critical properties that should be 
considered for compounds meant for oral administration, sometimes these rules are 
referred to as the drug-like properties (Di and Kerns, 2008). These guidelines are 
molecular weight < 500 daltons (Da), calculated octanol/water partition coefficient 
(clogP) < 5, number of hydrogen bond acceptors < 10 and number of hydrogen bond 
donors < 5 (Lipinski, 1997; Lipinski et al., 2004). Drugs that do not comply often have 
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1.9.2.2. Distribution or Promiscuity 
 
Distribution of a drug in the organism depends largely on lipophilicity ie log P. It is 
known that log P influences drug potency, pharmacokinetics and toxicity (Leeson and 
Springthorpe, 2007). If lipophilicity is too high there is an increased likelihood of binding 
to multiple targets and resultant pharmacologically based toxicity as well as poor 
solubility and metabolic clearance. The risk of unwanted pharmacology increases with 
lipophilicity and is dependent on ionization class (Azzaoui et al., 1997). However, 
promiscuity becomes less important if the selectivity for the desired target is high. 
Distribution can be measured by the volume of distribution VD which together with the 




The rate and extent of metabolism (turn over), the enzymes involved and the products 
formed are the main concerns when one refers to drug metabolism. The extent and rate of 
metabolism affects clearance whereas the involvement of a particular enzyme might lead 
to issues related to the polymorphic nature of some enzymes and to drug-drug 
interactions, (DDIs) (Van de Waterbeemd and Gifford, 2003). DDIs are possible when 
CYP induction or inhibition occur when drugs are co-administered. CYP induction 
increases metabolism of one of the drugs while CYP inhibition slows down the 
metabolism of one of the drugs (Zhou, 2008). 
 
Compounds with good solubility and permeability may have low oral bioavailability if 
the in vivo plasma/blood clearance is too high (Gleeson, 2008). In vivo clearance affects 
the half life of the compound and in turn the latter together with VD affects the dosing 
regimen. Clearance is via hepatic, renal and bilary processes and is considered to be the 
most difficult ADMET process to predict because it strongly depends on structural 
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In silico approaches have an increasingly important role as alternatives to in vitro 
metabolic studies. The in silico tools for predicting metabolism can be divided into 
QSAR and 3D-QSAR studies, protein pharmacophore models (eg AutoDock and 
MetaSite programs) and predictive databases eg Volsurf (Ekins et al., 2000, 2001, 2003, 
2007; De Groot et al., 1999). Early prediction of the vulnerability of metabolism of 
certain positions in the molecule might help to eliminate molecular liabilities and this is 
possible with programs like MetaSite.  
 
1.9.2.4. Toxicity  
 
Toxicity is responsible for many compounds failing to reach the market and for the 
withdrawal of a significant number of compounds from the market once they have been 
approved (Waterbeemd and Gifford, 2003). In vitro assays to determine toxicity include 
DDIs (due to CYP inhibition), hERG channel blocking, mutagenicity/genotoxicity, 
cytotoxicity, teratogenicity, selectivity and reactivity screens (Di and Kerns, 2008). 
 
 A number of in silico toxicity methods are in use and are broadly classified into two. 
First are knowledge based expert systems. These methods use expert systems that derive 
models on the basis of abstracting and codifying knowledge from human experts and 
scientific literature (Di and Kerns, 2008; Van de Waterbeemd and Gifford, 2003). Second 
are the statistically based in silico toxicity methods which rely on the generation of 
descriptors of chemical structures and statistical analysis of the relationships between 
these descriptors and the toxicological endpoint (Di and Kerns, 2008; Waterbeemd and 
Gifford, 2003). 
 
1.9.2.5. Drug-Drug Interactions  
 
Patients often receive several medications at the same time and if the drugs involved 
compete for the same enzymes to be metabolized or if the same transporters are involved 
in transporting the drugs across the membranes, this can lead to undesired effects with 
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using the victim perpetrator concept. One drug (the perpetrator) binds to the isozyme and 
the other drug (the victim) is excluded from metabolism, thus increasing toxic 
concentrations. A major cause of DDI is CYP3A4 inhibition. 
 
1.9.3. CYP3A4 Inhibition 
 
CYP3A4 belongs to the superfamily of P450 enzymes (CYPs) that is involved in the 
metabolism of endogenous and exogenous substrates in living organisms. They control 
oxidative metabolism clearance of drug molecules and other xenobiotics (Mao et al., 
2006). CYP3A4 is the predominant metabolic monooxygenase in intestinal and hepatic 
drug metabolism and is involved in clearance of more than 50% of all marketed drugs 
(Egan et al., 2004; Guengerich, 1997). The liver is frequently the target of toxic 
chemicals and since it lies between the portal and systemic circulation the liver will 
receive drugs entering via the portal system during oral absorption (Yan et al., 2001)  
 
To date the identified clinically important CYP3A4 inhibitors include macrolide 
antibiotics, anti-HIV agents, antidepressants, calcium channel blockers, steroids and their 
modulators and several herbal and dietary components (Zhou, 2008). Structural features 
associated with CYP3A4 inhibition are illustrated in Figure 1.30 and they include 
terminal olefins and acetylenes, quinolines, amines, hydrazines, hydrazones and 
methylene dioxy phenyls (Zlokarnik et al., 2005; Riley and Kenna, 2004).  
 
The large variety of structurally diverse drugs that are metabolized by CYP3A4 suggests 
a broad enzyme binding pocket (and thus a broad range of possible intermolecular 
interactions) for this enzyme (Mao, 2006). The non competitive inhibition of CYP3A4 
shows that multiple substrates or inhibitors can bind simultaneously in the enzyme pocket 
(Mao, 2006) and experimental and modeling evidence supports this (Ekins et al., 2003; 









































Figure 1.31: Crystal structures of erythromycin bound in CYP3A4 (Ekroos and Sjogren, 
2006) 
Recently the 3D structure of CYP3A4 has been determined by X-ray crystallography and 
it has been confirmed that a large binding site exists near the haem (Sevrioukova and 
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1.31 show the crystal structures of erythromycin bound in the CYP3A4; note the large 
binding pocket in the haem‟s vicinity 
 
P450s are known to contain a ferriprotoporphyrin IX (haem) prosthetic group and a 
polypeptide encoded by a single gene. The haem moiety acts as an oxidation reaction 
centre and the apoprotein determines the substrates specificity and the binding affinity of 
individual isozymes (Yan et al., 2001). In the hepatic microsomal membrane, the haem is 
in the ferric form Fe3+  and functions as an electron pair acceptor in oxidation reactions. 
Although CYPs have been detected in various tissues, the hepatic CYPs play the most 





                            A                                                                   B 
Figure 1.32: (A) Model of the Binding pocket of CYP3A4 (B) Sketch of the three putative 
parts of the active site (Tanaka et al., 2004) 
 
Experimental evidence shows that there are two substrate binding sub-pockets and one 
effector binding region in the CYP3A4 active site (Domanski et al., 2001). These sub-
pockets may be described as two distal binding sites and one proximal binding site with 
respect to the active site see Figure 1.32, (Tanaka, et al., 2004), Hydrogen bonding and 
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residues include Phe 108, Leu 210, Leu 211, Phe 241, Ile 301, Phe 304 while the polar 
pocket residues include Arg 106, Arg 372 and Glu 374 among others (Sevrioukova and 
Poulos, 2010; Ekroos and Sjogren., 2006; Tanaka et al., 2004). 
 
A growing body of evidence shows that the interactions between CYP3A4 and its 
substrates and inhibitors are complex (Yan et al., 2000). Atypical kinetic profiles 
(Kronbach et al., 1989), positive cooperativity (Ueng et al., 1997), and multiple apparent 
Km values (Bloomer et al., 1997) as well as substantial probe-substrate dependent 
qualitative and quantitative differences in the extent of inhibition of CYP3A4 have been 
reported (Kenworthy et al., 1999; Wang et al., 2000).  
 
The classical approach for in vitro P450 inhibition analysis is to use a drug as a probe 
substrate and measure inhibition over a range of substrate and inhibitor concentrations 
(Stresser et al., 2000). To reduce attrition of otherwise promising lead candidates due to 
toxicity liabilities from DDIs, in vitro screening tests of new chemical entities (NCEs) for 
the inhibition of drug metabolizing CYPs is important (Mao et al., 2006) 
 
In silico tools have been used to predict binding modes, sites of metabolism and affinities 
of NCEs in CYPs.  Docking techniques are increasingly used to support lead optimization 
efforts (Kitchen, 2004). Accurate predictions of binding affinities critically depend on 
finding correct binding conformations (Verdonk, 2006), thus docking programs need to 
produce reliable binding modes to obtain good enrichment in virtual screening 
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1.10 OBJECTIVES 
 
To identify novel antimalarial 4-aminoquinoline-3,4-hydroxypyridinone hybrid 
compounds with in vitro and in vivo potency 
To elucidate the mechanism of action with respect to haemozoin inhibition in P. 
falciparum 
 
1.11 HYPOTHESES  
Is it possible to enhance the in vitro and in vivo antimalarial activity of 3-hydroxypyridin-




2. Synthesis and studies of 3,4-HPOs as antimalarial inhibitors of haemozoin 
formation. 
3. Synthesis of hybrid structures of 3,4-HPOs with 4-aminoquinolines. 
4. Screening of the synthesized compounds for biological activity: in vitro and in 
vivo antimalarial activity, β-haematin inhibition and toxicity. 
1.13 JUSTIFICATION 
 
The resistance of P. falciparum to standard antimalarial drugs is still a problem hence the 
necessary search for new drugs with different or better modes of action. Most of the 
current antimalarial iron chelators (HPOs) were designed to treat iron overload and not 
malaria, hence the need to design and synthesize antimalarial. 3,4-HPOs that act by other 
mechanisms in addition to abrogation of iron from the intraerythrocytic parasite. 3,4-
HPO-quinoline hybrid molecules have not been synthesized nor studied as potential 
antimalarials. Synthesis and antimalarial evaluation of the hybrids may result in 
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1.14 Why Haemozoin Inhibitors for Antimalarial Therapy? 
 
The haem detoxification pathway of P. falciparum is a particularly attractive drug target 
because (1) It targets the parasites when they are causing the clinical pathologies (2) 
Humans detoxify free haem via the haem oxygenase/biliverdin reductase pathway (which 
is different from the parasites) hence a drug that interferes with haem processing in the 
parasite will not inhibit haem detoxification in humans. (3) Inhibition of haem 
detoxification would lead to a built up of high concentration of toxic free haem inside the 
parasite (Choi et al, 2002).  
 
1.15. Synthetic targets  
A number of known N-alkyl-3, 4-hydroxypyridinones (3,4-HPOs) were targeted for 
synthesis (Table 1.3). The length of the N-alkyl chain varied from one carbon to eight 
carbon atoms. The objective was to establish the baseline antiplasmodial activity of this 
class of compounds prior to conjugation with aminoquinolines or artemisinins. Most of 
the past literature reports gave the the antiplasmodial activity of this type of compounds 
in qualitative terms i.e. percentage inhibitions rather than quantitatively (IC50 values).  
 























1a - 1h 2a - 2h 3a - 3h  








a b c d e f g h 
 
Gallium (III) complexes of the 3,4-HPOs were prepared and these were tested alongside 
the corresponding ligands and their benzylated analogues. The aim was to investigate the 
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complexation on activity against resistant parasites. The most potent compound in the 
series was targeted for antimalarial combination therapy studies together with 
chloroquine or artemisinin to justify hybridization of the 3,4-HPOs and aminoquinolines. 
 








 series  A: R2 = Me;    series AB:  R2 = Et
 
Compound Series n R2 R3 
 
9 A 1 M  Benzyl (Bn) 
9a A 1 Me H 
10 AB 1 Et Bn 
10a AB 1 Et H 
11 A 2 Me Bn 
11a A 2 Me H 
12 AB 2 Et Bn 
12a AB 2 Et H 
13 A 3 Me Bn 
13a A 3 Me H 
13b A 3 Me Me 
14 AB 3 Et Bn 
14a AB 3 Et H 
14b AB 3 Et Me 
15 A 5 Me Bn 
15a A 5 Me H 
15b A 5 Me Me 
16 AB 5 Et Bn 
16a AB 5 Et H 
16b AB 5 Et Me 
 
 
The synergistic antiplasmodial effect of combining compound 2h with chloroquine 
motivated the synthesis of the 4-aminoquinoline-3,4-hydroxypyridinone hybrid 
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incorporated into the hydroxypyridinone via a Michael addition reaction making the 
targets retain the 3,4-HPO scaffold.  
 









series R:  R = Me
 series D:  R = Cyclopropyl
 
Compound Series n R R‟ R5 
 
23 R 1 Me H Benzyl(Bn) 
23a R 1 Me H H 
24 R 2 Me H Bn 
24a R 2 Me H H 
25 R 2 Me Me Bn 
25a R 2 Me Me H 
26 R 3 Me H Bn 
26a R 3 Me H H 
27 R 5 Me H Bn 
27a R 5 Me H H 
      
28 D 1 cyclopropyl H Bn 
28a D 1 cyclopropyl H H 
29 D 2 cyclopropyl H Bn 
29a D 2 cyclopropyl H H 
30 D 2 cyclopropyl Me Bn 
30a D 2 cyclopropyl Me H 
31 D 3 cyclopropyl H Bn 
31a D 3 cyclopropyl H H 
32 D 5 cyclopropyl H Bn 
32a D 5 cyclopropyl H H 
 
  
Preliminary screening indicated that the hybrids 9 - 16 and 9a – 16a (Series A and AB) 
had potential to cause CYP3A4 inhibition in the presence of testosterone. This data 
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physicochemical properties for improved CYP3A4 inhibition profile. As well 
incorporation of a tertiary amino group was envisaged in order to improve antiplasmodial 
potency via enhanced accumulation of the target molecules in the parasitic food vacuole. 
The modified hybrid targets (series R and D) are shown in Table 1.5 and were derived 
from kojic acid. 
 
Table 1.6. Gallium (III) and iron (III) complexes of series A and AB ligands 
 
Complex Ligand n R2 M (III) 
13c 13a 3 Me Fe 
13d 13a 3 Me Ga 
15e 15a 5 Me Fe 
15d 15a 5 Me Ga 

















Figure 1.33. Structure of complex 15e. 
 
Gallium (III) and iron (III) complexes of conjugates from series A and AB were 
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as availability of the ligand and the latter depended on their respective synthetic yields. 
On this basis the targets represented in Table 1.6 were prepared. 
 
Further synthetic targets were pursued and in the fifth series the aim was to replace the 
3,4-HPO moiety in the hybrid molecules with a biscatecholate group (Figure 1.34). The 
rationale behind this was to determine if the 3,4-HPO group has influence over the 
CYP3A4 inhibition property of this hybrid molecules, thus the appropriate bioisostere 
was used to replace 3,4-HPO.  
 
 
Figure 1.34. Biscatecholate-4-aminoquinoline conjugate 
 
In silico predictions, in vitro data and synthetic accessibility of the target compounds 
have in one way or another influenced the design of each series.  The design rationales 
for each series of compounds are systematically considered in the synthesis chapter with 
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CHAPTER TWO  
 
SYNTHESIS AND CHARACTERIZATION 
 
2.1 Synthesis and Characterization of 1-N-alkyl-3,4-Hydroxypyridinones and their 
Gallium (III) Complexes. 
 
The synthesis of 3,4-hydroxypyridinones involves a double Michael addition reaction 
between maltol, or ethylmaltol or a kojic acid derivative with a secondary amine as 
illustrated in Figure 2.1 (Molenda et al., 1994b, c). It involves ring opening and closure. 
There is competitive formation between the 3,4-hydroxypyridinones and corresponding 
Schiff bases depending on the solvent used in the reaction, for instance the use of protic 
solvents favour 3,4-HPO formation, but aprotic solvents promote the Schiff base 





















Double Michael additionSciff base formation
R" = Me, Et
 
Figure 2.1: Reaction conditions for Synthesis of 3,4-HPOs 
 
The two products can be differentiated, in that the Schiff base has a characteristic low 
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high melting points. More effectively, the UV spectra of their iron complexes differ and 
this can be used to identify the two. The Schiff base UV spectrum has a relatively low 




There was a need to establish the baseline antimalarial activity of known 1-N-alkyl-3,4-
hydroxypyridinones (3,4-HPO) before synthesis of new structurally modified 3,4-HPOs. 
Therefore a number of known 3,4-HPOs with variations in the N-alkyl chain length were 
synthesized and tested for antimalarial activity. The N-alkyl variation was meant to fine 
tune the lipophilicity of these iron chelators. Lipophilicity directly correlates with the 
chelators inhibitory activity against the malaria parasite Plasmodium falciparum as 
demonstrated for a number of chelators namely; N-alkyl derivatives of 3,4-
hydroxypyridinones (HPOs) and aminothiols. (Shanzer et al, 1991, Hershko et al., 1991, 
Loyevsky and Gorduek, 2001) 
 
Complexation with gallium (III) has been reported to enhance antimalarial activity and to 
overcome drug resistance in aminophenols (Ocheskey et al, 2003; 2005, Goldberg et al, 
1997). This has not been reported for the antimalarial activity of N-alkyl-3,4-HPOs, 
hence creating a reason to prepare and study the antimalarial activity of the 3,4-HPO 
gallium (III) complexes. 




























 Figure 2.2: Retrosynthetic analysis of 3,4-HPOs 
The retrosynthesis involves a deprotection of a benzyl ether disconnection C-O of ether 
formation and a functional group interconversion (FGI) involving a pyrone to a 
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The commercially available benzylhalide (BnBr or BnCl) and maltol (3,4-
hydroxypyrone) were selected as the starting materials for this synthesis.  
 
The C-3 position in 3-hydroxypyran-4(H)-pyranones is known to be highly reactive to 
electrophilic substitution (Atkinson et al 1979) but in benzylmaltol the benzyl protecting 
group activates the C-2 position making it more prone to a nucleophilic attack. If 
unprotected the maltol molecule will act it self as a nucleophile rendering it unfavourable 
for the nucleophilic attack by the primary amine. Lower yields in the synthesis of the 
hydroxypyridinones are inevitable if the protection of the 3-hydroxy group is excluded. 
2.1.3 Synthesis 
 
Benzylmaltol was prepared by refuxing benzylchloride and maltol in the presence of 
catalytic amounts of NaOH. The reaction progress was monitored by TLC and detection 
was by UV 254nm/ 330nm and emersion into 0.1M ferric ammonium sulphate solution, 
to form red colored Fe3+ complex for the unreacted maltol and a pale yellow color for the 
benzylated maltol. (Kruck et al., 2002) 
 
 
Figure 2.3: Synthesis of 3,4hydroxypyridinones 
 
The benzylmaltol was subjected to amination using a primary amine to form a benzylated 
hydroxypyridinone under refluxing conditions (Fig.2.3). This is a Michael addition 
reaction involving the free nitrogen of the primary amine attacking the pyran resulting in 
ring opening followed by ring closure mediated by a second nucleophilic attack by the 
nitrogen (Fig.2.4) This reaction is a thermodynamically controlled SN2 type reaction such 
that high temperatures over along period of time in a protic medium favour addition to 
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Clayden, et al 2001, Sainsbury, 2001). The unhindered β- carbon and the use of a soft 





























Figure 2.4: Mechanism of the Michael addition to the benzylmaltol 
 
The deprotection was achieved by acid catalysed hydrolysis or by hydrogenation (Harris, 
1976; Dehkordi et al., 2008), (Fig. 2.3). The hydrolysis phenomenom was also observed 
during the recrystallization of the benzylated analogues 1c and 1d (Table 2.1). The 
recrystalization procedure involved dissolution in EtOH/HCl (2M), concentration under 
reduced pressure at 70oC, before recrystalization from EtOH/Et2O. The acidic conditions 
and the moderate temperature favoured debenzylation.  
 
The yields of the benzylated 3,4-HPOs appear to be at optimum for compounds with the 
N-alkyl side chains of intermediate length (3 - 6 carbon atoms), but the yield is lower for 
compounds with shorter (1 or 2 Carbon atoms ) or longer (8 carbon) N-alkyl side chains. 
It may be assumed that the compounds with shorter side chains are more hydrophilic 
hence more soluble in the aqueous ethanolic reaction medium unlike the long chain 
analogues. During the workup, less of the hydrophilic compounds will partion into the 
organic solvent i.e. dichloromethane and thus more of these compounds will remain in 
the aqueous layer during the extraction hence poor yields. The opposite effect is assumed 
for the lipohilic compounds (compounds with longer N- alkyl chain). To rationalize poor 
yields for the N-octyl analogue, one could consider solubility of the aminoalkane in the 
aqueous ethanolic reaction mixture/medium. The octylamine which is used to prepare 
analogue 1h the may be assumed to less soluble in the reaction mixture hence less 
available for Michael addition during the reaction time. The other possible reason for the 
poor yield could be that the Octylamine has a longer chain which poses greater steric 
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There is no great difference in the yields amongst the deprotected N-alkyl-3,4-HPOs.  
 
2.1.4 Characterization 
Table 2.1: Yields of the benzylprotected 3,4-HPOs and their deprotected analogues 
 






Compound R1 R3 
 
% Yield 
1a Me Bn 48 
1b Et Bn 31 
1c n-Bu Bn 59 
1d cyclopropyl Bn 57 
1e i-Propyl Bn 50 
1f n-Propyl Bn 44 
1g n-Hexyl Bn 63 
1h n-Octyl Bn 28 
2a Me H 75 
2b Et H 55 
2c n-Bu H 32 
2d cyclopropyl H 47 
2e i-Propyl H 61 
2f n-Propyl H 83  
2g n-Hexyl H 74 
2h n-octyl H 69 
 
The compounds (Table 2.1) were characterized by MS, 1H and 13C NMR, melting point 
and elemental analysis. None of the compounds was novel except 1d and 2d. A typical 
proton NMR spectrum of these compounds consists of the two diagnostic doublets at δ7-
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region δ 7.4 – 7.0 ppm due to the benzyl aromatic protons as well as the singlet at δ 5 
ppm due to the benzyl methylene protons were conspicuously absent in the spectra of the 
deprotected analogues. The 13C NMR of the deprotected compounds indicated the 
absence of the peaks in the δ 129-127 ppm region corresponding to the aromatic carbon 
atoms of the benzyl group. 
 
Table 2.2:  Melting points of the benzylprotected 3,4-HPOs and their deprotected analogues 
Reported data is from Dobbin et al (1993) 
 
ND: not determined (oils) 
 
The melting points of the deprotected compounds were found to be much higher than that 
of the benzylated analogues (Table 2.2). This can be attributed to the presence of 
intermolecular hydrogen bonding via the hydroxyl group in the deprotected analogues. 
Compound Formula Mp (observed) oC Mp (reported) oC 
1a C14H16ClNO2.0.5H2O 190-192  207-208 
1b C15H18ClNO2.2.5H2O 151-154 178-179 
1c C17H22ClNO2. ND - 
1d C16H18ClNO2. ND - 
1e C16H20ClNO2.0.5H2O 171-173 - 
1f C16H20ClNO2.5H2O 64-66 - 
1g C19H26ClNO2 46-48 - 
1h C21H30ClNO2.H2O 55-57 - 
2a C7H10ClNO2.H2O 163-165 189-190 
2b C8H12ClNO2.0.5H2O 166-168 205-206 
2c C10H16ClNO2 163-166 199-200 
2d C9H12ClNO2 193-197 - 
2e C9H14ClNO21.5H2O 196-197 225-226 
2f C9H14ClNO2 187-189 206-207 
2g C12H20ClNO2.0.5H2O 163-164 166-167 
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The observed melting points are much lower than the ones reported by Dobbin et al 
(1993), however they have a narrow range implying they are pure. The presence of water 
of hydration as calculated from elemental analyses (Table 2.2) could be the cause of 
depressed melting points for some compounds. All the compounds reported in earlier 
reports were isolated as anhydrous salts and their melting points were uncorrected. 
 















































resonance form prerequisite for chelation
 
Figure 2.6: Prerequisite resonance before metal chelation 
 
The synthesis involved reflux of the ligand with gallium (III) nitrate nonahydrate (Fig. 
2.4). Gel filtration on Sephadex LH 20 was used for their purification.  
 
The resonance form 2a-1 (Fig. 2.5) is important for chelation to occur (Dobbin et al 
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responsible for the co-ordination induced shifts (CIS) observed in their proton and carbon 
13 NMR spectra (Fig 2.6, 2.7). 
 
Proton NMR and analytical TLC indicated the absence of the free ligand and the proton 
NMR spectrum showed only one pair of neat doublets for the H-6 and H-5 pyridinone 
protons (Fig 2.7) confirming the complete conversion of the ligand to the complex. The 
presence of co-ordination induced shift (CIS) observed for the pyridinone ring protons 
confirmed complex formation too (Ferreira et al., 2006; Green et al., 2005; Xiao et al., 
1992) such that downfield and upfield shifts were observed for H-5 and H-6 respectively 
(Fig. 2.7). Some CIS was also observed for the N-alkyl and the 2-methyl protons. 
 
In the 13C NMR spectra CIS was clearly observed for the carb n atoms bound to the 
coordinating oxygen atoms as expected for bidentate chelation, this is illustrated by the 
example in figure 2.8. For the carbonyl carbon a CIS of >8 ppm confirmed a dative bond 
while a similar CIS of similar magnitude for the adjacent hydroxyl carbon verified a 











































































































































































AAW C2B in D6-DMSO







































































Figure 2.8: Carbon-13 NMR spectra of compound 2b and its gallium complex 3b 
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Compound R Mp  
Of ligand  oC 
Mp of gallium 
complex oC 
Mp of gallium 
complex oC 
 
2a Me 163-165 326-329 280a 
2b Et 166-168 222-225 240b 
2c Bu 163-166 303-305 170c 
2d cyclopropyl 193-197 237-240 - 
2e isopropyl 196-197 259-260 - 
2f n-propyl 187-189 219-220 290c 
2g n-hexyl 163-164 ND 285a 
2h n-octyl ND ND -- 
a Nelson et al., 1988; b Nelson et al., 1989; c Simpson et al., 1991; 
 
In the mass spectra of these complexes the m/z observed corresponded to [ML3]+ or  
[ML3+Na]+. ML2 peaks were also observed and were due to fragmentation and this is 
consistent with what Nelson and co-workers (1988) have reported.  
 
X-ray crystallographic data of most of these complexes has been reported elsewhere 
(Xiao, G, 1992). The melting points of the complexes (Table 2.3) were found to be much 
higher than those of the corresponding ligands due to the strong hydrogen bonding 
network (Nelson, et al 1988). The high melting points are extra proof that complexation 
occurred. The literature reported melting points for some of the complexes do not 
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2.2 Synthesis and Characterization of N-(7-chloro-4-quinolyl)-1-(aminoalkyl)-3,4-
hydroxypyridinone Double Drugs Derived from Maltol and Ethylmaltol (A and AB 
series) 
2.2.1 Rationale 
Multi-therapies associating long acting and short acting compounds with different modes 
of action offer efficient treatment (Biot and Chibale, 2006). Such double drugs or 
bifunctional conjugates are known to be more effective against drug resistant organisms 
than the dual administration of the constituents (Biot and Chibale 2006; Bebbington, et 
al, 2000), in this respect 3,4-HPO-4-amino7-chloroquinolinyl double drugs were 
designed and synthesized. 
2.2.2 Design 
The figure below (Fig 2.9) shows the design of these double drugs synthesized by 










iron  (metal) chelation
variation of n to optimize lipophilicity to 
overcome resistance  and enhance HPO's 
antimalarial activity
Aminoquinoline 
nucleus for beta 
hematin binding
electron withdrawing 
group for beta 
hematin inhibition
 Base for 
accumulation 
in the parasitic 
food vacuole
 
Figure 2.9: The design of the 3,4-HPO- N1-(7-chloroquinolin-4-yl) diaminoalkane 
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The double drug was designed to incorporate two modes of antimalarial activity; iron 
chelation (sequestration) and inhibition of hemozoin formation. The structural features 
responsible for these biological activities are indicated in figure 2.9. 
2.2.3 Retrosynthetic Analysis 
 











































Figure 2.10: Retrosynthesis analysis of the maltol derived drug conjugates 
 
The retrosynthetic strategy involved C-O disconnections for an ether formation, a 
functional group interconvertion (i) involving a pyrone to a pyridinone via Michael 




All the starting materials (maltol, ethylmaltol, benzylchloride, iodomethane, 
dimethylsulfate, diaminoalkanes and 4,7-dichloroquinoline) for the synthesis were 
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using standard procedures as illustrated in Figure 2.11 (Yearick, et al 2008; Solomon, et 
al, 2007; Burgess, et al, 2006; Blackie, 2002). The reaction for the preparation of N-(7-
chloro-4-quinolyl)-diaminoalkanes is an addition–elimination reaction and the 
mechanism is illustrated in Figure 2.10.  The methyamine 6a was synthesised to enable 
incorporation of a tertiary amine group into the double drugs i.e. the R and D series. The 
3-hydroxy-4(1H)-pyranones maltol and ethyl maltol were benzylated in 90% aqueous 
















Figure 2.11: Mechanism for the coupling of 4,7-dichloroquinoline to the diaminoalkane 
 
A Michael addition of the primary amines (N-(7-chloro-4-quinolinyl)-diaminoalkanes) to 
the benzylated pyranones gave the benzylprotected double drugs as free bases. The 
workup involved washing off the unreacted benzylmaltol or ethylbenzylmaltol with 
diethylether at pH 1 and adjusting the pH (using 2M NaOH) to allow precipitation of the 
target compound leaving the unreacted 4-amino-7-chloroquinoline in solution. The pure 
compounds were obtained by filtration and washing with deionised water and drying 
under vacuum. The benzylated double drugs were deprotected by catalytic 
hydrogenolysis at high pressure or by acid hydrolysis. Catalytic hydrogenation has been 
observed to convert some aryl halides to aryls (March and Smith, 2007), but in this case 
such was not observed. Only the target debenzylated hybrid molecules (s) were obtained 
as supported by evidence from analytical TLC, MS, elemental and NMR data. 
 
The second phase of the synthesis involved the preparation of N-(7-chloro-4-quinolinyl)-
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The rationale was to investigate the effect of changing the protecting group at the C-3 
position of the pyridinone on the biological activity of these drug conjugates. 
 
The synthetic procedure involved reaction of 3-methoxylated pyranones 17 or 18 with N-
(7 chloro-4-quinolyl) alkanes (Fig. 2.12) and the products were isolated by precipitation 
at neutral to basic pH. The methoxylated pyranones were prepared by reacting 
methyliodide or dimethylsulphate with ethyl maltol and methylmaltol respectively. 
Dimethylsulphate was unreactive with ethylmaltol presumably due to the steric 
hinderance by the 2-ethyl group.  
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Table 2.4: Yields and melting points of the maltol and ethylmaltol derived double drugs  








compound N R2         R3 % Yield Mp  oC 
9 1 Me Bn 93 151-152 
9a 1 Me H 68 173-175 
10 1 Et Bn 36 154-157 
10a 1 Et H 30 178-180 
11 2 Me Bn 45 127-129 
11a 2 Me H 50 143-146 
12 2 Et Bn 21 129-130 
12a 2 Et H 40 ND 
13 3 Me Bn 40 128-130 
13a 3 Me H 70 124-25 
14 3 Et Bn 40 112-116 
14a 3 Et H 76 ND 
15 5 Me Bn 27 114-116 
15a 5 Me H 99 134-138 
16 5 Et Bn 34 168-170 
16a 5 Et H 88 ND 
16b 5 Et Me 50 68-69 
15b 5 Me Me 48 96-98 
14b 3 Et Me 70 165-167 
13b 3 Me Me 64 85-87 
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The average yield of the 3-methoxylated analogues was higher than those of the 
corresponding 3-benzyl analogues (Table 2.5) due to the ease of precipitation of the 
methoxy analogues at neutral to basic pH. The low aqueous solubility of the 3-
methoxylated analogues (Table 2.6) was the reason for ease of precipitation. This is 
illustrated by the difference in the solubility of two related compounds 15b a 
methoxylated analog (10µM) and 15 a benzylated analog (20µM) (Table 2.6).  
 
 







Compound n R2 R3 % Yield 
13b 3 Me Me 64 
13 3 Me Bn 40 
14b 3 Et Me 70 
14 3 Et Bn 40 
15b 5 Me Me 48 
15 5 Me Bn 27 
16b 5 Et Me 50 
16 5 Et Bn 34 
 
Ordinarily one would expect the less polar (3-methoxylated) analogues to be more 
soluble than the less polar (benzylated analogues), (Thomas, 2003). Other factors may be 
contributing to this anomally for example the nature of the lattice packing (Fray et al., 
2001; Kerns and Di, 2008). An out of plane substituents like the 3-methoxy  or the 3-
benzyl groups are likely to disrupt the crystal packing thus resulting in a high energy 
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disruption than the methoxy group resulting in greater solubility for the benzylated 
analogues than the methoxylated analogues. The crystal structure of compound 24 (page 
119) shows how the benzyl substituent can be out of plane with the pyridinone or 
quinoline nucleus at almost perpendicular angles.  However there is need to determine 
crystal structures of the analogues in question for a watertight conclusion. Eventhough 
melting points can be used to predict the strength of the crystal lattice and hence 
solubility, in this case it was not appropriate since the most of the compounds in question 
were not isolated as crystals but as precipitates. Therefore the solubility properties of 
precipitates cannot be similar to those expected of the crystals. 
 
2.2.5 Characterization 
Characterization was by 1H, 13C NMR, MS, IR and elemental analysis. Figure 2.13 and 
2.14 show typical examples of a proton and carbon-13 NMR spectra of the benzylated 
and methoxylated analogues. In the proton NMR spectra of the deprotected analogues the 
multiplet from the benzyl‟s aromatic protons and the singlet at δ5 ppm due to the benzyl 
(methylene) protons being absent. The fingerprint pyridinone H-5 and H-6 peaks are 
conspicuous as depicted in the Figure 2.13 and can be identified by their J value of less 
than 7Hz. Typical proton NMR peaks for the quinoline protons H-2‟‟ and 3‟‟ appear as 
doublets with J values 5 - 6Hz, (Yearick et al., 2008; Burgess et al., 2006; Sanchez-
Delgado et al., 2004). However, this was not true for some of the 3,4-hydroxypyridinone-
aminochloroquinoline double drug molecules synthesized in this study 
 
The coupling constants observed for H-2‟‟, H-3‟‟ in some of the double drugs exceeded 
7Hz. In most cases H-2‟‟ appeared to be the most deshielded quinoline proton as reported 
elsewhere. (Yearick et al., 2008; Burgess et al., 2006; Sanchez-Delgado et al., 2004) 
Comparing the carbon-13 NMR spectra (Fig 2.14) of the 3-methoxylated double drug 
molecules and that of the benzylated analogues, its clear that the signals due to the benzyl 
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AAW 14Aexp 3 in D6-DMSO





























































































































Figure 2.13: Proton NMR spectra of 3-methoxylated (13b) and 3-benzylated (13) 3,4-
HPO- N1-(7-chloroquinolin-4-yl) diaminoalkane double drug molecules 
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Figure 2.14: Carbon-13 NMR spectra for 3-methoxylated (13b) and 3-benzylated (13) 
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1H NMR spectra showed the presence of water in all the samples despite the thorough 
drying prior to their analysis (Fig. 2.13), this is further observed in the elemental analyses 
of these compounds. On this basis it may be concluded that these conjugates are 
hydrated. Indeed the deprotected analogues were highly deliquescent hence required 
special handling during the elemental analyses which was not available.  
 
Previous reports indicate that the 1-N-alkyl-3,4-HPOs are very hygroscopic hence the 
presence of the same moiety in the 1-N-alkyl-3,4-HPO-aminochloroquinoline conjugates 
may be the cause of the hygroscopic/deliquescent  behavior and require very drastic 
conditions (<0.3Torr, 90oC, 16-48h) to dehydrate them in order to achieve acceptable 
elemental analyses (Finnegan, et al 1987). Facilities to attain such conditions were not 
available hence most of the compounds were isolated as hydrates as indicated by the 
elemental analyses. 
 
HR-MS (positive mode) and LR-MS showed protonated molecular ion peaks (M+H) + for 
all the compounds. The FT-IR confirmed the characteristic features (N-H, C=O, C=N, 
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2.2.6 Physicochemical properties   
The solubility of the double drugs in water was determined using a turdimetric method 
(Table 2.6). The data was recorded either in 2 or 1 significant figures and no decimal 
point.  Drugs with solubility >100 µM were classified as soluble, those with 50-25 µM 
were termed partially soluble and those <25 µM insoluble. All the compounds were 
soluble and their solubility was above the recommended minimum (>20 µg/ml) for drug-
like oral compounds (Lipinski CA, 1997), the only exception was 16. It was 
demonstrated that conversion of 16 to its dihydrogenchloride salt (13AB2HCl) improved 
its solubility by more than two fold i.e 28 µg/ml which is above the recommended 
minimum.  
 
For optimal gastrointestinal absorption by passive diffusion after oral dosing, a drug 
needs to have a moderate log P (0-3). In this range of log P, there is a good balance of 
permeability and solubility. (Kerns and Di, 2008) The predicted log P values of these 
conjugates is in the range 2.6 – 4.5 and they have drug-like solubility i.e >20 µg/ml 
(Lipinski, 1997) hence these compounds are likely to be orally active in vivo.  
 
Lipophilicity was determined using reverse phase HPLC (see experimental section 5.5.6) 
and standard drugs with known retention times (tR) and retention capacity were (k‟) used 
for calibration.  Most of the compounds had log D values in the range 2.46 < log D7.4 > 
6.00 (Table 2.6) and compounds in this range are said to have good permeability but 
lower absorption owing to lower solubility (Kerns and Di, 2008). Conversely the actual 
solubility of these compounds is within the acceptable drug-like limits hence no issues 
are expected with absorption. All the compounds are more soluble than the least soluble 
standard niclosamide. Data for log D i.e. retention time tR was recorded to 3 significant 
figures and as well the k‟ and log D values for the standards were in 3 significant figures, 
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clog P  predicted from MoKa ®, ND: not determined 
 
 
Compound R2 n 
 
R3 Solubility 
          µM 
Solubility  





9 Me 1 Bn >100 > 42 3.80 4.02 
9a Me 1 H >100 > 32 2.00 1.94 
10 Et 1 Bn >100 > 43 4.20 4.54 
10a Et 1 H >100 > 34 2.50 2.46 
11 Me 2 Bn >100 > 43 4.30 4.07 
11a Me 2 H ND ND 2.50 ND 
12 Et 2 Bn >100 > 44 4.70 4.59 
12a Et 2 H >100 > 36 3.00 ND 
13 Me 3 Bn >100 > 44 4.80 4.59 
13b Me 3 Me >100 > 37 4.20 ND 
13a Me 3 H >100 > 36 3.00 ND 
14 Et 3 Bn >100 > 46 5.20 5.11 
14b Et 3 Me ND ND 3.86 ND 
14a Et 3 H >100 >37 3.50 3.11 
15 Me 5 Bn 25 48 5.70 5.48 
15b Me 5 Me 10 40 3.34 ND 
15a Me 5 H >100 > 38 4.00 3.52 
16b Et 5 Me ND ND 4.75 ND 
16 Et 5 Bn 25 12 6.2 6.00 
16. HCl salt Et 5 Bn 50 28 6.40 ND 
16a Et 5 H >100 > 40 4.50 4.05 
Paracetamol    >100    
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2.3 Preliminary studies on the gallium (III) and iron (III) complexes of N-(7-Chloro-
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Several reports indicate that metal complexes of chloroquine based ligands have 
improved activity against CQ sensitive and CQ resistant strains of P. falciparum as well 
good in vivo activity against P. berghei (Khanye, 2010; Ajibade and Kolawole; Navarro, 
et al, 2004; Blackie, 2002; Sanchez-Delgado, et. al., 1996). The structures of some of the 
complexes and their respective antiplasmodial activities are depicted in Figures 2.15 and 
Tables 2.7 and 2.8 respectively.   
 
Table 2.7. Antiplasmodial activity of some CQ based Ru and Rh complexes against CQ 
resistant FcB1, K1 and W2 strains of P. falciparum 
 
Compound  IC50 (µM) Reference 
 FcB1 W2 K1  
M 0.073 ND ND Sanchez-Delgado et. al., 1996 
N 0.018 ND ND Sanchez-Delgado et .al., 1996 
CQ 0.072 ND ND Sanchez-Delgado et. al., 1996 
 
 
Table 2.8. Antiplasmodial activity of some CQ based Au and Pt complexes against CQ 
resistant FcB1, K1 and W2 strains of P. falciparum 
 
Compound IC50 (µM) Reference 
 FcB1 W2 K1  
O 0.04 0.07 0.10 Navarro et. al., 2004 
P 0.04 0.04 0.06 Navarro et. al., 2004 
Q 0.04 0.05 0.09 Navarro et. al., 2004 
R 0.01 0.05 0.10 Navarro et. al., 2004 
S ND ND 0.16 Ajibade and Kolawole., 2008 
T ND ND 0.05 Navarro et. al., 2004 
U ND ND 0.04 Navarro et. al., 2004 




The choice of ligands for complexation was based on their in vitro antiplasmodial activity 
and availability of the material; hence ligands 16a, 15a and 13a were used. The synthesis 
involved the reaction of an aqueous solution of iron (III) nitrate nonahydrate or gallium 
(III) nonahydrate solution with a methanolic solution of the N-(7-chloro-4-quinolyl)-3-
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The equivalents of the reactants were varied to explore possibilities of forming ML3 and 
ML2 type of complexes (Fig. 2.16).  An assumption was made that the N-1 of the 
quinoline can participate in the coordination to give a complex with the proposed 
structure type C (Fig. 2.16) The spectroscopic data, however, ruled out coordination via 
the quinoline nitrogen and confirmed the sole participation of the 3,4-hydroxypyridinone 
group in the coordination. This was observed from the molecular ion peaks 
corresponding to ML3, and the absence of significant CIS in the proton NMR signals of 
the quinoline protons. Further details are considered for each complex later in the 
chapter. Six complexes were prepared, two with iron (III) and four with gallium (III) as 
their respective metal centres (Table 2.9). 
 
2.3.3 Characterization 
The complexes were characterised by 1H and 13C NMR, microanalysis and mass 
spectrometry. Proton NMR was used to confirm the metal chelation had occurred and that 
the product was not merely a mixture of the starting materials. The proton NMR spectra 
of the iron (III) complexes exhibited peak broadening and merging and only two peaks 
were observed due to the paramagnetic nature of iron (Fig.2.17). The two broad singlets 































Reagents and Conditions : M(NO)3. 9H2O, H2O/MeOH Reflux 80
oC or ambient temp.










































Figure 2.16: Synthesis of the double drug metal (III) complexes 
 
For the gallium complexes minimal peak broadening was observed in the proton NMR. 
However, co-ordination induced shifts (CIS) were observed for the H-5 and H-6 
pyridinone protons. In most of the complexes the peaks corresponding to these protons 
appeared as broad singlets or had diminished J values relative to the ligand‟s (Fig. 2.17 
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13c Fe 3 Me 72 225-226 124-125 
13d Ga 3 Me 81 215-216 124-125 
15c Fe 5 Me 66 198-200 134-138 
15d Ga 5 Me 81 194-196 134-138 
16c Ga 5 Et 24 202-204 N/A 
15e Ga 5 Et 50 183-184 134-138 
 
 
When the quinoline moiety participates in the complex formation the main coordination 
point is via the quinoline N-1 thus the H-2”, 3” and 8” are expected to show reasonable 
CIS on complexation (Blackie M, 2002; Sanchez-Delgado R.A., et al 2008), ie 1.8-0.5 
ppm for H-8” and >0.6ppm for H-2” and 3” (Sanchez-Delgado et al 1996; Lippard et al., 
1983). These CIS were not observed in any of the double drug complexes except in 13d 
(Tables 2.10-2.13).  This implied that the quinoline was just a pendant group and was not 
involved in the metal chelation.  
 
In the case of 13d, the Δppm for H-8” was significant ie >0.5 (Table 2.10) implying that 
either the quinoline N-1 was involved in the metal chelation or/and a long range 
electronic disturbance was strongly felt by the quinoline protons due to the reduced 
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13d showed an ML3 peak with 100% abundance and this meant complexation via N-1 did 
not occur because all the six coordination sites on the metal ion were occupied by the 
three hydroxypyridinone moieties. The double drugs hence behaved as bidentate 




Figure 2.17. Proton NMR spectrum of the iron (III) complex 13c 
 
 
Table 2.10: Coordination induced shift values (CIS Δppm) for 13d 
 





2” 8.50, d, J 7.2 8.41, d, J 4.8 0.09 
3” 6.86, d, J 6.9 6.27, d, J 7.2 0.59 
5” 8.87, d, J 9.3 8.29, d, J 7.8 0.58 
6” 7.70, dd, J 1.8, 9.0 7.46, m 0.24 
8” 8.10, d, J 2.1 7.52, s 0.58 
5 7.34, d, J 6.9 6.56, m 0.78 
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Figure 2.18: Proton NMR spectra of 15a and its gallium (III) complex 15d 
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Table 2.11: Coordination induced shift values (CIS Δppm) for 15d 
 





2” 8.37, d, J 7.2 8.32,m 0.05 
3” 6.88, d, J 7.2 6.76, d, J 6.0 0.12 
5” 8.48, d, J 9.2 8.32, m, 0.16 
6” 7.66, d, J 9.2 7.62, d, J 8.7 0.04 
8” 7.88, d, J 2.0 7.86, s 0.02 
5 7.10, d, J 6.8 6.40, d, J 5.4 0.70 




Table 2.12: Coordination induced shift values (CIS Δppm) for 15e 
 





2” 8.37, d, J 7.2 8.41, d, J 5.7 0.04 
3” 6.88, d, J 7.2 6.72, d, J 6.4 0.16 
5” 8.48, d, J 9.2 8.33, d, J 9.0 0.15 
6” 7.66, d, J 9.2 7.50, d, J 8.7 0.16 
8” 7.88, d, J 2.0 7.82, s 0.06 
5 7.10, d, J 6.8 6.53, m, 0.57 
6 8.20, d, J 6.8 7.71, d, J 5.4 0.49 
 
 
In each complex the H-5 and the H-6 had the greatest CIS chemical shifts. Longer NMR 
runs were required to achieve good carbon-13 NMR spectra for these complexes but for 
most them good resolution was not achieved even after longer periods. 
  
15e was confirmed to be a ML2 type of complex with the evidence from HR MS that 
shows a m/z corresponding to ML2 and none for ML3. The positive anion exchange 
reaction with PF6- indicated that 15e was a cationic complex quite unlike 15d. The 
difference in the melting points of 15d and 15e was ≈10oC (Table 2.9); this is extra 
evidence that the two complexes are not the same. The CIS for the pyridinone protons in 
the two closely related complexes, 15e and 15d, differ by a factor of 2 implying the H-5 
and H-6 of the respective complexes are not in similar chemical environments. One can 
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In the preparation of all the above complexes it was proved that the reaction went on to 
completion and no remnants of the free ligand were detectable from both proton NMR 
and analytical TLC. None of the complexes showed a positive anion exchange reaction 
with the PF6- except 15e. 
 
Table 2.13: Coordination induced shift values (CIS Δppm) for 16d 
 





2” 8.37, d, J 7.2 8.30, m, 0.07 
3” 6.94, d, J 7.2 6.40, d, J 6.8 0.54 
5” 8.40, d, J 9.3 8.30, m, 0.10 
6” 7.68, d, J 8.8 7.64, dd, J 1.6, 9.0 0.04 
8” 7.87, d, J 1.5 7.85, d, J 0.8 0.02 
5 7.10, d, J 7.2 6.76, d, J 6.8 0.34 
6 8.18, d, J 6.9 7.46, d, J 6.8 0.72 
 
The MS data of the two iron (III) complexes (13c, 15c) as well as that of 13d showed m/z 
corresponding to ML3 the expected molecular ion peak. The mass spectra of 15d and 16c 
did not show the molecular ions for ML3 but had peaks corresponding to ML2 and ML 
and L that were attributed to fragmentation.  
 
It is known that the ML2 complex species of 3-4-HPOs possess a single charge unlike the 
neutral ML3, hence it does not require further protonation or cationization in order to be 
detected in mass spectrometry. (Xiao et al, 2006) As a result, the relative abundance of 
the ML2 is overrepresented in the mass spectra of 15d and 16c assuming that the two 
readily fragmented in the MS. 
 
The melting points of all the complexes were found to be higher than those of their 
respective ligands. This can be attributed to the crystal packing effects due to different 
co-ordination complexes. This observation in it self is a confirmation of chelation of the 
metal by the ligand (Dobbin et al., 1993). A similar phenomenon was observed and 
explained for the gallium complexes of N-alkyl-3,4-HPOs (section 2.1). The melting 
points of the complexes of 13a (13d and 13c respectively)  and that of 15c were reported 
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complexes, 16c and 15e,  the difference between their melting points and the ligands is 
not substantial (Table 2.9). This implies that there are relatively stronger bonds in 13d, 
13c and 15c than in 15d and 16c. This data may be used to explain the absence of the 
molecular ion (ML3) peaks in the mass spectra of 15d, 16c and 15c due to ease of 
fragmentation. 
 
Crystallization was attempted for purification purposes and for X-ray crystallographic 
studies but this was unsuccessful. The X-ray crystallography studies would have given 
accurate data on the structure and formula of these complexes. Ordinary crystallization 
and crystallization by vapour diffusion using the following solvent pairs was pursued for 
the six complexes; MeOH/Et2O, MeOH/EtOAc, MEOH/heptane, 
MeOH/dichloromethane, dry MeOH/Et2O, MeOH/ACN, DMSO/dichloromethane but all 
were unsuccessful. 
 
To ensure that the experimental and calculated elemental analyses were acceptable the 
following assumptions were made; that traces of NaNO3 were present in most of the 
complexes, the varied moles of water of hydration where possible for 3,4-HPO 
complexes was allowed. (Xiao et al., 1992; Nelson et al., 1989) This should be treated as 
tentative pending X ray crystallographic experimental data. Conductivity measurements 
may also be used to confirm the cationic nature of 15e.  
 
   
The liability observed in these complexes is poor solubility in water, methanol and 
ethanol which may cause precipitation in bioassay media and impact negatively on 
evaluation of the biological activity. Similar observations on solubility of metal 
complexes have been reported by Puerta and co-workers (2006). These complexes were 
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2.4 Synthesis of Kojic acid -Derived Double drugs (R and D series) 
2.4.1 Rationale 
 
In order to maximize or retain the antimalarial activity of the previously synthesized 
double drugs (section 2.2) but minimize their CYP3A4 inhibition (section 3.8.2) in the 
presence of a substrate (i.e. testosterone), these compounds required structural 
modification to form the 2-((7-chloroquinolin-4-ylamino)alkylamino)methyl)-1-.alkyl-5-
hydroxypyridin-4(1H)-ones (kojic acid derived double drugs). 
2.4.2 Design 
Two universally accepted strategies for lessening CYP3A4 inhibition were considered 
when designing the new compounds: (a) Lowering the logD or logP of the drugs 
(lipophilicity) by introducing more polar groups (Kerns and Di, 2008; Gleeson, 2008), (b) 
Altering the molecular shape of the series (Yan and Caldwell, 2001). The other strategy 
was to introduce a tertiary amino group or an extra amino group on the side chain to 
enhance accumulation of the drugs in the food vacuole of the malaria parasite (Egan and 
Kaschula, 2007; Yearick, et al 2008).  
 
The design represented in Figure 2.20 is similar to that of the maltol/methyl maltol 
derived double drugs except for the extra basic group in form of a tertiary amine. The 
pyridinone‟s N-1 is a weaker base due to the resonance withdrawal of the lone pair of its 
electrons into the ring and hence has lower pKa of 2-4 (Dekhordi, et al 2008) relative to 
that of the tertiary terminal amino group in chloroquine which has a pKa of 
10.21(Volsurf®). Hence the former cannot effectively enhance accumulation of the drug 
in the parasitic food vacuole. This necessitated the introduction of a tertiary amino group. 
Tertiary amino groups in 3,4-HPOs have been proposed to enhance targeting of the 
parasitic lysosomes and other intracellular  acidic vacuoles (Dehkordi et al 2008). 
Therefore the presence of the tertiary amino group in the 3,4-HPO-aminoquinoline drug 
conjugates presents a mimic of the tertiary terminal amino group in chloroquine and 
related antimalarials. This is backed up by the Volsurf ® predicted pKa values for the 
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Altering the molecular shape by replacement of the maltol derived substructure with one 
from kojic acid was envisaged to affect the interraction of these compounds with the 
CYP3A4 active site. Introduction of steric bulk in the vicinity a heterocyclic nitrogen 
(especially in pyridines and quinolines) is expected to weaken the coordination of the 
nitrogen to the P450 prosthetic heme iron (Ridley et al 2001; Zlokarnik et al, 2005).  In 
this context, the introduction of a bulky group next to the pyridinone heterocyclic 
nitrogen is not expected to have a significant effect on the compounds interaction with 
the CYP3A4 active site as it could do for pyridines (Ridley, 2001; Zlokarnik, 2005), 
because the lone pair on the pyridinone N is not available for this interaction due to its 
withdrawal into the pyridinone ring via resonance.  
 
In addition predictions using Metasite (Fig.2.18) show that the quinoline moiety 16a is 
more exposed to the CYP3A4 active site but remains unreactive, such a prediction 
implies the quinoline may be responsible for the CYP3A4 inhibition and not the 
pyridinone moiety. Also it is known that hydroxypyridinones do not directly cause the 
inhibition of heme containing enzymes (Kayyali et al, 1997; 2001). Comparing the 
predicted exposure and reactivities of 16a, 27a and 32a, it appears that the quinoline 
moieties of 16a and 27a have similar exposure and reactivity but that of 32a has similar 
exposure but greater reactivity. This implies that 32a has a lesser potential to cause 
CYP3A4 inhibition than the other two. The introduction of the basic amine group 
increases the electron density (via the lone pair of electrons on N) which enhances 
enzymatic metabolism of the substrate (Kerns and Di, 2008). For this reason the R and D 
series which have an amine group in their side chains are expected to exhibit higher 
reactivity than the A/AB series.  
 
The bulky group ortho to the pyridinone N-1 was envisaged to contribute towards 
altering the molecular shape of these conjugates and hence proposed to be the cause of 



















Figure 2.19: Sites of exposure of the maltol and kojic acid derived double drug to the 
CYP3A4 active site [A 1,2,3] and sites of metabolism [B 1, 2, 3] from Metasite®  The red  
and blue circles indicate the extent of exposure or reactivity of the highlighted part i.e. 
blue shows greater exposure or reactivity than red. More intense circle implies greater 
exposure or reactivity and vice versa. Compound 32a quinoline groups appear to be 
more reactive in the CYP3A4 active site than the other two molecules 16a and 27a which 
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2.4.3 Attempted Synthesis of Kojic acid derived double drugs via a Mannich base 
intermediate 
 
The aim was to introduce tertiary amino groups into this class of conjugate via Mannich 








iron  (metal) chelation
variation of n to fine tune lipophilicity to 












tertiary amino for accumulation in parasitic
 food vacuole
Figure 2.20: Design of the Kojic acid derived double drugs with a Mannich base group 
 
2.4.3.1 Retrosynthesis 
Before synthesis the retrosynthesis was considered via one route (Fig. 2.21). The strategy 
involves a a C-O disconnection via dealkylation, FGI of a pyrone to a pyridinone, 
nucleophilic substitution and a 1,1-diX equivalent requiring a Mannich reaction. The use 
of kojic acid as the precursor was envisaged, with other main starting reactants being 
formaldehyde, piperidine, diamines and the 4,7-dichloroquinoline. Kojic acid was chosen 
as an alternative synthetic precursor for 3,4-HPO–quinoline conjugates because of its 
































































Figure 2.21:  Retrosynthesis of Mannich base intermediates 
 
The reaction was performed via a one pot direct multi-component protocol. Kojic acid 
readily reacted at room temperature with piperidine and aqueous formaldehyde to give 
the crystalline Mannich base. The reaction scheme and mechanism are depicted in figure 
2.22 and 2.23 respectively. The reactions proceeded via an iminium ion intermediate 
which was allowed to react with the unsaturated ketone to form the Mannich base 19. 
Selective benzylation of the 3-hydroxy group in 19 was not achieved as the proton NMR 
indicated benzylation had occurred simultenously at the 6-methylhydroxy and the 3-
hydroxy groups (Fig.2.23). Attempts to couple N-(7-chloro-4-quinolinyl) diaminoalkanes 
to the Mannich base intermediate 19a via a Michael addition of the amine was 


















































n = 1, 2, 3, 5
(a)
(C)



































































Figure 2.23: Mechanism for the synthesis of the Mannich base intermediate (Clayden et 
al 2001; Vogel, A, 1987) 
 
The mechanism for the formation of the Mannich base intermediate involves a 
nucleophilic attack on the formaldehyde carbonyl to form the double charged 
intermediate that undergoes intramolecular proton transfer then dehydration to give the 
iminium ion intermediate. The acidity of the pyridinone 3-hydroxy group favours the 
nucleophilic attack of imine by the   pyridone‟s C-6 atom. A second intramolecular 
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2.4.4 Synthesis of Kojic acid-derived double drugs via the alkylhalide intermediates 
 
An alternative strategy to kojic acid derived double drugs was adopted and it involved a 
2-alkylchloride intermediate of kojic acid on to which N-(7-chloro-4-quinolinyl)-
diaminoalkanes were coupled via substitution of the chloride. 
2.4.4.1 The design 
The design of the alternative conjugates is represented in figure 2.24. This design allowed 
for the simultaneous introduction of the secondary/tertiary amino group and the N(7-
chloro-4-quinolinyl) in one step and at the same site of the molecule. This design retained 







iron  (metal) 
chelation
variation of n to fine tune lipophilicity to 
overcone resistance  and enhance HPO's 
antimalarial activity
Aminoquinoline 
nucleus for beta 
hematin binding
electron withdrawing 














In the retrosynthesis (Fig. 2.25) the following were identified as the core reactants; kojic 
acid, 4,7-dichloroquinoline, diaminoalkanes, benzylchloride, cyclopropylamine or 
methylamine. Retrosynthesis included C-O ether dealkylation to deprotect the target 
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to the 7-choroquinolin-4-yl-diamine or the 4,7-dichloroquinoline to the diaminoalkanes. 


























































Figure: 2.25: Retrosynthesis of kojic acid derived double drugs  
 
2.4.4.3 Synthesis  
 
The initial step involved benzyl protection of the kojic acid. The relatively more acidic 5- 
hydroxyl group of the pyranone was selected over the 2-methylhydroxyl group to give 
the desired intermediate (Fig. 2.26). This was followed by Michael addition of 
methylamine or cyclopropylamine to give the pyridinone 21 or 21a. Chlorination of the 
pyridinone (21 or 21a) using neat thionylchloride afforded the alkylhalide intermediates 
22 or 22a. These intermediates were easily isolated as precipitates or crystals in moderate 
to high yields. Chlorination was initially confirmed from the proton NMR as significant 
deshielding was observed for the protons adjacent to the Cl i.e the signals for methylene 
protons at C-2 and the protons of the N-1 alkyl groups were shifted by >0.4ppm. Extra 
evidence was the decrease in the melting point upon chlorination, an example is 21a (mp 
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melting point was due to the absence of H-bonding in 22a. The chlorination was further 
confirmed by mass spectrometry. The chlorination mechanism involved substitution of 






















22: R = Me
22a: R = cyclopropyl
21a: R = 
cyclpropyl
21: R=Me
Reagents and conditions: (a) BnCl, NaOH, EtOH, reflux (b) CH3NH2, NaOH, 50% aq EtOH, reflux (c) [i] 
SOCl2,  -7










































Figure 2.27: Mechanism for the chlorination step in the alkylhalide intermediate 
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This chlorination involves the 2-hydroxy group of the pyridinone acting as a nucleophile 
and which attacks the sulfur of the thionylchloride causing the exit of the chloride 
followed by a proton transfer to the latter to form HCl. The resulting intermediate is 
thermodynamically unstable and at ambient temperature converts to the most stable 









































R and D series
 Reagents and conditions: (b)DMF, Et3N, Na2CO3, reflux, 24 h (c) H2, Pd/C, 4 







Reagents and conditions: (a) acetonitrile, Et3N, NaOH, Microwave  18min, 100
oC, 250W, 249bars
 











Andayi AW                                                                                                                    UCT 113 
The final step to the benzyl protected conjugates involved reaction of 22 or 22a with the 
appropriate N-(7-chloro-4-quinolinyl) diaminoalkane (Fig.2.28). The coupling was 
successful under both microwave and reflux reaction conditions. DMF or acetonitrile 
were used as solvents because they are polar aprotic and hence appropriate for 





























NaCl, CO2, Et3NH  Cl
 
Figure 2.29: Mechanism for the coupling of the alkylhalide intermediates to the N-(7-
chloro-4-quinoyl)diaminoalkane 
 
The bimolecular substitution of the chlorine on the alkylhalide intermediate by the amine 
group from the N-(7-chloro-4-quinoyl) diaminoalkane was followed by the deprotonation 
of the intermediate to give the target molecule. A combination of NaHCO3 and 
triethylamine were used as bases to optimize the neutralization of HCl which would 
otherwise protonate the amine and favor the reverse reaction and to optimize the 
deprotonation of the amine. The purification of the benzylated conjugates was by column 
chromatography, and where possible, crystallization. An alternative to column 
chromatography was the precipitation of the unreacted N-(7-chloro-4-quinolinyl) 











Andayi AW                                                                                                                    UCT 114 
 
Deprotection was achieved by palladium-catalysed hydrogenolysis or by acid-catalysed 
hydrolysis. The compounds were isolated in low to moderate yields for the R series 
(Table 2.14) but moderate to high yields in the D series (Table 2.15). 
 
 Attempts to purify the deprotected compounds by HPLC using a conventional bonded 
silica stationary phase resulted in poor recovery of the pure compounds. This could be 
due to the interaction of the chelators with metallic parts of the HPLC instrument or the 
interaction with the free saturable silanol groups and residual metal impurities on the 
bonded silica phases. Evidence for this was the multiple peaks and severe tailing in the 
preparative chromatograms when compared to the analytical chromatograms both under 
basic and acidic pH. Similar difficulties were reported for the HPLC purification or 
analysis of N-alkyl-3,4-hydroxypyridinones (Guo et al, 2001; Epemolu et al, 1990). The 
recommended Hamilton PRP-1 polymer column or porous graphitised carbon (PGC 
Hypercarb®) columns were not available. Inspite of this, further attempts were pursued 
to purify two of the compounds using the silica bonded stationary phase. 
 
The purification of compounds 30a and 32a were successful but only 10% of the sample 
was recovered. Different fractions collected from the preparative HPLC showed similar 
proton NMR profiles indicating the same compound or its metal complexes. Because of 
this challenge, crystallization was adopted as the most appropriate method for the 
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Table 2.14: 2-((7-chloroquinolin-4-ylamino)alkylamino)methyl)-5-benzyloxy-1-












Characterisation of the compounds was by proton and carbon-13 NMR, high resolution 
mass spectrometry, elemental analysis, melting point and X-ray crystallography. The 
aromatic region of the proton NMR spectra of these compounds was similar to that of the  
maltol-derived double drugs except for the pyridinone protons signals (H-3, H-6), which 
appeared as two singlets. The aliphatic region of the proton NMR of the kojic acid 
derived double drugs resembled that of the maltol derivatives except for the following 
features (a) a singlet at ≈ 3.7- 4.5ppm for the 2-CH2 protons. (b) a singlet at  ≈ 3.5 -
Compound n R‟ R” % Yield 
23 1 H Bn 12 
23a 1 H H 74 
24 2 Me Bn 40 
24a 2 Me H 46 
25 2 H Bn 58 
25a 2 H H 43 
26 3 H Bn 48 
26a 3 H H 56 
27 5 H Bn 44 
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4.5ppm for the N-1-CH3 group or  two multiplets at  ≈0.90 - 1.2ppm for H-7 and 3.5 - 
4.2ppm for H-8 and H-9 of the cyclopropyl group (Fig. 2.30, 2.31). 
 
Table 2.15: 2-((7-chloroquinolin-4-ylamino)alkylamino)methyl)-5-benzyloxy-1-










Compound n R‟ R” % Yield 
28 1 H Bn 87 
28a 1 H H 56 
29 2 H Bn 91 
29a 2 H H 60 
30 2 Me Bn 89 
30a 2 Me H  
31 3 H Bn 64 
31a 3 H H 58 
32 5 H Bn 51 
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Comparing the carbon-13 spectra of the maltol and kojic acid derived analogs, their 
spectra were found to have the same number of signals in the aromatic region but extra 
peaks were observed in the aliphatic region of the kojic derivative signals corresponding 
to the N-1 alkyl group and the 2-methylene amine. 
 
The HRMS of these compounds indicated m/z corresponding to the molecular ion peak. 
Peaks corresponding to M+H, M+2H and M+3H were also observed due to the 
protonation of the three amino groups present in each double drug molecule. The 
elemental analyses indicated the molecules to be hydrated and this was further 
corroborated by the proton NMR and the X-ray crystallographic data of one of the 
compounds; 24 (Fig 2.31 and 2.32). 
 
The X-Ray crystallographic analysis of 24 indicated that there was one methanol and 
three water molecules for each molecule of 24 (M.3H2O.CH3OH). The methanol 
molecule is disordered by alternating of the positions of C and O, and the C and O were 
refined isotropically due to its high thermal motions. Two of the water molecules are 
disordered with oxygen over two positions. The hydrogens on these disordered methanol 
and water molecules were excluded form the final structure model. 
 
For the main 24 molecule, all non-hydrogen atoms were refined anisotropically and all 
hydrogen atoms on carbons were positioned geometrically with C-H distances ranging 
from 0.95 Å to 1.00 Å and refined as riding on their parent atoms, with Uiso (H) = 1.2 - 
1.5 Ueq (C). The position of amine hydrogen H2N (on N2) was located in the difference 
electron density maps and refined with simple bond length constraints. The structure was 
refined successfully with R factor 0.0579. The parameters for crystal data collection and 
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Figure 2.32: Projection viewed along b. Note the disordered solvent molecules 
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Table 2.16:  Hydrogen bonds for 24 [A and deg.].  
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(2)-H(2N)...O(1)#1 0.956(10) 2.011(16) 2.908(2) 155(3) 
O(1W)-H(1W1)...O(1) 0.966(10) 1.813(14) 2.767(3) 169(4) 
O(1W)-H(1W2)...N(1)#2 0.961(10) 1.779(11) 2.740(3) 178(4) 
 
Further analysis show that the heterocyclic ring is not regular as it has two C-C [1.436 
(3), 1.419(3)], two C=C [1.364(3), 1.343(2)] and two C-N [1.371(3), 1.353(3)], bonds 
respectively. The C (17) - O(1) bond (1.276 Å) is significantly longer than  a pure ketone 
C=O bond (1.210 Å) [Dobbin et al 1993], this provides the O(1) with a partial negative 
charge that is used to form strong hydrogen bonds. The C (17) - O(1) bond length is 
similar to the corresponding bond length in the pyrone precursor kojic acid (1.244Å) and 
deferiprone 2a (1.278 Å) a closely related pyridinone [Lokaj et al 1991; Clarke et al, 
1992].  
 
The ketone oxygen O(1) is not protonated because protonation would have resulted in the 
extension of the C(17)-O(1) bond length to ≈1.346Å, the typical length of a protonated 
ketonic oxygen in a hydroxypyridinone (Dobbin et al 1993). Protonation is not expected 
since the compound was obtained as a free base and no acid was used in the 
recrystallization. The water molecules are shown to participate in intramolecular 
hydrogen bonding along with the ketonic oxygen O(1) and the quinoline nitrogens N(1) 
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 The first siderophore-antibiotic double drug to be designed for antimalarial purpose 
involved a catecholate siderophore conjugated to nalidixic acid and had excellent activity 
against the resistant Plasmodium (Pradines et al., 1996). To overcome membrane 
mediated resistance synthetic siderophore-drug conjugates may act as a shuttle for active 
transport of drugs into the microbial cell wall i.e. the “trojan horse antimicrobials” (Braun 
et al 2009, Ghosh et al 1996). The 3,4-hydroxypyridinone is known to be the synthetic 
bioisostere of the catecholate, the latter is known to be metabolically labile than the 
former.  We envisaged a strategy for novel antimalarials in which the hydroxypyridinone 
moiety in the 3,4-HPO-aminoquinoline double drugs is replaced with the catecholate with 
the hope that this may enhance or retain  the antimalarial potency and reduce the 
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Figure 2.33: Sites of exposure (A) and reactivity (B) of the biscatecholate double drug 
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reactivity of the highlighted part of the molecule i.e. blue shows greater exposure or 




Metasite® prediction showed the quinoline substructure in the novel biscatecholate (Fig 
2.32) to be less exposed and more reactive towards the active site (Fig 2.32).  Given that 
the quinoline is associated with CYP3A4 inhibition (Zlokarnik et al 2005; Riley and 
Kenna, 2004), such a prediction implied lesser potential for CYP3A4 inhibition. This 
contrasts the maltol and kojic derived double drugs profiles in the model in which the 
quinoline is more exposed but unreactive implying potential to inhibit CYP3A4. 
 
2.5.2 Design 
In the design the synthetic tetradentate bis-catecholate siderophore is attached to a N-(7-
chloro-4-quinoyl) diaminoalkane. The chelator groups are acetyl protected to form a 
prodrug which can be deprotected under physiological conditions (Braun et al 2009, 


















chelator group in prodrug form
siderophore
 
Figure 2.34: Design of the siderophore-aminoquinolie drug conjugate molecule 
 
2.5.3 Synthesis  
 
The siderophore fragment 36 was synthesized via several steps as illustrated in Figures 
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catechols are attached to give the siderophore.  The preparation of 35 involved a 
reductive amination reaction between 1,3-diaminopropane and 4-formylbenzoic acid 
(Fig. 2.35). The reduction was mediated by hydrogenation catalyzed by palladium on 












































Figure 2.35: Synthesis of the 4-((3-aminopropylamino)methyl)benzoic acid 35  and the 
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The reaction proceeded by the elimination of water from III to form the unstable imine 
intermediate IV. (Clayden et al 2001) The imine is selectively reduced leaving the 



















































Conditions and Reagents: (a) Ac2O, H
+, N2, 12h, (b) PCl5, CHCl3, N2, 0






Figure 2.36: Synthesis of C4 and mechanisms for the reaction. 
 
The diacyloxybenzoylchloride 34 was prepared as documented by Bergeron et al (1980) 
Initially the 2,3-dihydroxybenzoic acid was acetylated using acetic anhydride under inert 
atmosphere and acid catalysis (Fig. 2.36). The final step involved chlorination of 33 with 
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apparatus were used to avoid contamination from HCl corroding the rubber apparatus. 
The two compounds (34 and 33) were easily separated as crystals or as a solid. Both 
reactions proceded via unstable tetrahedhral intermediates as illustrated in Figure 2.35. 





















































Figure 2.37: Synthesis of the siderophore 36, and mechanisms for the reaction. 
 
The final step to the siderophore (36) was prepared by attaching two molecules of 
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assumed that the first nucleophilic attack occurs on the primary amine which is less 
hindered. The nitrogen of the amide formed is unreactive towards a second nucleophilic 
attack since its lone pair is delocalised via resonance with the carbonyl oxygen. Therefore 
the second nuceophilic attack will certainly occur on the hindered secondary amine to 
give the target C6. The siderophore was purified by recrystallization and preparative 
HPLC-MS before submitting for physicochemical characterization and biological testing. 
 
 The crude form of compound 36 was used in the subsequent step of coupling to the N-(7-
chloro-4-quinoyl) diaminoalkane 8 (Fig. 2.39). After purification by preparative HPLC-
MS (Fig. 2.38), the product was obtained in very low yields. The conjugate 37 was more 
polar (Rt 6.96min.) than the siderophore 36 (Rt 5.54min.) therefore, it eluted later in the 
HPLC (Fig. 2.38). 
 
Figure 2.38: Chromatogram and mass spectrum for the preparative HPLC-MS of 37 
The peaks at retention times 5.54, 5.90 and 6.96 minutes correspond to compounds 37, 
the diamine 8 and the siderophore 36 respectively. The mass spectrum peak at m/z 908.5 
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The synthesis involved the activation of the resonance stabilized unreactive carboxylic 
acid group in the siderophore. This was achieved by reacting 36 with 
chloromethylformate in the presence of an acid scavenger (N-methylmorpholine) to form 
the reactive ester intermediate VIII (Clayden et al., 2001; Mackie and Smith, 1985; 
Wipf, 1999). This intermediate readily underwent nucleophilic attack by the amine to 
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Figure 2.39: Synthesis of the siderophore-aminoquinoline conjugate 37 and mechanisms 
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The terminal methyl group on the mixed anhydride (VIII) causes a positive inductive 
effect which makes the less hindered carbonyl carbon less reactive when compared to the 
hindered carbonyl (Fig. 2.39). The hindered carbonyl is more reactive towards a 
nucleophilic attack because of the electron withdrawing effects of the aromatic ring and 
the oxycarboxylate group attached to it. 
 
2.5.4 Characterization 
The compounds were characterised by proton and carbon-13 NMR, elemental analysis, 
HRMS, and melting point determinations for the solids. HR-MS was important in helping 
to conclude the target conjugate 37 was isolated since the latter‟s proton NMR signals 
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CHAPTER THREE 
 BIOLOGICAL ACTIVITY 
 





There was need to establish the baseline antiplasmodial activity of known 1-N-alkyl-3,4-
hydroxypyridinones (3,4-HPOs) and confirm the role potential of iron chelation in the 
antimalarial activity of these compounds before synthesis of new structurally modified 
3,4-HPOs. Therefore a number of known 3,4-HPOs with variations in the chain length of 
the N-alkyl group were synthesized and tested for antiplasmodial activity. The N-alkyl 
variation was meant to fine tune the lipophilicity of these iron chelators. Lipophilicity has 
been shown to directly correlate with the inhibitory action of chelators against malaria 
parasites as demonstrated for a number of chelators namely; N-alkyl derivatives of 3,4-
hydroxypyridinones (3,4-HPOs) and aminothiols (Shanzer et al, 1991, Hershko et al., 
1991, Loyevsky et al., 1996). 
 
Complexation with gallium (III) has been reported to enhance antiplasmodial activity and 
to overcome drug resistance in aminophenols (Ocheskey et al, 2003; 2005, Goldberg et 
al, 1997). This has not been reported for the antiplasmodial activity of N-alkyl-3,4-HPOs, 
hence providing a reason to prepare and study the antiplasmodial activity of the 3,4-HPO-




The quantitative assessment of in vitro antiplasmodial activity in this work was against 
chloroquine sensitive (CQS) D10 and 3D7 strains and a chloroquine resistant (CQR) K1 
strain of Plasmodium falciparum. 
 
None of the N-alkyl-3,4-HPOs had activity comparable to CQ against either the resistant 
or sensitive strains (Table 3.1). The trend of antiplasmodial activity increasing with 
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R3 D10 3D7 K1 
2ª Me H 142 49.1 114.2 
1ª Me Bn >377 >50.0 >87.0 
2b Et H 67.2 ND ND 
1b Et Bn 234 >113 >82.0 
2c Bu H 35.9 79.2 7.65 
1c Bu Bn ND ND ND 
2d Cyclopropyl H 103.9 7.42 >99.5 
1d Cyclopropyl Bn ND >32.0 >78.0 
2e Isopropyl H 90.1 >77.8 >98.5 
1e Isopropyl Bn >343 >35.0 >77.0 
2f n-propyl H ND ND ND 
1f n-propyl Bn 256 11.5 >47.0 
2g n-hexyl H 14.7 3.54 4.16 
1g n-hexyl Bn 84.0 >98.0 >66.0 
2h n-octyl H 5.49 2.38 1.80 
1h n-octyl Bn 48.0 30.8 >61.0 
CQ   0.066 0.003 0.21 
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D10 3D7 K1 
2ª Me ligand 142 49.1 114.2 
3ª Me complex 205 87.4 41.3 
2b Et ligand 67.2 ND ND 
3b Et complex 33.5 7.05 38.0 
2c Bu ligand 35.9 79.2 7.65 
3c Bu complex 142 92.1 32.8 
2d Cyclopropyl ligand 103.9 7.42 >99.5 
3d Cyclopropyl complex >177 >99.5 >35.6 
2e Isopropyl ligand 90.1 >77.8 >98.5 
3e Isopropyl complex >175 >98.5 >35.2 
2g n-hexyl ligand 14.7 3.54 4.16 
3g n-hexyl complex 38.6 ND ND 
2h n-octyl ligand 5.49 2.38 1.80 
3h n-octyl complex 14.9 2.37 >25.7 
CQ   0.066 0.003 0.21 














Andayi AW                                                                                                                    UCT 134 
Iron chelation was hypothesised to be the major mode of antimalarial activity for the N-
alkyl-3,4-HPOs because blocking of the chelator group either by pre-complexation with  
gallium (III) or by benzyl protection negated the antiplasmodial activity of these 
compounds (Tables 3.1 and 3.2). 
Benzyl protection caused a decrease in the antiplasmodial activity against the sensitive 
strains but a similar trend was not observed in the resistant strain except for compounds 
2g and 2h (Table 3.1) 
 
Compounds 2g and 2h were the most active as expected since they were the most 
lipophilic and their antiplasmodial activity was consistent across the three strains of P. 
falciparum. Compound 2h (IC50 = 1.8 µM) was ≈ 30 times more active than its benzylated 
precursor 1h (IC50>61 µM) against the CQ resistant isolate K1 (Tables 3.1). 
Complexation with gallium (III) caused a decrease in antiplasmodial activity against the 
sensitive strains except for compound 2b. A similar trend was not observed in the 
resistant strain except for compounds 2c and 2h. There was a slight improvement in the 
antiplasmodial activity of some of the 3,4-HPOs on complexation with gallium (III) e.g. 
2a, 2d and 2e against K1. 
 
All the compounds were evaluated for β haematin inhibition using the phi-β assay 
(Ncokazi and Egan, 2005), and none of them showed inhibition at the highest 
concentration (IC50 equivalents = 10). 
 
  From the biological data presented, it was concluded that the compounds were not 
comparable let alone better than CQ and that they had poor activity against the resistant 
strains of P. falciparum. Therefore there was a need for further structural modification to 
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3.2 In vitro activity of combinations of 2h, 1h, dihydroartemisinin (DHA) and 
chloroquine diphosphate (CQ-DP). 
 
3.2.1 Rationale 
Conjugation of 3,4-HPOs with quinoline or endoperoxide antiplasmodial compounds to 
form double drugs was envisaged. Prior to synthesizing these double drugs there was 
need to ascertain whether or not this class of iron chelators synergizes or antagonizes the 
antiplasmodial activity of the endoperoxides and quinolines. To inform this, the 
antiplasmodial activity of combinations of selected 3,4-HPOs with dihydoartemisinin and 
chloroquine diphosphate was studied. Even though iron chelators have been reported to 
antagonize the in vitro antiplasmodial activity of artemisinins (Meshnick et al 1993; 
Stocks et al., 2007) or synergize the antiplasmodial activity of chloroquine CQ (Co et al., 
2009) it was important to ascertain this before further work.  
 
Compounds 2h and 1h, which had the best in vitro antiplasmodial activity among the 3,4-
HPOs were selected for drug combination studies. They were combined with chloroquine 
diphosphate CQ-DP or dihydroartemisinin (DHA) using a method that has been 
described in literature (Berenbaum 1978; Barquero et al., 1997; Adovelande et al., 1998; 
Pattanapanyasat et al., 2001; Ohrt et al., 2002), and the combinations were tested in vitro 
against K1 and 3D7 isolates of P. falciparum. 
 
The fractional inhibitory concentrations, FICs, were employed to determine synergistic or 
antagonistic or additive interactions of the drug combinations (He et al., 2010, Ohrt et al 
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FIC50 values were calculated by the formula shown below 
 
(1)  FIC50 (Bi) = IC50 (Ai+Bi) × Bi 
                  IC50 (B) 
 
(2)  FIC50 (Ai) = IC50 (Ai+Bi) × Ai 
                   IC50 (A) 
 
    (3)  Σ FIC50 = FIC50 (Ai) + FIC50 (Bi) 
 
Ai = fraction of A in a given combination 
Bi = fraction of B in a given combination 
IC50 (Ai+Bi) = IC50 of fraction combinations of two drugs A and B 
IC50 (B) = IC50 of fraction containing 100% B 
IC50 (A) = IC50 of fraction containing 100% A 
 
Compound 2h combinations with CQ or DHA were predominantly synergistic in both K1 
and 3D7 whereas its benzylated analogue 1h combinations with DHA and CQ were 
synergistic and antagonistic respectively 
 
3.2.2 In vitro Antiplasmodial Activity of Combinations of 1h or 2h with CQ 
 
The ΣFIC50 values for 2h/CQ-DP combinations are illustrated in Table 3.3 and the 
interaction was found to be strongly synergistic because the ΣFIC50<1 when tested 
against 3D7. A similar interaction was observed for this combination in the K1 strain 
except for two FIC50 values (2.81 and 2.04). If the two data points are treated as outliers 
then the interaction will be assumed to be synergistic. If the outliers are incorporated then 
the interaction may be considered additive. In fact additive interaction in combinations 
between a 3,4-HPO (2a) and quinolines (quinine and mefloquine) have been reported 
(Pattanapanyasat et al., 2002). There is some evidence that the three antimalarials MQ, 
CQ and QN kill the parasite by similar mechanisms (Tilley et al., 2001) therefore, one 
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Table 3.3: In vitro antiplasmodial activity against P. falciparum and FIC50 for different 







Σ FIC50  
(3D7) 
Σ FIC50  
( K1) 
1 0 1 1 
0.788 0.211 0.043 0.08 
0.647 0.353 0.007 2.81 
0.476 0.524 0.003 0.30 
0.35 0.65 0.0015 0.78 
0.261 0.739 0.0017 0.02 
0.18 0.82 0.0037 2.04 
0.115 0.885 0.0005 0.72 
0 1 1 1 
 
 
Table 3.4: In vitro antiplasmodial activity against P. falciparum and FIC50 for different 











1 0 1 1 
0.833 0.277 11.09 2.70 
0.7 0.3 1.69 1.94 
0.524 0.476 3.46 2.74 
0.455 0.545 2.25 5.88 
0.283 0.717 0.81 1.49 
0.18 0.82 0.31 0.99 
0.11 0.89 1.45 0.98 
0 1 1 1 
 
Compound 1h is inactive on its own (IC503D7 = 30.8μM, IC50K1 > 61μM) however the 
1h/CQDP combination was observed to be strongly antagonistic in both strains (Table 
3.4). Most of the ΣFIC50 values for the 1h/CQDP were >1 in either strain implying that 
the 1h and CQ interaction was predominantly antagonistic.  
 
The antagonistic or indifferent interaction observed for 1h/CQDP implicates competing 
modes of action between chloroquine and the benzyl protected iron chelator. To explain 
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and 4.6 respectively. The two compounds have similar lipophilicity hence may access 
similar intraparasitic compartments and possibly compete for similar pathways leading to 
antagonism when the two are combined. Such a possibility is minimal for 2h which is 
less lipophilic (cLogP of 2.8).  The benzyl group on the 3, 4-HPO could be interacting 
with some of the parasitic targets of CQ possibly by π –π stacking with the heme 
porphyrin. However, this interaction may be considered weak since the N-alkyl 3,4-HPOs 
were identified were found to be weak β-haematin inhibitors. Another possibility could 
be that the CQ interaction with its parasitic targets leads to a cascade of events that 
enables 1h to access the very targets it could not accesss on its own.  
 
3.2.3 In vitro Antiplasmodial Activity of combinations of 2h or 1h with DHA 
 
For the 9B/DHA all the ΣFIC50 values for K1 were less than one implying a synergistic 
interaction as depicted  in Table 3.5, but the ΣFIC50 values in the 3D7 data ranged from 
greater than 1 to less than one suggesting additive interaction. 
 
Table 3.5: In vitro antiplasmodial activity against P. falciparum and FIC50 for different 
combinations of 2h with DHA 
 
 
The synergistic interaction observed for 2h/DHA was not expected since 3,4-HPOs are 
known to antagonize endoperoxides (Meshnick et al, 1993; Pattanapanyasat et al, 2001; 
Stocks et al., 2007), via sequestration of the endogenous chelatable iron which is claimed 










1 0 1 1 
0.857 0.143 0.58 0.013 
0.733 0.26 1.70 0.029 
0.655 0.3448 0.17 0.001 
0.52 0.48 0.96 0.032 
0.345 0.655 0.33 0.001 
0.286 0.714 1.07 0.046 
0.133 0.866 0.87 0.006 
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al, 2007). Combinations of 2h with other endoperoxides may be investigated in the future 
to confirm whether the interactions depend on the type of endoperoxide or the type of 
3,4-HPO used.  
 
The 1h/DHA combination resulted in a synergistic interaction in both 3D7 and K1 strains 
(Table 3.6). The chelating group on 1h was blocked by the 3-benzyl group, and thus 
diminishing this compounds ability to act as an iron chelator. As such it was not expected 
to antagonize the antiplasmodial activity of the endoperoxide. This reaffirms that, apart 
from iron sequestration being the main mode of action for antiplasmodial N-alkyl-3,4-
HPOs, these compounds have additional modes of action whose effect may be realized on 
blocking the chelating group. These findings are comparable to experiments in which 
pre-complexation with iron (III) was used to block the chelating moiety to prevent the 
iron chelator from antagonizing the biological activity of artemisinins (Meshnick et al, 
2002).  
 
Table 3.6: In vitro antiplasmodial activity against P. falciparum and FIC50 for different 










  (K1) 
1 0 1 1 
0.89 0.11 0.0002 0.007 
0.813 0.188 0.0005 0.017 
0.636 0.364 0.0018 0.015 
0.56 0.44 0.0005 0.006 
0.41 0.59 0.0002 0.007 
0.31 0.69 0.0009 0.008 
0.14 0.86 0.002 0.072 
0 1 1 1 
 
 
Given that the 2h/CQ-DP combination is synergistic in the resistant and sensitive strains 
of P. falciparum, it was felt logical to synthesize 3,4-HPO-4-amino-7-chloroquinolinyl 
conjugates or hybrid molecules. To synthetically access this type of conjugate, it was 
inevitable to go through the benzyl protected analogues. Thus the subsequent stage of the 
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conjugates, which were then deprotected to deliver the target molecules. This direction 
does not rule out the development of artemisinin-iron chelator conjugates as 
antiplasmodials to fight drug resistance because Kamchonwongpaisan et al., (1995) 
demonstrated that an artemisinin-3,4-HPO conjugate retained antiplasmodial activity 
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3.3 Biological activity of the double drugs (hybrids) 
The double drugs were evaluated for the inhibition of β-haematin formation, in vivo and 
in vitro antiplasmodial activity, cytotoxicity and inhibition of CYP 3A4. The four series 
of hybrid molecules whose biological activities are considered in this chapter are A, AB, 
R and D these are predefined in section 1.15. 
 
3.3.1. In vitro antiplasmodial activity in CQ sensitive strain 3D7 
3.3.1.1. Antiplasmodial and β-haematin inhibition activities of AB series 
Table 3.7: In vitro antiplasmodial activity against CQ sensitive P. falciparum 3D7 











Compound R3 n βHIA IC50/equiv. P. falciparum 
IC50 (µM) 
    3D7  
10 Bn 1 0.50 0.95  
10a H 1 1.1 0.4  
12 Bn 2 0.41 0.12  
12a H 2 1.3 0.12  
14 Bn 3 0.19 0.004  
14a H 3 0.98 0.05  
16 Bn 5 0.16 0.007  
16 HCl salt Bn 5 --- 0.008  
16a H 5 0.49 0.079  
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In the in vitro tests, five isolates of P. falciparum were used namely, D10, 3D7 (CQ 
sensitive) and Dd2, W2 and K1 (CQ resistant). The CQ resistant W2 strain was from the 
Rosenthal Laboratory, (University of California, San Francisco) and is known to be  more 
susceptible to CQ than other W2  strains from elsewhere (Chibale, 2010: Personal 
communication)   The in vivo tests were performed in Swiss Webster female mice 
infected with P. berghei.  
 
The β-haematin inhibition activity assay is used to measure the ability of compounds to 
inhibit the formation β-haematin, the synthetic equivalent of haemozoin. Haemozoin is 
produced as an end product of heme released during the digestion of the host 
haemoglobin and this believed to be a detoxificaion pathway in the parasite (Egan, 2008). 
Blocking this pathway via haemozoin inhibition kills the parasite.  Aqueous pyridine (5% 
v/v, pH 7.5) forms a low-spin complex with haematin but not with β-haematin. The 
absorbance of the complex obeys Beer‟s law, making it useful for quantitating hematin 
concentration in hematin/β-hematin mixtures, allowing compounds to be investigated for 
inhibition of β-hematin formation (Ncokazi and Egan, 2004).  
 
For both the benzylated and deprotected analogues, β-haematin inhibition activity 
appeared to improve with increase in number of carbons in the side chain as depicted in 
Table 3.7. However, no significant difference was observed between compounds with 
alkyl linker of 4 or 6 carbons i.e. 14 (0.19 equiv.) and 16 (0.16 IC50/equiv). Deprotection 
was observed to cause a slight decrease in β-haematin inhibition activity e.g. when 10 
(0.5 IC50/equiv.) is compared to its deprotected analogue 10a (1.1 IC50/equiv.). The β-
haematin inhibition activity of all compounds was superior to that of CQ. 
 
The antiplasmodial activity seems to increase with increase with increase in number of 
carbons in the side chain for both benzylated and deprotected analogues. Deprotection is 
observed to cause a decrease in antiplasmodial activity against the 3D7 strain e.g. 
comparing 16 (IC50 = 0.007µM) to 16a (IC50 = 0.079µM). Three compounds were 
observed to be more active than CQ i.e. 14, 16 and its hydrogenchloride salt. Since 
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implied that their main mode of action could be by haemozoin inhibition. This is further 
reinforced by the observation that deprotection caused a decline in both β-haematin 
inhibition and antiplasmodial activity. 
 
3.3.1.2. Antiplasmodial and β-haematin inhibition activities of A series 
For both the benzylated and deprotected analogues, β-haematin inhibition activity 
appears to increase with increase in the number of carbons in the side chain [Table 3.8]. 
Deprotection was observed to cause a decrease in β-haematin inhibition activity e.g. 
comparing 9 (0.93 IC50/equiv.) to its deprotected analogue 9a (2.9 IC50/equiv.), details 
are also represented in Figure 3.1. The β-haematin inhibition activity of all compounds in 
the A series was superior to that of CQ except for 9a (2.9 IC50/equiv.). 
 
Table 3.8: In vitro antiplasmodial activity against CQ sensitive P. falciparum 3D7 strain 









β-HIA- β haematin inhibition activity;  





      
9 Bn 1 0.93 0.49  
9a H 1 2.9 10.8  
11 Bn 2 0.49 0.28  
11a H 2 ND ND  
13 Bn 3 0.27 0.05  
13a H 3 0.66 0.03  
15 Bn 5 0.25 35.7  
15a H 5 0.47 0.39  
















Figure: 3.1 Comparison of β- haematin inhibition activity among the four series. 
The A and AB series are closely related and data indicates the benzylated AB series to be 
more potent β-haematin inhibitors than the benzylated A series. R and D series are 
closely related hence the comparison and it is clear that the benzylated D series are more 
potent inhibitors than the benzylated R series. Deprotected analogues are seen to be 
weaker β-haematin inhibitors than the benzylated. No distinct trend was observed in the 
deprotected analogues. Benzylated analogues with tertiary amine groups were found to 
be weaker inhibitors than their analogues without a tertiary amino group. 
 
No trend was observed between antiplasmodial activity and lipophilicity in both 
benzylated and deprotected analogues of the A series. Deprotection was observed to 
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depending on the compound. Even though deprotection caused a decline in β-haematin 
inhibition; this did not translate into a drop in antiplasmodial activity for all compounds 
in the A series. This could mean other mechanisms play part in upholding the 
antiplasmodial activity of the deprotected compounds despite a decrease in β-haematin 
inhibition. These mechanisms could be related to iron chelation or access to the site of 
action or a favorable interaction of the hydroxypyridinone free OH with an intraparasite 
target.  
 
3.3.1.3. Antiplasmodial and β-haematin inhibition activities of R series 
Table 3.9: In vitro antiplasmodial activity against CQ sensitive P. falciparum 3D7 strain 









Compound n R5 R βHIA 
IC50 
equiv. 
P. falciparum  
IC50(µM)  
3D7 
      
23 1 Bn H 1.27 0.54 
23a 1 H H 0.63 0.58 
24 2 Bn Me 1.98 0.39 
24a 2 H Me 1.95 0.04 
25 2 Bn H 1.30 0.30 
25a 2 H H 6.12 0.12 
26 3 Bn H 0.42 0.24 
26a 3 H H ND 0.67 
27 5 Bn H 0.51 0.04 
27a 5 H H 0.70 0.19 
CQ    1.9 0.016 
βHIA: β haematin inhibition activity; ND not determined. 
 
No trend was observed between β-haematin inhibition and lipophilicity in both 
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lipophilic compounds (27 and 27a) exhibited the best β-haematin inhibition activity. 
Generally deprotection caused a decrease in β-haematin inhibition activity of these series 
except for 23. The β-haematin inhibition activity of all compounds was superior or 
comparable to that of CQ (1.9 equiv.) except for 25a (6.12 equiv.). The tertiary amino 
group was implicated to cause a decrease in the β-haematin inhibition activity for the 
benzylated analogues e.g. 25 (IC50/equiv. = 1.3) compared to 24 (IC50/equiv. = 1.98). In 
contrast the tertiary amino group caused an improvement in the β-haematin inhibition 
activity of the deprotected analogues e.g. 25a (6.12 equiv.) compared to 24a (1.95 
equiv.), [Fig.3.1].  
 
Antiplasmodial activity was observed to increase with increase in the number of carbons 
in the side chain. The activity of the R series against the sensitive strain 3D7 was lower 
than that of chloroquine (IC50 = 0.016µM). The most active compounds against 3D7 was 
27 (IC50 = 0.04µM) and 24a (IC50 = 0.04 µM) and the least potent in the series was 23 
(IC50 = 0.54µM). Deprotection was observed to cause either a decrease or an increase in 
antiplasmodial activity against the 3D7 strain depending on the compound. The 
incorporation of the tertiary amine group caused a drastic improvement in the activity of 
deprotected analogue but no significant effect on the activity of the benzyl protected 
analogue. This is clear when the benzylated analogues 24 (IC50 = 0.39µM) and 25 (IC50 = 
0.3µM) are compared and the deprotected analogues 24a (IC50 = 0.04µM) and 25a (IC50 
= 0.12µM) are compared.  This observation shows the dependence of the antiplasmodial 
activity of these compounds on β-haematin inhibition. The incorporation of the tertiary 
amine group in deprotected analogues appeared to cause an increase in β-haematin 
inhibition activity and as expected it translated into a significant increase in the 
antiplasmodial activity.  In contrast the incorporation of the tertiary amino group in 
benzylated analogues caused a decline in β-haematin inhibition activity and further 
translated into a less significant drop in antiplasmodial activity. Structurally it may be 
hypothesized that the presence of both a tertiary and benzyl group causes steric hindrance 
thus weakening/interfering with the π-π stacking interactions of the quinoline nucleus or 
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3.3.1.4. Antiplasmodial and β-haematin inhibition activities of D series against 3D7 
No trend was observed between β-haematin inhibition and increase in the number of 
carbons in the side chain in both deprotected and benzylated analogues (Table 3.10). 
Deprotection was found to cause a decrease in both β-haematin inhibition and 
antiplasmodial activity in all the compounds in the series. Deprotection caused a decline 
in the β-haematin inhibition for all the D series compounds. The decreased β-haematin 
inhibition did not translate to lower antiplasmodial activity in all the deprotected 
analogues. The tertiary amino group was found to cause a decrease in the β-haematin 
inhibition activity in both the deprotected and benzylated analogues i.e. 29 (0.22 equiv.) 
when compared to 30 (1.87 equiv.) or 29a (2.62 equiv.) when compared to 30a (5.24 
equiv.).  
 
Table 3.10: In vitro antiplasmodial activity against strain against CQ sensitive P. 












 IC50 (µM) 
     3D7 
28 1 Bn H 0.56 0.21 
28a 1 H H 1.41 0.23 
29 2 Bn H 0.22 0.19 
29a 2 H H 2.62 0.20 
30 2 Bn Me 1.87 0.15 
30a 2 H Me 5.24 0.30 
31 3 Bn H 0.82 0.16 
31a 3 H H 2.57 0.17 
32 5 Bn H 0.071 0.004 
32a 5 H H 1.39 0.03 
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Only compound 32 was more active than CQ against 3D7. The antiplasmodial activity in 
the 3D7 strain appears to be similar for most compounds except for the compounds with 
the longest chain (32 and 32a). Thus it is postulated that the variation of the side chain 
begins to have an effect on the antiplasmodial activity when it gets to 6 carbons. The 
introduction of the chelator group via deprotection did not cause any significant change 
in the antiplasmodial activity despite causing a significant decrease in the β-haematin 
inhibition. This may mean the benzyl group is involved in β-haematin inhibition and that 
the potential contribution of iron chelation towards the activity in the sensitive strain is 
minimal. In addition it could mean that other factors apart from β-haematin inhibition are 
important to the overall antiplasmodial potency. Such factors may include enhanced 
vacuolar accumulation due to the presence of the amino group which may not change on 
deprotection, or the chelator group may be triggering other mechanisms that compensate 
activity loss due to decrease in β-haematin inhibition. 
 
The tertiary amino group in the D series appeared to depress the activity in the sensitive 
strain for the deprotected compounds (29a compared to 30a) possibly due to the 
decreased β-hematin inhibition caused by the tertiary amine group. Therefore haemozoin 
inhibition seems to be important for the antiplasmodial activity of these compounds. The 
tertiary amine group seems to have lesser effect on the antiplasmodial activity of the 
benzylated analogues in the D series. 
 
3.3.2. In vitro antiplasmodial activity in CQ resistant W2 and K1 strain 
3.3.2.2.In vitro antiplasmodial activity of the AB series in W2 and K1 resistant 
strains 
In both the benzylated and deprotected analogues of the AB series, antiplasmodial 
activity in W2 was found to improve with increase in lipophilicity (Table 3.11). 
Deprotection was found to enhance activity in the analogues with shorter side chains (less 
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Table 3.11: In vitro antiplasmodial activity against CQ resistant P. falciparum K1 and 












In the K1 strain the activity of the benzylated analogues did not show a specific trend. 
But, the activity of the deprotected analogues increased with increase in lipophilicity. In 
both resistant K1 and W2 strains, deprotection was found to enhance activity in the 
analogues with shorter side chains (2 -3 carbon atoms in the side chain) but to cause a 
decline in activity of analogues with longer side chains (4 – 6 carbon atoms in the side 
chain)  
 
3.3.2.3. In vitro antiplasmodial activity of the A series in resistant W2 and K1 strains 
In both the benzylated and deprotected analogues, antiplasmodial activity in W2 was 
found to improve with increase in lipophilicity (Table 3.12). Deprotection was found to 




    K1 W2 
10 Bn 1 0.50 8.43 2.59 
10a H 1 1.1 0.89 1.24 
12 Bn 2 0.41 71.6 2.32 
12a H 2 1.3 0.38 0.54 
14 Bn 3 0.19 0.13 0.10 
14a H 3 0.98 0.27 0.16 
16 Bn 5 0.16 0.08 0.015 
16 HCl salt Bn 5 ND 0.1 ND 
16a H 5 0.49 0.61 0.09 
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enhance activity in the analogues with shorter side chains (less lipophilic analogues) but 
to cause a decline in the more lipophilic analogues. None of the compounds in the A 
series was more active than CQ in both K1 and 3D7 strains. Compound 13a (IC50 = 
0.03µM) had the highest activity in the series against the resistant K1 strain. 
 
In the K1 strain the activity of both the benzylated and deprotected analogues did not 
show a specific trend. Deprotection was found to enhance activity in K1 except for the 
least lipophilic compound, 9. 
 
Table 3.12: In vitro antiplasmodial activity against CQ resistant P. falciparum K1 and 








β-HIA- β haematin inhibition activity 
 
Deprotection is seen to enhance activity in the resistant strain for the series, therefore, it 
is speculated that, this may be a result of improved access to the site of action, 
contribution of iron chelation or favorable interaction of the free OH with an intraparasite 
target. 
Compound R3 N βHIA 
IC50/equiv 
P. falciparum 
IC50  (µM) 
    K1 W2 
9 Bn 1 0.93 3.15 9.93 
9a H 1 2.9 32.6 0.28 
11 Bn 2 0.49 3.57 2.15 
11a H 2 ND ND ND 
13 Bn 3 0.27 2.2 1.12 
13a H 3 0.66 0.07 0.08 
15 Bn 5 0.25 4.38 0.39 
15a H 5 0.47 0.16 0.07 
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3.3.2.4. In vitro antiplasmodial activity of the R series in resistant K1 strain 
In the benzylated analogues antiplasmodial activity was observed to increase with 
increase in the number of carbons in the side chain, however no trend was observed for 
the deprotected analogues (Table 3.13). The antiplasmodial activity was found to 
improve on deprotection for all compounds except 27. Only two compounds were potent 
more than CQ and coincidentally they were the deprotected analogues (24a and 26a).  
 
Table 3.13: In vitro antiplasmodial activity of kojic derived double drugs (R series) 









Compound n R5 R βHIA 
IC50 
equiv. 
P. falciparum  
IC50(µM) 
     K1 
23 1 Bn H 1.27 2.56 
23a 1 H H 0.63 1.75 
24 2 Bn Me 1.98 0.15 
24a 2 H Me 1.95 0.04 
25 2 Bn H 1.30 2.08 
25a 2 H H 6.12 0.27 
26 3 Bn H 0.42 1.71 
26a 3 H H ND 0.07 
27 5 Bn H 0.51 0.32 
27a 5 H H 0.70 0.32 
CQ    1.9 0.20 
βHIA: β-haematin inhibition activity; ND not determined. 
 
The introduction of a tertiary amine group enhanced the activity of the R series against 
resistant strain. This is clear when compound 24 (IC50 = 0.15µM) is compared to 25 (IC50   
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In the previous section it was observed that decline in β haematin inhibition activity for 
analogues with tertiary amine group caused a decline activity in the sensitive 3D7 strain. 
However, this did not translate into a decrease in activity in the K1 strain. It shows that 
other factors may be involved i.e. accumulation in the FV which is important in 
counteracting the drug export effect of the mutant PfCRT in the resistant strain. It is 
assumed that accumulation is enhanced by the presence of the tertiary amino group.  
 
All the other compounds in the R series (except 25a) were stronger β-haematin inhibitors 
than 24a but the latter had superior antiplasmodial activity to all. The most potent β-
haematin inhibitor (26) in the R series was not the most potent antiplasmodial agent. It 
may be assumed that other factors, other than β-haematin inhibition, are affecting the 
antiplasmodial activity of 24a. Probably the accumulation of this compound in the 
parasitic food vacuole is enhanced by the presence of the tertiary amino group. 
Furthermore compounds 24 and 24a exhibited higher antiplasmodial activity in K1 than 
related analogues that lack the tertiary amine group (25 and 25a). This shows that the 
tertiary amine group in 24 and 24a enhanced the antiplasmodial activity more than the 
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Table 3.14: In vitro antiplasmodial activity of kojic derived double drugs (D series) 









3.3.2.5. In vitro antiplasmodial activity of the D series in K1 resistant strains 
No trend was observed for the variation of the length of the side chain and antiplasmodial 
activity in both benzylated and deprotected analogues. None of the compounds was as 
active as CQ except 32 which happen to have the longest side chain (with greatest 
number of carbons in the side chain). Deprotection caused an increase or a decrease in 
antiplasmodial activity depending on the compound. Incorporation of the tertiary amine 
group suppressed the antiplasmodial activity against K1 in the protected analogue i.e. 30 
(IC50 = 0.97 µM) compared to 29 (IC50 = 0.27 µM). Since this was accompanied by a 
decline in β-hematin inhibition, it may be hypothesized that β-hematin inhibition is an 
important mode of action of this compounds. The tertiary amine group caused a slight 
increase in antiplasmodial activity against K1 in the deprotected analogue i.e. 30a (IC50 = 
0.46 µM) compared to 29a (IC50 = 0.72 µM).  




 IC50 (µM) 
     K1 
28 1 Bn H 0.56 1.45 
28a 1 H H 1.41 0.36 
29 2 Bn H 0.22 0.27 
29a 2 H H 2.62 0.72 
30 2 Bn Me 1.87 0.97 
30a 2 H Me 5.24 0.46 
31 3 Bn H 0.82 0.85 
31a 3 H H 2.57 0.36 
32 5 Bn H 0.071 0.03 
32a 5 H H 1.39 0.08 
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3.3.2.6. Resistance Indices of compounds from the R, D, A and AB series 
 








Compound R2 R3 n K1/3D7 W2/3D7 
 
10 Et Bn 1 8.9 2.7 
10a Et H 1 2.2 3.1 
12 Et Bn 2 596 19.3 
12a Et H 2 3.2 4.5 
14 Et Bn 3 32.5 25 
14a Et H 3 5.4 3.2 
16 Et Bn 3 11.4 2.1 
16. HCl salt Et Bn 5 12.5 ND 
16a Et H 5 7.7 1.1 
9 Me Bn 1 6.4 2.0 
9a Me H 1 3.0 0.026 
11 Me Bn 2 12.8 7.7 
13 Me Bn 2 44.0 22.4 
13a Me H 3 2.3 2.7 
15 Me Bn 3 0.12 0.01 
15a Me H 5 0.4 0.18 
CQ    48.9 10.8 
 
In the same laboratory, series A and AB were tested in one assay while the R and D 
series were tested in a different one. The RIK1/3D7 of the standard drug CQ from the two 
assays was different i.e. 12.2 versus 48.9. (Tables 3.15 and 3.16) Therefore the A and B 
series are discussed separately from the D and R series.   
 
Most compounds exhibited lower resistance indices than CQ implying that they have 
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Compound R1 R5 R N Resistance 
index  
K1/3D7 
23 Me Bn H 1 4.7 
23a Me H H 1 3.0 
24 Me Bn Me 2 0.4 
24a Me H Me 2 1.0 
25 Me Bn H 2 6.9 
25a Me H H 2 2.2 
26 Me Bn H 3 7.1 
26a Me H H 3 0.1 
27 Me Bn H 5 8 
27a Me H H 5 1.7 
28 cyclpropyl Bn H 1 7.2 
28a cyclpropyl H H 1 1.6 
29 cyclpropyl Bn H 2 1.4 
29a cyclpropyl H H 2 3.6 
30 cyclpropyl Bn Me 2 6.5 
30a cyclpropyl H Me 2 1.5 
31 cyclpropyl Bn H 3 5.3 
31a cyclpropyl H H 3 2.1 
32 cyclpropyl Bn H 5 7.5 
32a cyclpropyl H H 5 2.7 
CQ     12.2 
 
Generally deprotection was found to lower the resistance indices of most of the 
compounds. The A series (less lipophilic) had better resistance indices than the AB series 
(lipophilic), e.g. comparing 10 (RIW2/3D7 = 8.9; RI K1/3D7 = 2.7) to 9 (RIW2/3D7 = 6.4; RI 
K1/3D7 = 2.0) and given that the AB analogues are better β-haematin inhibitors than their A 
analogues it implies that potency against CQ resistant strains is not dependant on one 
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All the compounds in the R and D series had lower RIs, usually much lower RIs than CQ 
imply good potential to overcome resistant parasites. The general trend indicated that the 
deprotected analogues had lower RI values than their benzylated analogues. The 
introduction of the tertiary amine group improves the RI in the R series but not in the D 
series. The replacement of the N-cyclopropyl group in the D series with a methyl group 
enhances selectivity for the resistant strain. Tentatively it is proposed that a less bulky N-
alkyl group on the pyridinone and a tertiary amine group on the side chain act in concert 
to confer potency against the resistant strain. 
 
3.3.3. Investigation of the contribution of complexation to antiplasmodial activity 




















13c: ML3   M= Fe
3+ , L = 13a
13d: ML3   M= Ga
3+ , L = 13a
15c: ML3   M= Fe
3+ , L = 15a
15d: ML3   M= Ga
3+ , L = 15a
15e: ML2NO3H2O, M= Ga
3+ , L = 15a





Compound P. falciparum 
IC50 (µM) 
Resistance Index                                             
 D10 Dd2 Dd2/D10 
13a 0.75 0.53 0.70 
13c 0.73 0.6 0.8 
13d 0.61 0.34 0.5 
15 a 0.49 0.44 0.9 
15c 0.26 0.24 0.9 
15d 0.26 0.28 1.1 
15e 0.44 0.31 0.7 
16a 0.15 0.12 0.78 
16c 0.48 0.38 0.8 
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Further work was conducted to confirm the effect of complexation on the antiplasmodial 
activity of these compounds by evaluating the antiplasmodial activity of the gallium (III) 
and iron (III) complexes of the deprotected analogues in sensitive D10 and resistant Dd2 
strains (Table 3.17). 
The complexes and their ligands were found to be as active as CQ in the resistant Dd2 
strain, but less active than CQ (IC50 = 0.0155µM) in the sensitive strain D10, except for 
compound 16a (IC50 = 0.12 µM). In most cases there was no significant difference 
between the antiplasmodial activity or the resistance index of a ligand and that of its 
complex irrespective of the metal core. 
 
In the previous section (3.1.2), it was observed that complexation with gallium greatly 
reduced the antiplasmodial activity of N-alkyl-3,4-hydroxypyridinones, but in this case, 
the complexation of the aminoquinoline-3,4-HPO conjugates with gallium and iron (III) 
causes no significant change in antiplasmodial activity. This implies that unlike the N-
alkyl-3,4-HPOs, potential iron chelation is not the major mode of antimalarial activity for 
these conjugates. Therefore, other mechanisms predominate even after complexation. 
Hemozoin inhibition could be one of the mechanisms given the presence of the 7-
chloroquinolinyl substructure in these hybrids. It may be concluded that complexation 
with gallium (III) or iron (III) causes insignificant change in the antiplasmodial activity 
of these double drug ligands. This casts doubt on whether the presumed iron chelation 
contributes significantly to the antiplasmodial activity of these compounds.   
 
3.3.4. Involvement of the benzyl group in the β-haematin inhibition 
The benzylated double drugs showed better β-haematin inhibition activity than the 
deprotected analogues. Furthermore, the replacement of the benzyl protecting group with 
a methoxy group led to a significant decrease in the β-haematin inhibition activity as 
depicted for related compounds in Table 3.18.  This implies involvement of the benzyl 
group involvement in the inhibition of β-haematin formation probably via the aromatic 
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From the data set in Table 3.18, the benzylated analogues were observed to be better 
antiplasmodials than the 3-methoxylated analogues against W2. The factors contributing 
to this could be the superior β-haematin inhibition activity exhibited by the benzylated 
analogues as well as their high lipophilicity (see clogP and logD values in Table 2.6), 
enabling them to penetrate cellular membranes easily. This data in itself strongly supports 
the role of β-haematin inhibition in the mode of action for these hybrid molecules. 
 





















     3D7 K1 W2 
13 Me 3 Bn 0.27 0.05 2.2 0.05 
13b Me 3 Me 0.75 0.07 0.22 0.76 
14 Et 3 Bn 0.19 0.004 0.13 0.09 
14b Et 3 Me 1.71 ND ND 0.21 
15 Me 5 Bn 0.25 35.7 4.38 0.08 
15b Me 5 Me 1.07 0.13 2.8 0.09 
16 Et 5 Bn 0.16 0.008 0.1 0.07 
16b Et 5 Me 0.47 ND ND 0.22 
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32:  R = Bn 16
13a24a
32a:  R = H
 
 













    3D7 K1  
16 6.2 - 0.16 0.007 0.08 11.4 
32 5.3 5.47 0.07 0.004 0.03 7.5 
32 a 3.6 8.34 1.3 0.03 0.08 2.7 
13a 3.0 - 0.66 0.03 0.07 2.3 
24a 2.1 6.78 1.95 0.04 0.04 1.0 
CQ   1.9 0.013* 
(0.009 or 0.016) 
0.32* 
(0.44 or 0.20) 
24 
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3.3.5 Antiplasmodial activities of the most potent conjugates 
The most potent antiplasmodial compounds from the four series i.e. 16, 32, 32a, 13a and 
24a were compared as illustrated in Table 3.15. This group consists of compounds with a 
varied number of carbon atoms (3C, 4C and 6C) and the conjugates with 6C in the side 
chain exhibited stronger antiplasmodial activity against the sensitive strain. However, 
their activity against the resistant strain was comparable to that of the short side chain 
conjugates.  
 
The β-haematin inhibition activity of all the compounds was better or similar to that of 
chloroquine (IC50/equiv = 1.9). On this basis it was hypothesized that, to retain or 
enhance antiplasmodial activity in this type of compound, β-haematin inhibition activity 
seems necessary especially for activity against the sensitive strain e.g. the 32 and 16, the 
two compounds have the strongest inhibition of β-haematin and the best potency in the 
sensitive strain. 
 
The introduction of a secondary amine group into 32 appeared to cause the increase β-
haematin inhibition and antiplasmodial activities in both strains by 2 fold. Note that this 
change can not only be attributed to the amino group since several structural differences 
exist between 16 and 32. Even though deprotection was seen to cause a decrease in 
activity in the sensitive strains the consequence were improved resistance indices. 
Compounds 32, 32a and 16 were more active in the sensitive strain than the resistant 
strain implying potential for cross resistance with CQ. Only compound 24 was equipotent 
in both the resistant and sensitive strains hence can be a good template on which 
structural modifications may be performed on to improve activity in both resistant and 
sensitive strains. 
 
Compounds 13a and 24a appear to be the best candidates for further development since 
they have the lowest resistance indices. Structurally, these two molecules contain an iron 
chelating group and/or a tertiary amine group in the side chain. Presumably the 3,4-HPO 
chelator moiety enhances activity for the resistant strain possibly via some favourable 
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may be enhancing drug accumulation in the food vacuole of the resistant strains as 
discussed earlier. Therefore, it is hypothesized that incorporation of the iron chelator 
group or the amino group or both in this type of antiplasmodial compounds may enhance 
activity against resistant strains.  
 
Considering this data, it seemed that lipophilicity is not the only factor involved in 
overcoming drug resistant malaria parasites in this class of compounds. An optimum 
balance of lipophilicity and basicity are essential in addition to the type of N-1 alkyl 
group on the pyridinone moiety.  
 
3.3.6. Antiplasmodial activity of the molecular fragments of the A/AB double drugs 
The synthetic intermediates i.e. 7-chloroquinolinyl-4-diaminoalkanes and benzylated 
pyranones were tested for activity against W2. The rationale was to confirm which 
fragment of the conjugates contributes more to the activity and whether the conjugation 
enhances antiplasmodial activity or not.  
 
The three 7-chloroquinolinyl-4-diaminoalkane intermediates showed similar 
antiplasmodial potency against the CQR strain W2 except for the intermediate 5 and their 
activity was close to that of chloroquine (Table 3.20). The two benzylated pyranone 
intermediates were inactive against W2 at the maximum concentration (20µM) tested 
(Table 3.21).  
 
The IC50W2 values of the benzylated double drugs were in the range of 9.92 - 0.015µM 
(Tables 3.7 and 3.8). This implies that conjugation via covalent bonding to make the 
double drugs resulted in an additive /synergistic effect unlike the antagonism observed in 
the combinations (section 3.1.2). This is true if one considers the antiplasmodial activity 
of the fragments of one of the most active compounds, 16, it is clear that their respective 
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Table 3.20: Antiplasmodial activity of aminoquinoline intermediates 





    
Intermediate/fragment n P.falciparum IC50 (µM) 
W2 
4 1 0.15 
5 2 2.01 
7 3 0.14 
8 5 0.16 
CQ  0.097 
 
  
Table 3.21: Antiplasmodial activity of benzylated pyranone intermediates 





    
Intermediate/fragment R2 P. .falciparum IC50 ( M) 
W2 
1 Me >20 
2 Et >20 
CQ  0.097 
 
 
The combination of 1h, a benzylated N-alkyl-3,4-HPO with CQ-diphosphate, resulted in 
a predominantly antagonistic interaction (section 3.1.2), whereas the conjugation of a 
benzylated 3,4-HPO (1) and a quinoline (8) resulted in synergy. Therefore, the 
interactions resulting from the individual combination of two therapeutic agents, each as 
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3.3.7 Quantitaive correlations involving β-haematin inhibition and lipophilicity  
The lipophilicity of 3,4-HPOs is influenced by the N-1 alkyl group and this is expected to 
affect the antiplasmodial potency. In addition, it was observed that more lipophilic double 
drugs displayed better antiplasmodial and β-haematin inhibition activity. To further probe 
these relationships, correlations between lipophilicity (clog P), and β-haematin inhibition; 
or antiplasmodial activity were measured. Correlations were only observed for the A/AB 
series compounds. 
 
Figure 3.2: Correlation between Lipophilicy (clog P) and in vitro antiplasmodial activity 
against W2 parasites for benzylated (A) and deprotected (B) compounds. 
 
 
Figure 3.3: Correlation between β-haematin inhibition and lipophilicity (predicted log P) 
of benzylated (A) and deprotected double drugs (B). 
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Figure 3.4: Correlation between β-haematin inhibition activity and antiplasmodial 
activity for the benzylated series A- against 3D7 & B- against W2 strains and deprotected 
analogues C- against 3D7 & D- against W2.  
 
All the double drugs in the A and AB series were combined together in the analysis and 
the correlation between their lipophilicity and in vitro antiplasmodial activity in 3D7, W2 
and K1 were determined. The correlations were not significant in all the resistant and 
sensitive strains of P. falciparum. Further determinations for the separate groups, i.e. 
protected (nonchelating) and deprotected (chelating), was considered (Fig. 3.2). 
Significant correlation between lipophilicity and antiplasmodial activity was only 
observed in the W2 resistant strain for deprotected analogues (R2=0.41) and benzylated 
analogues (R2=0.88). as illustrated in Figure 3.2. The significant correlation in the 
deprotected compounds is consistent with literature reports indicating that lipophilicity 
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determines antiplasmodial activity of 3,4-HPOs in resistant strains except that it is single 
point dependant. 
 
The correlations between β-haematin inhibition and clog P were determined and 
significant correlations were observed for benzylated (R2 = 0.59) or deprotected (IC50 = 
0.76) analogues (Fig.3.3). This confirmed that lipophilic molecules have the potential of 
being good β-haematin inhibitors. The data shows β-haematin inhibition of these 
compounds is related to lipophilicity. It could imply that β-haematin inhibition 
contributes significantly towards the antiplasmodial activity of these compounds whether 
the chelator group is protected or not. β-haematin inhibition is considered a major mode 
of action for quinoline antiplasmodials hence it was important to consider the correlation 
between β-haematin inhibition and antiplasmodial activity (Fig. 3.4). 
 
Strong correlations were observed between β-haematin inhibition and antiplasmodial 
activity in 3D7 (R2 = 0.96) and W2 (R2 = 0.93) for the benzylated analogues. At first 
sight, the correlation also appears to be strong in 3D7 (R2 = 0.92) and W2 (R2 = 0.95) for 
the deprotected analogues. However, if the data point at (2.9, 10.8) is omitted in the 
determination of the correlation for deprotected analogues in 3D7, the R2 value drops to 
0.045, strongly suggesting that the correlation is fortuitous. However, the other 
significant correlations observed may be used as a basis to conclude that β-haematin 
inhibition is a major mode of action of these conjugates in both resistant and sensitive 
strains at least for the protected analogues. 
 
For the R series, no significant correlation was observed between the clog P and β-
haematin inhibition activity or antiplasmodial activity, and between β-haematin inhibition 
and antiplasmodial activity for the group as a whole. Even after separating the 
deprotected and the benzylated compounds, no significant correlations were observed.  A 
similar picture was observed in the D series. This could mean that after the incorporation 
of the amino groups more factors come into determining the antiplasmodial activity i.e. 
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3.3.8. General conclusion on in vitro antiplasmodial activity and β-haematin 
inhibition activity 
β-haematin inhibition was found to be an important mode of antiplasmodial action for 
many if not all of the hybrid molecules. Strong correlations were observed between β-
haematin inhibition and antiplasmodial activity for the benzylated conjugates in the A 
and AB series.  
 
The β-haematin inhibition activities were determined in a cell free assay whereas 
antiplasmodial activity assays involved a medium containing cells; therefore, good β-
haematin inhibition activity did not necessarily translate into good antiplasmodial activity 
because the effect entirely depends on ability of the conjugates to access the intracellular 
target. In order to exert optimal antiplasmodial activity, the test compounds have to 
access their intracellular targets e.g heme. Access to heme is dependent on lipophilicity 
and the ability to accumulate in the parasitic food vacuole (especially for the resistant 
strain) through pH trapping. The β-haematin inhibition activity of these hybrids may be 
attributed to the quinoline nucleus and not the pyridinone substructure since the N-alkyl-
3,4-HPOs did not show any inhibition of β-haematin.  
 
Strong haematin inhibition activity was observed to translate into strong antiplasmodial 
activity in the sensitive 3D7 strain more than in the resistant K1 strain. The explanation to 
this could be that the mutant PfCRT in the resistant strain was involved in exporting the 
test compounds out of the FV thus lowering the concentration of the drug at the target 
site. 
 
Blocking of the iron chelator group in itself was observed not to cause significant 
antiplasmodial activity this is seen in the dismal potency of the N-alkyl-3,4-HPOs (IC50K1  
>1.8µM; IC503D7  > 2.38µM) as well as in the assays involving protected or pre-
complexed hybrid molecules. It is important to note that deprotection or availability of 
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3.4.  In vivo antimalarial activity of 16a (13AB1) and 16. HCl salt (13AB.2HCl)  
The dihydrogen chloride salt of compound 16 [16.2HCl or 13AB 2HCl] showed the best 
in vitro antiplasmodial potency and was selected for in vivo testing. Its deprotected 
analogue 16a (13AB1) was also tested to investigate the effect of chelation on in vivo 
antiplasmodial activity. The preliminary findings indicated that iron chelation was not 
effective against an animal model of malaria. Compound 32 which showed good potency 
in vitro against resistant and sensitive strains of P. falciparum is awaiting in vivo tests.   














16 .HCl  salt (13AB.2HCl) 16a (13AB1)  
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The assay involved intra peritoneal administration of the drugs 16. HCl salt and 16a to 
Swiss Webster female mice and chloroquine was used as the standard. Dosage was IP 2x 
day 50mg/kg and the drugs were dissolved in 5% DMSO/ 5% Cremophor EL in saline. 
 
Considering the data represented in Figure 3.5, the group that was treated with 16a 
showed a similar pattern as the untreated group and on day 7 no mice survived in both 
groups. The mice that were treated with compound 16. HCl salt behaved like the mice 
treated with CQ but the percent survival in the presence of the former was lower (40%) 
compared to chloroquine (80%). 
 
The poor performance of 16a in the in vivo assay could be attributed to the lack of 
susceptibility of the P. berghei to the test compound, absence of the target and poor 
absorption. Even though 16 and 16a showed good in vitro activity against P. falciparum, 
In vitro efficacy against human malaria causing P. falciparum does not always translate 
to in vivo efficacy against the rodent malaria causative agent P. berghei (S. Wittlin, 2010-
Personal Communication). P. berghei in mice lacks hemozoin because mice are not their 
natural hosts (Peters et al., 1986), and since the test compounds 16a and 16. HCl salt 
were confirmed to target haemozoin/β-haematin formation it may be assumed that one of 
the main targets of these compounds was absent in the test organism. There is a need to 
confirm the susceptibility of the P. berghei to the test compounds by testing the drugs 
against in vitro P. berghei or by use of the humanized SCID mouse model to provide an 
explanation for the lack of a PK/PD relationship in this case. It may not be assumed that 
since the test compounds are 4-aminoquinolines then the P. berghei parasite will be 
susceptible to them as it is to chloroquine. 
 
Intra peritoneal (i.p) administration is known to favor the absorption of more lipophilic 
drugs (Kerns and Di, 2008), since 16 and 16a have a log D of 6.00 and 4.05 respectively, 
one would expect 16 absorption to be more favorable than that of 16a in an i.p 
administration. Tentatively, it may be hypothesized that 16a was not effectively absorbed 
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3.7 Antiplasmodial and β-haematin inhibition activity of catecholate double drug 37  
The siderophore 36 (IC50/equiv.=5.09), exhibited a lower β-haematin inhibition activity 
than the siderophore-4-aminoquinoline hybrid 37 (IC50/equiv. =1.04), this 5 fold 
difference is mainly due to the influence of the 7-chloro-4-aminoquinolinyl moiety which 











Figure 3.6: Structures of compound 36 and 37 
 
Table3.22. In vitro antiplasmodial activity and haematin inhibition activity of 
catecholates and related D and AB series analogues 
 
Compound BHIA IC50/equiv. P.falciparum. IC50 µM against D10 
37 1.04 3.17 
36 5.09 29.6 
32 0.07 0.15 
16 0.16 0.05 
16. HCl salt - 0.22 
CQ 1.95 0.04 
BHIA β-haematin inhibition activity 
 
The antiplasmodial acivities of the 36 and 37 were evaluated along side related double 
drugs against CQ sensitive D10 strain (TableS). Compound 37 (IC50 = 3.17µM) was 
found to be about 6 times more potent than 36 (IC50 = 29.6µM) this may imply the main 
mode of activity of the catecholate double drug is via haemozoin inhibition or by 
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The β-haematin inhibition activity 37 was 10 times lower than other structurally related 
4-aminoquinoline-3,4-HPO double drugs i.e. 16 (IC50/equiv.=0.16; IC50D10 = 0.05µM) 
and 32 (IC50/equiv.= 0.07; IC50D10 = 0.15µM) and this was reflected in their 
antiplasmodial activity i.e. they were more potent. This observation therefore reinforces 
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3.8. In vitro Toxicity Assay 
3.8.1. Cytotoxicity 
The in vitro selectivity index (SI) of these compounds for the parasite over host cells was 
determined using the KB human nasopharynx carcinoma cell line and the Plasmodium 
falciparum 3D7 and K1 isolates (Table 3.23).  
 
Table 3.23: In vitro toxicity data; Cytoxicity and CYP3A4 inhibition 

















9 22.5 53.7 0.49 3.15 109 17 7.3 
9a ND ND 10.8 32.6 ND ND 5.87 
10 23.3 52.9 8.43 53.6 6.3 1.0 3.07 
10a ND ND 0.4 0.89 ND ND 12.34 
11 28.9 66.6 3.57 66.5 18.7 1.0 1.77 
11a ND ND ND ND ND ND 14.87 
12 6.6 14.7 71.6 14.8 0.21 1.0 1.18 
12a 19.5 45.3 0.384 45.4 117 1.0 ND 
13 53.2 118.9 0.051 2.17 2331 54.7 1.0 
13a 66.3 154.1 0.03 0.07 5136 2201 ND 
14 4.16 9.0 0.004 0.13 2250 69 1.21 
14a 28.3 63.8 0.054 0.27 1181 236 6.52 
15 75.3 158.2 4.38 158.2 36 1.0 2.25 
15a 1.38 3.0 0.161 3.2 18 1.0 4.29 
16 1.86 3.8 0.011 3.79 345 1.0 1.36 
16a 17.7 37.6 0.079 0.61 475.9 61.6 4.04 
16.HCl salt 3.27 5.8 0.007 0.089 828.6 65.1 0.29 
15b 18.6 46.6 0.13 0.28 358.5 166.4 2.52 
13b 10.3 27.7 0.07 0.22 395 125.9 12.8 
16b ND ND ND ND ND ND 2.16 
14b ND ND ND ND ND ND 6.12 
CQ 10.9 34.3 0.009 0.44 3811.1 77.95 ND 
POD 0.0003 ND ND ND 0.0007 ND ND 
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The assay method considers compounds with IC50< 10 µg/ml to be cytotoxic to 
mammalian cells (see experimental section), thus more than half of the compounds tested 
(11 out of 16) were not cytotoxic. Compounds 15a, 16a, 16, 14 and 12 were identified to 
be toxic. Eleven compounds had a toxicity profile that was comparable or better than that 
chloroquine. In general the compounds were far less toxic than podophyllotoxin POD 
(the control drug). POD had IC50 of 0.0003µg/ml compared to the most cytotoxic of the 
test compounds, 15a which had and IC50 of 1.38µg/ml.  The cytotoxic compounds appear 
to be the most lipophilic in the series i.e. with clog P >4  
 
All the compounds tested except 12 (SI = 0.2) had SI greater than one for the 3D7 over 
KB, implying that the compounds have the desired potential of being more toxic to the 
target organism than the host‟s cells.  None of the compounds had better selectivity index 
than CQ (SI = 3811) when 3D7 was considered except 13a. However, 13, 14, 14a and 16. 
HCl salt had selectivity indices close to that of chloroquine.  
 
Ordinarily the CQ sensitive strains of P. falciparum are used to assess cytotoxicity, but 
the resistant strain was also used in this study. The data indicated that the compounds had 
poor selectivity for the resistant parasites over the mammalian cells with only 3 
compounds i.e. 13a (SI = 2201), 14a (SI = 236), 15c (SI = 166), and 13b (SI =125), 
showing better selectivity indices than chloroquine (SI = 77.8). Only 9 out of the 16 
compounds tested showed SI of greater than one. This was lower than was been observed 
in the 3D7 strain. This confirmed that most of the compounds were less active against 
resistant strains (Guetzoyan et al., 2009; Manohar et al., 2010).  
 
3.8.2. In vitro CYP3A4 inhibition activity 
3.8.2.1 Rationale  
CYP3A4 metabolizes over 50% of the drugs on the market and some drugs are known to 
be inhibitors of CYP3A4 leading to fatal drug-drug interactions (DDIs) when co-
administered with other drugs. Such drugs may be withdrawn from the market or their 
development halted. To avoid such expensive consequences drugs are evaluated for the 
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CYP3A4 inhibition of the compounds was investigated by determining the percent 
inhibition and the inhibition IC50 values. Testosterone was used as the substrate probe. In 
the first assay the test compounds inhibited CYP3A4 at both high (20 µM) and low 
concentrations (3µM) and the inhibition was concentration dependent (Fig. 3.7).  
 
3.8.2.2. In vitro CYP3A4 inhibition activity of A/AB series 
All the compounds tested showed inhibitions in the range 20% - 100% at 3µM 
concentrations compared to 35% for ketoconazole (Fig. 3.7). This shows that the 
compounds were moderate to strong CYP3A4 inhibitors (Kerns and Di, 2008). At higher 
concentration (20 µM) the inhibition rose to over 70% for most compounds compared to 
70 % for ketoconazole. 
 
 
Figure 3.7: CYP3A4 inhibition by the maltol and ethyl maltol derived double drugs. 
NOTE: Laboratory codes were used in the graph above thus their equivalent numbering 
in the text are as follows:  11A = 9; 11A4 = 9a; 11B = 10; 12A = 11; 12AB = 12; 13A = 
15; 13A1 = 15a; 13AB = 16; 13AB1 = 16a; 13AB.2HCl = 16. HCl salt; 14A = 13; 14AB1 
= 14a; 14AB = 14; 17A = 15b and 18A = 13b. Compounds 9, 16, 14, 14a, 13b 15a, and 
16b exhibited 100% inhibition at the two concentrations. 
 
In the second assay represented in Table 3.23, the trend observed was that the CYP3A4 
inhibition increased with increase in the number of carbons in the alkyl linker especially 
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than the benzylated analogues but the former were more potent than the deprotected 
compounds.  
 
Figure 3.8: Correlations between CYP3A4 and log P (A and B) or BHIA and CYP3A4 (C 
and D) for benzylated and deprotected conjugates. When log – log plots was considered 
for these data similar correlations were observed (same R2 values were observed). 
 
The deprotected compounds were found to be weaker CYP3A4 inhibitors when 
compared to their benzyl protected analogues e.g compounds 11 (IC50 = 1.77 µM) when 
compared to 11a (IC50 = 14.87 µM) or 10 (IC50 = 3.07 µM) when compared to 10a 
(IC50=12.3 µM).  
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General rules derived from multiple ADMET assays involving drugs with diverse 
structures shows that compounds with desirable CYP3A4 inhibitory profiles have 
molecular weights < 400 and clog P < 4 (Gleeson, 2008). In this respect all the 
benzylated analogues violated these criteria (MWT > 400 and clog P > 4). The 
deprotected compounds were found to be relatively less strong inhibitors and this is 
expected because their clog P and MWT values are within the prescribed limits (Gleeson, 
2008).  
 
If a more stringent standard pertaining CYP3A4 inhibition (Kerns and Di, 2008) is 
applied then all the compounds tested would not pass the test except compounds 10a and 
11a (IC50 > 10 µM). Most of the compounds therefore have a potential to cause drug-drug 
interaction when co-administered with other drugs since they inhibit CYP3A4 (in the 
presence of testosterone).  
 
The most potent inhibitor was 16 dihydrogen chloride salt with an IC50 of 0.29µM. The 
other potent inhibitors included 11 (IC50 = 1.77µM), 12 (IC50 = 1.18µM) and 13 (IC50 = 
1.0µM); the common structural feature in them being the benzyl group.   
 
In reversible CYP3A4 inhibition, lipophilicity and molecular shape are known to enhance 
the binding of any ligand to the enzyme‟s active site, in this case the heme (Yan and 
Caldwell, 2001). Gleeson, (2008) confirmed that CYP3A4 inhibition depends on the 
substrate‟s lipophilicity and found that inhibition increased with increase in the clog P. 
This prompted investigation of how the log D and predicted log P (clog P) of these 
compounds correlated with their CYP3A4 inhibition. Correlation between the log D and 
CYP3A4 inhibition was not significant i.e. < 0.5 (Fig. 3.8 A and B) so was the correlation 
between CYP3A4 inhibition and clog P. Therefore it was assumed that altering the 
lipohilicity alone may not confer a favorable CYP 3A4 inhibition profile to these 
molecules. Thus structural modifications were envisaged so as to confer better 
physicochemical properties to reduce the CYP3A4 inhibition of these compounds i.e. by 
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The CYP 3A4 binding pocket contains a heme group as the active site and the 
erythrocytic heme is known to be one of the major targets for quinoline antiplasmodials 
(Ekins et al, 2003; Garrett and Grisham, 2005). Since these double drugs were found to 
be strong β-haematin inhibitors, it was necessary to investigate whether their interaction 
with the hemoglobin heme is similar to that of the heme in CYP3A4. To investigate this, 
the correlation between the β-haematin inhibition and CYP 3A4 inhibition among the 
benzylated and among the deprotected analogues was separately determined (Fig. 3.8 C 
and D). The correlation was at first sight found to be significant (R2 > 0.8) in the 
benzylated analogues and not in the deprotected analogues (R2 = 0.18). However, in the 
first group it was heavily dependant on a single point (0.93, 7.3). Despite this the 
benzylated compounds were generally observed to be strong CYP3A4 and β-haematin 
inhibitors despite the lack of a correlation between the two types of inhibition activities. 
The benzyl group therefore may be involved in both the CYP3A4 and β-haematin 
inhibition activities of these compounds. Further work was performed in terms of in silico 
docking of the molecules to the CYP3A4 receptor using Autodock 4.2. to investigate the 
mode of interaction between the conjugates and the CYP3A4 heme.  
 
The CYP3A4 in vitro inhibition data represented in this section may be considered 
inconclusive because quantitative and qualitative inhibition parameters are dependent on 
the CYP3A4 substrate (Stresser et al, 2000). It is possible that the extensive inhibition of 
CYP3A4 caused by some drugs under some conditions could be overlooked or 
underestimated leading to errors in predicting important drug-drug interactions DDIs 
(Kenworthy et al., 1999). Currently it is recommended that investigators screening for 
inhibition of CYP3A4-mediated metabolism to highlight potential DDIs should use a 
substrate probe from each of the three designated groups (Kenworthy et al., 1999) or use 
two substrate probes from the same group (Lin et al., 2007; Mao et al., 2006). In this case 
only one substrate probe i.e. testosterone, was used. Because of this the data should be 
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CHAPTER FOUR 
 
IN SILICO ADMET PROFILING 
 
The in silico prediction data indicated that structural modifications were likely to enhance 
the ADMET profile of these hybrid molecules. The R and D series were predicted to have 
better CYP 3A4 profile than their A/AB analogues. The in silico and in vitro trends were 
comparable, however the in silico predictions in conjunction with the β-hematin 
inhibition trend data showed that good β-hematin inhibitors were not necessarily potent 
CYP3A4 inhibitors.  Two unique docking conformations were identified each 
corresponding to weak (deprotected and 3-methoxylated) and strong inhibitors 
(benzylated analogues) respectively. Structures responsible for high CYP3A4 affinity 
were identified and appropriate modifications recommended. 
 
4.1 In silico Prediction of Drug-likeness 
 
Physicochemical properties of these compounds such as molecular weight (MWT), 
clogP, hydrogen bond acceptors ( HBA) and hydrogen bond donors (HBD) were studied 
to identify any violations of the Lipinski guidelines or adherence to drug like properties 
(Lipinski, 1997), and some of them (cLog P and MWT)  were used to predict their 
potential to inhibit CYP3A4 (Gleeson, 2008). The relevant data is represented in Tables 
4.1 and 4.2 and the predictions were conducted with respect to all the four series of the 
double drugs. Among the benzylated group, the cLog P values predicted for the D and 
A/AB series were similar but lower than those for the R series (Table 4.1). Half of the 
benzylated analogues in the D and R group were found to violate 1 or 2 of the Lipinski 
guidelines and about 70% of the benzylated analogues in each of the three series have 
MWT >400, cLogP >4 hence have higher chances of inhibiting CYP3A4 (Gleeson, 
2008). Therefore the in vitro CYP3A4 inhibition potential of the benzylated compounds 
was expected not to change significantly after the structural modification. The predicted 
drug like properties and physicochemical data for the deprotected analogues seem better 
because all of them complied with the Lipinski guidelines (Table 4.2). The predicted data 
indicated that the pyranone precursors to the double drugs i.e. kojic acid and maltol had 
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R series R = Me
D series R = Cyclopropyl
A series R2 = Me
AB series R2 = Et
compounds 30 and 24; R' = Me
 *Predicted from MoKa 
 
 
Compound Series Linker  




cLog P* HBA HBD Violations 
9 A 1 419.9 3.8 5 2 0 
10 AB 1 433.9 4.2 5 2 0 
23 R 1 448.1 2.7 6 3 0 
28 D 1 474.2 3.4 6 3 0 
        
11 A 2 433.9 4.3 5 2 0 
12 AB 2 447.9 4.7 5 2 0 
24 R 2 477 3.7 6 2 0 
25 R 2 462.2 3.2 6 3 0 
29 D 2 489.2 3.9 6 3 0 
30 D 2 502.2 4.4 6 2 1 (MWT ) 
        
13 A 3 447.9 4.8 5 2 0 
14 AB 3 461.9 5.2 5 2 1 (clog P) 
26 R 3 477.2 3.7 6 3 0 
31 D 3 503.2 4.3 6 3 1 (MWT) 
        
15 A 5 476 5.7 5 2 1 (clog P) 
16 AB 5 490 6.2 5 2 1 (clog P) 
27 R 5 504.2 4.7 6 3 2 (clog P, MWT) 
32 D 5 530.2 5.3 6 3 2 (clog P, MWT) 
Kojic acid   142 -1.5 2 2 0 
maltol   139 -0.1 2 1 0  
Deferiprone   139.2 -0.6 2 1 0 
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R series R = Me
D series R = Cyclopropyl
A series R2 = Me
AB  series R2 = Et











cLog P* HBA HBD Violations 
9a 1 329.8 2.5 5 3 
 
0 
10a 1 343.1 2.5 5 3 0 
23a 1 358.1 1.0 6 4 0 
28a 1 384.1 1.6 6 4 0 
       
11a 2 344.1 2.5 5 3 0 
12a 2 357.1 3.0 5 3 0 
24a 2 398.1 2.1 6 4 0 
25a 2 372.1 1.5 6 4 0 
29a 2 387.1 2.0 6 5 0 
30a 2 412 2.6 6 5 0 
       
13a 3 357.1 3.0 5 3 0 
14a 3 371.9 3.5 5 3 0 
26a 3 386.2 2.0 6 4 0 
31a 3 412.1 2.6 6 4 0 
       
15a 5 385.9 4.0 5 3 0 
16a 5 399.9 4.5 5 3 0 
27a 5 414 3.0 6 4 0 
32a 5 440 3.6 6 4 0 
Kojic acid  142 -1.5 2 2 0 
maltol  139 -0.1 2 1 0 
Deferiprone  139.2 -0.6 2 1 0 
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Violation of the Lipinski guidelines by some of the hybrid molecules does not rule out 
further development of these series since not all drugs on the market comply with the 
guidelines fully. An example is chloroquine which does not comply fully with the 
Lipinski guidelines (clogP>4) yet it was used successfully to treat malaria. 
 
 
Figure 4.1.  PLS plots for solubility prediction in Volsurf modeller®: The benzylated 
analogues are enclosed in the white rectangles and deprotected analogues are outside 
the rectangles.  A/AB, R and D series are depicted by plots A, B and C respectively. The 
extreme right handside or blue zone (x>0) represents highly soluble compounds whereas 
compounds on the extreme left hand side or magenta zone are less soluble (x<0). The 
standard drug chloroquine is represented by the yellow dot immediately below the “CQ 
mol2 1” label. 
 
In the R and D series, 77% of the deprotected analogues have cLogP<4 and MWT<400 
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hypothesized that the structurally modified deprotected analogues from R and D series 
are weaker CYP3A4 inhibitors than their analogues in A/AB series. Because of their 
compliance with Lipinski‟s guidelines, it is presumed that these compounds will be orally 
bioavailable. It is noteworthy that the Lipinski guidelines are mere guidelines and should 
be used with caution as they are subject to other factors such as the role of any active 
transport mechanisms.  
 
Oral administration is a desired route for antimalarials because it maximises patient 
compliance and reduces ancillary care costs (Ray, 2010). For orally administered drugs 
adequate aqueous solubility is of paramount importance since dissolution of the active 
drug (or its prodrug form) in the gastrointestinal fluids precedes its oral absorption from 
the gastrointestinal system (Kharkar, 2010). Oral bioavailability or the fraction of the 
active form of an orally administered drug that reaches systemic circulation is thus 
largely dependent on aqueous solubility as well as membrane permeability especially 
human intestinal permeability, pKa (ionizability) and presystemic metabolism. 
 
The solubility predictions in Volsurf modeler (Fig. 4.1) did not show any significant shift 
when series R and D were compared to the initial series A and AB. The deprotected 
analogues in the A and AB series were predicted to have solubility that was comparable 
to that of chloroquine.  However, the deprotected analogs in the R and D series were 
more soluble than chloroquine. This can be attributed to the presence of the extra amine 
group on the side chain. This group is protonable, thus enhances pH dependant solubility. 
Therefore, it is anticipated that the R and D series will have enhanced solubility under 
gastrointestinal pH (<5). Benzyl protected analogues were predicted to be less soluble 
than the deprotected analogues. This is attributable to the conversion of a less polar group 
(O-benzyl) to a more polar one (hydroxyl) via deprotection. Considering that the 
experimentally determined solubility (turbidimetric) of the A and AB series was found to 
be within the druglike limits i.e. 25µg/mL, (Table 2.6) for both benzyl protected and 
deprotected analogs, it may be stated with some certainty that most compounds in these 
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Note that, although the predicted solubility for the benzylated analogues in the A and AB 
series looks poor on the PLS plot, the actual solubility from experimental determinations 
(Table 2.6), were good and within the drug like limits.  
 
4.2 In silico Prediction for CYP3A4 inhibition 
 
4.2.1. Validation of the Accuracy and performance of AutoDock.4.2. 
 
All the docking experiments were done using AutoDock 4.2. The validation of the 
accuracy and performance was done by inspecting how closely the best docked 
conformation of a known inhibitor ketoconazole resembled the bound ligand in the 
experimental crystal structure. The best docked conformation seems to be exactly 
superimposed on the native bound one (Figure 4.2) and the docked ligand interaction 
with the amino acid residues in the binding pocket was similar to that of the native bound 
one 
4.2.2 Affinity for the CYP3A4 
The affinity of the ligand (substrate or inhibitor) for the enzymes active site is represented 
by Ki and it is referred to as the affinity constant or the binding constant or the inhibition 
constant. The Ki experimental was determined in the presence of an inhibitor (a double 
drug) and the substrate (testosterone). The experiments and data analyses were performed 
by R. Thelingwani at the AIBST, Harare. The in vitro experiments and the data analyses 
were done as described elsewhere (Shou, 2008; Obach 2008). The data was analysed 
using the GraphPad Prism software. The predicted Ki was obtained by docking the 
energy the ligands into the CYP3A4 crystal structure using AutoDock 4.2. The details are 
given in the experimental section. The inhibition constants of the lowest energy 
conformation were used in the analyses that follow.  
 
Initial work involved comparing the in vitro CYP3A4 inhibition data of A/AB series 
compounds to the AutoDock 4.2 predicted values so as to further confirm the accuracy of 
the prediction. Of the 20 compounds docked in CY3A4 (PDB code 1TQN), only 6 (30%) 
had predicted inhibition/affinity constants Ki values similar or very close to the in vitro 


























Figure 4.2: Two ketoconazole molecules binding in to CYP3A4 stacked in an anti-
parallel orientation to each other (green) superimposition of the ketoconazole (grey) 
docked in CYP3A4 active site (PDB code 1TNQ) in AutoDock 4.2 The histogram 
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In spite of this, significant correlation (R2 = 0.6) was observed between experimental and 
predicted Ki values for the A and AB series (Figure 4.3), implying that further 
optimization of the docking parameters may improve the accuracy of the AutoDock 
predictions. When the data for the 3-methoxylated analogues was included no significant 
correlation was observed between the experimental and predicted Ki, thus the correlation 
depicted in Figure 4.3 excluded data for the methoxylated analogues. 
 
Table 4.3: Experimental and predicted inhibition constants Ki for some compounds 
Compound CYP3A4 
IC50 in µM 
Ki 
in vitro in  µM 
Ki 
Predicted  µM 
9 7.3 9.66 1.17 
9a 5.87 39.6 2.04 
10 3.07 0.97 0.23 
10a 12.34 70.9 4.97 
11 1.77 0.38 0.59 
11a 14.87 5.42 1.49 
12 1.18 1.14 0.22 
12a ND ND 1.05 
13 1.0 1.19 1.10 
13a ND ND 1.03 
13b 12.8 3.69 0.23 
14 1.21 27.6 0.5 
14a 6.52 6.7 1.20 
14b 6.12 3.95 1.37 
15 2.25 3.73 0.23 
15a 4.29 5.81 1.14 
15b 2.52 4.38 5.72 
16 1.36 0.79 0.97   
16a 4.04 3.39 2.71 
16b 2.16 3.58 2.79 
36 ND ND 0.06 
37 ND ND 0.44 
DFP ND ND 426 
CQ ND ND 5.08 
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ND: not determined 


































Figure 4.3: Experimental and predicted inhibition constants correlations for benzylated 




Figure 4.4: Predicted CYP3A4 inhibition constant Ki trends in the A and AB series 
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Figure 4.5: Predicted CYP3A4 inhibition constants Ki trends in the R and D series 
 
Figure 4.6: Predicted CYP3A4 inhibition constants Ki trends in all the four series; A, 
AB, R and D. TERT: analogues with tertiary amino group  
 
Using the predicted inhibition constants from the docking studies it was clear that 
structural modification may help improve the CYP3A4 profile of these compounds. Most 
compounds from the R and D series were predicted to have lower affinity or inhibition 
potential than their analogues in the A/AB series (Fig.4.6). Specifically the R series seem 
to have lower affinities for CYP3A4 than the D series and this implies that the former are 
likely to be weaker CYP3A4 inhibitors. This prediction concurs with predictions obtained 
using other in silico tools i.e. when predicted physicochemical data from Volsurf 
Modeller and MoKa were used in conjunction with Gleeson criterion (2008) and Lipinski 
guidelines (section 4.1). All the compounds were predicted to have higher affinity for 
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426µM) and CQ (Ki =5.08 µM). None was predicted to have higher affinity for CYP3A4 
than the potent inhibitor ketoconazole (Ki =0.33µM), except compound 37 (Ki = 
0.06µM). Compound 36 (Ki =0.44µM) the synthetic precursor of 37, showed a low 
affinity for the CYP3A4 but the affinity increased by more than 10- fold on incorporation 
of the quinoline moiety to form 37. This was expected because the quinoline moiety is 
known to cause CYP3A4 inhibition. 
 
The benzylated double drugs with tertiary amino group: 30 (Ki =0.41 µM) and 24 (Ki 
=0.81µM), were predicted to be stronger CYP3A4 inhibitors than their analogues lacking 
the tertiary amino group: 29 (Ki =1.85 µM) and 25 (Ki =2.43 µM). This trend is not the 
same as what was observed for β-hematin inhibition since the benzylated compounds 
with the tertiary amino group were weaker β-hematin inhibitors than their analogues 
without the tertiary amino group. On deprotection, their predicted CYP3A4 
inhibition/affinities were similar or less than that of their analogues without a tertiary 
amino group i.e. when comparing 30a (Ki =1.85µM) to 29a (Ki =1.81 µM) and 24a (Ki 
=3.79 µM) to 25a (Ki =3.28 µM). This trend is not same for the β-hematin inhibition data 
of these compounds. These observations also emphasize the point that the 
chelating/deprotected analogues are likely to have better CYP3A4 inhibition profiles than 
their protected/benzylated analogues and that β-hematin inhibitors are not necessarily 
CYP3A4 inhibitors. 
 
4.2.3 Docking conformations in CYP3A4 
All the compounds were docked into the templates of the crystal structure of CYP3A4 
(Protein Data Bank entry 1TQN). Illustrations that follow are for a few selected 
compounds, criterion for selection included, accuracy of their predicted Ki values, 
representative of a series and the magnitude of the affinity/inhibition constants. The 
docking solutions were groups of conformational clusters in which all-atom root mean 
square deviation (rmsd) was within 2.0 Ǻ and were ranked by the lowest estimated free 
energy of docking for analysis. It is hoped that the data generated will help inform future 
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4.2.3.1 Compounds 16 (13AB) and 16a (13AB1) 
Both in vitro data and docking calculations indicated compound 16 to be among the most 
potent CYP3A4 inhibitors in the A/AB series, and it had the best β-hematin inhibition 
and antiplasmodial activity in the series. From the docking models, the lowest energy 
conformation (-8.2Kcal/mol) had a predicted Ki value of 0.97µM versus the experimental 
value of 0.79 µM. No clustering was observed therefore the docking was repeated using 
10 times more evaluations relative to the default evaluations. The resultant lowest energy 
conformation (-8.5Kcal/mol) had a predicted Ki value of 0.68µM versus the in vitro 
experimental value of 0.79 µM. The conformations in the first and second run were 
similar and clustering was observed in the second run (Fig 4.7). 
 
The lowest energy cluster conformation for 16 had the benzyl gr up oriented toward the 
CYP‟3A4 active site (Fig 4.7), and the rest of the ligand was observed to be interacting 
strongly with the hydrophobic pocket residues (Phe108, Leu210, Leu211, Phe241, 
Ile301, Phe304). The quinoline nucleus is positioned in a manner that enhances a π bond 
T stacking with the Phe103 residue. The pyridinone and the benzyl group are seen to 
interact with Phe304 and Ile301 residues respectively. The described binding mode was 
observed in most of the molecular models of the benzylated double drugs in the docking 
calculations.  
 
The abundant cluster conformation for 16 showed the ligand had a higher affinity for the 
hydrophobic pocket. In both the lowest energy and the abundant cluster conformations, 





































Figure 4.7: Molecular models of 16 (13AB) in the active site of CYP3A4 predicted by 
AutoDock version 4.2. The upper panel (1) depicts a representative conformation from 
the lowest energy cluster whereas the lower panel (2) depicts a representative 
conformation from the most abundant cluster. The hydrophobic pocket consists of 
Phe108 (pink), Leu210 (blue), Leu211 (red), Phe241 (green), Ile301 (yellow), Phe304 
(blue-green). The polar pocket residues include Arg372, Arg106 and Glu374. The 
clusters are shown in the histogram on the right of the lower panel with most abundant  
 


























Figure 4.8a: Molecular models of 16a (13AB1), CQ and DFP in the active site of 
CYP3A4 predicted by AutoDock version 4.2 .A representative conformation from the 
lowest energy cluster (LECC) and a representative conformation from abundant cluster 
conformation (ACC) of 16a (13AB1) are depicted in panes 3 and 4 respectively. For CQ 
and DFP the LECC and ACC were the same for each; see the clustering histograms in 














































Figure 4.8 b: Clustering histograms of 16a (13AB1), CQ and DFP 
 
 
Ketaconazole, a known strong inhibitor of CYP3A4, binds simultaneously to the distal 
and proximal binding sites (Tanaka, et al 2004; Fig 4.2). Similarly, compound 16 (13AB) 
as shown in Figure 4.7 appears to bind simultaneously to the hydrophobic pocket (a distal 
site) and the heme (a proximal site). This partly explains why 16 (13AB) inhibits 
CYP3A4 and has a higher affinity for the same. 
 
Compound 16a (13AB1) [the deprotected analogue of 16 (13AB)] had a predicted Ki of 
2.71µM that was closer to the in vitro value (3.39 µM). Its binding energy (-7.6 
Kcal/mol) was higher than that of 16 (13AB) (-8.5Kcal/mol) implying weak affinity for 
CYP3A4 than 16 (13AB). The mode of binding which was different from the benzylated 
analogue is predicted to be via π-π stacking interaction of the quinoline with the 
porphyrin ring of the heme and the amino group at position 4 of the quinoline ring is 
closer to the heme iron (Fig. 4.8 a). In this case the quinoline nucleus are more exposed to 
the active site and are likely to be metabolized hence less CYP3A4 inhibition is expected. 
In fact, the predicted sites of metabolism from Metasite, indicate that the amino group at 
position 4 of the quinoline ring as one of the sites of metabolism for this of class 
compounds (Fig.2.18). From the models the hydroxypyridinone moiety seems to prefer 
































24 (46R) 24a (46R1) 31 (D14)
Figure 4.9 a: Molecular models of 24 (46R), 24a (46R1) and 31 (D14) in the active site 
of CYP3A4 predicted by AutoDock version 4.2. A representative conformation from the 
lowest energy cluster (LECC), in the right hand side panes and a representative 
conformation from the abundant cluster (ACC), in the left hand side panes. The 


























Figure 4.9 b: Clustering histograms of 24 (46R), 24a (46R1) and 31 (D14) 
 
The lowest energy and most abundant conformations for 16a (13AB1) were similar 
except for the orientation of the hydroxypyridinone moiety. The clustering observed 
indicated convergence of the docking data hence adding confidence to the quality of the 
prediction for 16a (13AB1) (Fig. 4.8 b).The orientation of the quinoline nucleus towards 
the CYP3A4 heme in this case, and in all other deprotected analogues, and in 3-methoxy 
analogues closely resembles the one observed in chloroquine-hematin complexes (Leed 
et al., 2002). This docking mode also resembles that of chloroquine in CYP3A4 as 
predicted by the docking models in Figure 4.8 a.  
 
4.2.3.2 Compounds 24 (46R) and 24a (46R1) 
Compound 24 (46R) was predicted to have a higher affinity for CYP3A4 (Ki = 0.81µM; 
binding energy -8.3 Kcal/mol) but it was not tested in vitro. Visualization of its docking 
modes was important because its deprotected analogue (24a i.e. 46R1) had previously 
showed excellent antiplasmodial activity and represents the double drugs with a tertiary 
amino group. The lowest energy and most abundant cluster conformations of 24 (46R) 
were found to be similar to that of other benzylated analogues (Fig. 4.9 a), i.e. the benzyl 
group was oriented towards the active site of the CYP3A4 just as in 16 (13AB). For 
compound 24a (46R1), its lowest energy conformation showed a π-π stacking interaction 
between the quinoline nucleus and the heme‟s porphyrin ring in a manner similar to other 
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was found to be similar to the lowest energy conformation except that their N-1 groups 
were oriented differently towards the heme. 
 
4.2.3.3 Compounds 31 (D14) and 31a (D141) 
Compound 31 (Ki =1.06µM; binding energy -8.15 Kcal/mol) represents compounds from 
the D series and its deprotected analogue 31a was predicted to have the lowest affinity 
for CYP3A4 (Ki = 6.4µM; binding energy -7.09 Kcal/mol). The representative 
conformation from the most abundant cluster for 31 showed an interaction that was 
similar to other benzylated analogues (Fig 4.10 a), but in the lowest energy conformation 
the quinoline is involved in π-bond T stacking with the porphyrin ring of the heme. This 
interaction is long range and the quinoline is far removed from the active site hence one 
can speculate lower chances of metabolism and higher probability of inhibition. This in a 
way explains why compound 31 was predicted to have higher affinity for CYP3A4 like 
the other benzylated analogues. The representative comformation from the abundant 
cluster indicated a high affinity for the hydrophobic pocket just as observed in other 
benzylated double drugs.  
 
The lowest energy conformation of 31a was observed to be similar to other deprotected 
analogues except that the chloro substituent on the quinoline was oriented towards the 
heme iron (Fig. 4.10 a). Its most abundant cluster conformation was different from that of 
the aforementioned deprotected analogues because the pyridinone N-1 (and the 
cyclopropyl ring) are oriented towards the heme iron. This binding mode is comparable 
to that of deferiprone (DFP) in Figure 4.8 a. DFP was predicted to have a relatively poor 
affinity for CYP3A4 ( Ki = 426µM; binding energy -4.6 Kcal/mol) and has not been 
reported to cause any DDIs or CYP3A4 inhibition. It was reported to have no β-hematin 
inhibition activity in the previous section (3.1), hence it is hypothesized that DFP does 
not bind heme in the parasitic food vacuole unlike the double drugs reported herein. It 
can, therefore, be assumed that the binding modes of both the lowest energy and 
abundant clusters of 31a (D141) result in metabolism and less inhibition hence the lower 















Figure 4.10 a: Molecular models of 31a (D141), 32 (D13) and 32a (D131) in the active site of 
CYP3A4 predicted by AutoDock version 4.2. The representative conformation from the lowest 
energy cluster (LECC), in the right hand side panes and the representative conformation from the 
abundant cluster (ACC), in the left hand side panes for 31a (D141). The LECC of 32 (D13) was 
same as its ACC. No abundant cluster was observed for 32a (D131); see Figure 4.10 b 
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4.2.3.4. Compounds 32 (D13) and 32a (D131) 
 
32 was found to have the best in vitro antiplasmodial activity in D series and the best 
hematin inhibition activity overall. The compound was predicted to have a very high 
affinity for CYP3A4 (Ki = 0.8µM; binding energy -9.10 Kcal/mol). The lowest energy 
conformation of 32 which was the same as the most abundant cluster conformation had 
the benzylated pyridinone substructure oriented close to the CYP3A4 active site (Fig 
4.10). Compound 32a docks in a manner similar to other deprotected analogues but its 
quinoline N-1 is closer to the heme. However, none of its clustering showed convergence 
(Fig. 4.10b). It may be assumed that orientation of the quinoline towards the porphyrin 
ring is a metabolically active orientation since this orientation is adopted mainly by the 
deprotected analogues which are relatively weaker inhibitors. No abundant cluster was 
observed for 32a even after increasing the number of evaluations tenfold. 
 
The lowest energy conformation of 32a was found to be similar to what has been 
observed before for other deprotected compounds. However, the pyridinone group 
appears to be docked deeper into the hydrophobic pocket with a very close interaction 
with the Phe304 residue more than what was observed for 16a. This could be due to the 
presence of the hydrophobic cyclopropyl group that interacts more with the hydrophobic 
pocket and positions the ligand far from the CYP3A4 active site. This may explain why 
32a has been predicted to have a higher affinity (Ki = 0.56µM) for CYP3A4 than 16a (Ki 

































Figure 4.11 a: Molecular models of 9a (11A4), 13b (18A)  and 16b (A24) in the active 
site of CYP3A4 predicted by AutoDock version 4.2 .A  representative conformation from 
the lowest energy cluster (LECC), in the right hand side panes and a representative 
conformation from the abundant cluster  (ACC), in the left hand side panes. See the 


































Figure 4.11 b: Clustering histograms of 9a (11A4), 13b (18A) and 16b (A24). 
 
 
In both 16a (13AB1) and 32a (D131), the alkyl linker chain seems to contribute to the 
binding in the hydrophobic pocket via interaction with the Ile 301 residue. Future drug 
design for these types of molecules may consider use of hydrophilic linkers to reduce this 
interaction and hence improve the CYP3A4 inhibition profile of the compounds. The 
hydrophobic alkyl linker prevents the ligand from binding to the polar pocket which is 
closer to the CYP3A4 active site. Instead it enables it to bind strongly inside the 
hydrophobic pocket pulling it off the proximity of the active site. The double drugs with 
smaller alkyl linkers eg 9a (11A4) interact less with the Ile 301 hence bind easily to the 
polar pocket (Fig. 4.11 a) and consequently are docked in the proximity of the active site.  
 
4.2.3.5 Compounds 13b (18A), 16b (A24) and 9a (11A4) 
Docking conformations of three of the four 3-methoxy protected double drugs were via 
the quinoline nucleus π-π stacking to the heme‟s porphyrin rings. This resembles the 
predicted interactions of the deprotected double drugs in the CYP3A4 active site. For 
example the conformations of 13b are similar to that of the deprotected double drugs with 
short alkyl linkers like 9a (Fig. 4.11 a). Such conformations as observed for deprotected 
and methoxylated analogues may be used to distinguish weak inhibitors from potent 
ones. The conformations of 9a and 13b, show the ligands placed very close to the active 
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9a (Ki =39.6µM) has the lowest in vitro affinity constant for CY3A4 in the A/AB series 
(Table 4.1) 
 
Compound 16b docking mode (Figure 4.10) was observed to be similar to that of DFP 
(Fig. 4.9 a) and compound 31a (Fig. 4.10 a). Such a mode was assumed to be 
metabolically active and hypothesized to result in less inhibition of CYP3A4 or less 
affinity for CYP3A4. 
 
 
Figure 4.12: Comparing the in vitro determined (actual) and in silico predicted affinity 
constants, and the in vitro CYP3A4 inhibition activity of benzylated and methoxylated 
double drugs from the A/AB series. 
 
                           R3          n        R2      
        
14A  (13)             Bn        3        Me      
18A  (13b)           Me        3        Me
14AB (14)           Bn        3         Et
A25  (14b)           Me       3         Et
13A  (15)             Bn       5         Me
17A (15b)            Me       5         Me
13AB  (16)           Bn       5         Et
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The actual affinity of 3-methoxy protected analogues for CYP3A4 was found to be less 
than that of the benzylated analogues (Fig. 4.12a, b, Table 4.2), the exceptional pair was 
14 (14AB) and 14b (A25). A similar trend was observed in the predicted Ki with one 
exceptional pair 13 (14A) and 13b (18A). This shows that to a greater extend there  is an 
agreement between the predicted and actual affinity trends, the deviations noted could be 
due to in vitro experimental error. It is suggested that replacing the benzyl or methoxy 
groups with smaller and polar protecting groups such as the acetates and use of 
hydrophilic linkers such as ethers may enhance binding of these ligands into the polar 
pockets. Such binding would orient the ligand closer to the CYP3A4 active site and 
















Figure 4.12a: Molecular models of the 36 (C6) and 37 (C7R) in the active site of CYP3A4 
predicted by AutoDock version 4.2. Only a representative conformation from the lowest energy 
clusterLECC is depicted for each catecholate compound since no abundant cluster was observed 
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4.2.3.5 Compounds 36 (C6) and 37 (C7R) 
 
The docking conformation of compound 36 shows the acetate group is closely docked 
towards the active site whereas in 37 it is the Cl of the quinoline that is oriented closer to 
the active site (Fig. 4.13) 
 
The orientation of compound 36 in the active site is assumed to result in metabolism 
because its binding affinity (Ki = 0.44µM) for CYP3A4 was lower than that of 37 (Ki = 
0.06µM). The  37 (C7R) docking mode seems to pull the quinoline group away from the 
active site into the hydrophobic pocket thus less metabolism and greater inhibition is 
expected. Since the lowest energy conformation for 37 resembles that of deprotected 
double drugs, it was hypothesized that decreasing the number of carbon atoms on the 
alkyl side chain linking the siderophore to the aminoquinoline may lower its CYP3A4 
affinity. This strategy is viable because compounds with 6C in the linker have exhibited 
higher experimental and predicted affinity for CYP3A4 than those with fewer carbons. 
Since no clustering was observed (Fig. 4.12b) for the two compounds this experiment is 


































5.1 Reagents and Purification of solvents 
All reagents used in the synthesis were purchased from Sigma Aldrich as analytical grade 
reagents and were used without further purification. The solvents used were of AR 
quality and where necessary distilled. Tetrahydrofuran, diethylether and ethanol were 
dried over sodium wire using benzophenone as indicator. 
5.2 Chromatographic separation 
Column chromatography was performed using Merck Kieselgel 60: 70-230. Reactions 
were monitored by thin layer chromatography (TLC) using Merck F254 aluminuim backed 
silica gel 60 pre-coated plates. Detection and visualization of the spots was by ultra violet 
light (254/366 nm), charring, 0.125 M ferric ammonium sulfate or 2% ninhydrin in 
methanol. Purification of the compounds by preparative high pressure liquid 
chromatography (HPLC) and purity analysis was performed on a SPECTRA SYSTEM 
apparatus with XBridge columns (USA) prep. C18, 5 µm, 19 mm x 250 mm preparative 
column and XBridge columns (USA) C18, 5µm, 4.6 mm x 150 mm 100A analytical 
column respectively. Eluents were acetonitrile and water, beginning with ratio of 10:90 
(v/v) and reaching 100:0 (v/v) after a period of 15min. (flux rate, 20 or 10mL/min). 
 
5.3 Physical and Spectroscopic characterization 
Melting points were determined using a Reichert-Jung Thermovar hot stage microscope 
and are uncorrected. 1H NMR spectra were recorded using a Varian Mercury 
spectrometer (300MHz) or on a Bruker spectrometer (400MHz). All spectra were 
recorded in deuterated chloroform or dimethylsulfate or methanol with tetramethylsilane 
as an internal standard. 13C NMR was recorded with the same instruments at 75MHz or 
100MHz. Chemical shifts (δ) are reported in parts per million (ppm) downfield from the 
internal standard tetramethylsilane (TMS). High resolution Mass spectrometry (TOF MS 
ES or ESI) was performed using a Waters API Q-TOF Ultima at Stellenbosch University, 
Cape Town. Low resolution mass spectrometry (EI+) was performed on a JOEL GC mate 
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Fisons EA 1108; C, H, N, S instrument. Infrared spectra were recorded on a Thermo 
Nicolete FT-IR instrument in the 4000-300 cm-1 range using KBr discs.  
 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K  radiation (  = 0.71073 Å). Data 
collection was carried out at 100(2) K. Temperature was controlled by an Oxford 
Cryostream cooling system (Oxford Cryostat). Cell refinement and data reduction were 
performed using the program SAINT1. The data were scaled and empirical absorption 
corrections were performed using SADABS. The structure was solved by direct methods 
using SHELXS-97 and refined by a full-matrix least-squares methods based on F2 using 
SHELXL-97 and using the graphics interface program X-Seed. The programs X-Seed 
and POV-Ray were both used to prepare molecular graphic images.  
 
Solubility was determined using a turbidimetric method at pH 7.4 and was carried out at 
the AiBST, Harare, Zimbabwe. 
5.4 Synthesis 
Synthesis of the 3,4-hydroxypyridinones followed documented procedures as described 
elsewhere (Dobbin P, et al 1994; Storr T, et al 2003; Ma Y et al 2004; Dehkordi et al 
2008) with some modification. Aminoquinoline intermediates were synthesized as 
described by Solomon et al, 2007. The metal complexes were prepared as described in 
various references (Green, DE, et al, 2005 and Xiao, G. et al 1993) with some 
modifications. Hydrogenation was performed on a Parr instrument at pressures of 1-4 
atm. at ambient temperature. Compound purification included crystallization, solvent 
extraction, precipitation, freeze drying, and column chromatography and HPLC. 
5.4.1 Synthesis of N-alkyl-3,4-hydroxypyridinones and their gallium (III) complexes 
2-methyl -3-(benzyloxy)-4-pyranone (benzylmaltol) (1)  
To a solution of 3-hydroxy-2-methylpyranone (maltol) (5.00g; 39.70mmol) in MeOH 
(38ml) was added NaOH (5ml; 10M)  followed by benzylmaltol (6.70g; 52mmol) 
dropwise. The mixture was refluxed for 22h at 92oC. Complete removal of the solvent 
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extracted into CH2Cl2 (80mL×3). The combined organic extracts were washed with 5% 
(aq) NaOH (80ml×2) followed by water (80ml ×1). The extract was dried over anhydrous 
Na2SO4 and concentrated to give orange oil (1). 
 
Orange oil, (9.45g, 69%). Rf (10% MeOH/CH2Cl2) 
0.64; H (300MHz, CDCl3) 7.58 (1H, d, J 4.8, H-6), 
6.36 (1H, d, 5.0 H-5), 7.27-7.25(2H, m, H- 4‟, 6‟), 
7.42-7.30(3H, m, H-3‟,5‟,7‟), 5.16 (2H, s, H-1‟), 2.09 
(3H, s, CH3-2); c (75MHz, CDCl3) 174.9, 159.5, 
153.3, 143.7, 136.8, 128.9, 128.6 (2C), 128.3, 128.2, 117.0, 73.4, 14.6; 
 
Synthesis of 1-Ethyl-2-methyl-3-(benzyloxy)-4(1H)-pyridinone (2)  
Ethylmaltol (l7.84g, 56mmol) was dissolved in MeOH, 10M NaOH (6.9ml, 60mmol) was 
followed by addition of benzylchloride (6.9ml, 60mmol). The mixture was refluxed at 
99oC for 7h. A solid residue (NaCl) was filtered off and the filtrate concentrated to 
dryness. The resultant oily residue was taken up in CH2Cl2 (25ml), washed with 5% w/v 
NaOH (aq) (3×13ml), finally with water (21×3ml) and dried over anhydrous Na2SO4 to 
give 10.335g of bright orange oil. 
Bright orange oil (10.335g, 80%), 
H (400MHz, CDCl3) 7.6 (1H, d, J 
5.6, H-6), 7.39 (2H, dd, J 2, 7.8 H-
4”, 6”), 7.35-7.31 (3H, m, H-3”, 5”, 
7”),  6.3 (1H, d, J 5.6, H-5), 5.2 
(2H, s, H-1”), 2.5 (2H, q, J 7.6 CH2-
2), 0.99 (3H, t, J 7.6, CH3-2); C (100MHz, CDCl3) 176, 164, 144, 138, 129 (2C) 128.4 
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Synthesis of 1,2-Dimethyl-3-(benzyloxy)-4(1H)- pyridinone hydrochloride (1a)  
 
To a solution of benzylmaltol (1.25g; 5.80mmol) in 50% (aq) EtOH (20ml) was added 
40% (aq) methylamine (0.8ml; 9.00mmol). Afterwards a catalytic amount of 2N NaOH 
(0.05ml; 0.01mmol) was added. The mixture was refluxed for 18h at 105oC. The pH of 
the resultant mixture was adjusted to 7 using NaOH (10N) then extracted into CH2Cl2 
(50ml×3). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. The green oil obtained was dissolved in 35ml EtOH/HCl (1:1)), 
concentrated then recrystalised from EtOH/Et2O to give a white solid, compound 2. The 
other benzylprotected HPOs were synthesized using a similar procedure. Ethylamine, n-
butylamine, cyclopropylamine, tert-propylamine, n-propylamine, n-hexylamine and n-
octylamine were used in place of methylamine for the preparations of compounds 1b, 1c, 
1d, 1e, 1f, 1g, and 1h respectively. 
 
1,2-Dimethyl-3-(benzyloxy)-4(1H)- pyridinone hydrochloride (1a) 
White solid (793mg, 48%); m.p. 190-192; Rf (10% 
MeOH/CH2Cl2) 0.32; Vmax (KBr) cm-1 3448 (H2O), 
3280 (NH) 1628 (C=O), 843 (py C-H); H (300MHz, 
CDCl3) 7.38 (2H, dd, J 2.1, 7.3, H-4”, 6”), 7.3-7.2 (3H, 
m, H-3”, 5”, 7”) 7.14 (1H, d, J 7.5, H-6), 6.34 (1H, d, J 
7.4, H-5), 5.16 (2H, s, H-1”), 3.48 (3H, s, NCH3), 2.07 (3H, s, CH3-2); Anal.Calcd 
(found) for C14H16ClNO2.0.5H2O: C, 61.2 (62.9); H, 6.24(5.8); N 5.1(5.1). 
 
1-ethyl-2methyl-3-(benzyloxy)-4(1H)-pyridinone hydrochloride (1b) 
Cream crystals (600mg, 31%); m.p. 151-154oC; Rf 
(10%MeOH/CH2Cl2) 0.25; H (400MHz, CDCl3) 
7.4(2H, dd, J 1.8, 7.8, H-4”, 6”), 7.3(3H, m, H-3”, 5”, 
7”), 7.2 (1H, d, J 7.5, H-6), 6.4(1H, d, J 7.5, H-5), 
5.2(2H, s, H-1”), 3.8(2H, q, J7.25, H-1‟), 2.1(3H, s, CH3-2), 1.3(3H, t, J 7.5 NCH2CH3-
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127.9, 117.7, 72.97, 48.6, 15.79, 12.2; Anal. Calcd (found) for C15H18ClNO2.2.5H2O: C 
55.47 (55.2), H,7.14 (6.4), N 5.4 (4.31). 
1-butyl-2-methyl-3(benzyloxy)-4(1H)-pyridinone hydrochloride (1c) 
Orange oil (1.1g, 59%); Rf (10%MeOH/CH2Cl2) 
0.25; H (300MHz, CDCl3) 7.2 (1H, d, J 7.5, H-6), 
6.4 (1H, d, J 7.5 H-5), 7.42-7.37 (2H, m, H-4”, 6”), 
7.35-7.24 (3H, m, H-3”, 5”, 7”), 5.2 (2H, s, CH2-1”), 
3.65 (2H, t, J 7.4 H-1‟), 2.1 (3H, s, CH3-2), 1.6 (2H, 
q 7.4, H-2‟), 1.3 (2H, m, H-3‟), 0.93(3H, t, J 7.28 H-4‟); C (75MHz, CDCl3) 173.3, 
146.1, 140.5, 138, 137.7(2C), 129.1 (2C), 128.2 (2C), 127.9, 72.9, 53.5, 32.7, 20.0, 13.6, 
12.4. 
 1-cyclopropyl-2-methyl-3(benzyloxy)-4(1H)-pyridinone hydrochloride (1d) 
Yellow oil (989.3mg, 47%) Rf (10%MeOH/CH2Cl2) 
0.38; H (400MHz, CDCl3) 7.41 (2H, dd, J 1.6, 7.8, 
H-4”, 6”), 7.3 (3H, m, H-3”, 5”, 7”), 7.2 (1H, d, 7.5, 
H-6) 6.33(1H, d, J 7.7, H-5), 5.2 (2H, s, H-1”), 3.2 
(1H, septet, J 4.0 H-1‟), 2.15 (3H, s, CH3-2), 
1.01(2H, m, H-2‟), 0.93(2H, m, H-3‟);  C (100MHz, CDCl3)145.8, 142.9, 138.1, 137.8 
(2C), 129, 128.4 (2C), 128.2, 127.9, 116.7, 72.9, 35.4, 12.7, 8.3, 6.5, 5.2. HR-MS (ESI+) 
found 256.1338 (M+H) C16H18NO2 [M+H] requires 256.1338. 
1-isopropyl-2-methyl-3-(benzyloxy)-4(1H)-pyridinone hydrochloride (1e) 
Orange crystals (800mg, 50%), m.p. 171-173oC); Rf 
(10%MeOH/CH2Cl2) 0.54; H (300MHz, CDCl3) 
7.4(2H, dd, J 7.6, 1.9, H-4”, 6”), 7.31(1H, d, J 7.8, 
H-6), 7.7(1H, d, J 7.7, H-5), 7.32-7.26 (3H, m, H-3”, 
5”, 7”), 5.2 (2H, s, H-1‟‟), 4.3(1H, septet, J 6.6, H-
1‟). 2.3 (3H, s, CH3-2), 1.36 (6H, d J, 6.6,H-2‟, 3‟); C (75MHz, CDCl3) 173.1, 145.9, 
140.4, 137.7, 132.6, 129.1, 128.2, 127.9, 117.7, 73, 51.6, 22.7, 12.1 (2C).; Anal.Calcd 
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1-propyl-2-methyl-3(benzyloxy)-4(1H)-pyridinone hydrochloride (1f) 
Golden brown crystals (977mg, 44%); m.p. 64-66oC; 
Rf (10% MeOH/CH2Cl2) 0.5; H (400MHz, DMSO) 
8.44 (1H, d, J 7.14, H-6), 7.52 (1H, d, J 7.14, H-5), 
7.4 (2H, d , J, 1.7, 7.8, H-4”, 6”), 7.38-7.36 (3H, m, 
H-3”, 5”, 7”), 5.09 (1H, s, H-1”), 4.3 (2H, t, 7.4, H-
1‟), 2.4 (3H, s, CH3-2), 1.71(2H, sextet  J 7.5 H-2‟), 0.89(3H, t, J 7.4, H-3‟); C 
(100MHz, DMSO) 163.7, 149.1, 142.7, 141.9, 136, 128.7 (2C), 128.4 (2C), 128.38, 
112.5, 74.1, 57.1, 22.7, 12.95, 10.2. Anal.Calcd (found) C16H20ClNO2.5H2O: C 61.63 
(60.97): H 7.11 (6.97); N 4.49 (4.14). 
1-Hexyl-2-methyl-3(benzyloxy)-4(1H)-pyridinone hydrochloride (1g) 
Colourless needles (1.2g, 63%); m.p. 46-48oC. Rf 
(10% MeOH/ CH2Cl2) 0.43; H (300MHz, CDCl3) 
7.4 (2H, dd, J 2.7, 7.2, H-4“, 6“), 7.3 (1H, d, J 7.2, 
H-6), 7.3-7.23(3H, m, H-3”, 5”, 7”), 6.68(1H, d, J 
7.32, H-5), 5.2 (1H, s, H-1”), 3.75 (2H, t, J 7.5, H-
1‟), 2.09 (3H, s, CH3-2), 1.6 (2H, quintet, J 7.2, H-2‟), 1.25 (6H, m, H-3‟, 4‟, 5‟), 0.88 
(3H, t, J 6.6, H-6‟); C (75MHz, CDCl3) 171.1, 145.6, 142, 138.7, 137.2, 129.1, 128.3 
(2C),128.1 (2C), 116.6, 73.3, 54.4, 31.2, 30.6, 25.9, 22.4, 13.8, 12.5. Anal.Calcd (found) 
for   C19H26ClNO2 : C 67.94 (67.73); H 7.8 (6.55); N 4.17 (3.78).  
Octyl-2-methyl-3(benzyloxy)-4(1H)-pyridinone hydrochloride (1h) 
Colourless crystals (630mg, 28%); m.p. 55-57oC; 
Rf (5%MeOH/CH2Cl2) 0.36; H (400MHz, 
CDCl3) 8.38 (1H, d, J 7.02, H-6), 7.99 (1H, d, J 
7.06, H-5), 7.36-7.31(5H, m, H-benzyl), 5.18 
(2H, s, H-1”), 4.28(2H, t, J 7.5, H-1‟), 2.38(3H, s, 
H-2), 1.8-1.67(2H, m, H-2‟), 1.37-1.18(10H, m, H-3‟- 7‟), 0.87(3H, t, J 6.75, H-8‟); C 
(100MHz, CDCl3) 164.7, 147.9, 143.4, 141, 135.8, 129.1, 128.8 (2C), 128.6 (2C), 113.5, 
74.9, 56.95, 31.6, 30.5, 29.0, 28.9, 26.2, 22.5, 14, 13.3;  
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Hydrogenolysis of compound 1a  
A solution of compound 1a (155mg, 0.57mmol) was dissolved in 90% (aq) EtOH and 
transferred into a 250ml hydrogenation flask, to it was added 8g Pd/C (10%w/w) 
suspension in 90% (aq) EtOH. The pH was adjusted to 1 (conc. HCl) before 
hydrogenation at 4bars (58psi) for 4h. Afterwards the mixture was filtered concentrated 
and recrystalised from EtOH/Et2O to give a white powder 1C2. A similar method was 
applied in the deprotection of the other 3,4-HPOs.  
 
Deprotection of compound 1f by acid hydrolysis. 
Compound 1f (39mg, 0.125mmol) was dissolved in ethanolic HCl~2M, (4mL, 8mmol) 
and refluxed at 90oC for 4h. The solvent was removed by evaporation under reduced 
pressure followed by recrystalization from EtOH/Et2O to give yellow crystals of 
compound, 2f. 
1,2-Dimethy-3-hydroxy4-(1H)-pyridinone hydrochloride (2a) 
White solid (84mg, 75%); m.p. 163-165oC; Rf 
(10%MeOH/CH2Cl2) 0.25; Vmax (KBr) cm-1 3448 
(H2O), 3300 (OH), 3287 (NH), 1632 (C=O), 809 (py 
C-H); H (300MHz, CDCl3) 8.21 (1H, d, J 6.95, H-
6), 7.32(1H, d, J 6.95, H-5), 3.99(3H, s, NCH3), 
2.5(3H, s, CH3-2);  C (75MHz, CDCl3) 158.6, 142.5, 141.9, 138.3, 110.4, 43.7, 12.6. 
Anal. Calcd (found) for C7H10ClNO2.H2O: C 43.42(43.17); H 6.25(5.54); N 7.24 (7.03). 
1-Ethyl-2-methyl-3-hydroxy-4(1H)-pyridinone Hydrochloride (2b) 
White solid (60mg, 55%); Rf (10%MeOH/ CH2Cl2) 
0.36; m.p. 166-168oC; H (300MHz, DMSO) 
8.24(1H, d, J 6.95, H-6), 7.36(1H, d, J 6.93, H-5), 
4.34(2H, q, J 7.23, H-1‟), 2.53 (3H, s, CH3-2), 
1.37(3H, t, J 7.2 H-2‟); C (75MHz, DMSO) 158.6, 
142.8, 140.95, 137.3, 110.9, 51, 15, 12.1; Anal. Calcd. (found) for C8H12ClNO2.0.5H2O: 
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1-Butyl-2-methyl-3-hydroxy-4(1H)-pyridinone hydrochloride (2c) 
White crystals (350mg, 32%); Rf (10%MeOH/ 
CH2Cl2) 0.38; m.p. 163-166oC;  H (300MHz, 
DMSO) 8.23(1H, d, J 6.97, H-6), 7.38 (1H, d, J 6.9, 
H-5), 4.35(2H, t, J 7.5, H-1‟), 2.5(3H, s, CH3-2), 1.8-
1.64(2H, m, H-2‟) 1.3 (2H, sextet, J 7.3 H-3‟) 
0.9(3H, t, J 7.2 H-4‟); C (75MHz, DMSO) 158.6, 142.8, 141, 137.8, 110.7, 55.5, 31.3, 
18.7, 13.1, 12.3; Anal. Calcd. (found) for C10H16ClNO2: C 55.17(55.35), H 7.4 (6.99), N 
6.43(6.17) 
1-Cyclopropyl-2-methyl-3-hydroxy-4(1H)-pyridinone Hydrochloride (2d) 
Colourless crystals (467mg, 47%); m.p. 193-197oC; 
Rf (10%MeOH/ CH2Cl2) 0.47; H (300MHz, DMSO) 
8.2 (1H, d, J 6.3, H-6), 7.30 (1H, d, J 7.2 H-5), 3.87 
(1H, q, J 5.7, H-1‟), 2.6(3H, s, CH3-2), 1.2(4H, d, J 
5.4, H-2‟, 3‟); C (75MHz, DMSO) 159.1, 143.5, 
142.3, 137.8, 110.1, 40.3, 12.8, 7.4 (2C).; Anal. Calcd. (found) for C9H12ClNO2: C 53.6 
(52.99), H 6.00(5.81), N 6.95 (6.84). HR-MS (ESI+) found 166.0852 (M+H) C9H12NO2 
[M+H] requires 166.0852 
1-isoPropyl-2-methyl-3-hydroxy-4(1H)-pyridinone hydrochloride (2e) 
White crystals (85mg, 61%); m.p. 196-197; Rf 
(10%MeOH/ CH2Cl2) 0.45; H (300MHz, DMSO) 
8.32 (1H, d, J 7.2, H-6), 7.38(1H, d, J 6.9. H-5), 4.9 
(1H, septet, J 6.6, H-1‟), 2.58 (3H, s, CH3-2), 1.46 
(6H, d, J 6.6, H-2‟, 3‟); C (75MHz, DMSO) 158.4, 
142.5, 141.0, 133.7, 111.2, 55.5, 22, 12 (2C); Anal. Calcd. (found) for 
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1-Propyl-2-methyl-3-hydroxy-4(1H)-pyridinone hydrochloride (2f) 
Yellow crystals (86.1mg, 83%* or 23.7mg, 78 %**); 
m.p. 187-189oC; Rf (10%MeOH/ CH2Cl2) 0.45; H 
(300MHz, DMSO) 8.22 (1H, d, J 6.9, H-6), 7.33 
(1H, d, J 6.9, H-5), 4.27 (2H, t, J 7.5, H-1‟), 2.52 
(3H, s, CH3-2), 1.76 (2H, sextet, J 7.44, H-2‟), 
0.89(3H, t, J 7.4); C (75MHz, DMSO) 158.7, 142.8, 141.1, 137.9, 110.6, 57, 22.7, 12.3, 
10.1; . Anal. Calcd. (found) for C9H14ClNO2: C 53.08 (53.03); H 6.93 (5.2); N 6.88 
(6.77). *Hydrogenation product, **hydrolysis product. 
1-Hexyl-2-methyl-3-hydroxy4-(1H)-pyridinone hydrochloride (2g) 
White crystals(77.3mg, 59%); m.p. 163-164oC; Rf 
(10%MeOH/ CH2Cl2) 0.55; H (300MHz, DMSO) 
8.2(1H, d, J 7.2, H-6), 7.27 (1H, d, J 7.2, H-5), 4.3 
(2H, t, J 7.5, H-1‟), 2.4(3H, s, CH3-2) 1.7 (2H, 
quintet, J 7.6, H-2‟), 1.28 (6H, m, H-3‟, 4‟, 5‟), 
0.85 (3H, t, J 4.5); C (75MHz, DMSO) 158.8, 142.9, 140.9, 137.8, 110.7, 55.7, 30.4, 
29.3, 25.0, 21.7, 13.5, 12.3; Anal. Calcd. (found) for C12H20ClNO2.0.5H2O: C 56.58 
(57.8); H 8.31 (7.2); 5.5 (5.19).  
Octyl-2-methyl-3hydroxy-4(1H)-pyridinone hydrochloride (2h) 
White crystals (155mg, 69%) from EtOH/Et2O; 
m.p. 55-57oC; Rf (50%MeOH/EtOAc) 0.73; H 
(300MHz, CD3OD) 8.15 (1H, d, J 6.9, H-6), 
7.1 (1H, d, J 6.9 H-5), 4.37(2H,t, J 7.5, H-1‟), 
2.6(3H, s, CH3-Py), 1.86 (2H, sextet, J 7.8 H-
7‟), 1.36 (10H, m, H-2‟- 6‟), 0.9(3H, t, J 6.9, 
H-8‟); C (75MHz, CD3OD) 159.6, 145, 143, 139, 111, 57, 32.8, 31.3, 30.2, 30.1, 27.3, 
23.6, 14.4, 12. Anal. Calcd. (found) for C14H24ClNO2.1H2O: C 57.62 (57.26); H 8.98 
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Synthesis of Tris (3-hydroxy-1,2-dimethyl-4-pyridinonato) gallium (III) [3a] 
To a solution of compound 2b, (46mg, 0.3mmol) in MeOH (1ml), was added an aqueous 
solution of Ga(NO)3.9H2O (41.8mg, 0.121mmol) while stirring for 3min.The pH was 
adjusted to 8 (0.1M NaOH), before refluxing (4h at 80oC). Evaporation to dryness under 
reduced pressure gave a white powder (68mg), which was dissolved in 1:1 H2O/MeOH 
and purified by gel filtration on Sephadex LH 20 with MeOH as the mobile phase. 
Analogous procedures were used to prepare all the other 3,4-HPO-gallium (III) 
complexes. 
Tris(3-hydroxy-1,2-dimethyl-4-pyridinonato) gallium (III), (3a)   
White solid (62mg, 72.1%) m.p. 326-329oC; Rf 
(10%MeOH/ CH2Cl2) 0.07 H (400MHz, DMSO) 7.45 
(1H, d, J 6.7, H-6), 6.26 (1H, d, J 6.7, H-5), 3.7 (3H, 
s, CH3-1), 2.28 (3H, s, CH3-2); MS  found  506.11 
(ML3 + Na), 569 (ML3 + NaNO3)  
 
Tris(3-hydroxy-2-methyl-1-(ethyl)-4-pyridinonato) gallium (III), (3b) 
Pink solid 69.7 mg (85%) m.p. 222- 225oC; Rf 
(10%MeOH/ CH2Cl2) 0.08; H (400MHz, DMSO) 
7.5 (1H, d, J 6.16, H-6), 6.3 (1H, d, J 6.29, H-5), 4.1 
(2H, t, J, 7.2, H-1‟), 2.3 (3H, s, CH3-2), 1.27 (3H, t, 
J 6.8, H-2‟); C   (100MHz, DMSO) 167.4, 132.2, 
128.6, 119.7, 110.2, 106.5, 49.0, 16.0.  
 
Tris(3-hydroxy-2-methyl-1-(butyl)-4-pyridinonato) gallium (III) (3c) 
White solid (40.8mg, 59.1%) m.p. 303-305oC; Rf 
(10%MeOH/ CH2Cl2) 0.41 or ( EtOAc/MeOH, 1:1) 
0.21; H (400MHz, DMSO) 7.5 (1H, d, J 6.8, H-6), 
6.29 (1H, d, J 6.4, H-5), 4.0 (2H, t, J, 7.2, H-1‟), 2.3 
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septet, J 7.6, H-3‟), 0.9(3H, t, 7.7, H-4‟); C (100MHz, DMSO) 164.7, 153.5, 132.7, 
128.3, 105, 53.9, 32.1, 19.0, 13.4, 11.7 Anal. Calcd. (found) for C30H42GaN3O6.4.5H2O: 
C 52.11(52.45); H 7.43 (7.11); N 6.08 (5.54). HR-MS (ESI+) found 610.2408 (ML3 -2H) 
C30H30GaN3O6 [ML3-2H] requires 610.2408. 
Tris(3-hydroxy-2-methyl-1-(cyclopropyl)-4-pyridinonato) gallium (III), (3d) 
White solid (87mg, 69%); m.p. 237-240 oC; Rf 
(30%EtOAc/MeOH) 0.18; H (300MHz, DMSO) 7.5 
(1H, d, 6.9, H-6) 6.2 (1H, d, J 6.9, H-5), 3.6 (1H, 
septet, J 4.5 H-1‟), 2.4 (3H, s, CH3-2), 1.1 (4H, m, 
H-2‟,3‟);  C (100MHz,DMSO)167.9, 152.8, 132.3, 
130.9, 105.7, 36.5, 12.2, 12.4 (2C). MS found 
397.08 (ML2), 586.15 (ML3+Na+2H) 
Tris(3-hydroxy-2-methyl-1-(isopropyl)-4-pyridinonato) Gallium (III) (3e) 
Golden brown crystals (85mg, 75%), m.p. 259-
260oC); Rf (7:1MeOH/EtOAc) 0.29; H (400MHz, 
DMSO) 7.6 (1H, d, J 6.99, H-6), 6.32 (1H, d, J 6.9, H-
5), 4.6 (1H, septet, J 6.5, H-1‟), 2.3 (3H, s, CH3-2), 
1.37 (6H, d J, 6.6, H-2‟, 3‟); C (100MHz, DMSO) 
167.2, 128.7, 128.67, 128.1, 110.3, 52.7, 22.4, 11.8 
(2C); MS  found 401.11 (ML2), 590.19 (ML3 + Na).  
Tris(3-hydroxy-2-methyl-1-(propyl)-4-pyridinonato) gallium (III) (3f) 
Pink powder (53mg, 47%); m.p. 219-220oC; Rf 
(30%EtOAc/MeOH) 0.29; H(300MHz, DMSO) 7.5 
(1H, d, J 6.7, H-6), 6.26 (1H, d, J 6.8, H-5), 3.98 
(2H, t, 6.7, H-1‟), 2.3 (3H, s, CH3-2), 1.67 (2H, 
sextet  J 7.49, H-2‟), 0.87 (3H, t, J 7.36, H-3‟); C 
(100MHz, DMSO) 167.5, 153.4, 132.6, 128.3, 
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Tris(3-hydroxy-2-methyl-1-(hexyl)-4-pyridinonato) gallium (III) (3g) 
White solid (25mg, 21%); Rf 
(30%EtOAc/MeOH) 0.77; H (300MHz, 
DMSO) 7.5 (1H, d, J 6.7, H-6), 6.27 (1H, 
d, J 6.7 H-5), 4.01(2H, t, J 6.9, H-1‟), 2.3 
(3H, s, CH3-2), 1.67(2H, m, H-2‟), 1.3 
(6H, m, H-3‟- 5‟), 0.86 (3H, t, J 6.8, H-
6‟); C (100MHz, DMSO) 168, 128 (2C), 110, 106, 54.1, 30.6, 30.1, 25.4, 21.8, 13.7, 
11.9; MS 485.20 (ML2), 716.33 (ML3 + Na).  
Tris(3-hydroxy-2-methyl-1-(octyl)-4-pyridinonato) Gallium (III) (3h) 
pink resin (73.5mg, 96%) Rf 
(50%EtOAc/MeOH) 0.83; H 
(300MHz, CD3OD) 7.51 (1H, d, J 6.6, 
H-6), 6.51 (1H, d, J 6.6 H-5), 4.1 (2H, 
t, J 7.4, H-1‟), 2.4 (3H, s, CH3-2), 
1.76 (2H, m, H-2‟), 1.33 (10H, m, H-
3‟- 7‟), 0.9 (3H, t, J 6.9, H-8‟); C (75MHz, CD3OD) 168.6, 154, 134.8, 133, 108.6, 56.4, 
32.9, 31.9, 30.3, 27.4, 23.7, 14.4 (2C), 12.; MS 541.27(ML2), 778.46 (ML3+H), Anal. 
Calcd. (found) for C42H66GaN3O6H2O [ML3H2O] C 63.62 (63.10);  H 8.82 (8.20);  N 
5.18 (4.85).  
 
5.4.2. Synthesis of 4-aminoquinoline-3,4-hydroxypyridinone hybrids (A/AB series) 
Synthesis of N-(7-chloro-4-quinolyl)-1,3-diaminopropane (4) 
A mixture of 1,3-diaminopropane (3.7g, 50mmol) and  4,7-dichloroquinoline (2.293g, 
11.6mmol) was heated to 80oC for 1.5h under nitrogen atmosphere and subsequently at 
145oC for 4h with continuous stirring. After cooling, 2M NaOH (10ml) was added and 
stirred to precipitate the product, this was washed with water before drying to give 2.83g 
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N-(7-chloro-4-quinolyl)-1,2-diaminoethane (4) 
Creme solid (1.62g, 97%) Rf (10%MeOH/ CH2Cl2) 
0.32; H (300MHz, DMSO) 8.4 (1H, d, J 8.4, H-5‟), 
7.8 (1H, d, J 5.4, H-2‟), 7.8 (1H, d, J 2.1, H-8‟), 7.4 
(1H, dd, J 2.4, 9.0, H-6‟), 6.6 (1H, d, J 5.2, H-3‟), 




White solid (2.83g, 90%); Rf (20%MeOH/ EtOAc) 
0.15; Vmax (KBr) cm-1  3279w (NH), 1575s (C=N), 
1532m (C=C),  H (400MHz, DMSO) 8.38, (1H, d, J 
5.2, H-2‟), 8.3(1H, d, J 8.8, H-5‟), 7.7 (1H, d, J 2.4, 
H-8‟), 7.38 (2H, dd, J 2.4, 9.0, H-6‟), 6.47 (1H, d, J 
5.6, H-3‟), 3.36 (2H, t, J 6.8, H-1) 1.88 (2H, t, J 6.8, 
H-3), 1.6 (2H,  quintet, J 6.8, H-2). 
 
N-(7-chloroquinolin-4-yl)propane -1,3-diamine (6) 
Pale brown solid (1g, 98.3%) Rf 0.11 
(MeOH/CH2Cl2)),  δH (DMSO d6), 8.4 (1H, 
d, J 5.2, H-2”), 8.2 (1H, d, J 8.8, H-5”), 7.8 
(1H, br.s, H-8”), 7.52 (1H, br.s,1‟- NH), 
7.43 (1H, d, J 8.8, H-6”) 6.46 (1H, d, J 5.2, 
H-3”) 3.3 (2H, m, H-3‟ obscured by H2O 
peak) 2.61 (2H, t, J 6.4, H-3‟), 2.52 (1H, 
br.s, 3‟-NH), 2.31 (3H, s, 1-NCH3) 1.8 (2H, q, J 6.4, H-2‟); δC (DMSO d6, 100MHz), 
152.6, 150.8, 149.8, 133.9, 128.2, 124.7, 124.6, 118.2, 99.2, 50.2, 41.8, 36.9, 28. 
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N-(7-chloro-4-quinolyl)-1,4-diaminobutane (7) 
Pale yellow solid (2.158g, 79%) ; H (400MHz, 
DMSO) 8.37 (1H, d, J 5.6, H-2‟), 8.2 (1H, d, J 
8.8, H-5‟), 7.7 (1H, d, J 2.0, H-8‟), 7.4 (1H, dd, J 
2.0, 9.0, H-6‟), 6.45 (1H, d, J 5.2, H-3‟), 3.2 (2H, 
t, J 6.9, H-1), 2.6 (2H,  t, J 6.4, H-4), 1.7 (2H, q, J 
7.2, H-2), 1.47 (2H, q, J 6.9, H-3); C (75MHz, 
DMSO) 151.7, 149.99, 148.98, 133, 127.3, 123.9, 123.7, 117.4, 98.5, 42.3, 41.1, 30.5, 25. 
 
N-(7-chloro-4-quinolyl)-1,6-diaminohexane (8) 
White solid (3.823g, 92%) , H ; (400MHz, 
DMSO) 8.37 (1H, d, J 5.6, H-2‟), 8.25 (1H, 
d, J 8.8, H-5‟), 7.7 (1H, d, J 2.0, H-8‟), 7.4 
(1H, dd, J 2.4, 9.0, H-6‟), 6.4 (1H, d, J 5.2, 
H-3‟), 3.2 (2H, q, J 6.0, H-1), 1.67 (2H, 
quintet, J 6.4, H-6), 1.4 (8H, m, H-2,3,4,5); 
C (100MHz, DMSO) 152.5, 150.9, 149.9, 134, 128.2, 124.7, 124.6, 118, 99.3, 43.2, 28.6, 





















































 Ethylbenzylmaltol (2, 552mg, 2.4mmol) and N-(7-chloro-4-quinolyl)-1,2-diaminobutane 
(7, 1.0g, 3.7mmol) were dissolved in ethanol, then water (25ml) was added to the mixture  
to obtain a 50% aqueous EtOH solution. The pH of the solution was adjusted to 13 (2M 
NaOH) before refluxing at 110oC for 24h. Afterwards the pH was adjusted to 1 (2M HCl) 
before washing with diethylether (50mlx2). On adjustment of the pH to 7 (2M NaOH), a 
yellow precipitate formed which was filtered and washed with water and dried  under 
vacuum to give 425mg (36%) of the pure compound 14.  




Bright yellow crystals, (366mg, 93%), from 
EtOH/EtOAc; mp. 151-152 0C. Rf (50%MeOH/ CH2Cl2) 
0.5; Vmax (KBr) cm-1 3448w (H2O), 3280w (NH) 1628s 
(C=O), 1624s (C=N), 1600s (C=N), 1491m (C=C), 
822m (py C-H); H (400MHz, DMSO) 8.77 (1H, d, J 
9.0, H-5”), 8.6 (1H, d, J 7.2, H-2”), 8.34 (1H, d, J 7.2, 
H-6), 8.16 (1H, d, J 2.0, H-8”), 7.65 (1H, dd, J 2.0, 9.0, 
H-6”), 7.45-7.28 (5H, m, H-benzyl),7.27 (1H, d, J 7.27, 
H-5), 6.99 (1H, d, J 7.2, H-3”), 4.92 (2H, s, CH2-Bn),  
4.7 (2H, t, J 7.2, H-1‟), 4.04 (2H, q, J, 7.2, H-2‟), 2.5 
(3H, s, CH3-2); C(100MHz, DMSO) 164, 156.9, 151.8 (2C), 139.5, 128.1 (2C), 128 
(2C), 127.6, 127.5 (2C), 124.3, 124 (2C), 123.8, 123.6, 115.99, 110, 98.7, 71.8, 70.1 
(2C), 21.6; HRMS m/z calculated for C24H23N3O2Cl [M+H] 420.1490 found 420.1479; 
Anal. Calcd. (found) for C 44.2 (45.23), H 5.7 (4.73), N 8.6 (7.73), C24H22ClN3O2 4H2O; 






























Yellow-orange crystals  (220mg, 36%), from 
CHCl3/Et2O;  mp 154-157 oC; Rf (50%MeOH/ 
CH2Cl2) 0.6; Vmax (KBr) cm-1 3400w (H2O), 3212w 
(NH) 1629s (C=O), 1607s (C=N), 1582m (C=C),  
834m (py C-H); H (400MHz, DMSO) 8.37 (1H, d, J 
5.6, H-2”), 8.32 (1H, d, J 8.9, H-5”), 7.83 (1H, d, J 
2.2, H-8”), 7.63 (1H, d, J 7.6, H-6), 7.5 (1H, dd, J 2.2, 
8.99, H-6”), 7.32-7.29 (5H, m, H-benzyl), 6.5 (1H, d, J 
5.66, H-3”), 6.1 (1H, d, J 7.2, H-5), 4.92 (2H, s, CH2-
Bn)  4.18 (2H, t, J 6.3, H-2‟), 3.6 (2H,  t, J 7 H-1‟), 
2.64 (2H, q, J, 7.2, CH3CH2-2), 0.98 (3H, t, J 7.6, CH3CH2-2); C (100MHz, DMSO) 
209, 150.5, 150.4, 150.39, 145.38, 145.3, 145, 139.8, 139.74,139.78, 139.71, 124.7(2C), 
124.6(2C), 116, 98.5 (2C), 71.9, 71.8, 50.5, 42.8, 18.7, 13.1; HRMS m/z calculated for 
C25H25N3O2Cl [M+H] 434.1635 found 434.1645. Anal. Calcd. (found) for C 55.41 




White  powder  (675mg, 45%); m.p 125-127 0C; Rf 
(Et3N/MeOH/ CH2Cl2 ; 0.1:2:8) 0.27; Vmax (KBr) cm-1 
3433w (H2O), 3224w (NH) 1617s (C=O), 1544s (C=N), 
1506m (C=C),  815m (py C-H); H (400MHz, DMSO) 9.4 
(1H, s, NH), 8.69 (1H, d, J 9.2, H-5”), 8.53 (1H, d, J 6.8, 
H-2”), 8.04 (1H, d, J 1.6, H-8”), 7.6 (2H, m, H-6, 6”), 
7.38-7.29 (5H, m, H-benzyl), 6.81 (1H, d, J 6.8, H-3”), 
6.15 (1H, d, J 7.2, H-5), 4.99 (2H, s, CH2-Bn)  4.06 (2H, t, 
J 7.2, H-1‟), 3.5 (2H,  q, J 5.6 H-3‟), 2.1 (3H, s, CH3-Py), 
2.05 (2H, quintet, J, 6.8, H-2‟ ). C (100MHz, DMSO) 
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129.2 (2C), 129.1 (2C), 129, 128, 127, 126.6 (2C), 120.6, 116.7, 99.3, 72.5, 51.1, 29.2, 
12.6; HRMS m/z calculated for C25H25N3O2Cl [M+H] 434.1635 found 434.1652. Anal. 
Calcd. (found) for C 55.41 (55.51),  H 6.69 (5.47),  N 7.75 (7.83) C25H24ClN3O2 6H2O; 




Yellow powder  (319mg, 21%); m.p 129-130oC Rf 
(Et3N/MeOH/ CH2Cl2 ; 0.1:2:8) 0.36; Vmax (KBr) cm-1 
3430w (H2O), 3233w (NH) 1614s (C=O), 1541s (C=N), 
1502m (C=C),  818m (py C-H);  H (400MHz, DMSO) 
9.6 (1H, s, NH), 8.73 (1H, d, J 8.8, H-5”), 8.54 (1H, d, J 
7.2, H-2”), 8.06 (1H, d, J 2, H-8”), 7.75-7.71 (2H, m, H-
6, 6”), 7.39-7.28 (5H, m, H-benzyl), 6.85 (1H, d, J 7.2, 
H-3”), 6.19 (1H, d, J 7.6, H-5), 5.06 (2H, s, CH2-Bn), 
4.06  (2H, t, J 7.2, H-1‟), 3.56 (2H, q, J 5.6, H-3‟), 2.57 
(2H, q, J 7.6, CH3CH2-Py), 2.08 (2H,  quintet, J 7.2 H-
2‟) ,0.97 (3H, t, J 7.6, CH3CH2-Py), C (100MHz, DMSO) 172.5, 155.8, 146, 145, 144, 
140, 139.7, 138.5, 138.4, 128.9(2C), 128.8(2C), 128.4, 127, 126.7, 120, 117, 108, 99, 72, 
50, 30 (2C), 19, 14.; HRMS m/z calculated for C26H27N3O2Cl [M+H] 448.1972 found 
448.1774 Anal. Calcd. (found) for C 56.16 (56.57), H 6.89 (6.24), N 7.56 (7.65), 




Cream powder  (403mg, 40%); mp 128-130oC; Rf (Et3N/MeOH/ CH2Cl2 ; 0.1:2:8) 0.36; 
Vmax (KBr) cm-1 3400w (H2O), 3034w (NH) 1614s (C=O), 1544s (C=N), 1494m (C=C),  
811m (py C-H); H (400MHz, DMSO) 9.8 (1H, m, NH), 8.8 (1H, d, J 9.2, H-5”), 8.5 (1H, 
d, J 7.2, H-2”), 8.1 (1H, d, J 2, H-8”), 8.0 (1H, d, J 7.6, H-6), 7.7 (1H, dd, J 2, 9.2, H-6”), 
7.4-7.33 (5H, m, H-benzyl), 6.8 (1H, d, J 7.2, H-3”), 6.6 (1H, d, J 7.2, H-5), 5.03 (2H, s, 
CH2-Bn),4.12  (2H, t, J 7.2, H-1‟), 3.55 (2H, q, J 6, H-4‟), 2.8 (3H, s, CH3-2), 1.77 (4H, 
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129.4, 129.3, 129.1, 128.9, 128.7, 127.4, 
126.8, 119.7, 116, 115, 99, 74.2 54, 43, 
27.9, 24.9, 13; HRMS m/z calculated for 
C26H27N3O2Cl [M+H] 448.1792 found 
448.1777; Anal. Calcd. (found) for C 
56.16(56.69), H 6.89 (5.84), N 7.56 (7.62) 






Bright yellow powder  (403mg, 40%); Mp 
112-116oC Rf (Et3N/MeOH/ CH2Cl2 ;  
0.1:2:8) 0.36; Vmax (KBr) cm-1 3392w 
(H2O), 3226w (NH) 1613s (C=O), 1575s 
(C=N), 1540m (C=C),  809m (py C-H);  H 
(400MHz, DMSO) 8.6 (1H, d, J 8.8, H-5”), 
8.47 (1H, d, J 6.8, H-2”), 7.96 (1H, d, J 2, 
H-8”), 7.64. (1H, d, J 7.2 H-6), 7.63. (1H, 
dd, J 2, 9.2, H-6”),7.5-7.4 (5H, m, H- 
benzyl), 6.73 (1H, d, J 6.4, H-3”), 6.15 (1H, d, J 7.2, H-5), 5.1 (2H, s, CH2-Bn), 3.92  
(2H, t, J 6.4, H-1‟), 3.46 (2H, m, H-4‟), 2.9 (2H, q, J 7.2, CH3CH2 Py), 1.78-1.68 (4H, m, 
H-2‟, 3‟) 0.98 (3H, t , J 7.2, CH2CH3-2); C (100MHz, DMSO) 174, 146, 145, 140, 137 
(2C), 128.9, 128.84 (2C), 128.1 (2C), 128.3(2C), 126.6, 126.5, 126, 122, 116.9, 99 (2C), 
72.4, 52.5, 43.3, 29.1, 25, 19.6, 14.1; HRMS m/z calculated for C27H29N3O2Cl [M+H] 
462.1948 found 462.1951; Anal. Calcd. (found) for C 65.12 (65.86), H 6.48 (6.35), N 

















































Orange oil  (330mg, 27%);  Rf 
(Et3N/MeOH/ CH2Cl2 ; 0.1:2:8) 0.69; Vmax 
(KBr) cm-1 3400w (H2O), 3943w (NH) 
1630s (C=O), 1618s (C=N), 1580m (C=C),  
800m (py C-H);  H (300MHz, CDCl3) 8.45 
(1H, d, J 5.4, H-2”), 7.95 (1H, d, J 2.1, H-
8”), 7.85 (1H, d, J 9, H-5”), 7.32-7.25 (6H, 
m, H-benzyl, H-6”), 7.1 (1H, d, J 7.5, H-6), 
6.4 - 6.33 (2H, d, J 7.5, H-5, 2”), 5.16 (2H, 
s, CH2-Bn), 3.68  (2H, t, J 7.5, H-1‟), 3.25 (2H, q, J 6.6, H-6‟), 2.09 (3H, s, CH3-2), 1.7 
(2H,  quintet, J 7.2 H-2‟) 1.57 (2H,  quintet, J 7.2 H-5‟), 1.41-1.22 (2H,  m, H-3‟, 4‟) C 
(75MHz, CDCl3) 173, 151.7, 150, 149, 140.6, 138, 134.6, 128.8(2C), 128.3 (2C), 128.2, 
128, 127.9 (2C), 124.9, 121.8, 117, 98.8 (2C), 72.9, 53.6, 42.9, 30.5, 28.6, 28.4, 26.9, 
12.3;  HRMS m/z calculated for C28H31N3O2Cl [M+H] 476.2105 found 476.2094; Anal. 
Calcd. (found) for C 66.85 (66.91), 6.61 (6.58), 8.35 (5.09), C28H30ClN3O2 1.5H2O; 




Yellow powder  (360mg, 34%); Mp 168-
170oC Rf (Et3N/MeOH/ CH2Cl2 ; 0.1:2:8) 
0.65; Vmax (KBr) cm-1 3302w (H2O), 3103w 
(NH) 1609s (C=O), 1575s (C=N), 1532m 
(C=C),  870m (py C-H);  H (300MHz,   
CDCl3) 8.47 (1H, d, J 6, H-2”), 7.92 (1H, d, 
J 3, H-8”), 7.78 (1H, d, J 9, H-5”), 7.41-
7.13 (6H, m, H-benzyl, H-6”), 7.14 (1H, d, 
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d, J 6, H- 5),   5.24 (2H, s, CH2-Bn), 3.73  (2H, t, J 6, H-1‟), 3.28 (2H, m, H-6‟), 2.56 
(2H,  q, J 7.5, CH3CH2-2), 1.78- 1.62 (4H,  m,  H-2‟, 5‟) 1.53 – 1.3 (4H,  m, H-3‟,4‟), 
1.41-1.22 (2H,  m, H-3‟, 4‟), 1.01 (3H, t, J 7.5, CH2CH3-2) C (75MHz, CDCl3) 173.5, 
151.5, 150, 148.7, 145.9, 145.6, 138.1, 137.7, 134.9, 128.5(2C), 128.2 (2C), 127.9, 125, 
121.4, 117.4, 117.2, 98.8 (2C), 72.8, 53.1, 43, 31.2, 29.6, 28.5, 26.7, 19.5, 13.3; HRMS 
m/z calculated for C29H33N3O2Cl [M+H] 490.2261 found 490.2265; HPLC purity 
analysis >98%. 
N-(7-chloro-4-quinolyl)-1-(6-aminohexyl)-3-(benzyloxy)-2-ethyl-4(1H)-pyridinone 
dihydrogenchloride (16.HCl salt) 
 
0.6ml of 1.25 M HCl (0.75mmol) in MeOH 
solution was added to 16 (101mg, 
0.207mmol) and stirred overnight in a 
sealed flask. Ethylacetate was added until 
precipitation was complete, solvent was 
removed and the white solid dried under 
vacuum for 2h to give the dry salt Yellow 
deliquescent solid  (550mg, 86%) ; H 
(300MHz, CD3OD) 8.48 (1H, d, J 8.8, H-
5”), 8.38 (2H, m, H-2”, 6), 7.88 (1H, d, J 1.5, H-8”), 7.65 (1H, dd, J 2, 9.2, H-6”), 7.60 
(5H, m, H-benzyl), 7.25 (1H, d, J 7.2, H- 3”), 6.88 (1H, d, J 7.2, H- 5),   5.25 (2H, s, 
CH2-Bn), 4.37  (2H, t, J 7.6, H-1‟), 3.62 (2H, t,  J 7.2, H-6‟), 2.92 (2H,  q, J 7.6, CH3 
CH2-2), 1.85 (4H,  m,  H-2‟, 5‟) 1.51 (4H,  m, H-3‟,4‟), 1.48 (3H, t, J 7.6, CH3CH2-2),  C 
(100MHz, CD3OD) 155.8, 148.1, 146.1(2C), 135.2, 134.2, 133.7, 131.5, 130.5, 127.9, 
120.4 (2C), 120.2 (2C), 119.1, 116.8, 110.7, 107.4, 104.8, 90.3, 66.7, 47.9, 35.2, 22.7, 
19.4, 17.9, 17.4, 12.1, 3.45; HR-MS  m/z calculated for 490.2557 C29H33Cl3N3O2.  [M + 
H]  found 492.2278; Anal. Calcd. (found) for C 56.45 (56.77), H 6.53 (6.51), N 6.81 
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Representative procedure for the synthesis of N-(7-chloro-4-quinolinyl)-
diaminoalkyl-3-(hydroxy)-2-alkyl-4(1H)-pyridinones (deprotection) 
 
237mg (0.48mmol) of compound 16 was dissolved in 30ml 2M ethanolic-HCl then 
subjected to hydrogenation in the presence of Pd/C 40mg (10 %w/w), 4 atmospheres 
pressure for 6.5h. Then the catalyst was filtered off and the solvent removed by rotary 
evaporation to give 169mg (88%) of a brown resin, 16a. Similar procedures were used to 
deprotect the other compounds with recrystalisation where possible. 
N-(7-chloro-4-quinolinylaminoethyl)-3-(hydrox)y-2-methyl-4(1H)-pyridinone  
dihydrogen chloride (9a) 
White crystals  (42mg, 68%), from EtOH/EtOAc; Mp 
173-175oC Rf (20%MeOH/ CH2Cl2) 0.35; Vmax (KBr) 
cm-1 3398br.w (OH), 3224w (NH) 1624s (C=O), 1606s 
(C=N), 1588m (C=C),  825m (py C-H); H (300MHz, 
CD3OD); 8.5 (1H, d, J 7.6, H-2”), 8.4 (1H, d, J 9.3, H-
5”), 8.16 (1H, d, J 6.9, H-6 ), 7.95 (1H, d, J 1.8, H-8”), 
7.7 (1H, dd, J 1.8, 9.3, H-6”), 7.06 (1H, d, J 6.9, H-5 
Py), 7.01 (1H, d, J 7.2, H-3”), 4.8 ( masked by H2O 
peak, H-1‟), 4.17 (2H, t, J, 6, H-2‟), 2.7 (3H, s, CH3-
2);  C (75MHz, CD3OD) 160, 144.6, 141.5, 139.9, 
132, 129.3 (2C), 129.3 (2C), 126.2, 126.1, 120.6, 
111.9, 99.9, 55.4 25, 13. MS. m/z calculated for C17H16N3O2Cl [M+H] 329.78 found 
330.1 (100%); Calcd. (found) for C 39.97 (40.08), H 5.92 (5.03), N 8.23 (9.19) 


































Andayi AW                                                                                                                    UCT 223 
                                                         
N-(7-chloro-4-quinolyl)-1-(2-aminoethyl)-3-(hydroxy)-2-ethyl-4(1H)-pyridinone 
dihydrogen chloride (10a) 
Cream crystals  (33mg, 30%), from Et2O; Mp 178-
180oC Rf  (50%MeOH/ CH2Cl2) 0.22; Vmax (KBr) cm-1 
3411br.w (OH), 3212w (NH) 1624s (C=O), 1602s 
(C=N), 1582m (C=C),  815m (py C-H); H (400MHz, 
CD3OD) 8.5 (1H, d, J 6.8, H- 2”), 8.4 (1H, d, J 9.2, H-
5”), 8.17 (1H, d, J 6.8, H-6), 7.95 (1H, d, J  2, H-8”), 
7.7 (1H, dd, J 2.0, 9.0, H-6”), 7.07 (1H, d, J 6.8, H-5 
Py), 6.98 (1H, d, J 7.2, H-3”), 4.18 (2H, t, J 6.0, H-1‟), 
3.3 (masked by H2O peak H-2‟), 3.14 (2H, q, J, 7.6, 
CH3 CH2-2 ), 1.3 (3H, t, J 7.6, CH2CH3-Py); C 
(75MHz, CD3OD) 160, 157, 148, 145, 144, 141, 140, 129(2C), 126, 120, 117,112, 99, 54, 




The benzylated analogue 11, (45mg 0.104mmol) was dissolved in a solvent mixture 
(water, conc. HCl, EtOH, 1:3:2) and the 
resultant slurry refluxed at 74oC, for 12h. 
Solvent removal by evaporation in vacuo 
afforded compound 11a. Which was 
further dried under vacuum. Bright 
orange powder (25mg, 50%); mp. 143-
146 0C; Rf 0.24 (MeOH/ CH2Cl2 1:1), 
Vmax (KBr) cm-1 3422br.w (OH), 3226w 
(NH) 1636s (C=O), 1613s (C=N), 1590m (C=C),  759m (py C-H);  δH (CD3OD, 
400MHz) 8.5 (1H, d, J 9.2, H-5”), 8.45 (1H, d, J 6.8, H-2”), 8.31 (1H, d, J 6.4, H-6), 7.9 
(1H, d, J 2,  H-8”), 7.71 (1H, dd, J 1.6, 9.0, H-6”), 7.1 (1H, d, J 6.4, H-3”), 6.99 (1H, d, J 
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m, H-2‟).; δC (CD3OD, 100MHz), 158, 156, 142, 140 (2C), 136, 126 (2C), 123.6 (2C), 
117.6, 109, 114, 97.3, 54, 39, 26.9, 10.1; MS. m/z calculated for C18H18N3O2Cl [M+H] 
344.11 found 344.1 (100%); Anal. Calcd (found) for C18H20Cl3N3O2 4H2O, C 44.23 
(43.95), H 5.77 (5.24), N 8.60 (9.31); HPLC purity analysis >98% 
 
N-(7-chloro-4-quinolyl)-1-(3-aminopropyl)-3-(hydroxy)-2-ethyl-4(1H)-pyridinone  
dihydrogen chloride (12a) 
Brown powder  (70mg, 40%);  mp.180 - 184oC Rf (50% 
MeOH/ CH2Cl2 ) 0.54; Vmax (KBr) cm-1 3443br.w (OH), 
3241w (NH) 1632s (C=O), 1613s (C=N), 1586m (C=C),  
820m (py C-H); H (400MHz, CD3OD) 8.5 (1H, d, J 9.2, 
H-5”), 8.4 (1H, d, J 7.2, H-2”), 8.3 (1H, d, J 7.2, H-6), 
7.9 (1H, d, J 1.6,  H-8”), 7.7 (1H, dd, J 2.0, 8.8, H-6”), 
7.1 (1H, d, J 6.8, H-3”), 7.0 (1H, d, J 7.2, H-5), 4.6 (2H, 
t, J 7.6, H-1‟), 3.8 (2H, t, J 6.8, H-3‟), 3.1 (2H, q, J 7.6, 
CH3CH2-2), 2.4 (2H, quintet, J 6.8, H-2‟), 1.27 (3H, t, J 
7.6 CH2CH3-2); C (75MHz, CD3OD) 159.9, 157.7, 
147.9, 144.9, 144.1, 139.9, 139.5, 128.8(2C), 126.5, 120.3, 117, 112, 100, 54, 30.7, 41.7, 
21.2, 12.2.; MS. m/z calculated for C19H21N3O2Cl [M+H] 358.13 found 358.1. Anal. 
Calcd. (found) for C 42.35 (41.76), H 6.36 (5.58), N 7.8 (8.10), C19H22ClN3O2 6H2O; 
HPLC purity analysis >98% 
 
N-(7-chloro-4-quinolyl)-1-(4-aminobutyl)-3-(hydroxy)-2-methyl-4(1H)-pyridinone  
dihydrogen chloride (13a) 
Brown crystals  (100mg, 70%) from hot  
Et2O; Rf (50% MeOH/ CH2Cl2) 0.3; Vmax 
(KBr) cm-1 3399br.w (OH), 3239w (NH) 
1632s (C=O), 1609s (C=N), 1577m (C=C),  
813m (py C-H); H (400MHz, DMSO) 9.9 
(1H, m, NH), 8.87 (1H, d, J 9.3, H-5”), 8.5 
(1H, d, J 7.2, H-2”), 8.36 (1H, d, J 6.9, H-
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1.8, 9.0, H-6”), 7.34 (1H, d, J 6.9, H-5), 6.86 (1H, d, J 6.9, H-3”), 4.43  (2H, t, J 7.2, H-
1‟), 3.58 (2H, q, J 6, H-4‟), 2.5 (3H, s, CH3-2) 1.92-1.77 (4H, m, H-2‟, 3‟); C (100MHz, 
DMSO) 159, 156, 143.6, 143.3  142, 139, 138.8, 127 (2C), 126.9, 119, 116, 111, 99, 
70.8, 56, 42.9, 24.8, 13.2.; MS. m/z calculated for C19H21N3O2Cl [M+H] 358.13  found 
358.1 (100%); HPLC purity analysis >98%  
 
N-(7-chloro-4-quinolyl)-1-(4-aminobutyl)-3-(hydroxy)-2-ethyl-4(1H)-pyridinone  
dihydrogen chloride (14a) 
 
Brown sticky solid (163mg, 76%); Rf (50% 
MeOH/ CH2Cl2 ;  1:2:8) 0.48; Vmax (KBr) 
cm-1 3391br.w (OH), 3272w (NH) 1632s 
(C=O), 1615s (C=N), 1594m (C=C),  797m 
(py C-H); H (400MHz, CD3OD) 8.5 (1H, 
d, J 8.8, H-5”), 8.4 (1H, d, J 7.2, H-2”), 
8.25 (1H, d, J 7.2, H-6), 7.89 (1H, d, J 2.0, 
H-8”), 7.69 (1H, dd, J 2.0, 8.2, H-6”), 7.1 
(1H, d, J 7.2, H-5), 6.9 (1H, d, J 7.2, H-3”), 4.47  (2H, t, J 7.6, H-1‟), 3.67 (2H, t, J 7.2, 
H-4‟), 3.08 (2H, t, J 7.6, CH3CH2-2), 2.05-1.9 (4H, m, H-2‟, 3‟) 1.29 (3H, t , J 7.6, CH2 
CH3-2); C (100MHz, CD3OD) 158.7, 146.7, 142.6 (2C), 138.2, 133.8, 127.5 (2C), 122.9, 
119.9, 115.8, 110.8, 98.7, 98.1, 55.7, 42.9, 28.6, 24.7, 19.9, 11.0: MS. m/z calculated for 
C20H23N3O2Cl [M+H] 372.15  found 372.1 (100%); Anal. Calcd. (found) for C 44.91 
(44.16), H 6.41 (6.01), N 7.84 (8.05), C20H24Cl3N3O25H2O: HPLC purity analysis > 98% 
 
N-(7-chloro-4-quinolyl)-1-(6-aminohexyl)-3-(hydroxy)-2-methyl-4(1H)-pyridinone  
dihydrogen chloride (15a) 
                                                                               
White powder (179mg, 90%), 
from hot Et2O; Mp 134-138oC Rf 
(50% MeOH/ CH2Cl2) 0.61; Vmax 
(KBr) cm-1 3425br.w (OH), 
3226w (NH) 1632s (C=O), 
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816m (py C-H); H (400MHz, CD3OD) 8.48 (1H, d, J 9.2, H-5”), 8.37 (1H, d, J 7.2, H-
2”), 8.2 (1H, d, J 6.8, H-6), 7.88 (1H, d, J 2, H-8”), 7.66 (1H, dd, J 2.0, 9.2 H-6”), 7.1 
(1H, d, J 6.8, H-5), 6.88 (1H, d, J 7.2 H-3”), 4.4 (2H, t, J 8.0, H-1‟), 3.6 (2H, t, J 7.2, H-
6‟), 2.6 (3H,  s, CH3-2), 1.9 – 1.8 (4H, m,  H-2‟,5‟) 1.56 – 1.48 (4H,  m,  H-3‟, 4‟); C 
(100MHz, CD3OD) 158.3, 156.4, 143.9, 142.5, 142, 138.8, 138,  127.4 (2C), 125, 119.8, 
115.7, 110.7, 98.6, 65.7, 56.7, 43.6, 30, 27.7, 25.8, 11.6.; MS. m/z calculated for 
C21H25N3O2Cl [M+H] 386.16  found 386.0 (100%); Anal. Calcd. (found) for C54.97 
(54.87), H 5.71 (5.94), N 9.16 (9.35), C21H26Cl3N3O2; HPLC purity analysis >98%. 
 
N-(7-chloro-4-quinolyl)-1-(6-aminohexyl)-3-(hydroxy)-2-ethyl-4(1H)-pyridinone 
dihydrogen chloride (16a) 
 
Brown resin  (169mg, 88%);  Rf 
(50% MeOH/CH2Cl2) 0.64; Vmax 
(KBr) cm-1 3302br.w (OH), 
3103w (NH) 1624s (C=O), 
1616s (C=N), 1609m (C=C),  
862m (py C-H) H (400MHz, 
CD3OD) 8.4 (1H, d, J 9.3, H-5”), 
8.37 (1H, d, J 7.2, H-2”), 8.18 
(1H, d, J 6.9, H-6), 7.87 (1H, d, J 1.5 H-8”), 7.68(1H, d, J 8.8, H-6”), 7.1 (1H, d, J 7.2, 
H-5), 6.94 (1H, d, J 7.2, H-3”), 4.39  (2H, t, J 7.5, H-1‟), 3.62 (2H, J  7.5, H-6‟), 3.06 
(2H, q, J 7.5, CH3CH2 -2), 1.97-1.79 (4H, m, H-2‟, 5‟), 1.55-1.15 (4H, m, H-3‟, 4‟), 1.29 
(3H, t , J 7.5, CH2CH3-2); C (100MHz, DMSO) 159, 156, 146.7, 143.6, 143.4, 139.1, 
138.9, 138.7, 127.5 (2C), 126.2, 119.8, 111.7, 99.3, 56.1, 43.9, 31.3, 28.2, 26.7, 26.2, 
20.3, 12.6; MS. m/z calculated for C22H26N3O2Cl [M+H] 400.18 found 400.2 (100%); 
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5.4.3. Synthesis of 4-aminoquinoline-3,4-hydroxypyridinone hybrids (3-OMe 
analogues) 
2- Ethyl-2-methoxy-pyranone (17) 
 To a solution of ethylmaltol (7.0g, 50mmol) in acetone (20ml), 
was added 2.5M KOH (20ml, 50mmol) followed by 
methyliodide (7.76g, 55mmol) drop wise. After a 12h stirring, 
the solvent was removed under pressure and the product 
extracted into CH2Cl2. The organic extract was dried over 
anhydrous MgSO4 then concentrated to give 17. 
Pale orange oil (4.46g, 58%) Rf 1.6 (CH2Cl2) δH (CDCl3, 300MHz), 7.61 (1H, d, J 5.7, H-
6), 6.3 (1H, d, J 5.7 H-5), 3.82 (3H, s, 3-OCH3), 2.66 (2H, q, J 7.5, 2- CH2CH3) 1.19 (3H, 
t, J 7.5, 2-CH2CH3). 
2-Methyl-2-methoxy-pyranone (18). 
 Compound 18 was prepared using a method similar to that of 
17 using dimethylsulphate as the methylating agent. Orange oil 
(5.7g, 41%) Rf 0.44 (10% MeOH /CH2Cl2) δH (CD3OD, 
300MHz), 7.95 (1H, d, J 5.7, H-6), 6.41 (1H, d, J 5.7 H-5), 3.94 




To a solution of 17 (200mg, 1.3mmol) in EtOH was added N-(7-chloro-4-quinolinyl)-1,6-
diaminohexane (8), (555mg, 1.85mmol) then water was added to make a 50% aq EtOH 
solution. After pH adjustment to 13 (2M NaOH) the mixture was refluxed for 24h. 
Removal of the solvent under reduced pressure, was followed by addition of 25ml of 
water, pH adjustment to 1 (Concentrated HCl) and washing with Et2O (50ml ×2). The pH 
was adjusted to 8 and the compound extracted into CH2Cl2 (50ml ×3), the organic extract 
was dried over anhydrous MgSO4 before concentration to give a yellow resin which was 

























Andayi AW                                                                                                                    UCT 228 
N-(7-chloro-4-quinolinyl)-1-(6-aminohexyl)-3-(methoxy)-2-ethyl-4(1H)-pyridinone 
(16b) Yellow powder (226mg, 50%); 
mp. 68 - 69 0C.  Rf 0.6 (MeOH/ CH2Cl2 
1:1),  δH (DMSO d6, 300MHz), 8.38 
(1H, d, J 5.4, H-2‟‟), 8.25(1H, d, J 9.0, 
H-5”), 7.77 (1H, d, J 2.4, H-8”), 7.54 
(1H,  d, J 7.5, H-6 Py) 7.41 (1H, dd, J 
2.1, 9.0, H-6”), 7.19 (1H, br.s, N-H), 
6.44 (1H, d, J 5.7, H- 3”), 6.1 (1H, d, J, 
7.5, H-5 Py), 3.86 (2H, t, J, 7.5, H-6‟), 3.75 (3H, s, 3- OCH3), 3.25 (DMSO, masking H-
1‟), 2.64 (2H, q, J, 7.5, CH2CH3-2), 1.67 (4H, m, H-2,‟ 5‟-H), 1.40 (4H, m, H- 3‟, 4‟), 1.1 
(3H, t, J 7.5, CH2CH3-2);  δC (DMSO d6, 100MHz), 172.6, 152.6, 150.9, 149.8, 147.3, 
145.7, 140.1, 134.1, 128.2, 124.9, 124.7, 118.2, 117.0, 99.4, 59.4, 52.9, 43.1, 31.7, 28.4, 
26.9, 19.6 (2C), 14.4; HR MS. m/z calculated for C23H27 Cl N3O2 [M-H] 412.1792  found 
414.1792; Anal. Calcd (found) for C23H28ClN3O2 H2O, C 62.45 (62.28), H 6.49 (6.79), N 




To a solution of 17 (200mg, 1.3mmol) in EtOH was added N-(7-chloro-4-quinolinyl)-1,4-
diaminobutane (7), (522mg, 1.85mmol) followed by water to make a 50% aq EtOH 
solution. After pH adjustment to 13 (2M NaOH) the mixture was refluxed for 24h. 
Removal of the solvent by evaporation, was followed by addition of an equal amount of 
water, pH adjustment to 1 (Concentrated HCl) and washing with Et2O (50ml×2). Further 
pH adjustment to 8 resulted in precipitatation of the product, which was filtered and 
washed with water and recrystallised from methanol/ ethylacetate. This method was used 
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N-(7-chloro-4-quinolyl)-1-(4-aminobutyl)-3-(methoxy)-2-methyl-4(1H)-pyridinone 
(13b)  
Pale yellow powder (1.02g, 64%); mp. 87 
– 87 0C; Rf 0.35 (MeOH/ CH2Cl2 1:1),  δH 
(CD3OD d4, 400MHz), 8.34 (1H, d, J 5.6, 
H-2‟‟), 8.05(1H, d, J 9.2, H-5”), 7.78 (1H, 
d, J 2.4, H-8”), 7.63(1H, d, J 7.2 H-6), 7.38 
(1H, dd, J 2.0, 9.2, H-6”), 6.5 (1H, d, J 5.6, 
H- 3”), 6.4 (1H, d, J, 7.6, H-5), 4.07 (2H, t, 
J, 7.5, H-4‟), 3.75 (3H, s, OCH3-3), 3.4 (2H, t, J 6.8, H-1‟), 2.41 (3H, s, CH3-2), 1.8 (4H, 
m, H-2‟, 3‟); δC (CD3OD, 100MHz), 165.3, 143.2, 142.8, 142, 140.2, 135, 131.4, 126.9, 
118.2, 116.7, 114.6, 109.3, 107.9, 90.3, 50.5, 45.4, 33.9, 19.7(2C), 16.8; HR MS. m/z 
calculated for C20H23 Cl N3O2 [M-H] 372.1479 found 372.1471; Anal. Calcd (found) for 





Yellow powder (400mg, 70%); mp. 166 - 
165 0C; Rf 0.45 (MeOH/ CH2Cl2 1:1),  δH 
(DMSO d6, 300MHz), 8.4 (1H, d, J 5.4, 
H-2‟‟), 8.26 (1H, d, J 9.0, H-5”), 7.78 
(1H, d, J 2.1, H-8”), 7.58(1H, d, J 7.5 H-
6 py), 7.44 (1H, dd, J 2.1, 9.0, H-6”), 
7.34 (1H, br.s, N-H), 6.5 (1H, d, J 5.4, H- 
3”), 6.1 (1H, d, J, 7.5, H-5), 3.93 (2H, t, 
J, 6.9, H-4‟), 3.75 (3H, s, OCH3-3), 2.65 (2H, q, J, 7.5, CH2CH3-2), 1.74 (6H, m, H-1‟, 
2‟, 3‟-H), 1.1 (3H, t, J 7.5, 2- CH2CH3 );  δC (DMSO d6, 75MHz), 171.7, 151.1, 150.2, 
148.4, 146.4, 144.7, 139.1, 133.5, 126.9, 124.0, 123.9, 117.2, 116.1, 98.6, 58.5, 51.8, 
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found 384.1482; Anal. Calcd (found) for C21H24ClN3O2 1.5H2O, C 60.22 (60.15), H 6.32 




Yellow powder (883mg, 48%); mp. 96 – 98 
0C; Rf 0.54 (MeOH/ CH2Cl2 1:1),  δH 
(CD3OD d4, 400MHz), 8.34 (1H, d, J 6.4, 
H-2‟‟), 8.24 (1H, d, J 9.2, H-5”), 7.8 (1H, 
d, J 2.0, H-8”), 7.67 (1H, d, J 7.2 H-6), 
7.53 (1H, dd, J 2.0, 9.2, H-6”), 6.68 (1H, d, 
J 6.8, H- 3”), 6.41 (1H, d, J, 7.6, H-5), 4.03 
(2H, t, J, 6.9, H-6‟), 3.75 (3H, s, OCH3-3), 
3.48 (2H, t, J 7.2, H-1‟), 2.43 (3H, s, CH3-2), 1.78 (4H, m, H-2‟, 5‟), 1.5 (4H, m, H-3‟, 
4‟);  δC (CD3OD, 100MHz), 165.1, 145, 135, 138, 131.7, 129.4, 117.9 (2C), 115.7 (2C), 
114, 108.2, 107.8, 90.2, 50.6, 45.7, 38.9, 34.9, 22.0, 19.6, 18.2, 17.6; HR MS. m/z 
calculated for C22H25 Cl N3O2 [M-H] 398.1635  found 398.1644; Anal. Calcd (found) for 
C22H26ClN3O2.5H2O, C 52.0 (52.13), H 6.98 (6.74), N 9.10 (8.22); HPLC purity analysis 
>98% 
 
5.4.4. Attempted Synthesis of Kojic derived 4-aminoquinolines-3,4-
hydroxypyridinone  via Mannich base intermediates 
 
Synthesis of 3-hydroxy-6-hydroxymethyl-2-piperidinomethylpyran-4-(1H)-one (19) 
To a solution of formaldehyde 37% (1.8g, 
60mmol), and piperidine (3.4g, 40mmol) in 
EtOH (96%), was added kojic acid (4.26g, 
30mmol), in 40ml in EtOH, 96%), then 
stirred for 1h before overnight refrigeration. 
The resultant white crystals were filtered off, 
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drying under vacuum to afford compound 19 as white crystals. Positive reaction with 4% 
methanolic ninhydrin confirmed piperidine incorporation. 
White solid (5.788g, 85%), Rf 0.38 (MeOH/ CH2Cl2 1:1) δH (DMSO d6, 400MHz) 6.33 
(1H, s, H-5), 4.32 (2H, s, CH2OH-6), 3.5 (2H, s, CH2N(CH3)CH2-2), 2.43 (4H, m, -CH2-
N-CH2-(piperidine)), 1.52 (6H, m, -CH2-CH2-CH2-(piperidine)); δC (DMSO d6, 
100MHz), 173.4, 167.4, 146.8, 143.6, 108.9, 59.6, 54.4, 53.6 (2C), 25.4 (2C), 23.6. 
    
Synthesis of 3-Hydroxy-6-hydroxymethyl-2-piperidinomethylpyran-4-(H)-one (19a) 
To a solution of 19 (4.12g, 18mmol) in MeOH was added 4.5M NaOH (5ml, 22.5mmol). 
The mixture was heated to reflux (83oC) before addition of benzylbromide (3.926g, 
22.5mmol) drop wise then refluxed further for 6h. The mixture was later evaporated 
cooled, and water (50ml) added, before extraction into dichloromethane (50ml ×3). The 
combined organic extracts were washed with 5% NaOH (aq) (50ml ×2), and water 
(50ml×2) then dried over anhydrous MgSO4 filtered and concentrated to afford 19a 
orange oil which was further dried under vacuum. 
Orange oil (3.313g, 58%) Rf 0.8 
(MeOH/ CH2Cl2 1:1); δH (DMSO d6, 
400MHz), 7.5-7.3 (10H, m, H-benzyl)  
6.48 (1H, s, H-5), 5.12 (2H, s, CH2Bn-
3), 4.41(2H, s, CH2OCH2Bn-6), 3.50 
(2H, s, CH2OCH2Bn-6), 3.45 (2H, s, 
CH2N(CH3)CH2-2), 2.38 (4H, m, -
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5.4.5. Synthesis of kojic derived 4-aminoquinoline -3,4-hydroxypyridinone hybrids 
via alkylhalide intermediates (R series) 
 
Synthesis of 5-(benzyloxy)-2-(hydroxymethyl)-4-(1H)-pyran-4-one (20) 
 To a solution of kojic acid (7.3g, 50mmol) in MeOH was added 11M NaOH (5ml, 
55mmol). The mixture was heated to reflux (80oC) before addition of benzylchloride 
(6.43g, 55mmol) dropwise then refluxed at 84oC for 12h. White crystals formed on 
cooling to room temperature and were washed in water and cold MeOH then dried under 
vacuum to give 20. 
White needles (8.55g, 74%); mp. 119-122 0C; Rf 
0.93 (MeOH/ CH2Cl2 1:3), δH (DMSO d6, 400MHz), 
8.15 (1H, s, H-6), 7.37 (5H, m, Bn C-H), 6.32 (1H, 
s, H-3), 4.94 (2H, s, CH2-Bn-5), 4.28 (2H, s, 
CH2OH-2), δC (DMSO d6, 100MHz), 173.2, 167.9, 
146.6, 141.3, 136.1, 128.4 (2C), 128.1, 128, 111.2, 
111.1, 70.6, 59.3.  
 
Synthesis of 5-(benzyloxy)-2-(hydroxymethyl)-1-methypyridin-4 (1H)-one (21) 
5ml of 40% methylamine (1.8g, 11mmol) was added to a solution of 20 (1.4g, 6.03mmol) 
in EtOH, refluxed at 70 oC in a sealed tube for 12h. pH adjustment to 1 (concentrated 
HCl) gave a thick precipitate, the solvent was removed by evaporation before washing 
the residue with diethylether. More water was added (25ml) to the residue and pH 
adjusted to 9 followed by washing with water and drying the product under vacuum.  
White needles (1.359g, 91%); mp. 205-207 0C  Rf 
0.72 (MeOH/ CH2Cl2 1:1) ), δH (DMSO d6, 
300MHz), 7.54 (1H, s, H-6), 7.36 (5H, m, Bn C-H), 
6.26 (1H, s, H-3), 5.01 (2H, s, CH2-Bn-5), 4.36 (2H, 
s, CH2OH-2), 3.58 (3H, s, NCH3-1) δC (DMSO d6, 
75MHz), 172, 148.5, 146.7, 137.1, 129.7, 127.9 
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2-(chloromethyl)-5-(benzyloxy)- 1-methypyridin-4 (1H)-one (22) 
 To neat thionyl chloride (9.82g, 
82mmol) below 0oC (ice/acetone 
mixture) was added 21 (2.45g, 9.9mmol) 
then stirred at room temperature 
overnight in a sealed flask. The crystals 
formed were washed with petroleum 
ether  and dried under vacuum to give white 22. White crystals (2.55g, 97%); mp. 168-
169 0C  Rf 0.47 (MeOH/ CH2Cl2 1:1), δH (DMSO d6, 300MHz), 8.86 (1H, s, H-6), ), 7.7 
(1H, s, H-3), 7.41 (5H, m, Bn C-H) 5.24 (2H, s, 5-CH2-Bn), 5.1 (2H, s, 2-CH2Cl), 4.15 
(3H, s, 1-NCH3). 
 
Synthesis of 5-(benzyloxy)-2-((2-(7-chloroquinolin-4-ylamino)hexylamino)methyl)-1-
methylpyridin-4 (1H)-one (27) –Method A 
To a solution of 22 (193mg, 0.73mmol), and 8 (244mg, 0.88mmol) in 3ml 
dimethylformamide , was added triethylamine (87mg, 0.86mmol) and anhydrous Na2CO3 
(92.4mg, 0.88mmol) before refluxing at 80oC for 24h. After adding dichloromethane 
(6ml) the mixture was washed with water (6ml ×2) then the solvent was removed under 
reduced pressure. The residue was subjected to column chromatography on silica gel via 
gradient elution with 0, 10, 20, 30, 50% MeOH/EtOAc. The title compound was eluted 
by 30-50% MeOH/EtOAc. Evaporation under reduced pressure afforded a yellow oil 
which was titurated in EtOAc to give a white solid on drying under vacuum. Further 
drying was done under vacuum at 
60oC for 6h. Compounds 26, 25 
and 23 were synthesized using a 
similar procedure. White solid 
(220mg, 44%); mp. 116 – 117 0C; 
Rf 0.17 (MeOH/ EtOAc 1:1) ) δH 
(CD3OD, 400MHz), 8.3 (1H, d,  J 
5.6, H-2”), 8.08 (1H, d, J 8.8,  H-
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3), 6.46 (1H, d, J 5.6, H-3”), 5.05 (2H, s, 5-CH2Bn), 3.73 (3H, s, 1-CH3), 3.67 (2H, s, 2-
CH2NH), 2.6 (2H, t, J 7.2, H-6‟), 1.73 (2H, t, J 7.2, H-1‟), 1.48 (8H, m, H-2‟- 5‟). δC 
(CD3OD, 100MHz),172.5, 151.4, 150.9, 148.5, 146.8, 136.5, 134.9, 129, 128.9, 
128.1(2C), 127.7(2C), 127.6, 126.1, 124.5, 123.1, 117.4, 115.9, 98.2, 71.2, 55.2, 49.4, 
48.9, 42.6, 39.9, 29.3, 27.9, 26.7;  MS. m/z calculated for C29H34 ClN4O2 [M+H] 505.23 
found 505.2 (100%);  Anal. Calcd (found) for C29H33ClN4O2  2H2O . C 64.37(64.99), H 




22 (263mg, 1mmol ) and 7 
(299mg, 1.2mmol) were used to 
prepare compound 26 using a 
method similar to the one 
described for 27, above. White 
solid (  218mg ,48%); mp. 80-
81 0C; Rf 0.1 (MeOH/ EtOAc, 
1:1) δH (CD3OD, 400MHz), 8.3 
(1H, d,  J 5.6, H-2”), 8.06 (1H, d, J 8.8,  H-5”), 7.74 (1H, d, J 2, H-8”), 7.5 (1H, s, H-6) 
7.3 (6H, m, benzylCH, H-6”), 6.5 (1H, s, H-3), 6.48 (1H, d, J  5.6, H-3”), 5.03 (2H, s, 5-
CH2Bn), 3.71 (3H, s, 1-NCH3), 3.70 (2H, s, 2-CH2N), 3.36 (2H, t, J, 7.2, H-4‟), 2.67 
(2H, t, J 7.2, 2-H-1‟), 1.7 (4H, m,  H-2‟, 3‟); δC (CD3OD, 75MHz),173.8, 157.6, 152.8, 
152.1, 149.4, 146.7, 137.7, 136.4, 130.1, 129.5 (2C), 129.2, 129 (2C), 127.3, 125.9, 
124.4, 116.7, 116.6, 99.7, 72.4, 62.3, 43.7, 41.6, 41.3, 28.4, 26.5; MS. m/z calculated for 
C27H30 ClN4O2 [M+H] 477.2  found 477.2 (100%);  Anal. Calcd (found) for 
C27H29ClN4O2  2H2O . C 63.21(63.71), H 6.48 (6.78), N 10.92 (11.76). HPLC purity 99% 
Rt   13.80 min. 
Method-B: To a solution of 7 (250mg, 1mmol) in 3ml dimethylformamide  triethylamine 
(101mg, 1mmol) and anhydrous NaHCO3 (168mg, 2mmol) was added compound 22 
(263mg, 1mmol ) before refluxing at 90oC for 20h., After adding dichloromethane (15ml) 
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observed on addition of brine] and water (10mlx2) The solution was filtered to remove 7, 
then dried over anhydrous sodiumsulphate. The solvent was removed under reduced 
pressure to give a bright orange oil (280mg, 59%). Further drying was done under 
vacuum at 30-60oC for 6h to get the pure compound. The elemental analysis data of the 
dry compound was similar to the product from method A. This method was applied 




Yellow solid (270mg, 58%), Rf 
0.37 (MeOH/ EtOAc 1:1) δH 
(CD3OD, 400MHz), 8.26 (1H, d,  
J 6.0, H-2”), 7.9 (1H, d, J 8.8,  
H-5”), 7.69 (1H, br.s, H-8”), 
7.41(1H, s, H-6) 7.3(6H, m, 
benzyl-CH, H-6”), 6.48 (1H, s, 
H-3), 6.42 (1H, d, J  5.2, H-3”), 
4.95,(2H, s,5-CH2Bn), 3.65 (3H, 1-NCH3), 3.36 (2H, t, J, 6.8, H-3‟), 3.23 (2H, s, 2-
CH2NH), 2.72 (2H, t, J 6.4, H-1‟), 1.86 (2H, q, J 6.4, H-2‟); δC (CD3OD, 75MHz), 173.9, 
152.8, 152.4, 149.8, 149.6, 149.3, 148.9, 137.8, 136.4, 130.2, 129.9, 129.5, 129.2, 129.1, 
127.6, 126, 124.2, 118.8, 117.2, 117.1, 99.6, 72.4, 50.9, 42.4, 41.2, 29.2; MS. m/z 
calculated for C26H28ClN4O2 [M+H] 463.19 found 463.2 (100%);  Anal. Calcd (found) 
for C26H27ClN4O2 H2O . C 64.92(64.11), H 6.04 (6.64), N 11.65 (11.91). HPLC purity 




To a solution of 6 (250mg, 1mmol) in acetonitrile (10ml) was added 22 (263mg, 1mmol) 
followed by NaOH (44mg, 1.1mmol), sonicated to dissolve then sujected to microwave 
conditions (250W, 100oC, 249 bars, 18min.) MeOH was added to dissolve the precipitate, 
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chromatography on silica gel via gradient elution with 0; 20; 30% MeOH/EtOAc. 24 was 
eluted by 30% MeOH/EtOAc and the fraction was subsequently rotaevaporated to give a 
white hygroscopic solid which was recrystalised from methanol/water. 
 
Colourless needles from methanol/H2O 
(190mg, 40%);  mp. 84-87 0C; Rf 0.4 
(MeOH/ EtOAc 1:1) δH (CD3OD, 
300MHz), 8.33 (1H, d, J 5.6, H-2”), 
8.01 (1H, d, J 8.8,  H-5”), 7.74 (1H, d, J 
1.6, H-8”), 7.32 (7H, m, benzylCH, H-
6, H-6”), 6.5 (1H, d, J 6.0, H-3”), 6.45 
(1H, s, H-3), 4.87 (2H, s, 5-CH2Bn), 
3.71 (3H, s, 1-CH3), 3.44 (2H, s, 2-CH2NH), 3.36 (2H, t, J 6.8, H-3‟), 2.56 (2H, t, J 6.4, 
H-1‟), 2.70 (3H, s, CH3-N(CH2)CH2), 1.90 (2H, m, H-2‟). δC (CD3OD, 75MHz), 173.4, 
153.6, 150.9, 149.1, 148.3, 147.9, 137.7, 129.9, 129,5(2C), 129.1(2C), 129.0(2C), 126.5, 
126.3, 124.6, 118.8, 118.4, 99.6, 72.2, 60.3, 55, 42.1, 41.9, 26.7; MS. m/z calculated for 
C27H30ClN4O2 [M+H] 477.21 found 477.2 (100%); Anal. Calcd (found) for 
C27H29ClN4O2 2H2O C 63.21 (63.57), H 6.48 (6.13), N 10.92 (11.09); HPLC purity 
analysis 95%. 
Alternative method B was used to prepare more of the compound 24; 300mg, (65% 
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5-(benzyloxy)-2-((2-(7-chloroquinolin-4-ylamino)ethylamino)-1-methylpyridin-4 (1H)-
one (23)                                                                                                                                 
Orange resin (56mg, 12.5%); 
mp. Rf 0.1 (MeOH/ EtOAc 1:1) 
δH (CD3OD, 300MHz), 8.34 
(1H, d,  J 5.7, H-2”), 8.05 (1H, 
d, J 9.0,  H-5”), 7.77 (1H, d, J  
2.1, H-8”), 7.42 (7H, m, 
benzylCH, H-6, 6”), 6.53 (1H, 
s, H-3), 6.52 (1H, m, H-3, 3”), 
5.0 (2H, s, CH2Bn), 3.78 (2H, s, 2-CH2NH), 3.74 (3H, 1-NCH3), 3.48 (2H, t, J, 6.3, H-
2‟), 2.98 (2H, t, J 6.3, H-1‟);  δC (DMSO, 100MHz): 171.9, 151.8, 150.3, 147.8, 147.4, 
147.2, 137.7, 134.9, 129.9, 128.7 (2C), 128.4(2C), 128.3, 126.1, 125.1, 124.9, 117.5, 
116.9, 99.2, 71.1, 49.5, 47.0 (2C), 43.0;  MS. m/z calculated for C27H30ClN4O2 [M+H] 
449.17 found 449.2 (100%); Anal. Calcd (found) for C25H25ClN4O2 3H2O . C 60.79 ( 




A solution of 24  (221mg, 0.46mmol) in 2M ethanolic HCl was subjected to 
hydrogenolysis in the presence of Pd/C 30mg (10 %w/w), 4 atm pressure for 4h. Then the 
catalyst was filtered off on celite and the solvent removed by evapouration under reduced 
pressure to give an orange oil which was titurated in MeOH/EtOAc to give a 100mg of a 
yellow solid (24a) on drying under vacuum. Extra drying was done at 30-60oC for 6h. 
Similar procedures were used to prepare compounds 25a, 24a and 23a. Compound 27a 
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2-((3-(7-chloroquinolin-4-ylamino)hexylamino)methyl)-5-hydroxy-1-methylpyridin-
4(1H)-one.(27a) 
Off white powder (110mg, 
99%).; δH (CD3OD, 300MHz); 
mp. 177-180 0C; Rf 0.1 
(NH3/MeOH/EtOAc, 0.01:1:9); 
8.45 (1H, d,  J 6, H-2”), 8.32 
(1H, d, J 9,  H-5”), 8.20 (1H, d, J 
2.8, H-8”), 7.86 (1H, s, H-6) 7.63 
(1H, dd, J 9, 3, H-6”), 7.59 (1H, 
s, H-3), 6.88 (1H, d, J 6, H-3”), 4.19 (3H, s, CH3-1), 3.61 (2H, t, J 6, H-6‟), 3.28 (4H, m, 
CH2NH-2, H-1‟), 1.86 (4H, m, H-2‟, 5‟), 1.55 (4H, m, H-3‟- 4‟); δC (CD3OD, 75MHz) 
160.8, 156.3, 145.9, 142.3, 140.4, 139.7, 138.6, 133.8, 127.3, 124.8, 118.9, 115.6, 115.3, 
198.5, 48.7, 45.7, 43.9, 43.4, 27.3, 25.8, 25.7, 25.5; HRMS. m/z calculated for 
C22H26ClN4O2 [M-2H] 413.1744 found 413.1734; Anal. Calcd (found) for 
C22H35Cl4N4O2 3H2O,  C 45.77 (45.93), H 6.11 (6.08), N 9.70 (9.84); HPLC purity 




White solid (100mg, 56%), mp. 183-
184 0C  Rf 0.21 (NH3/MeOH/EtOAc, 
0.01:1:9) δH (DMSO, 300MHz), 10.1 
(1H, brs, OH), 9.79 (1H, s, NH),  
8.87 (1H, d,  J 9.0, H-5”), 8.51 (1H, 
d, J 6,  H-2”), 8.31 (1H, s, H-6), 8.14 
(1H, s, H-8”) 7.72 (1H, dd, J 9.0, 
3.0, H-6”), 7.6 (1H, s, H-3), 6.90 (1H, d, J  6, H-3”), 4.41(2H, s, CH2NH-2),  4.17 (3H, s, 
NCH3-1), 3.58 (2H, m, H-1‟), 3.15 (2H, t, J 9, (H-4”), 1.86 (4H, m, 2‟, 3‟); δC (DMSO, 
75MHz) 160.5, 155.8, 145.9, 143.2, 140.9, 139.0, 138.4, 133.1, 127.2, 126.6, 119.5, 
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C20H24ClN4O2 [M+H] 387.1588 found 387.1 (90%); Anal.Calcd (found) for 
C20H26Cl4N4O2  4H2O . C 42.27 (41.96), H 6.03 (5.11), N 9.86 (9.85); HPLC purity 




White solid (21mg, 43%), mp. 163-
165 0C  Rf 0.09 (NH3/MeOH/EtOAc, 
0.01:1:9) δH (CD3OD, 300MHz), 
8.57 (1H, d,  J 9.0, H-5”), 8.43 (1H, 
d, J 6,  H-2”), 8.26 (1H, s, H-6), 7.90 
(1H, d, J 3, H-8”) 7.67 (2H, m, H-3, 
6”),  7.0 (1H, d, J 6, H-3”), 4.6 (2H, 
s, CH2NH-2), 4.25 (3H, s, NCH3 -1), 
4.09 (2H, m, H-1‟), 3.82 (2H, m, H-3‟), 3.47 (2H, m, H-2‟); δC ( CD3OD, 75MHz), 160.4, 
156.3, 145.8, 142.7, 140.3, 139.7, 138.6, 133.9, 127.4, 125.1, 118.9, 115.7, 115.4, 98.7, 
46.1, 45.8, 44.2, 40.3, 24.5. MS. m/z calculated for C19H19ClN4O2  (M+K-2H) 409.0834 
found  409.1 (100%); Anal. Calcd (found) for C19H34Cl4N4O2  5H2O . C 39.87 (40.21), H 
5.99 (5.39), N 9.79 (9.88); HPLC purity analysis 99% Rt   11.91 min. .  
 
2-(((3-(7-chloroquinolin-4-ylamino)propyl)(methyl)amino)methyl)-5-hydroxy-1-
methylpyridin-4(1H)-one (24a)       Colourless needles (MeOH/EtOAc), (37mg, 46%); 
mp. 154-156 0C; δH (CD3OD, 
300MHz), 8.50 (1H, d,  J 9, H-
5”), 8.40 (1H, d, J 6,  H-2”), 
8.27 (1H, s, H-6),  7.89 (1H, s, 
H-8”), 7.67 (2H, m, H-3, 6”),  
6.99 (1H, d, J 6.0, H-3”), 4.27 
(2H, s, 2-CH2NH), 3.76 (2H, 
m, H-3‟), 3.57 (2H, m, H-1‟), 
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75MHz), 160.2, 156.4, 146.2, 142.7, 139.7, 138.6, 134.6, 127.4(2C), 125.2, 118.9, 117.1, 
115.7, 98.8, 54.5, 54.2, 44.7, 40.4, 39.6, 22.4.; MS. m/z calculated for C20H24ClN4O2 
(M+H) found 387.1 (100%); Anal. Calcd (found) for C20H26Cl4N4O2 2.5H2O,  C 44.38 




 Colorless needles (1.25M 
methanolic HCl/H2O/EtOAc), 
(23mg, 74%); mp. 174-175 0C  
Rf 0.04 (NH3/MeOH/EtOAc, 
0.01:1:9) δH (DMSO, 300MHz), 
10.3 (1H, br.s OH), 9.78 (1H, s, 
NH), 8.82 (1H, d, J 9, H-5”),  
8.68 (1H, d,  J 6, H-2”), 8.26 
(1H, s,  H-6), 8.06 (1H, s, H-8”), 7.81 (1H, d, J 9,  H-6”), 7.50 (1H, s, H-3),  7.10 (1H, d, 
J 6, H-3”), 4.55 (2H, s, CH2NH-2), 4.16 (3H, s, NCH3-1), 4.0 (2H, m, H-2‟), 3.17 (2H, m,  
H-1‟); δC (DMSO, 75MHz), 162.4, 156.2, 145.9, 143.8, 141.1, 138.9, 138.7, 133.2, 127,4 
(2C), 126.9, 119.5, 116.2, 99.5, 45.8 (2C), 45.6, 44.6; MS. m/z calculated for 
C18H20ClN4O2 (M+H) 359.1275 found 359.1 (100%); Anal. Calcd (found) for 
C18H19Cl4N4O2,2H2O C 42.88 (43.07), H 5.20 (6.17), 11.11 (10.53); HPLC purity 
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5.4.6. Synthesis of kojic derived 4-aminoquinoline -3,4-hydroxypyridinone hybrids 
via alkylhalide intermediates (D series) 
 
5-(benzyloxy)-2-(hydroxymethyl)-1-cyclopropylpyridin-4 (1H)-one, (21a) 
3.4ml 98% cyclopropylamine (2.775g, 48mmol) was added to a solution of 20 (5.813g, 
25mmol) in 50% aq EtOH, refluxed at 70 oC in a sealed tube for 12h. pH adjustment to 1 
( conc. HCl) then put in the freezer to maximize 
precipitation (4h). The precipitate was filtered and 
the residue washed with cold water and diethylether 
to give 3.4g of an off white solid on drying in the 
oven at 50oC for 8h.  
Off white solid (3.444g, 50%); mp. 174 – 175 oC δH 
(DMSO d6, 400MHz), 8.28 (1H, s, H-6), 7.56 (1H, s, H-3), 7.40  (5H, m, Bn C-H), 5.26 
(2H, s, 5-CH2-Bn), 4.86 (2H, s, 2-CH2OH), 2.5 (1H, m, H-7), 1.30-1.17 (4H, m, H-8, 9) 
δC (DMSO d6, 100MHz), 162, 155.4, 143.7, 135.5, 130.7, 128.3 , 128.2 (2C) , 127.9 
(2C),, 110.5, 71.6, 57.9, 37.1, 7.35(2C); HRMS. m/z calculated for C16H18ClNO3 [M+H]   
272.1299 found 272.12887; Anal. Calcd (found) for  C16H17ClNO2 3H2O, C 59.06 
(60.00), 7.13 (8.03), 4.31 (1.82). 
 
5-(benzyloxy)-2-(chloromethyl)-1-cyclopropylpyridin-4 (1H)-one hydrogenchloride, 
(22a) 
To neat thionyl chloride (11.42g, 96mmol)   below 
0oC (ice /acetone mixture) was added 21a (3.3g, 
12.08mmol) then stirred further at ambient 
temperature for 1h. Diethylether was added to the 
preformed solid then put in a freezer for 1h, the solid 
was washed with petroleum-ether to give brown sticky/hygroscopic crystals. These were 
further dried in a dessicator under vacuum to give the product. Brown crystals (3.444g, 
83%); mp. 132 – 133 oC; δH (DMSO d6, 400MHz), 8.39 (1H, s, H-6), 7.37  (5H, m, Bn C-
H), 6.34 (1H, s, H-3), 5.27 (2H, s, CH2-Bn-5), 5.17 (2H, s, CH2Cl-2), 3.99 (1H, m, H-7), 
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129.1 , 128.9 (2C) , 128.6 (2C), 114.4, 72.2, 40.6, 39.1, 8.44 (2C); HRMS. m/z calculated 
for C16H17ClNO2 [M+H]  290.0948  found 290.0930; Anal. Calcd (found) for  




22a (290mg, 0.89mmol) was added to a solution of 8 (277mg, 1mmol) in DMF followed 
by triethylamine (100mg, 1mmol) and sodiumhydrogencarbonate (84mg, 1mmol) then 
refluxed at 110oC for 24h. After cooling the reaction mixture was diluted with water 
(15ml)and extracted with dichloromethane (15ml×3) before washing with water 





give an orange 
residue which was 
subjected to 
column chromatography (with MeOH/EtOAc/0.05%NH3 as the eluant). Compound 32 
was eluted in the 15%MeOH/EtOAc fraction and evaporated to give a white solid. 
Further drying was done under vacuum at 30-60oC for 6h to get the pure compound. This 
procedure was employed for the preparation of the successive compounds. 
White solid (250mg, 51%); mp. 138-141 0C  Rf 0.82 (NH3/MeOH/ EtOAc 0.01:1:1) δH 
(DMSO, 300MHz), 8.38 (1H, d, J 6.0, H-2”), 8.28 (1H, d, J 9.0,  H-5”), 7.76 (1H, d, J 3, 
H-8”), 7.35 (7H, m, benzylCH, H-6, H-6”), 7.21 (1H, m, NH), 6.44 (1H, d, J 6.0, H-3”), 
6.29 (1H, s, H-3), 5.01 (2H, s, 5-CH2Bn), 3.78 (2H, s, 2-CH2NH), 3.49 (1H, m, H-7), 
2.56 (obscured by DMSO, H-6‟), 1.99 (2H, t, J 6.0, H-1‟), 1.39 (8H, m, H-2‟- 5‟), 1.0 
(4H, m, H-8, 9). δC (DMSO, 75MHz) 171.7, 151.7, 149.9, 149.8, 148.9, 146.0, 137.2, 
133.1, 128.0 (2C), 127.7, 127.6 (2C), 127.5, 127.3 (2C), 123.9, 123.7, 115.5, 98.4, 70.6, 
48.6, 48.3, 42.2, 33.9, 29.3, 27.7, 26.4, 26.3, 7.41 (2C); HRMS. m/z calculated for 
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Bright yellow resin (300mg, 
64%); mp. 73-74 0C  Rf 0.75 
(NH3/MeOH/ EtOAc 0.01:1:1) 
δH (DMSO, 300MHz), 8.39 
(1H, d,  J 6.0, H-2”), 8.27 (1H, 
d, J 9.0,  H-5”), 7.7 (1H, d, J 3, 
H-8”), 7.36 (7H, m, benzylCH, 
H-6”, H-6), 7.33 (1H, m, NH), 
6.46 (1H, d, J 6.0, H-3”), 6.31 (1H, s, H-3), 5.01 (2H, s, CH2Bn-5), 4.25 (1H, br.s, NH), 
3.8 (2H, s, CH2NH-2), 3.42 ( 3H, m, H-4‟, 7), 1.65 (4H, m, H-2‟- 3‟), 1.05 (4H, m, H-8, 
9). δC (DMSO, 75MHz) 172.2, 152.4, 150.1, 150.5, 149.6, 146.7, 137.8, 133.8, 128.7 
(2C), 128.4 (2C), 128.2, 127.5, 127.3, 124.6, 124.4, 117.9, 115.9, 99.1, 71.1, 49.1, 48.9, 
40.2, 34.6, 26.1, 22.9, 8.09 (2C); HRMS. m/z calculated for C29H31ClN4O2 [M+H]  
503.2214  found 503.2225; Anal. Calcd (found) for C29H31ClN4O2 2H2O . C 64.61 
(64.54), 6.54(6.20), N 10.39 (10.88); HPLC purity analysis 91.5% Rt   9.79 min. . 
 
5-(benzyloxy)-2-(((3-(7-chloroquinolin-4-ylamino)propyl(methyl)amino)methyl)-1-
cyclopropylpyridin-4(1H)-one. (30)                 
A solution of 6 (250mg, 1mmol) 
triethylamine (196mg, 2mmol), and 
sodiumhydrogencarbonate (168mg, 
2mmol) in DMF 3ml was heated to 
50oC before adding 22a (300mg, 
0.9mmol), then refluxed at 90 oC for 
12h. After a workup similar to that 
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from MeOH/EtOAc. Alternatively method B was used to prepare more of this 
compound using 6 (112mg, 0.448mmol) and compound 22a (100mg, 1mmol),and sodium 
hydrogencarbonate (84mg, 1mmol) to give a brown oil ( 200mg, 88%) .Colourless cubes 
(MeOH/ EtOAc 1:1), (427 mg, 89%); mp. 76 - 77 0C  Rf 0.84 (NH3/MeOH/ EtOAc 
0.01:1:1) δH (DMSO, 300MHz), 8.39 (1H, d,  J 6.0, H-2”), 8.23 (1H, d, J 9.0,  H-5”), 
7.76 (1H, d, J 3, H-8”), 7.37 (7H, m, benzylCH, H-6”, H-6), 7.14 (1H, t, J 6, NH), 6.44 
(1H, d, J 6.0, H-3”), 6.25 (1H, s, H-3), 4.96 (2H, s, CH2Bn-5), 3.57 (2H, s, CH2NH-2), 
3.52 (1H, m, H-7), 2.56 (2H, t, J 6, H-3‟), 2.22 (3H, s, CH3N), 2.71 (2H, t, J 6,  H-1‟), 
1.89 (2H, m, H-2‟), 0.91 (4H, m, H-8, 9). δC (DMSO, 75MHz) 171.9, 152.4, 150.6, 149.6, 
148.4, 146.9, 137.7, 133.8, 128.7 (2C), 128.4 (2C), 128.2, 128.1, 127.9, 124.5, 124.4, 
117.9, 117.7, 99.1, 71.0, 58.4, 55.1, 42.0, 40.8, 34.9, 25.9, 7,95 (2C); HRMS. m/z 
calculated for C29H32ClN4O2 [M+H]  503.2214 found 503.2228; Anal. Calcd (found) for 
C29H31ClN4O2  3.5H2O,   C 61.53 (61.40) H 6.77 (6.08), N 9.90 (9.84); HPLC purity 




Yellow foam (420 mg, 
91%); mp. 58 - 600C; Rf 
0.75 (NH3/MeOH/ EtOAc 
0.01:1:1) δH (DMSO, 
300MHz), 8.39 (1H, d,  J 
6.0, H-2”), 8.21 (1H, d, J 
9.0,  H-5”), 7.7 (1H, d, J 3, 
H-8”), 7.36 (8H, m, benzyl-
CH, H-6”, H-6, NH), 6.48 (1H, d, J 6.0, H-3”), 6.33 (1H, s, H-3), 5.01 (2H, s, 5-CH2Bn), 
3.82 (2H, s, 2-CH2NH), 3.50 (1H, m, H-7), 3.37 (2H, t, J 6, H-3‟), 2.71 (2H, t, J 6,  H-1‟), 
1.85 (2H, m, H-2‟), 0.98 (4H, m, H-8, 9). δC (DMSO, 75MHz) 172.2, 152.4, 150.6, 150.4, 
149.5, 146.7, 137.8, 133.8, 128.7 (2C), 128.4 (2C), 128.2, 128.1, 127.9, 124.5 (2C), 
117.9, 116.0, 99.1, 71.1, 48.9, 47.3, 40.3, 34.6, 28.5, 8.09 (2C); HRMS. m/z calculated 
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C28H29ClN4O2  1H2O,   C 66.33(66.08) H 6.16 (6.16), N 11.04 (11.47); HPLC purity 




Orange foam (390 mg, 87%); mp. 56-570C  Rf 0.74 (NH3/MeOH/EtOAc 0.01:1:1) δH 
(DMSO, 300MHz), 8.40 (1H, d,  J 
6.0, H-2”), 8.23 (1H, d, J 9.0,  H-
5”), 7.78 (1H, d, J 3, H-8”), 7.37 
(7H, m, benzylCH, H-6”, H-6), 7.17 
(1H, m, NH), 6.52 (1H, d, J 6.0, H-
3”), 6.33 (1H, s, H-3), 5.01 (2H, s, 
CH2Bn-5), 3.87 (2H, s, CH2NH-2), 
3.50 (1H, m, H-7), 3.40 (2H, t, J 6, 
H-2‟), 2.89 (2H, t, J 6,  H-1‟), 0.95 (4H, m, H-8, 9). δC (DMSO, 75MHz) 172.2, 152.3, 
150.6, 150.3, 149.6, 146.7, 137.8, 133.8, 128.7(2C), 128.4 (2C), 128.2 (2C), 127.9, 
124.5(2C), 117.9, 116.0, 99.2, 71.1, 48.7, 47.3, 43.0, 34.6, 8.04(2C); MS. m/z calculated 
for C27H28ClN4O2 [M+H]  475.19 found 475.2(100%); Anal. Calcd (found) for 
C27H27ClN4O2  1H2O,   C 65.78 (65.00) H 5.93 (5.97), N 11.36 (12.20); HPLC purity 




White solid (250mg, 51%); Rf 0.12 (NH3/MeOH/ EtOAc 0.01:1:1) δH (DMSO, 300MHz), 
10.2 (1H, br.s, 
OH), 9.72 (1H, m, 
NH),  8.82 (1H, d,  
J 9.0, H-5”), 8.49 
(1H, d, J 6, H-2”), 
8.33 (1H, s, H-6), 
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H-8”), 7.70 (1H, dd, J 3.0, 9.0, H-6”), 7.67 (1H, s, H-3), 6.87 (1H, d, J 6.0, H-3”), 4.55 
(2H, s, 2-CH2NH), 4.23 (1H, m, H-7), 3.56 (1H, m, H-6‟), 3.08 (2H, m, H-1‟), 1.76 (4H, 
m, H-2‟, 5‟), 1.38 (4H, m, H-3‟, 4‟), 1.3 (4H, m, H-8, 9). δC (DMSO, 75MHz) 161.2, 
155.8, 145.2, 143.1, 139.1(2C), 138.4, 132.4, 127.2, 126.6(2C), 119.5, 115.8, 99.04, 48.1, 
45.2, 43.4, 27.8, 26.2, 26.1, 25.6, 22.9, 8.53 (2C); HRMS. m/z calculated for 
C24H30ClN4O2 [M+H]  441.2057 found 441.2074;  Anal. Calcd (found) for 
C24H32Cl4N4O2  4H2O,   C 46.31 (45.72), H 6.48 (6.74), N 9.00(9.69); HPLC purity 




Sticky white solid (100mg, 58%) 
Rf 0.1 (NH3/MeOH/ EtOAc 
0.01:1:1) δH (CD3OD, 300MHz), 
8.55 (1H, d,  J 9.0, H-5”), 8.40 
(1H, d, J 6.0,  H-2”), 8.27 (1H, s, 
H-6), 7.89 (2H, m, H-8”, NH), 
6.46 (2H, m, H-3, 6”), 6.95 (1H, 
br.s, H-3”), 4.95 (obscured by 
H2O, CH2NH-2),  4.19 (1H, br.s, H-7), 3.42 ( 2H, m, H-4‟), 2.0 (4H, m, H-2‟- 3‟), 1.19 
(4H, m, H-8, 9); δC (CD3OD, 75MHz) 162.3, 157.7, 146.6, 144, 143.8, 140.9, 139.9, 
134.3, 128.6, 126.5, 124.2, 120.4, 115.8, 100.1, 47.1, 44.0, 40.5 (2C), 26.1, 24.6, 9.34 
(2C); HRMS. m/z calculated for C22H26ClN4O2 [M+H]  413.1744 found 413.1763;  Anal. 
Calcd (found) for C22H28Cl4N4O2 4.5H2O  C 43.79 (44.58), H 6.18 (6.96), N 9.26 (8.04); 







































cyclopropylhydroxypyridin-4(1H)-one trihydrogenchloride (30a) 
Brown oil (20mg, 24%), Rf 0.21 
(NH3/MeOH/EtOAc 0.01:1:1) 
δH(CD3OD, 300MHz), 8.43 (1H, 
d,  J 7.2, H-2”), 8.37 (1H, d, J 
8.1,  H-5”), 8.01 (1H, s, H-6), 
7.90 (1H, d, J 4, H-8”), 7.71 (1H, 
dd, J 9.1, 2.0, H-6”),  7.25 (1H, s, 
H-3), 6.91 (1H, d, J  7.2, H-3”), 
4.25 (2H, s, 2-CH2NH),  4.12 (1H, m, H-7), 3.69 (2H, t, J 7, H-3‟), 2.99 (1H, t, J 7.8, H-
1‟), 2.61 (3H, s, CH3N), 2.16 (2H, m,  H-2‟), 1.30 (4H, m, H-8, 9). δC (CD3OD, 75MHz)  
156.3, 145.1, 142.5, 139.8, 138.6, 130.2, 127.4 (2C), 124.4, 119.0 (2C), 115.5, 114.1, 
98.3, 56.5, 54.3, 41.1, 40.7, 37.5, 24.7, 7.56 (2C); HRMS. m/z calculated for 
C22H26ClN4O2 [M+H]  413.1744 found 413.1753; Anal. Calcd. (found) for 
C22H30Cl4N4O2, C50.40 (36.53), H 5.77 (4.26), N 10.61 (6.79); HPLC purity analysis 





Yellow foam (150mg, 60%); mp. 
89-91 0C  Rf 0.15 (NH3/MeOH/ 
EtOAc 0.01:1:1) δH (DMSO, 
300MHz), 10.3 (1H, br.s, OH), 
9.92 (1H, s, NH),  8.86 (1H, d,  J 
9.0, H-5”), 8.56 (1H, d, J 6.0,  H-
2”), 8.30 (1H,s, H-6), 8.14 (1H, d, 
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3.0, H-6”), 7.47 (1H, s, H-3), 6.96 (1H, d, J 6, H-3”), 4.59 (2H, s, 2-CH2NH), 4.22 (1H, 
m, H-7), 3.75 (2H, m, H-3‟), 3.28 (2H, t, J 6,  H-1‟), 2.25 (2H, m, H-2‟), 1.31 (4H, m, H-
8, 9). δC (DMSO, 75MHz)  161.7, 155.2, 145.0, 142.6, 142.2, 138.4, 137.8, 130.9, 126.6, 
126.0, 118.8, 118,8, 115.5, 98.6, 45.1(2C), 44.8, 38.1, 18.3, 7.92(2C); HRMS. m/z 
calculated for C21H24ClN4O2 [M+H]  399.1583 found 399.1598; Anal. Calcd (found) for 
C21H26Cl4N4O22H2O. C 46.34 (46.26), H 5.56 (5.74), N 10.29 (10.22); HPLC purity 




Cream solid (108 mg, 56%); mp. 
215-217 0C  Rf 0.11 (NH3/MeOH/ 
EtOAc 0.01:1:1); δH (DMSO, 
300MHz), 9.55 (2H, br.s OH, NH), 
8.93 (1H, d,  J 9.0, H-5”), 8.63 
(1H, d, J 6.0,  H-2”), 8.32 (1H, s, 
H-6), 8.17 (1H, d, J 3, H-8”), 7.75 
(1H, dd, J 3.0, 9.0, H-6”), 7.48 
(1H, s, H-3), 7.11 (1H, d, J 6,  H-3”), 4.71 (2H, s, CH2NH-2), 4.25 (1H, m, H-7), 4.07 
(2H, m, H-2‟), 3.54 (2H, m,  H-1‟), 1.27 (4H, m, H-8, 9). δC (DMSO, 75MHz) 144.9, 
142.9, 142.2, 138.3, 137.9, 131.0, 126.6 (2C), 126.4 (2C), 118.8, 115.6, 115.1, 98.8, 45.4 
(2), 44.8, 38.2, 7.93 (2C); HRMS. m/z calculated for C20H22ClN4O2 [M+H]  385.1400 
found 385.1405; Anal. Calcd (found) for C20H24Cl4N4O21.5H2O. C 46.08 (45.45), H 5.22 
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5.4.7. Synthesis of gallium (III) and iron (III) complexes of A/AB series 
 
Tris(3-hydroxy-2-methyl-N-(7-chloro-4-quinoinlyl)-1-(6-aminobutyl)-3-(hydroxy)-2-
methyl-4(1H)-pyridinonato iron (III)  (13d) 
A solution of iron (III) nitrate nonahydrate (20.2mg, 0.05mmol) in 1ml deionised water 
was added to a stirred solution of 13a (67.8mg, 0.15mmol), in 2ml MeOH at pH 8 (2M 
NaOH). The mixture was refluxed at 80oC for 4h. The resultant precipitate was washed 
with water, MeOH/H2O 5:1 and cold MeOH in that order then freeze dried for 3h at -
57oC to obtain a brick red solid. 
Analogous procedure was applied to synthesize complexes 13e, 15d and 15e using 
compounds ligands 13a and 15a respectively. 
 
Brick red solid (48mg, 72%); mp. 225-226 oC; Rf 0.04 ( MeOH/CH2Cl2 1:1) δH 
(DMSOd6, 400MHz),  9-6 (br.s – quinolinyl, pyridinone C-H), 4-2 (br.s, aliphatic C-H); 
δC (DMSOd6, 100MHz) no peaks observed (30oC); Anal. Calcd (found) for 
C57H57Cl3FeN9O6 10H2O NaNO3 . C 48.71(49.73), H 5.52 (5.00), N 9.97 (9.46); MS 
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Tris (N-(7-chloro-4-quinolinyl)-1-(6-aminobutyl)-3-(hydroxy)-2-methyl-4(1H)-
pyridinonato gallium (III)  (13e) 
 
Dark brown solid (117mg, 81%); mp. 215 – 216 oC; Rf 0.14 ( MeOH/ CH2Cl2,1:1). δH 
(DMSOd6, 400MHz) 8.41 (1H, d, J 4.8, H-2”), 8.29 (1H, d, J 7.8, H-5”), 7.52 (1H, s, H-
8”), 7.46 (2H, m, H-6, 6”),  6.56 (1H, m, H-5), 6.27 (1H, d, J 7.6, H-3”), 4.18 (2H, m, H-
1‟), 3.38 (masked by H2O, H-4‟), 2.31 (3H, s, CH3-py), 1.79 (4H, m, H-2‟, 3‟),  δC 
(DMSOd6, 100MHz) , 168.5, 167.1 (2C), 154.0 (3C), 152.6, 152.5 (2C), 151.9 (2C), 
151.7 (2C), 151.4 (2C), 148.9 (2C), 148.7, 135.1 (2C), 134.7, 131.6 (3C), 129.5, 127.6 
(2C), 127.3, 125.1 (6C), 118.1 (2C), 107.8 (2C), 106.9, 99.5 (3C), 55.1 (2C), 54.7, 42.8 
(2C), 42.7, 28.7, 28.5 (2C), 25.5, 25.4 (2C), 12.7 (3C).. Anal. Calcd (found) for 
C57H57Cl3GaN9O6 NaNO3 12H2O . C 47.50(47.63), H 5.66 (5.04), N 9.72 (9.53); MS 
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Tris(3-hydroxy-2-methyl-N-(7-chloro-4-quinolinyl)-1-(6-aminohexyl)-3-(hydroxy)-2-
methyl-4(1H)-pyridinonato iron (III)  (15d) 
 
Brick red solid (90mg, 66%); 196 – 200 oC; Rf 0.1 ( MeOH/ CH2Cl21:1) δH (DMSOd6, 
400MHz),  9-6 (br.s – quinolinyl, pyridinone C-H), 4-2 (br.s, aliphatic C-H); δC 
(DMSOd6, 100MHz) no peaks observed (30oC);  Anal. Calcd (found) for 
C63H69Cl3FeN9O6 7H2O . C 56.61(56.34), H 6.26(5.81), N 9.43(10.06); MS found 1233 
([ML3 +2H + Na, 100%). 
 
Bis-(N-(7-chloro-4-quinolinyl)-1-(6-aminohexyl)-3-(hydroxy)-2methyl-4(1H)-
pyridinonato gallium (III)  (15e) 
 
Pink shiny solid (101mg, 81%); mp. 194 – 196 oC; Rf 0.14 ( MeOH/ CH2Cl2,1:1) δH 
(CD3OD, 400MHz) 8.32 (2H, m, H-2”, 5”), 7.86 (1H, s, H-8”), 7.62 (1H, d, J 8.7, H-6”), 
7.46 (1H, d, J 5.2, H-6 py), 6.76 (1H, d, J 6.0, H-3”), 6.40 (1H, d, J 5.4, H-5 py), 4.08 
(2H, m, H-1‟), 3.55 (2H, m, H-6‟), 2.40 (3H, s, CH3 py), 1.78 (4H, m, H-2‟, 5‟), 1.43 (4H, 
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(hydroxy)-2-methyl-4(1H)-pyridinonato-nitrato- gallium (III)  (15f) 
 
 
A solution of gallium (III) nitrate nonahydrate (31.2mg, 0.075mmol) in 1ml deionised 
water was added dropwise  to a solution of compound 15a (66mg, 0.15mmol), in 2ml 
MeOH, pH was adjusted to 8 (2M NaOH). The resultant precipitate was washed with 
water, MeOH/H2O 5:1 then cold MeOH and freeze dried for 1.5h at -57oC to obtain a 
pale pink solid. To confirm anion exchange in 15f, an aqueous solution of sodium 
hexafluoride phosphate was added to a hot solution of the complex in DMSO, a 
precipitate formed afterwards. This test was repeated for the other complexes and none of 
them formed a precipitate. 
 
Pale pink solid (40mg, 50%); mp. 183 – 184 oC; Rf 0.14 ( MeOH/ CH2Cl2,1:1); δH 
(DMSOd6, 300MHz) 8.41 (1H, d, J 5.7, H-2”), 8.33 (1H, d, J 9, H-5”), 7.82 (1H, d, J 1.5, 
H-8”), 7.71 (1H, d, J 5.4, H-6 py), 7.50 (1H, dd, J 9, 1.8, H-6”), 6.72 (1H, d, J 6.4, H-3”), 
6.53 (1H, m, H-5 py) , 4.13 (2H, t, J 7.2, H-1‟), 3.44 (obscured by H2O, H-6‟), 2.44 (3H, 
s, CH3 py), 1.69 (4H, m, H-2‟, 5‟), 1.40 (4H, s, H-3‟, 4‟). δC (DMSOd6, 75MHz) 169.3, 
151.8, 146.8, 143.1, 135.9, 134.3, 130.8, 126.5, 126.2, 122.8, 120.9, 117.2, 106.9, 98.5, 
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] 3H2O NaNO3 . C 48.48 (48.52), H 5.04 (5.62), N 10.77(10.04); HRMS. m/z calculated 
for C42H46Cl2GaN6O4 [M+H]  837.2213 found 837.2210. 
 
Bis(N-(7-chloro-4-quinolyl)-1-(6-aminohexyl)-3-(hydroxy)-2-ethyl-4(1H)-pyridinonato 
gallium (III)  (16d) 
A solution of gallium (III) nitrate nonahydrate (21mg, 0.5mmol) was added dropwise 
while stirring to an aqueous solution of 16a (45mg, 0.1mmol). After pH adjustment to 7 
(0.1M NaOH), the mixture was refluxed for 4h at 85oC, then left to cool overnight. TLC 
indicated all the ligand had been used up in the reaction. Drying by rotary evaporation 
afforded an orange powder, which was washed with water to give orange crystals, which 
were further dried under vacuum. 
 
 
Orange crystals (10mg, 24%), from H2O; mp. 200 – 204 oC; Rf (50% MeOH/ CH2Cl2) 
0.24; H (400MHz, CD3OD) 8.3 (2H, m, H2”-5”), 7.85 (1H, d, J 0.8, H-8”), 7.64 (1H, dd, 
J 1.6, 9.0, H-6”), 7.46 (1H, d, J 6.8, H-6), 6.76 (1H, d, J 6.8, H-5), 6.4 (1H, d, J 6.8, H-
3”), 4.09 (2H, t, J 8.7, H-1‟), 3.56 (2H, t, J 7.6, H-6‟), 3.41 (2H, m, CH2CH3-Py), 2.4 
(3H,  br.s, CH2CH3-Py), 1.8–1.72 (4H, m, H-2‟,5‟), 1.5–1.38(4H, m, H-3‟, 4‟); MS found 
974 (ML2 +2Na + NO3, 100%), ML3 (absent); Anal. Calcd (found) for C66H75Cl3GaN9O6 
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5.4.8. Synthesis of 4-aminoquinoline-biscatecholate hybrids 
 
2, 3-Diacetoxybenzoic acid (33) 
To 2,3-dihydroxybenzoic acid 99% ( 4.70g, 30mmol) was added 
acetic anhydride (6.16g, 60mmol), followed by 3drops of conc. 
Sulphuric acid then the  mixture was stirred under nitrogen, a white 
precipitate was observed after 20minutes. After 12h of reaction the 
slurry was poured over ice (200g) and extracted with 
dichloromethane (100ml ×7). The organic layer was back-extracted 
with ice water (50mL × 3), dried over anhydrous Na2SO4, filtered and reduced in vacuo to 
the product. White solid (5.945, 82%); mp. 145-1480C, Rf 0.49 ( EtOAc)  δH (CDCl3, 
300MHz), 7.97 (1H, d, J 7.6, H-3), 7.37 (2H, m, H-4, 5), 2.33(3H, s, CH3OCO), 2.32 
(3H, s, CH3OCO). 
 
2,3-Diacetobenzoylchloride (34) 
A solution of 33 (5.428g, 32mmol) in dry ethanol-free chloroform 
(120ml), was cooled to 0oC under nitrogen before adding 
phosphorous(V) pentachloride (10g, 48mmol), the mixture was 
allowed to warm to ambient temperature and stirred for 24h. After 
concentration in vacuo the residue was redissolved in benzene 
(250mL), washed with 5% NaHCO3, (w/v) (20ml×3), dried over 
anhydrous MgSO4 , filtered, evaporated under vacuo to give a yellow oil that crystalised 
on standing. White crystals (5.456, 67%); mp. 116-118 0C  Rf 0.71 ( EtOAc) δH (CDCl3, 
300MHz), 7.91 (1H, dd, J 7.6, 1.7, H-3), 7.61-7.08 (2H, m, H-4, 5), 2.26 (3H, s, 
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4-((3-aminopropylamino)methyl)benzoic acid (35) 
4-Formylbenzoic acid 97% (7.5g, 50mmol) 
was dissolved in MeOH (15ml) followed 
by the addition of 1,3-diaminopropane 
(4.4g, 60mmol), then Pd/C (1.0g) was 
added under nitrogen. The mixture was 
hydrogenated at ambient temperature and 
atmospheric pressure for 2days. TLC showed incomplete convertion hence further 
hydrogentaion was done at 1 atmosphere on the Parr hydrogenator for complete 
reduction. Then, the reaction mixture was filtered over celite and the solvent evapourated 
to give thick oil that solidified on standing. The residue was co-distilled with toluene 
(10ml×10) to remove the amine residue. This yielded a golden solid.  
Golden solid (7.45g, 67%); mp. 78-81 0C  δH (D2,O, 300MHz), 7.72 (2H, d, J 8.2, H-3, 
7), 7.23 (2H, d, J 8.2 H-4, 6), 3.65 (2H, s, H-8), 2.82 (2H, m, H-9), 2.56 (2H, m, H-11), 
1.71 (2H, m, H-10). δC (D2,O, 75MHz) 175.0, 140.8, 135.8, 129.5, 129.3, 129.1, 128.9, 
51.9, 45.8, 38.0, 26.9. Anal. Calcd (found) for C11H16N2O2  H2O,   C 58.39 (59.24), H 




A solution of 35 (1.846g, 7.21mmol) in 
0.5M NaHCO3 (60ml, 30mmol) was 
sonicated at 0-5oC, then a solution of 34 
(3.580g, 14mmol) in dry THF (20ml) 
was added to it dropwise with stirring for 
30 minutes. The mixture was reduced in 
vacuum to remove THF, cooled to 0oC, 
then acidified to pH 1 (6N, HCl). The 
resultant white sticky precipitate was 
extracted into ethylacetate (30ml x 3). The organic layer was washed with brine (50ml x 
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as an off white solid which was recrystalised from Methanol. White powder (3.02g, 
65%); mp.168 - 170 oC;  Rf 0.74 ( MeOH/ EtOAc 1:1) δH (CDCl3, 300MHz), 8.03-7.91 
(4H, m, H-3, 4, 6, 7), 7.23 (6H, m, 3”, 4”, 5”), 3.46 (2H, s, H-8), 2.24-2.39 (16H, 
CH3OCO, H-9, 11), 1.78 (2H, m, H-10). ). δC (CDCl3, 75MHz), 191.3, 169.7, 168.9, 
168.2, 167.6, 167.4, 165.1, 143.5, 142.7, 139.1, 131.0, 130.7, 130.6, 129.9, 129.4, 128.3, 
128.1, 127.0, 126.6, 126.4, 126.3, 125.7, 124.6, 124.1, 123.8, 60.3, 52.11, 47.9, 46.4, 
41.9, 36.8, 29.6, 26.9. HRMS. m/z calculated for C33H33N2O12 [M+H]  649.2034 found 




diacetoxybenzamido)propyl)carbamoyl)-1, 2-phenylene  diacetate. (37) 
A solution of 36 (519mg, 0.8mmol) and N-methylmorpholine (99µl) was dissolved in dry 
THF (8ml) and cooled to -
20oC, methylformate (116 µl)  
was added then stirred for 1h 
at -10oC. To the mixture a 
solution of 8 (243mg, 
0.88mmol), triethylamine (123 
µl, 0.88mmol) in 5ml 
THF/water (4:1) was added 
and stirred at -10oC for 12h. 
The solvent was removed 
under vacuum, attempts to 
redissolve the residue in EtOAc failed; hence it was redissolved in MeOH/ACN dried 
over Na2SO4, evapourated under vacuum to give 200mg of the crude product as a white 
foam. 100mg of this was purified by HPLC to give 30mg of the pure compound.  White 
hygroscopic solid (30mg, 8%); mp. 117–120 oC: Rf 0.22 (MeOH/EtOAc1:1); δH 
(CD3OD, 300MHz),  8.31 (2H, m), 7.99 (3H, m, H-5”, H-3, 7), 7.82 (1H, d, J 2.1, H-8”), 
7.45 (3H, m), 7.28 (9H, m), 3.55 (2H, m, H-6”‟), 3.34 (2H, s, H-8), 3.15 (2H, m, H-1”‟), 
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(2H, m, H-10), 1.50 (4H, m, H-3”‟, 4”‟); HRMS. m/z calculated for C48H50ClN5O11 
[M+H]  908.3274 found 908.3275. 
 
 
5.5. Procedures for biological assays 
 
5.5.1 phiβ-Haematin Inhibition Assay 
The assay is based on the ability of haematin, but not β-haematin to form a low spin 
complex with aqueous pyridine at pH 7.5. The assay has been fully described by Ncokazi 
and Egan, 2005. It involves serial dilution of the drug solutions in triplicate in a 96 well 
plate using a multichannel pipette. The test drugs (compounds) were dissolved in DMSO 
or methanol.  Drug concentrations varied from 1-10 equivalents relative to haematin, 
each well containing 10.12µL in the final mixture. 101.2 µL of haematin stock solution 
(1.68mM in 0.1M NaOH) was added to each well followed by 10.12 µL of 1.0M HCl. 
The 58.7 µL of acetate solution (12.9M, pH 5.0) which was preincubated at 60oC was 
added and the plate incubated at 60oC for 60 minutes. The mixture was quenched with 80 
µL of 30% (v/v) pyridine solution in 20mM HEPES, pH 7.5 and allowed to settle at 
ambient temperature. Afterwards 30 µL of the supernatant was transferred to another 
plate and diluted to 250 µL with 30% (v/v) pyridine solution (pH 7.5, 20mm HEPES). 
The absorbance was read at 450nm using an ASYS UVM 340 plate reader. The IC50 
values for β-haematin inhibition were determined by fitting the absorbance data to a 
sigmoidal dose response curve by non-linear least squares fitting using GraphPadPrism 
software. 
 
5.5.2 In vitro Antiplasmodial assays:  
In vitro Antiplasmodial assays: Dd2 and D10 strains of Plasmodium falciparum 
Compounds were tested in duplicate on one occasion against D10 Chloroquine sensitive 
(CQS) and Dd2 Chloroquine resistant (CQR) strains.  Continuous in vitro cultures of 
asexual erythrocyte stages of P. falciparum were maintained using a modified method of 
Trager and Jensen (1976). The quantitative assessment of antiplasmodial activity in vitro 
was determined via the parasite lactate dehydrogenase assay using a modified method by 
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10% methanol and were sonicated to enhance solubility. The samples were tested as a 
suspension if not completely dissolved.  The stock solutions were stored at -20oC and 
further dilutions were prepared on the day of the experiment. Chloroquine (CQ) was used 
as the reference drug in all experiments.  A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% parasite growth (IC50 value). 
Compounds were tested at a starting concentration of 100µg/ml, which was then serially 
diluted 2-fold in complete medium to give 10 concentrations; with the lowest 
concentration being 0.2µg/ml. The same dilution technique was used for all the samples. 
CQ was tested at a starting concentration of 100ng/ml. The highest concentration of 
solvent to which the parasites were exposed had no measurable effect on parasite 
viability (data not shown). The IC50 values were obtained using a non-linear dose-
response curve fitting analysis via GraphPad Prism v.4.0 software. 
 
In vitro Antiplasmodial assays: W2 strain of Plasmodium falciparum 
The protocol to this assay is as described by Rosenthal, et al, 1996. The W2 (CQ 
resistant) strain of P. falciparum (1% parasitemia, 2% hematocrit), were cultured in 0.5ml 
of medium in 48-well culture dishes. Stock solutions of inhibitors (10mM) in DMSO 
were added to cultured parasites to a final concentration of 20µM. From the 48-well 
plates, 125µM of culture was transferred to two 96-well plates (duplicates). Serial 
dilutions (1%) of inhibitors were made to final concentrations of 10µM, 2µM, 0.4µM, 
80nM, 16nM, and 3.2nM. Cultures were maintained at 37oC for 2 days after which the 
parasites were washed and fixed with 1% formaldehyde in PBS. After 2 days parasitemia 
was measured by flow cytometry using the DNA stain YOYO-1 as a marker of cell 
survival (Greenbaum, 2004). 
 
In vitro Antiplasmodial assays: 3D7 and K1 strains of Plasmodium falciparum 
The 3D7 clone is known to be sensitive to all antimalarials whereas the K1 which 
originates from Thailand is resistant to CQ and pyrimethamine, but sensitive to 
mefloquine. The cultures are naturally, asynchronous (65-75% ring stage) and are 
maintained in continuous log phase growth in RPMI 1640 supplemented with 5% washed 
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bovine serum albumin) (GIBCO, Grand Island, NY) (CM). All cultures and assays were 
conducted at 37oC under an atmosphere of 5% CO2 and 5% O2 with the balance N2. ges 
This assay was performed in various stages i.e. the primary and secondary screens. 
 
Stock solutions were prepared in 100% DMSO at 20mg/ml and futher dilutions were 
done using complete medium RPMI 1640 supplemented with 15nM cold hypoxanthine 
and AlbuMAXII. Assays were performed in sterile 96-well microtitre plates; each plate 
containing 100µl of parasite culture (0.5% parasitemia, 2.5% hematocrit). Each drug was 
tested in triplicate and parasite growth compared to the control and blank (uninfected 
erythrocytes) wells. After 24h incubation at 37oC, 3.7 Bq of [3H] hypoxathine was added 
to each well. Cultures were incubated for a further 24h before harvesting them onto glass 
fibre filter mats. Radioactivity was counted using a Wallac Micr beta 1450 scintillation 
counter. The results were recorded as counts per minute (CPM) per well at each drug 
concentration, control and blank. Percentage inhibition was calculated from comparison 
to blank and control wells, and IC50 values were calculated using Microsoft XLFit line 
fitting software (IDBS, UK). 
(a) Primary Screen 
The primary screen used the 3D7 strain. The test compounds are tested at 4 
concentrations (30, 10, 3, 1, 0.3, and 0.1µg/ml). Compounds that did not affect parasite 
growth at 10µg/ml are considered inactive, between 10 and 11µg/ml are designated as 
partially active and if <1µg/ml the compound was classified as active and was further 
evaluated by 3-fold serial dilutions in a repeat test. 
(b) Secondary Screen  
In this screen both 3D7 and K1 were used. The test drug was diluted 3-fold over at 12 
diffierent concentrations with appropriate starting concentrations based on the primary 
screen. The IC50 was determined by sigmoidal dose response analysis using Microsoft 
XLFit (IDBS, UK). For each assay, the IC50, and IC90 values for each parasite line were 
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5.5.3. Mammalian cell toxicity Assay 
KB cells is a cell line derived from a human carcinoma of the nasopharynx, typically is 
used as an assay for antineoplastic agents. The KB cells were maintained as monolayers 
in RPMI 1640 + 10% HIFC. All cultures and assays were conducted at 37oC under an 
atmosphere of 5%CO2/ 95% air mixture. The Assay takes upto 5days.  
 
(a) Day 1:  
KB cells are harvested, counted and washed in serum free medium (2000rpm, 10 
minutes. 4oC), and resuspended in fresh medium (RPMI 1640 + 10% HIFC) at a 
concentration of 4 x 104/ml. 100µl is added to wells on a 96- well plate (4 x 103/well). 
The plate was incubated overnight at 37oC under an atmosphere of 5%CO2/ 95% air 
mixture to allow cells to adhere. 
(b) Day 2:  
Test compounds were prepared in 100% DMSO 20mg/ml and diluted to a starting 
concentration of 600µg/ml (2 x top concentration) with RPMI + 10% HIFC. The control 
wells had no drug. A 10-fold serial dilution was performed across the plate ie 300, 30, 3, 
etc. The plate was then incubated for 72h at atmosphere of 5%CO2/ 95% air mixture. 
Podophyllotoxin was used as the reference drug.  
( c) Day 5: 
Each well was assessed by microscopic observation. 20µl Alamar Blue was added to 
each well then the plates were incubated for 2-4h before reading (Gemini, EX/EM 
530/580, cut-off 550nm) IC50 values were calculated using sigmoidal regression analysis 
(MS XLFit) 
 
5.5.4. In vivo antiplasmodial assay against P. berghei 
The in vivo tests were performed in Swiss Webster female mice infected with 
Plasmodium berghei. It involved intra peritoneal administration of the drugs 16.HCl salt, 
16a and chloroquine as the reference at a dosage of 2x day 50mg/kg. The drugs were 
dissolved in 5% DMSO 5% Cremophor EL in saline before administration. The control 
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5.5.5. In silico ADME studies 
The insilico studies included prediction of compliance to the Lipinski guidelines 
(drugability), physicochemical properties and ADME properties. The drugability 
predictions were performed using Volsurf modeller and Chemaxon calculator plugins 
(www.chemaxon.com) whereby a set of 4 guidelines predicting for a compound to have 
good oral absorption and permeation i.e. < hydrogen bond donors, <10 hydrogen bond 
acceptors, <500 molecular weight, and a calculated logP (ClogP) of <5. MoKa software 
(www.moldiscovery.com) was used to predict pKa. Solubilities of the compounds were 
profiled in Volsurf (www.moldiscovery.com ) and this was projected onto a model of 
known drugs. The sites of metabolism in CYP3A4 were predicted using MetaSite 
(www.moldiscovery.com ). 
 
In silico Docking in the CYP 3A4 active site 
The study employed a cytochrome P450 (CYP3A4) crystal structure [protein data bank; 
PDB code 1TQN] to predict the modes of binding and the affinity constants of the 
synthesised ligands/substrates at the lowest binding energy conformation. The ligand 
docking program Autodock 4.2.3 was used and no partial charges were added to the P450 
heme moiety. The Autodock 4.2.3 was obtained from the Scripps institute (La Jolla, CA). 
In AutoDock 4.3.2 all the substrates were treated as flexible ligands by modifying their 
rotatable torsions but the CYP3A4 template was considered to be a rigid receptor. The 
3D coordinates of the CYP3A4 structure (1TQN) was acquired from the PDB and was 
used without further modification. The structures of the substrates were built using 
Chemdraw 12 then converted to SYBL MOL2 format using Chem3D Ultra 10 
(CambridgeSoft Corp., Cambridge, MA). The substrates were modified with Gasteiger 
atomic charges assignment and flexible torsions were defined. The default settings were 
used for docking. The grid box was centered at 18.599, 7.921 and 57.938, with 
dimensions of 30×36×60. Docking was accomplished on a Linux workstation with 64bit 
Dual Core Intel Xenon Enterprise Linux WS4 operating system. The maximum number 
of energy evaluations and the maximum number of generations was set at the default 
values of 250,000 and 27,000 respectively. The rest of the parameters were set at their 
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and 10 LGA runs were conducted for each template and docking solutions were groups of 
conformational clusters in which all atom root mean square deviations (rmsd) within 
2.0Å of each other were clustered together using Autodock 4.2.3 tools.  
 
5.5.6. Physicochemical and In Vitro ADMET Studies  
Purity Analysis 
Initially the purity of the test compounds was determined using reversed phase HPLC 
according to published methods (de Aquino Ribeiro, 2007, Patel, P 2004, Xie 2003) on a 
Zorbax C18, 4.6x150mm, 5µm column, with mobile phase of A; 
water/acetonitrile/trifluoroacetic acid (95:5:0.1) and  B: acetonitrile/trifluoroacetic acid 
(100:0.1). The gradient elution started with 10% B attaining 90% in 10min and back to 
10% in another 5 min. 
Lipophilicity 
Lipophilicity was determined using reverse phase HPLC and standard drugs with known 
retention times (tR) and retention capacity were (k‟) were used for calibration. A Zorbax 
C18, 4.6 x 150mm, 5µm column, with a mobile phase of A:10mM ammonium acetate in 
acetonitrile/water (5:95), B:10mM ammonium acetate in water/acetonitrile (95:5) starting 
with 0% B, attaining 100% B in 20minutes were the chromatographic conditions used. 
Linear regression curves with accurate k‟ values on the Y axis and tR on the X axis for the 
reference compounds were used to estimate the k‟ values for the test compound [i.e tR of 
the test compounds were used to extrapolate their k‟ values on the curves]. A second 
curve plotted from published logD values against tR of reference compounds was used to 
estimate the logD of the test compounds.The reference compounds used were 
metroprolol, propanolol, testosterone and felodipine. 
Solubility 
A turbidimetric method was used to determine solubility. Compounds were pre-diluted 
from stocks in 100% DMSO before dilution in 0.1M buffered saline pH 7.4 to desired 
concentrations. Serial dilutions from the highest concentrations were made to obtain 2.5, 
1.25, 0.63, 0.31, 0.16 and 0.08mM working concentrations. Working stocks were further 
diluted in PBS to make the required concentrations (100, 50, 25, 12.5, 6.25, 3.125 and 
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prepared to determine if the increase in absorbance was due to the compound itself with 
increase in concentration and not due to the formation of a precipitate. The plates were 
incubated at 37oC for 2hours followed by UV detection at 595nm. Two compounds were 
used as controls:  one poorly soluble compound (niclosamide solubility < 1µM) and one 
very soluble compound (paracetamol solubility>100µM). 
 
Lower limits of solubility were estimated as values at which a rise in absorbance from 
baseline/blank is observed. Absorbance values above 0.05 were also used as a 
complimentary diagnostic tool for formation of precipitate.  The compounds were 
classified into three broad categories according to their aqueous solubility. Compounds 
with solubility below 20µM were classified as poorly soluble, between 20 and 100µM as 
partially soluble and above 100µM as soluble. The lower bound solubility (the solubility 
at which the compound begins to precipitate) was used in classifying the compounds. As 
expected the two controls (niclosamide and paracetamol) gave values which were 
consistent with previously reported literature.  
CYP3A4 inhibition 
 
In this assay, testosterone was used as a probe substrate and its β hydroxylation was used 
as a marker reaction. Two concentrations were used, 3µM and 20µM to investigate if the 
inhibition was concentration dependent. The inhibition effects were investigated using 
ketoconazole (known potent inhibitor of CYP3A4) and the uninhibited reaction as 
references. Components in the incubation mixture (total volume = 200µl) were HLM 
0.5mg/ml, phosphate buffer pH7.4 0.1M,  NADPH 1mM, test compound 320µM and 
20µM and testosterone 100 µM. 
 
DMSO concentrations were kept constant in all the reactions (0.2%) and the substrate 
was dissolved in methanol giving a final concentration of 40% methanol in the incubation 
mixture. The reaction was stopped by addition of a double volume of ice cold methanol. 
The mixture was vortexed for a minute followed by centrifugation at 00C for 15minutes. 
Supernatant was collected and the centrifugation repeated. The supernatant was 
evaporated under a gentle stream of nitrogen gas followed by reconstitution in mobile 
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following conditions Zorbax C18, 4.6 x 150mm, 5µm diameter sample solvent 50% 
methanol/water (v/v), mobile phase A: 50mM KH2PO4 B: methanol, by isocratic elution 
50% A:50% B at 1ml/min flow rate. The injection volume of 100µl with uncontrolled 
temperature detection at 254nm and a running time of 15minutes. 
 
The extent of CYP3A4 inhibition was also shown by the IC50. The IC50 is the amount of 
compound that is required to cause 50% inhibition. One point IC50 calculation was used 
to estimate the IC50 for both the test compounds and the control. Estimations were done 
using inhibition data at 3µM using the relationship below. 
IC50 = x  100 -  percent control at x
                  percent control at x
1/h
  



































CONCLUSION AND RECOMMENDATIONS 
 
The main aim of this project was to synthesise novel hybrid structures of 3,4-HPOs 
with 4-aminoquinolines and screening of the synthesized compounds for biological 
activity i.e. in vitro and in vivo antimalarial activity, β-haematin inhibition and 
cytotoxicity. Alongside this, N-alkyl-3, 4-HPOs and their gallium (III) complexes 
were synthesised. Iron (III) and gallium (III) complexes of selected hybrid molecules 
were also prepared to investigate the contribution of iron chelation or complexation to 
antiplasmodial activity. In addition to these one biscatecholate -4-aminoquinoline 
conjugate 37 was prepared. All the compounds were characterised using 1H and 13C 
NMR spectroscopy, IR spectroscopy, MS and elemental analysis. The purity of the 
hybrids/conjugates was ascertained by analytical HPLC. The X-ray structure of one 
of the kojic acid derived hybrids, 24, was determined. Solubility profiles were 
determined for some of the compounds using turbidimetry and the log D values of 
selected compounds were also determined.  
 
All the compounds were tested for in vitro antiplasmodial activity and only two (16 
and 16a) were evaluated for in vivo antiplasmodial efficacy in mice. The simple N-
alkyl-3,4-HPOs were found to be less active compared to CQ and their main mode of 
action was linked to iron chelation. Their potency was observed to increase with 
increase in lipophilicity and none of them inhibited β-haematin formation at the 
highest concentration (10µM) tested.  
 
Even though β-haematin inhibition was identified as one of the major modes of action 
for the synthesised 4-aminoquinoline-3,4-HPO conjugates, a free 3-hydroxy group on 
the hydroxypyridinone moiety was found to play an important role in enhancing 
activity against the resistant strain. The 4-aminoquinoline-3,4-HPO conjugates were 
found to be stronger β-haematin inhibitors than CQ and the benzyl group was 
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resistance indices than CQ indicating potential to act against resistant malaria. The 
tertiary amine was identified to be more effective in enhancing the activity of the 
conjugates against the resistant strain. 
 
The most potent conjugates 13a, 16, 24a, 32 and 32a, were identified and all were 
more potent than CQ in the resistant strain. Of these only the ones with the longest 
side chain (6 carbon atoms) were more potent than CQ in the sensitive strain. 
Therefore modification of the side chain was found to be important in enhancing 
activity against the sensitive strains. All the compounds had significantly similar 
activity in the resistant strain but 24a and 13a had the best resistance indices. 
 
Increasing the length of the alkyl side chain did not enhance activity against the 
resistant strain significantly as well this strategy caused an increase in the potential to 
cause CYP3A4 inhibition or drug-drug interactions (DDIs). Consequently among the 
most potent compounds only 24a and 13a were identified as the best candidates 
because they were equipotent in both the resistant and sensitive strains showed 
reduced potential to cause CYP3A4 inhibition as deduced from in vitro and/or in 
silico data. Therefore, controlled lipophilicity is important in designing potent 
antimalarials with acceptable ADMET/physicochemical properties. Future synthetic 
work should consider conjugates that are structurally related to compound 24a i.e. 
containing both chelator and tertiary amino groups. Crystal structures of complexes of 
haematin and such compounds may help elucidate the role or interaction of the two 
groups with respect to β-hematin inhibition. 
 
Both in silico and in vitro data alongside correlation studies showed that the CYP3A4 
and haematin inhibition activities of the drug conjugates are independent from each 
other and that a strong inhibitor of CYP3A4 is not necessarily a strong inhibitor of β-
haematin.  
 
Protection of the iron chelation group by benzylation was found to enhance inhibition 
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vitro CYP3A4 inhibition i.e. A/AB series, were found to have greater potential to 
cause DDIs in the presence of testosterone but this data should be treated with caution 
until the assay is repeated using other substrate probes. The structural modification 
strategies of alteration of the molecular shape and incorporation of extra polar groups 
was found to have potential to improve the CYP3A4 inhibition profile of the 4-
aminoquinoline -3,4-HPO hybrids. This was deduced from the in silico and in vitro 
data. 
 
Docking conformations of the conjugates in AutoDock 4.2 were found to be reliable 
in distinguishing strong CYP3A4 inhibitors from weak CYPA4 inhibitors. The N-
alkyl side chain and the benzyl group were identified to be the main substructures 
whose interaction with the CYP binding pockets was predicted to influence 
inhibition. Thus the docking experiments may be used to screen designed molecules 
prior to synthesis. A strategy of modification of the alkyl side chain via its 
functionalization to incorporate hydrophilic groups and the use of less lipophilic 
hydroxyl-protecting groups or the use of shorter alkyl side chains may be adopted in 
future to synthesise hybrids with better CYP3A4 profiles. 
 
Structural features incorporated into antiplasmodial molecules aimed at improving 
potency may suppress or enhance each others effect or affect the ADME profile of the 
new chemical entity. The tertiary amine group together with the chelator group 
(hydroxypyridinone), were observed to enhance activity against the CQ resistant 
strain, but they caused a decrease in β-haematin inhibition for compound 24a. The 
same tertiary amino group was predicted to enhance CYP3A4 inhibition in the 
conjugates. Similarly aromatizing of the protecting group at the 3-position was 
identified to enhance CYP3A4 and β-haematin inhibition. Incorporation of the benzyl 
group to enhance haematin inhibition in future work may require adoption of 
uniquely designed structures that have an iron chelating group and some extra polar 
groups to counteract the lipophilicity of the aromatic ring so as to avoid high affinity 
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efficient if in silico tools are employed to detect and avoid potential ADMET 
liabilities and undesired physicochemical properties prior to synthesis. 
 
Preliminary synthesis of the gallium (III) and iron (III) complexes of the conjugates 
was important in studying the potential contribution of iron chelation towards the 
antiplasmodial activity of the conjugates. However, the characterization was 
incomplete. Therefore, future work should aim at the preparation of X-Ray quality 
crystal of complexes of the A/AB, R and D series to enhance complete structural 
elucidation. Metallation of the quinoline heterocyclic N-1 which is known to enhance 
potency against resistant strains may be pursued for the aminoquinoline-3,4-HPO 
hybrids with or without complexation of the hydroxypyridinone moiety. 
 
In vivo screening of these double drugs was performed for 16a and 16.HCl salt and 
their efficacy against P.berghei in mice was dismal when compared to CQ. The cause 
of the failure of the in vitro potency of these compounds to translate to in vivo 
potency was not resolved fully. Future work in different animal models or against 
different strains of Plasmodia is important. Currently in vivo screening for related 
compounds to study their PK/PD interactions is under way. It is recommended that 
compounds 24a and 13a which were identified to have the best antiplasmodial and 
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IC50 ( µg/mL ) 
against 3D7 
IC50 ( µg/mL ) 
against K1 
Σ FIC50  
(3D7) 
Σ FIC50  
( K1) 
1 0 3.512 3.306 1 1 
0.788 0.211 0.183 0.095 0.043 0.08 
0.647 0.353 0.036 2.281 0.007 2.81 
0.476 0.524 0.02 0.18 0.003 0.30 
0.35 0.65 0.012 0.388 0.0015 0.78 
0.261 0.739 0.015 0.009 0.0017 0.02 
0.18 0.82 0.04 0.831 0.0037 2.04 
0.115 0.885 0.007 0.273 0.0005 0.72 
0 1 20 0.3413 1 1 
 
 







IC50 ( µg/mL ) 
against 3D7 






1 0 20 20 1 1 
0.833 0.277 0.32 2.659 11.09 2.70 
0.7 0.3 0.045 1.778 1.69 1.94 
0.524 0.476 0.058 1.608 3.46 2.74 
0.455 0.545 0.033 3.028 2.25 5.88 
0.283 0.717 0.009 0.586 0.81 1.49 
0.18 0.82 0.003 0.343 0.31 0.99 
0.11 0.89 0.013 0.311 1.45 0.98 





















Table A1.3: In vitro activity and FIC50  for different combinations of 2h and DHA 
 
 






IC50 ( µg/mL ) 
against 3D7 
 






  (K1) 
1 0 8.55 0.716 1 1 
0.89 0.11 0.002 0.003 0.0002 0.007 
0.813 0.188 0.005 0.005 0.0005 0.017 
0.636 0.364 0.019 0.003 0.0018 0.015 
0.56 0.44 0.006 0.001 0.0005 0.006 
0.41 0.59 0.003 0.001 0.0002 0.007 
0.31 0.69 0.013 0.001 0.0009 0.008 
0.14 0.86 0.029 0.007 0.002 0.072 



















IC50 ( µg/mL ) 
against 3D7 






1 0 0.684 0.463 1 1 
0.857 0.143 0.008 0.002 0.58 0.013 
0.733 0.26 0.013 0.003 1.70 0.029 
0.655 0.3448 0.001 0.0001 0.17 0.001 
0.52 0.48 0.004 0.002 0.96 0.032 
0.345 0.655 0.001 0.0001 0.33 0.001 
0.286 0.714 0.003 0.002 1.07 0.046 
0.133 0.866 0.002 0.0002 0.87 0.006 















X-Ray Crystallography Data 
 
Table A2.1.  Crystal data and structure refinement for 24.  
   
      Empirical formula                 C28 H39 Cl N4 O6  
       Formula weight                    563.08  
      Temperature                       100(2) K  
      Wavelength                        0.71073 A  
      Crystal system, space group       Triclinic,  P-1  
      Unit cell dimensions              a = 9.5389(15) A   alpha = 67.050(2) deg.  
                                        b = 11.3729(17) A    beta = 78.186(3) deg.  
                                        c = 14.358(2) A   gamma = 86.383(3) deg.  
        Volume                            1403.7(4) A^3  
        Z, Calculated density             2,  1.332 Mg/m^3  
        Absorption coefficient            0.185 mm^-1  
        F(000)                            600  
        Crystal size                      0.17 x 0.16 x 0.15 mm  
        Theta range for data collection   1.94 to 28.39 deg.  
        Limiting indices                  -12<=h<=12, -15<=k<=15, -19<=l<=19  
        Reflections collected / unique    22961 / 7020 [R(int) = 0.0389]  
        Completeness to theta = 28.39     99.5 %  
        Absorption correction             Semi-empirical from equivalents  
        Max. and min. transmission        0.9728 and 0.9692  
        Refinement method                 Full-matrix least-squares on F^2  
        Data / restraints / parameters    7020 / 5 / 372  
        Goodness-of-fit on F^2            1.074  
        Final R indices [I>2sigma(I)]     R1 = 0.0579, wR2 = 0.1648  
        R indices (all data)              R1 = 0.0772, wR2 = 0.1790  
        Extinction coefficient            n/a  
        Largest diff. peak and hole       0.490 and -0.886 e.A^-3  
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Table A2.2.  Atomic coordinates ( x 10^4) and equivalent isotropic displacement 
parameters (A^2 x 10^3) for 24. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
          ________________________________________________________________  
                          x             y             z           U(eq)  
         ________________________________________________________________  
           Cl(1)        6001(1)      14554(1)       -987(1)       25(1)  
          O(1)        -2793(2)        779(1)       6392(1)       22(1)  
          O(2)         -108(2)        -29(1)       6458(1)       21(1)  
          N(1)         3509(2)      11075(2)      -1429(1)       22(1)  
          N(2)         2346(2)       8943(2)       1761(1)       21(1)  
          N(3)         -578(2)       5565(2)       3204(1)       19(1)  
          N(4)          442(2)       2792(2)       4046(1)       19(1)  
          C(1)         3822(2)      11512(2)       -732(2)       19(1)  
          C(2)         4594(2)      12688(2)      -1133(2)       20(1)  
          C(3)         4967(2)      13152(2)       -472(2)       20(1)  
          C(4)         4582(2)      12520(2)        606(2)       20(1)  
          C(5)         3834(2)      11384(2)       1003(2)       19(1)  
          C(6)         3442(2)      10845(2)        355(2)       17(1)  
          C(7)         2697(2)       9632(2)        740(2)       18(1)  
          C(8)         2391(2)       9220(2)          6(2)       22(1)  
          C(9)         2819(3)       9959(2)      -1038(2)       23(1)  
          C(10)        1569(2)       7721(2)       2182(2)       21(1)  
          C(11)         -16(2)       7880(2)       2131(2)       22(1)  
          C(12)        -720(3)       6654(2)       2247(2)       22(1)  
          C(13)       -1311(3)       5812(2)       4110(2)       30(1)  
          C(14)       -1194(2)       4433(2)       3176(2)       20(1)  
          C(15)        -912(2)       3223(2)       4046(2)       18(1)  
          C(16)       -2007(2)       2558(2)       4830(2)       19(1)  
          C(17)       -1787(2)       1421(2)       5664(2)       18(1)  
          C(18)        -320(2)       1041(2)       5641(2)       18(1)  
          C(19)         737(2)       1715(2)       4841(2)       19(1)  
          C(20)        1630(3)       3416(2)       3170(2)       27(1)  
          C(21)        1335(2)       -392(2)       6550(2)       20(1)  
          C(22)        1272(2)      -1556(2)       7539(2)       20(1)  
          C(23)          84(3)      -1811(2)       8337(2)       25(1)  
          C(24)          60(3)      -2872(2)       9254(2)       31(1)  
          C(25)        1221(3)      -3672(2)       9375(2)       31(1)  
          C(26)        2402(3)      -3422(2)       8583(2)       29(1)  
          C(27)        2432(3)      -2364(2)       7662(2)       24(1)  
          O(1A)       -6062(7)       5642(5)       4065(5)      128(2)  
          C(1A)       -4868(5)       5089(5)       4024(4)      101(1)  
          O(1B)       -4868(5)       5089(5)       4024(4)      101(1)  
          C(1B)       -6062(7)       5642(5)       4065(5)      128(2)  
          O(1W)       -5265(2)       2163(2)       6519(1)       40(1)  
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          O(3WA)      -3977(5)      -2618(5)       5361(4)       37(1)  
          O(2WB)      -4183(6)       -951(5)       5899(4)       42(1)  





         ________________________________________________________________  
  
           Table A2.3.  Bond lengths [A] and angles [deg] for 24.  
           _____________________________________________________________  
   
            Cl(1)-C(3)                    1.744(2)           O(1)-C(17)                    1.276(2)  
            O(2)-C(18)                    1.360(2)            O(2)-C(21)                    1.428(3)  
            N(1)-C(9)                     1.325(3)            N(1)-C(1)                     1.366(3)  
            N(2)-C(7)                     1.345(3)            N(2)-C(10)                    1.462(3)  
            N(2)-H(2N)                    0.956(10)           N(3)-C(13)                    1.466(3)  
            N(3)-C(14)                    1.466(3)            N(3)-C(12)                    1.472(2)  
            N(4)-C(15)                    1.353(3)            N(4)-C(19)                    1.371(3)  
            N(4)-C(20)                    1.480(3)            C(1)-C(2)                     1.419(3)  
            C(1)-C(6)                     1.423(3)            C(2)-C(3)                     1.362(3)  
            C(2)-H(2)                     0.9500             C(3)-C(4)                     1.407(3)  
            C(4)-C(5)                     1.370(3)            C(4)-H(4)                     0.9500  
            C(5)-C(6)                     1.414(3)            C(5)-H(5)                     0.9500  
            C(6)-C(7)                     1.443(3)            C(7)-C(8)                     1.395(3)  
            C(8)-C(9)                     1.389(3)            C(8)-H(8)                     0.9500  
            C(9)-H(9)                     0.9500            C(10)-C(11)                   1.525(3)  
            C(10)-H(10A)                  0.9900             C(10)-H(10B)                  0.9900  
            C(11)-C(12)                   1.521(3)            C(11)-H(11A)                  0.9900  
            C(11)-H(11B)                  0.9900             C(12)-H(12A)                  0.9900  
            C(12)-H(12B)                  0.9900             C(13)-H(13A)                  0.9800  
            C(13)-H(13B)                  0.9800             C(13)-H(13C)                  0.9800  
            C(14)-C(15)                   1.509(3)            C(14)-H(14A)                  0.9900  
            C(14)-H(14B)                  0.9900             C(15)-C(16)                   1.373(3)  
            C(16)-C(17)                   1.419(3)            C(16)-H(16)                   0.9500  
            C(17)-C(18)                   1.436(3)            C(18)-C(19)                   1.364(3)  
            C(19)-H(19)                   0.9500             C(20)-H(20A)                  0.9800  
            C(20)-H(20B)                  0.9800             C(20)-H(20C)                  0.9800  
            C(21)-C(22)                   1.510(3)            C(21)-H(21A)                  0.9900  
            C(21)-H(21B)                  0.9900             C(22)-C(27)                   1.388(3)  
            C(22)-C(23)                   1.391(3)            C(23)-C(24)                   1.393(3)  
            C(23)-H(23)                   0.9500             C(24)-C(25)                   1.383(4)  
            C(24)-H(24)                   0.9500             C(25)-C(26)                   1.381(4)  
            C(25)-H(25)                   0.9500             C(26)-C(27)                   1.395(3)  
            C(26)-H(26)                   0.9500             C(27)-H(27)                   0.9500  
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            O(1W)-H(1W1)                  0.966(10)           O(2WA)-O(2WB)                 0.713(5)  
            O(3WA)-O(3WB)                 0.699(6)         C(18)-O(2)-C(21)            117.91(16)  
            C(9)-N(1)-C(1)              116.14(18)         C(7)-N(2)-C(10)             122.16(19)  
            C(7)-N(2)-H(2N)             119.2(19)          C(10)-N(2)-H(2N)            118.5(19)  
            C(13)-N(3)-C(14)            110.89(18)          C(13)-N(3)-C(12)            110.68(18)  
            C(14)-N(3)-C(12)            107.76(16)          C(15)-N(4)-C(19)            120.43(18)  
            C(15)-N(4)-C(20)            121.49(17)          C(19)-N(4)-C(20)            117.99(19)  
            N(1)-C(1)-C(2)              117.14(19)          N(1)-C(1)-C(6)              123.70(19)  
            C(2)-C(1)-C(6)              119.1(2)           C(3)-C(2)-C(1)              119.58(19)  
            C(3)-C(2)-H(2)              120.2           C(1)-C(2)-H(2)              120.2  
            C(2)-C(3)-C(4)              122.28(19)           C(2)-C(3)-Cl(1)             118.55(16)  
            C(4)-C(3)-Cl(1)             119.15(17)           C(5)-C(4)-C(3)              118.8(2)  
            C(5)-C(4)-H(4)              120.6           C(3)-C(4)-H(4)              120.6  
            C(4)-C(5)-C(6)              121.45(19)           C(4)-C(5)-H(5)              119.3  
            C(6)-C(5)-H(5)              119.3           C(5)-C(6)-C(1)              118.77(19)  
            C(5)-C(6)-C(7)              123.29(18)           C(1)-C(6)-C(7)              117.93(19)  
            N(2)-C(7)-C(8)              122.82(19)           N(2)-C(7)-C(6)              120.47(19)  
            C(8)-C(7)-C(6)              116.70(19)           C(9)-C(8)-C(7)              120.0(2)  
            C(9)-C(8)-H(8)              120.0            C(7)-C(8)-H(8)              120.0  
            N(1)-C(9)-C(8)              125.5(2)           N(1)-C(9)-H(9)              117.2  
            C(8)-C(9)-H(9)              117.2           N(2)-C(10)-C(11)            112.51(17)  
            N(2)-C(10)-H(10A)           109.1           C(11)-C(10)-H(10A)          109.1  
            N(2)-C(10)-H(10B)           109.1           C(11)-C(10)-H(10B)          109.1  
            H(10A)-C(10)-H(10B)         107.8          C(12)-C(11)-C(10)           112.45(18)  
            C(12)-C(11)-H(11A)          109.1          C(10)-C(11)-H(11A)          109.1  
            C(12)-C(11)-H(11B)          109.1          C(10)-C(11)-H(11B)          109.1  
            H(11A)-C(11)-H(11B)         107.8          N(3)-C(12)-C(11)            113.56(18)  
            N(3)-C(12)-H(12A)           108.9           C(11)-C(12)-H(12A)          108.9  
            N(3)-C(12)-H(12B)           108.9          C(11)-C(12)-H(12B)          108.9  
            H(12A)-C(12)-H(12B)         107.7          N(3)-C(13)-H(13A)           109.5  
            N(3)-C(13)-H(13B)           109.5         H(13A)-C(13)-H(13B)         109.5  
            N(3)-C(13)-H(13C)           109.5           H(13A)-C(13)-H(13C)         109.5  
            H(13B)-C(13)-H(13C)         109.5           N(3)-C(14)-C(15)            112.13(17)  
            N(3)-C(14)-H(14A)           109.2           C(15)-C(14)-H(14A)          109.2  
            N(3)-C(14)-H(14B)           109.2           C(15)-C(14)-H(14B)          109.2  
            H(14A)-C(14)-H(14B)         107.9            N(4)-C(15)-C(16)            119.89(18)  
            N(4)-C(15)-C(14)            119.13(18)       C(16)-C(15)-C(14)           121.0(2)  
            C(15)-C(16)-C(17)           122.8(2)         C(15)-C(16)-H(16)           118.6  
            C(17)-C(16)-H(16)           118.6           O(1)-C(17)-C(16)            123.7(2)  
            O(1)-C(17)-C(18)            121.60(18)        C(16)-C(17)-C(18)           114.67(18)  
            O(2)-C(18)-C(19)            124.6(2)          O(2)-C(18)-C(17)            114.52(17)  
            C(19)-C(18)-C(17)           120.88(18)        C(18)-C(19)-N(4)            121.3(2)  
            C(18)-C(19)-H(19)           119.4          N(4)-C(19)-H(19)            119.4  
            N(4)-C(20)-H(20A)           109.5          N(4)-C(20)-H(20B)           109.5  
            H(20A)-C(20)-H(20B)         109.5          N(4)-C(20)-H(20C)           109.5  
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            O(2)-C(21)-C(22)            107.28(17)         O(2)-C(21)-H(21A)           110.3  
            C(22)-C(21)-H(21A)          110.3          O(2)-C(21)-H(21B)           110.3  
            C(22)-C(21)-H(21B)          110.3          H(21A)-C(21)-H(21B)         108.5  
            C(27)-C(22)-C(23)           119.6(2)        C(27)-C(22)-C(21)           119.5(2)  
            C(23)-C(22)-C(21)           120.9(2)        C(22)-C(23)-C(24)           120.1(2)  
            C(22)-C(23)-H(23)           120.0          C(24)-C(23)-H(23)           120.0  
            C(25)-C(24)-C(23)           120.1(2)        C(25)-C(24)-H(24)           119.9  
            C(23)-C(24)-H(24)           119.9         C(26)-C(25)-C(24)           119.9(2)  
            C(26)-C(25)-H(25)           120.1         C(24)-C(25)-H(25)           120.1  
            C(25)-C(26)-C(27)           120.3(2)         C(25)-C(26)-H(26)           119.8  
            C(27)-C(26)-H(26)           119.8          C(22)-C(27)-C(26)           120.0(2)  
            C(22)-C(27)-H(27)           120.0          C(26)-C(27)-H(27)           120.0  
            H(1W2)-O(1W)-H(1W1)         101(3)         
_____________________________________________________________  
   
     
 
Table A2.4.  Anisotropic displacement parameters (A^2 x 10^3) for 24. The anisotropic 
displacement factor exponent takes the form: -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* 
U12 ]  
     
_______________________________________________________________________  
               U11        U22        U33        U23        U13        U12  
    
_______________________________________________________________________  
     Cl(1)    26(1)      16(1)      27(1)      -5(1)       0(1)      -5(1)  
    O(1)     21(1)      21(1)      18(1)      -2(1)      -2(1)      -5(1)  
    O(2)     22(1)      17(1)      19(1)      -1(1)      -5(1)      -1(1)  
    N(1)     24(1)      25(1)      19(1)      -9(1)      -6(1)       1(1)  
    N(2)     24(1)      16(1)      20(1)      -6(1)      -4(1)      -6(1)  
    N(3)     26(1)      13(1)      17(1)      -3(1)      -6(1)      -3(1)  
    N(4)     20(1)      16(1)      17(1)      -4(1)      -1(1)      -3(1)  
    C(1)     18(1)      18(1)      20(1)      -6(1)      -5(1)       2(1)  
    C(2)     20(1)      18(1)      19(1)      -4(1)      -2(1)       2(1)  
    C(3)     18(1)      12(1)      25(1)      -4(1)      -3(1)      -1(1)  
    C(4)     22(1)      17(1)      22(1)      -8(1)      -4(1)      -1(1)  
    C(5)     20(1)      17(1)      18(1)      -6(1)      -4(1)       0(1)  
    C(6)     17(1)      16(1)      19(1)      -7(1)      -3(1)       0(1)  
    C(7)     17(1)      17(1)      21(1)      -7(1)      -4(1)       1(1)  
    C(8)     23(1)      18(1)      27(1)     -11(1)      -6(1)      -2(1)  
    C(9)     25(1)      27(1)      24(1)     -14(1)      -9(1)       2(1)  
    C(10)    23(1)      15(1)      25(1)      -5(1)      -5(1)      -3(1)  
    C(11)    22(1)      15(1)      26(1)      -4(1)      -4(1)      -1(1)  
    C(12)    24(1)      16(1)      22(1)      -2(1)      -7(1)      -3(1)  
    C(13)    45(2)      23(1)      21(1)     -10(1)      -4(1)      -1(1)  
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    C(15)    24(1)      14(1)      18(1)      -6(1)      -5(1)      -3(1)  
    C(16)    19(1)      18(1)      20(1)      -6(1)      -4(1)      -2(1)  
    C(17)    22(1)      16(1)      16(1)      -6(1)      -3(1)      -5(1)  
    C(18)    23(1)      15(1)      16(1)      -5(1)      -5(1)      -2(1)  
    C(19)    22(1)      16(1)      19(1)      -6(1)      -4(1)      -1(1)  
    C(20)    24(1)      23(1)      22(1)      -1(1)       3(1)      -2(1)  
    C(21)    21(1)      17(1)      19(1)      -6(1)      -4(1)       0(1)  
    C(22)    26(1)      17(1)      21(1)      -7(1)      -9(1)      -1(1)  
    C(23)    27(1)      23(1)      21(1)      -5(1)      -7(1)       2(1)  
    C(24)    34(1)      30(1)      23(1)      -2(1)      -7(1)      -4(1)  
    C(25)    39(1)      22(1)      30(1)       0(1)     -19(1)      -6(1)  
    C(26)    32(1)      20(1)      41(1)     -10(1)     -22(1)       3(1)  
    C(27)    25(1)      22(1)      29(1)     -12(1)     -10(1)       0(1)  
    O(1W)    45(1)      47(1)      21(1)      -9(1)      -6(1)      19(1)  
    O(2WA)   38(3)      38(3)      63(3)     -31(2)     -19(2)       5(2)  
    O(3WA)   41(3)      31(2)      36(2)      -5(2)     -15(2)     -12(2)  
    O(2WB)   39(3)      33(3)      57(3)     -21(2)     -12(2)       5(2)  
    O(3WB)   74(4)      45(3)      41(3)     -17(3)     -25(3)       9(3)  
    
_______________________________________________________________________  
  
         Table A2.5.  Torsion angles [deg] for 24.  
         ________________________________________________________________  
   
          C(9)-N(1)-C(1)-C(2)                                 178.3(2)  
          C(9)-N(1)-C(1)-C(6)                                  -0.3(3)  
          N(1)-C(1)-C(2)-C(3)                                -178.3(2)  
          C(6)-C(1)-C(2)-C(3)                                   0.4(3)  
          C(1)-C(2)-C(3)-C(4)                                  -1.6(3)  
          C(1)-C(2)-C(3)-Cl(1)                                176.54(16)  
          C(2)-C(3)-C(4)-C(5)                                   1.5(3)  
          Cl(1)-C(3)-C(4)-C(5)                               -176.60(17)  
          C(3)-C(4)-C(5)-C(6)                                  -0.3(3)  
          C(4)-C(5)-C(6)-C(1)                                  -0.8(3)  
          C(4)-C(5)-C(6)-C(7)                                 177.9(2)  
          N(1)-C(1)-C(6)-C(5)                                 179.4(2)  
          C(2)-C(1)-C(6)-C(5)                                   0.8(3)  
          N(1)-C(1)-C(6)-C(7)                                   0.5(3)  
          C(2)-C(1)-C(6)-C(7)                                -178.07(19)  
          C(10)-N(2)-C(7)-C(8)                                 -2.1(3)  
          C(10)-N(2)-C(7)-C(6)                                178.96(19)  
          C(5)-C(6)-C(7)-N(2)                                  -0.6(3)  
          C(1)-C(6)-C(7)-N(2)                                 178.2(2)  
          C(5)-C(6)-C(7)-C(8)                                -179.6(2)  
          C(1)-C(6)-C(7)-C(8)                                  -0.8(3)  
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          C(6)-C(7)-C(8)-C(9)                                   0.9(3)  
          C(1)-N(1)-C(9)-C(8)                                   0.4(4)  
          C(7)-C(8)-C(9)-N(1)                                  -0.7(4)  
          C(7)-N(2)-C(10)-C(11)                               -75.1(3)  
          N(2)-C(10)-C(11)-C(12)                              162.18(18)  
          C(13)-N(3)-C(12)-C(11)                               63.2(3)  
          C(14)-N(3)-C(12)-C(11)                             -175.41(19)  
          C(10)-C(11)-C(12)-N(3)                               56.6(3)  
          C(13)-N(3)-C(14)-C(15)                              -67.1(2)  
          C(12)-N(3)-C(14)-C(15)                              171.61(19)  
          C(19)-N(4)-C(15)-C(16)                               -2.0(3)  
          C(20)-N(4)-C(15)-C(16)                              174.6(2)  
          C(19)-N(4)-C(15)-C(14)                              178.21(19)  
          C(20)-N(4)-C(15)-C(14)                               -5.3(3)  
          N(3)-C(14)-C(15)-N(4)                               -68.8(3)  
          N(3)-C(14)-C(15)-C(16)                              111.4(2)  
          N(4)-C(15)-C(16)-C(17)                                0.5(3)  
          C(14)-C(15)-C(16)-C(17)                            -179.69(19)  
          C(15)-C(16)-C(17)-O(1)                             -178.8(2)  
          C(15)-C(16)-C(17)-C(18)                               1.9(3)  
          C(21)-O(2)-C(18)-C(19)                                7.6(3)  
          C(21)-O(2)-C(18)-C(17)                             -173.47(18)  
          O(1)-C(17)-C(18)-O(2)                                -1.2(3)  
          C(16)-C(17)-C(18)-O(2)                              178.15(18)  
          O(1)-C(17)-C(18)-C(19)                              177.8(2)  
          C(16)-C(17)-C(18)-C(19)                              -2.9(3)  
          O(2)-C(18)-C(19)-N(4)                              -179.52(19)  
          C(17)-C(18)-C(19)-N(4)                                1.6(3)  
          C(15)-N(4)-C(19)-C(18)                                0.9(3)  
          C(20)-N(4)-C(19)-C(18)                             -175.7(2)  
          C(18)-O(2)-C(21)-C(22)                              177.12(17)  
          O(2)-C(21)-C(22)-C(27)                              158.3(2)  
          O(2)-C(21)-C(22)-C(23)                              -23.3(3)  
          C(27)-C(22)-C(23)-C(24)                               0.0(4)  
          C(21)-C(22)-C(23)-C(24)                            -178.4(2)  
          C(22)-C(23)-C(24)-C(25)                               0.3(4)  
          C(23)-C(24)-C(25)-C(26)                              -0.4(4)  
          C(24)-C(25)-C(26)-C(27)                               0.1(4)  
          C(23)-C(22)-C(27)-C(26)                              -0.3(3)  
          C(21)-C(22)-C(27)-C(26)                             178.2(2)  
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       ________________________________________________________________  
   




   D-H...A                      d(D-H)      d(H...A)    d(D...A)    <(DHA)  
   N(2)-H(2N)...O(1)#1          0.956(10)   2.011(16)   2.908(2)    155(3)  
 O(1W)-H(1W1)...O(1)          0.966(10)   1.813(14)   2.767(3)    169(4)  
 O(1W)-H(1W2)...N(1)#2        0.961(10)   1.779(11)   2.740(3)    178(4)  
 _______________________________________________________________________ 
   Symmetry transformations used to generate equivalent atoms:#1 -x,-y+1,-z+1    #2 x-
1,y-1,z+1      
 
 
 
 
 
 
 
 
 
 
 
